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Ten percent of the world have chronic kidney disease (CKD). In some patients, CKD 
can be catastrophic, leading to end stage kidney disease (ESKD), requiring lifelong 
dialysis or kidney transplant. Identification and analysis of molecules that can halt the 
progression of CKD to ESKD has the potential to save lives. The glomerulus is the 
site of the kidney, where the blood is filtered to produce urine. The glomerular 
filtration barrier consists of endothelial cells, a basement membrane and podocytes, 
epithelial cells with a unique shape maintained by the actin cytoskeleton. Damage to 
the structure of podocytes, is a significant contributing factor to CKD progression, 
and disorganisation of the podocyte cytoskeleton is a key factor associated with 
podocyte damage. Thymosin b4 (TB4) is the major G-actin sequestering molecule in 
mammalian cells and it regulates cell morphology, inflammation, and fibrosis. TB4 
has beneficial effects in rodent models of kidney injury, including protection of the 
glomerulus, but the effect of exogenous TB4 on podocytes is currently unknown. The 
aim of this thesis was to examine the effect of exogenous TB4 in cytotoxic and 
immune mediated podocyte injury models. Podocyte injury induced by the toxin 
Adriamycin (ADR) resulted in downregulation of the mRNA transcript for TB4 in 
podocytes. Examination of the F-actin cytoskeleton in mouse immortalised 
podocytes by phalloidin staining demonstrated that exogenous TB4 completely 
prevented ADR-induced F-actin disorganisation in vitro, a key factor in glomerular 
filtration barrier damage in vivo. The effect of exogenous TB4 was then examined in 
ADR nephropathy and nephrotoxic serum (NTS) nephritis in mice. Systemic 
upregulation of TB4 was achieved by recombinant adeno associated virus (AAV) 
mediated gene delivery prior to disease induction. Exogenous TB4 prevented 
damage to the glomerular filtration barrier, shown by reduced urine levels of albumin, 
in ADR nephropathy and early NTS nephritis. This was most likely due to prevention 
of podocyte loss, protection of glomerular F-actin in ADR nephropathy, and 
suppression of inflammation in NTS nephritis, as determined by light and fluorescent 
microscopy. In summary, this thesis has provided strong evidence that exogenous 
TB4 is a beneficial molecule in the context of glomerular and podocyte injury. In the 
future, it is hoped that use of exogenous TB4 can translate to human physiology and 
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 1 
Chapter 1: General introduction 
 Structure and function of the kidney 
1.1.1 What do the kidneys do? 
The kidneys are two bean shaped organs located in the upper abdomen of most 
vertebrates (Figure 1.1a) (Ditrich 2007). Each adult human kidney measures 
between 12.4 – 13.7 cm in length and weighs between 81 – 176 g (Moëll 1956; 
Molina and DiMaio 2012). The kidneys are vital for homeostasis, excreting unwanted 
substances from the blood by filtering up to 180 litres of blood per day, whilst 
conserving those substances that are required for healthy physiology (Shoskes and 
McMahon 2012). The ultrafiltration of the blood is considered their main 
responsibility, however the kidneys also produce erythropoietin to stimulate red 
blood cell production (Zhou and Sacks 2001), renin which maintains sodium balance 
and blood pressure (Castrop et al. 2010), calcitriol to modulate bone homeostasis 
(Gallagher, Rapuri, and Smith 2007) and gluconeogenesis during fasting (Stumvoll 
et al. 1998). The kidneys contain nerves from both the autonomic and somatic 
nervous system to tailor their function to the body’s current requirements (Shoskes 
and McMahon 2012).  
 
1.1.2 Blood filtration and reabsorption by the nephron 
Uninterrupted and regulated blood flow is critical for proper kidney function. The 
kidneys regulate the composition of the blood plasma by filtration, secretion and 
reabsorption of molecules (Pocock and Richards 2009). Blood enters the kidney via 
the renal artery at the hilus, which branches into arcuate arteries distributed in the 
outer medulla. The arcuate arteries branch into cortical radial arteries, then afferent 
arterioles that enter the glomerulus, which supply nephrons (Shoskes and McMahon 
2012). Nephrons are the functional unit of the kidney and are responsible for the 
filtration of blood and production of urine (Figure 1.1b) (Bertram et al. 2011). The 
nephron is composed of 5 main components: renal corpuscle; proximal convoluted 
tubule; loop of Henle; distal convoluted tubule and the collecting duct (Shoskes and 
McMahon 2012).  
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The renal corpuscle is where blood enters the nephron and is the site of ultrafiltration 
(Deen et al. 1972). The renal corpuscle is composed of the Bowman’s capsule (lined 
by parietal epithelial cells), afferent and efferent arterioles and the glomerular tuft. 
The glomerular tuft contains a complex network of capillaries, mesangial cells, the 
glomerular basement membrane (GBM) and glomerular epithelial cells called 
podocytes (Mueller, Mason, and Stout 1955). Ultrafiltration of the blood occurs 
across the glomerular filtration barrier, which is comprised of the capillary endothelial 
cells, the GBM and podocyte foot processes (Figure 1.2a). Small (<40 nm), 
positively charged molecules are forced through the glomerular filtration barrier into 
the urinary space to form the ultrafiltrate (Pocock and Richards 2009; Shoskes and 
McMahon 2012). Examples of such molecules are, glucose, amino acids, water, 
sodium and calcium ions (Wartiovaara et al. 2004). Molecules that are larger than 40 
nm and negatively charged, such as albumin, are not filtered in healthy glomeruli (G. 
W. Liu et al. 2018; Rodewald and Karnovsky 1974). Neutrally charged molecules 
smaller than 40 nm are also freely filtered through the glomerular filtration barrier 
(Miner 2008). The ultrafiltrate exits the renal corpuscle via the proximal convoluted 
tubule (Pocock and Richards 2009; Shoskes and McMahon 2012).  
 
The glomerular capillaries re-join to form the efferent arteriole through which the 
















Figure 1.1 – Macro and microstructure of the kidney. Diagram to illustrate the different 
parts of the kidney responsible for the ultrafiltration of the blood. The diagram shows (a) the 
whole kidney and (b) a single nephron. Black dashed line indicates cortex-medullary 
boundaries. C, Cortex; M, Medulla; RP, Renal Pelvis; U, Ureter; RA, Renal Artery; RV, 
Renal Vein; G, Glomerulus; PT, Proximal tubule; PTC, Peritubular Capillaries; LH, Loop of 
Henle; DT, Distal tubule; CD, Collecting duct. Original figure. 
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peritubular capillaries that wrap around the tubules throughout the whole nephron 
(Seldin and Giebisch 2008). The proximal convoluted tubule is one of the sites of 
reabsorption of molecules back into the blood stream and is lined by thick cuboidal 
cells (Curthoys and Moe 2014). Reabsorption occurs via membrane transporters or 
points of passive transport on the proximal tubular cells, and molecules such as 
amino acids, small positively charged proteins and peptides, glucose and salts are 
reabsorbed into the blood (Shoskes and McMahon 2012). Secretion from the 
peritubular capillaries allows molecules that were not filtered by the glomerulus to be 
added to the ultrafiltrate. Such molecules include urea, uric acid, some forms of 
drugs, and hydrogen ions (Braam et al. 1993). The ultrafiltrate is forced through the 
proximal convoluted tubule lumen by hydrostatic pressure to the descending limb of 
the loop of Henle in the medulla (Vallon et al. 2011).  
 
Secretion and reabsorption also occur in the loop of Henle, which is located in the 
renal medulla and split into two components, the thin descending limb followed by 
the thick ascending limb (Seldin and Giebisch 2008; Shoskes and McMahon 2012). 
The squamous epithelial cells of the thin descending limb allow water to be 
reabsorbed to concentrate the ultrafiltrate, and urea to be secreted from the 
peritubular capillaries (Kokko 1970). When the ultrafiltrate reaches the thick 
ascending limb, ions, such as sodium, potassium and chlorine are reabsorbed into 
the blood stream while the ultrafiltrate travels to the distal convoluted tubule. The 
thick ascending limb is impermeable to water, therefore the ultrafiltrate becomes 
more dilute the further it travels (Mount 2014).  
 
The thick ascending loop of Henle travels back to the renal cortex before becoming 
the distal convoluted tubule. The distal convoluted tubular epithelial cells are 
cuboidal and the lumen loops back on itself several times in the cortex (Pocock and 
Richards 2009). Once again, the ultrafiltrate undergoes reabsorption and secretion, 
where sodium and chlorine ions and water leave the ultrafiltrate to re-join the blood 
stream, and hydrogen and potassium ions leave the blood stream (Elalouf, Roinel, 
and de Rouffignac 1984). The distal convoluted tubule then becomes the collecting 
duct. The peritubular capillaries drain into stellate veins, cortical radial veins and 
arcuate veins before leaving the kidney via the renal vein (Pocock and Richards 
2009). The collecting duct lumen is much wider than the tubular lumen in diameter 
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and travels deep into the kidney medulla (Shoskes and McMahon 2012). When the 
ultrafiltrate travels through the medulla, water is reabsorbed into the blood stream 
through aquaporin II channels to concentrate the urine (Deen, Van Balkom, and 
Kamsteeg 2000). The collecting duct joins the minor and major calyces in the renal 
pelvis, where it pools the urine produced by all nephrons. The kidneys are connected 
to the bladder by a duct called the ureter, which transports freshly produced urine to 
the bladder, ready for excretion (Shoskes and McMahon 2012).  
 
 Podocytes 
1.2.1 What are podocytes?  
The glomerular filtration barrier is comprised of 3 components, the capillary 
endothelial cells, the GBM and podocytes (Jarad and Miner 2009). Podocytes are 
terminally differentiated epithelial cells that form a key component of the glomerular 
filtration barrier (Reiser and Altintas 2016). They are located in the renal corpuscle 
on the glomerular tuft, wrapping around the glomerular capillaries and are highly 
specialised with a unique structure that facilitates their crucial role in homeostasis. 
Podocytes have a cell body, that projects cellular extensions called processes, that 
vastly increase their surface area, allowing individual podocytes to reach distant 
areas of the glomerular tuft (Faul et al. 2007).  
 
There are three types of podocyte processes: primary processes, secondary 
processes and foot processes (Garg 2018). The primary processes are the largest of 
the three types and extend from the cell body. They are crucial for podocyte 
structure as they protrude many secondary processes, which can reach a large 
surface area of the capillary walls (Figure 1.2b) (Pavenstädt, Kriz, and Kretzler 
2003). The secondary processes are affixed to the GBM and extend along the GBM 
to portions that are relatively far from the cell body. The secondary processes then 
project fine foot processes, which are ultimately responsible for ultrafiltration (Faul et 
al. 2007).  
 
Podocytes are constantly subjected to a strong hydrostatic pressure of the 
ultrafiltrate, so tightly regulated adherence to the GBM is crucial for glomerular 
health. A recent study in rat glomeruli in vivo characterised a “ridge like process” that 
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runs longitudinal to the GBM, and serves to anchor the podocyte cell body and 
primary processes to the GBM (Ichimura et al. 2019). The discovery and 
characterisation of the sub-podocyte space (Arkill et al. 2014; Neal et al. 2005) 
suggests that the cell body is “floating” in the urinary space and that podocytes 
adhere to the GBM through their processes. The foot processes adhere to the GBM 
via expression of a3b1 integrin and a & b dystroglycan molecules that bind to laminin 
or agrin in the GBM (Korhonen et al. 1990; Pozzi et al. 2008; Raats et al. 2000; 




1.2.2 Podocyte development in mice 
Most experiments undertaken in this thesis were based on mouse podocytes, 
therefore this section will focus on mouse podocyte development. Kidney 
development initiates at embryonic day 11 in mice from 2 distinct components, the 
ureteric bud and metanephric mesenchyme (Costantini and Kopan 2010). Mature 
podocytes, along with epithelial cells from other nephron components, are derived 
Figure 1.2 - Structure and components of the renal corpuscle. (a) Diagram depicting 
the key components of the renal corpuscle. (b) Enhanced view of adjacent podocyte foot 
processes wrapping around GBM. (c) Lateral view of the glomerular filtration barrier. 
Podocyte foot processes of differing colours represent two different podocytes. 
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from metanephric mesenchymal nephron progenitor cells (Kobayashi et al. 2008). 
Wnt signalling from the ureteric bud causes the formation of the pretubular 
aggregate, which is a cluster of nephron progenitor cells (Stark et al. 1994). The 
pretubular aggregate undergoes mesenchymal to epithelial transition to form a 
spherical arrangement of cells called the renal vesicle (Carroll et al. 2005; Stark et al. 
1994). The renal vesicle then elongates, and the nephron progenitor cells begin to 
differentiate into their respective cell types. The proximal pole starts to express 
podocyte related genes, such as Wt1, MafB and Sulf1 (Brunskill et al. 2014; 
Moriguchi et al. 2006; Mundlos et al. 1993). A Wnt/b-catenin activity gradient is 
formed along the nephron, with the lowest b-catenin levels at the proximal pole 
(Lindström et al. 2014; Yoshimura and Nishinakamura 2019). The nephron epithelia 
undergo segmentation, stimulated by different strengths and durations of ureteric 
bud Wnt9b signalling, to form the S shaped body which contains the precursors to 
podocytes. Fully formed glomeruli can be detected at embryonic day 14.5 in mice 
and it is suggested that they start to filter urine at embryonic day 16.5 – 17.5 
(McMahon 2016). New-born mice have a fully formed and functioning glomerulus 
(Farber et al. 2018).  
 
1.2.3 How do podocytes filter the blood?  
Podocyte foot processes are approximately 500 - 600 nm in width in humans and 
200 – 300 nm in mice (Deegens et al. 2008; Wharram et al. 2000) and adjacent 
podocyte foot processes interdigitate to form a slit diaphragm (SD) (Karnovsky and 
Ainsworth 1972). The foot process shape is dictated by the F-actin cytoskeleton and 
is critical for glomerular function (Welsh and Saleem 2012), and will be described in 
detail in later sections of this introduction (1.3.3). The SD is regarded as a modified 
adherens junction that allows molecules smaller than 40 nm to be filtered into the 
urinary space from the blood stream, while preserving larger molecules (Figure 
1.2c) (Reiser et al. 2000; Wartiovaara et al. 2004).  
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Figure 1.3 – Molecular view of the SD. A diagram of some of the proteins that compose 
the SD, which is approximately 40 nm wide in mice. The large blue structures are adjacent 
podocyte foot processes that form the SD. The red structures are F-actin filaments that 
dictate the shape of the foot processes and anchor the cell to the GBM via integrin and 
dystroglycan. Original diagram. 
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The foot processes contain a rich network of extracellular and intracellular SD 
proteins that form homophilic and heterophilic bonds, produce signalling cascades 
and maintain the size and charge selectivity of the glomerular filtration barrier 
(Barletta et al. 2003; Grahammer, Schell, and Huber 2013; Khoshnoodi et al. 2003). 
Nephrin was one of the first SD proteins to be discovered in the late 1990s, when it 
was identified that some cases of the congenital nephrotic syndrome of the Finnish 
type were due to NPHS1 mutations (Kestilä et al. 1998). This study prompted more 
investigation, and a year later it was shown that nephrin belongs to the 
immunoglobulin G (IgG) superfamily of cell surface receptors and plays a crucial role 
in cell-cell adhesion and intracellular signalling (Lenkkeri et al. 1999).  
 
Since then, research on nephrin, and other SD proteins, has grown exponentially. 
Nephrin is linked to the actin cytoskeleton by the CD2 associated protein 
(CD2AP)/Nck complex (Jones et al. 2006; Yuan, Takeuchi, and Salant 2002) and its 
phosphorylation sets off intracellular signalling cascades that affect podocyte 
polarity, survival, calcium mechano-signalling, membrane trafficking and actin 
organisation (Martin and Jones 2018). The extracellular SD protein podocin is also 
linked to the cytoskeleton via CD2AP and Nck and interacts with nephrin (Roselli et 
al. 2002; Schwarz et al. 2001; Tryggvason, Pikkarainen, and Patrakka 2006). 
Podocin recruits nephrin to the SD and mutations to the podocin gene 
NPHS2/Nphs2 have been linked with the development of nephrotic syndrome and 
decline in kidney function (Amr et al. 2020; Tabatabaeifar et al. 2017) demonstrating 
the crucial role of podocin in podocyte health. There are also two proteins, known as 
NEPH1 and NEPH2 which are structurally similar and are ligands to nephrin in the 
SD (Gerke et al. 2003, 2005). NEPH1 and NEPH2 link to the cytoskeleton via zonula 
occludens-1 (ZO-1) and membrane associated guanylate kinase, WW and PDZ 
domain containing 2 (MAGI-2) (Wagner et al. 2008; Yamada et al. 2020) and 
disruption of their genes results in heavy proteinuria, foot process effacement and 
perinatal death in mice (Donoviel et al. 2001).  
 
The main SD protein that is responsible for charge exclusion of the ultrafiltrate is 
podocalyxin (Nielsen and Mcnagny 2009). Podocalyxin is coated in sialic acid 
residues (Kerjaschki, Sharkey, and Farquhar 1984), rendering the protein negatively 
charged and repelling negatively charged molecules to remain in the blood stream. 
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Podocalyxin is linked to the cytoskeleton in foot processes via the ezrin/sodium-
hydrogen exchange regulatory cofactor NHE-RF2 (Nherf2) complex (Orlando et al. 
2001; Takeda 2003) and it has recently been shown that schwannomin interacting 
protein 1 (Schip1), a novel foot process protein first characterised in the brain, is also 
a member of this complex (Perisic et al. 2015). Breakdown of this complex and 
mutations in the PODXL/Podxl gene has been linked with foot process effacement, 
albuminuria and development of CKD in mice and humans (Lin et al. 2019; Takeda 
et al. 2001).  
 
FAT1 and FAT 2 are intracellular protocadherin SD proteins that are essential for the 
maintenance of the SD (Yaoita et al. 2005). FAT1/2 are linked to the cytoskeleton via 
ZO-1 and b-catenin molecules, and it has been shown that mice lacking Fat1 
experience perinatal mortality through lack of SD formation and impaired renal 
function (Ciani et al. 2003). In contrast, the intercellular protein P-cadherin is not 
essential for SD development and maintenance, as P-cadherin null mice showed no 
renal phenotype (Radice et al. 1997). Collectively, it is clear that the SD protein 
network is complex and finely tuned. There are many different molecules that form 
the SD and maintain its function; however, the one common feature is the majority of 
SD molecules are all linked to the actin cytoskeleton (Figure 1.3).  
 
 The actin cytoskeleton 
1.3.1 What is the cytoskeleton? 
There are three main types of cytoskeletal structures: microtubules, intermediate 
filaments and microfilaments (Gavin 1997; Goldman et al. 1996; Hollenbeck 2001). 
Their names derive from their sizes, as microtubules are thought to be 24 nm in 
diameter, intermediate filaments 10 nm and microfilaments 7 nm in diameter in mice 
(Franke, Grund, and Fink 1978; Kandel et al. 2017; Steinert, Jones, and Goldman 
1984). Microtubules are composed of heterodimers of a and b-tubulin that form 
hollow, unstable, tubular polymers from less than 1 µm to more than 100 µm in 
length (Goodson and Jonasson 2018). They are highly dynamic structures that 
originate in the perinuclear region of podocytes and extend to the primary processes 
(Andrews 1977). Microtubules undertake roles in maintaining cell shape and can 
facilitate mitosis, actuation of cilia and intracellular trafficking (Hueschen et al. 2017; 
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Vladar et al. 2012; Welte 2004). Podocyte microtubules are essential for process 
formation and their role in the maintenance of cell shape is crucial, as impairment of 
microtubule formation results in altered podocyte morphology in vitro (Kim et al. 
2010; Kobayashi et al. 1998, 2001; Mon La et al. 2020; Welsh and Saleem 2012).  
 
Intermediate filaments are located in the nucleus and the cytoplasm of cells and form 
by self-assembly (Kim and Coulombe 2007; Pinto et al. 2014). Intermediate filaments 
are extremely stable and less dynamic than microtubules and microfilaments, and 
intermediate filaments mainly serve to preserve cellular structure, cell signalling and 
cell adhesion (Etienne-Manneville 2018). In podocytes, intermediate filaments are 
localised to the primary processes and cell bodies (Drenckhahn and Franke 1988). 
Intermediate filaments are heterogenous, and podocytes express three types of 
intermediate filament proteins: vimentin, desmin and nestin (Zou et al. 2006). 
Intermediate filaments in podocytes are thought not to be essential to process 
formation, however their role in signalling and transport of intracellular cargo is 
hypothesised to be important for podocyte function (Schell and Huber 2017).  
 
Microfilaments, also known as the actin cytoskeleton, are structural cellular 
formations found in most eukaryotic cell types and can mediate a variety of 
functions, such as motility, polarity, adhesion and mitosis (Faul et al. 2007; Heng and 
Koh 2010; Mitchison and Cramer 1996; Parsons, Horwitz, and Schwartz 2010). The 
actin cytoskeleton is comprised of globular actin (G-actin) monomers which 
polymerise to form filamentous actin (F-actin) (Oosawa et al. 1959). F-actin 
microfilaments are polarised, as the barbed end (positive) polymerises faster than 
the pointed end (negative) (Woodrum, Rich, and Pollard 1975). F-actin 
polymerisation is reversible at both ends and F-actin filaments are highly dynamic 
structures that undergo “treadmilling” as a form of regulation. Treadmilling is defined 
as the turnover of actin filaments, where “newer” G-actin monomers join at the 
barbed end and “travel” down the filament as the “older” G-actin monomers 
dissociate at the pointed end. Treadmilling is mediated by a number of cellular 
proteins, such as the Rho family of small GTPases, Cofilins, Profilins, and TB4 (Hall 




1.3.2 F-actin dynamics 
There are three distinct stages of actin polymerisation: activation, nucleation and 
elongation (Steinmetz, Goldie, and Aebi 1997). A visualisation of actin dynamics, 
including all the following proteins, is provided (Figure 1.4). 
 
1.3.2.1 Activation  
G-actin exists in the cytosol bound to actin sequestering molecules, such as 
thymosin b-4 (TB4), thymosin b-10 and profilin (Yu et al., 1993; Xue et al., 2014), 
and actin dynamics are controlled by ATP hydrolysis (Rould et al. 2006). TB4 is the 
main G-actin sequestering peptide in the cytosol and serves to preserve a pool of G-
actin that does not readily polymerise (Sanders et al. 1992). G-actin bound to ATP, 
Mg2+ and TB4 is the dominant form in the cytosol (Carlier et al. 1993). However, 
there are small numbers of G-actin monomers that bind to Ca2+, ADP+Pi and AMP, 
which are far less stable than the dominant form (Carlier et al. 1993; A Weber et al. 
1992). 
 
TB4 and profilin maintain the cytoplasmic G-actin concentration between 20 – 100 
µM, which is 200 – 1000-fold higher than the critical concentration required for actin 
polymerisation (0.1 µM) (Carliers, Pantalonis, and Korns 1987; Xue et al. 2014). The 
TB4-G-actin complex is incapable of polymerisation (Yu et al., 1993), therefore, there 
must be an exchange of G-actin between TB4 and profilin. The profilin-G-actin 
complex readily promotes G-actin polymerisation and profilin competes with TB4 for 
the binding of G-actin (Goldschmidt-Clermont et al. 1992), creating a system which 
can be tuned by the cell to promote or prevent polymerisation (Figure 1.4a). The 
TB4-G-actin complex can readily support the formation of a ternary complex 
including profilin (Goldschmidt-Clermont et al. 1992; Xue et al. 2014). This ternary 
complex formation causes TB4 to undergo allosteric changes and releases the G-
actin monomer to profilin (Xue et al. 2014). The profilin-G-actin complex is then 
ready for polymerisation. This exchange also promotes the conversion of ADP-G-
actin to ATP-G-actin, which polymerises much more readily (Goldschmidt-Clermont 




All actin filaments must originate from somewhere and the process of polymerisation 
initiation is called nucleation. Nucleation is mediated by several actin binding 
proteins, such as formins. Formins have been associated with the formation of stress 
fibres, actin rings and actin cables (Miao et al. 2013; Takeya et al. 2008; Tolliday, 
VerPlank, and Li 2002). Formins contain the unique FH2 domain that promote de 
novo actin nucleation. Two FH2 domains from a dimer that stabilises G-actin 
monomers in the cytosol, bringing them to close proximity and catalyse G-actin 
dimer formation. This is a slow process, as the affinity for FH2-G-actin is low (<5 
µM), however, it has been shown that the actin binding protein profilin vastly 
accelerates the subsequent elongation process (Figure 1.4a) (Neidt, Scott, and 
Kovar 2009; Romero et al. 2004; Yu et al. 2018). At low cellular concentrations, it 
has also been shown that cofilin promotes the de novo nucleation of F-actin 
filaments (Andrianantoandro and Pollard 2006; Siton and Bernheim-Groswasser 
2014). 
 
The second actin nucleation promoting molecule is the Arp2/3 complex which works 
in conjunction with nucleation promoting factors, such as Wiskott-Aldrich syndrome 
protein (WASP) and SCAR/WAVE (Pollitt and Insall 2009; Robinson et al. 2001; 
Rouiller et al. 2008). Arp2/3 complex catalyses polymerisation of an F-actin filament 
that is branched from an already existing filament (Smith et al. 2013), mimicking the 
structure of G-actin to recruit 1 to 2 G-actin monomers, therefore stimulating 
nucleation and polymerisation (Figure 1.4a) (Rouiller et al. 2008). The key difference 
between formins and the Arp2/3 complex is the necessity of a pre-existing F-actin 
filament, however, both methods of nucleation serve their own respective cellular 
purposes. This form of F-actin nucleation is most commonly associated with 
lamellipodia and focal adhesion formation (Suraneni et al. 2012). 
 
1.3.2.3 Elongation 
Once nucleation is complete, actin filaments readily extend at their barbed end until 
the reservoir of G-actin is depleted, or capping proteins halt this extension (Atkinson, 
Hosford, and Molitoris 2004; Edwards et al. 2014). Since these capping proteins are 
abundant in cells, there are factors present that “shield” the barbed end of the 
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polymerising filament. The nucleation factors formins use their unique donut shaped 
FH2 domain homodimers to encapsulate the barbed end of the filament and move 
along the growing filament to shield the barbed end from capping factors (Vavylonis 
et al. 2006). The FH1 domains of formins interact with profilin with an affinity of 3.4 – 
17.8 µM (Kursula et al. 2008; Neidt et al. 2009) to recruit G-actin monomers to the 
barbed end of the filament, accelerating F-actin polymerisation up to 5-fold over free 
barbed ends (Kovar et al. 2006; Paul and Pollard 2009), although the exact 
mechanism by which this occurs is still unclear. The dissociation constant of profilin 
to G-actin monomers is much lower (~0.1 µM) than F-actin (~25 µM) (Bubb et al. 
2003; Courtemanche and Pollard 2013; Le et al. 2020), meaning that profilin will 
dissociate from the G-actin monomers once they polymerise (Figure 1.4b).  
 
Another polymerising factor is the Ena/vasodilator stimulated phosphoprotein 
(VASP) protein family (Kwiatkowski, Gertler, and Loureiro 2003). These proteins 
localise to actin-rich areas of cells, such as focal adhesions, stress fibres, cell-cell 
contacts, lamellipodia and filopodia and contribute to cell motility and adhesion 
(Chesarone and Goode 2009). The Ena/VASP proteins have three parts: an N-
terminal EVH1 domain, a central proline-rich region and a C-terminal EVH2 domain 
(Gertler et al. 1996; Kwiatkowski et al. 2003). The EVH1 domain links VASP to key 
ligands, such as formins and is important for cellular localisation (Ball et al. 2002; 
Bilancia et al. 2014). The central region contains at least three binding sites for 
profilin-G-actin and G-actin and the EVH2 region interacts with G-actin and F-actin 
(Ferron et al. 2007; Hansen and Mullins 2010; Harker et al. 2019). Ena/VASP 
proteins form tetramers that bind to the profilin-G-actin complex and can protect the 
growth of the barbed from capping proteins, but this requires much higher 
concentrations of Ena/VASP compared to formins (Applewhite et al. 2007; 
Bachmann et al. 1999; Breitsprecher et al. 2011). Formins and Ena/VASP mediated 




1.3.2.4 Filament capping, severing and depolymerisation 
Actin filaments will polymerise indefinitely if the components are available and 
therefore need to be negatively regulated. Proteins that cap the barbed end of 
filaments contribute to this negative regulation. The heterodimeric a and b subunits  
of CapZ form a capping protein complex that binds to the barbed end of filaments 
with a high affinity (dissociation constant of ~ 1 nM) (Wegner et al. 1989). The 
binding of capping protein halts the polymerisation of actin and also prevents loss of 
monomers, therefore stabilising the filament (Figure 1.4c) (Yamashita, Maeda, and 
Maéda 2003). Gelsolin is another molecule involved in actin capping, which relies on 
intracellular Ca2+ concentration (Silacci et al. 2004). Gelsolin has two G-actin 
binding domains and one F-actin binding domain and can bind to the barbed end of 
the filament, breaking non-covalent bonds between actin filaments and ceasing 
polymerisation (Figure 1.4c) (Feldt et al. 2019; Nag et al. 2013).  
 
F-actin is a slow hydrolyser of ATP, therefore the ATP-G-actin monomers that 
comprise the newly polymerised F-actin will mediate ATP hydrolysis to ADP + Pi the 
longer they remain in the filament (Carliers et al. 1987; McCullagh, Saunders, and 
Voth 2014). F-actin bound to ADP is less stable than ATP bound F-actin, so is more 
likely to disassemble at the pointed end, where polymerisation is slower than the 
barbed end (Isambert et al. 1995; Kardos et al. 2007; Merino et al. 2018). Actin 
depolymerisation factor (ADF) and cofilin are a protein family involved in the severing 
and depolymerisation of F-actin filaments (Andrianantoandro and Pollard 2006; 
Bernstein and Bamburg 2010). ADF and cofilin bind to F-actin regions that contain 
ADP bound monomers creating ADF/cofilin domains of the filament (Suarez et al. 
2011; Wioland et al. 2017). These saturated domains become more flexible and 
shorten their helical structure (Fan et al. 2013; Huehn et al. 2018; Prochniewicz et al. 
2005). The saturated regions themselves do not sever, but the regions at domain 
boundaries will sever and in effect, these severed filaments become their own 
outright filament (Figure 1.4d) (De La Cruz 2009; Ngo et al. 2015). It is currently not 
clear how these severed filaments depolymerise, and it is suggested that the 
severed filaments undergo slow depolymerisation from the pointed end (Figure 




Figure 1.4 – Schematic of actin dynamics in eukaryotic cells. Diagram depicting the 
stages of actin treadmilling. (a) Activation and nucleation. G-actin exists in cells sequestered 
by TB4. Profilin binding initiates activation and nucleation via either Formins or the Arp2/3 
complex. (b) Elongation occurs after nucleation. F-actin filaments polymerise de novo from 
G-actin monomers catalysed by formins or the Arp2/3 complex. (c) F-actin filaments are 
capped by either gelsolin or capping proteins. (d) Severing of F-actin occurs via cofilin/actin 
depolymerising factor (ADF) and depolymerisation occurs naturally from severed filaments. 
Black lines indicate movement of G-actin. Dashed line indicates detachment of F-actin/G-
actin. Original diagram. 
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has been shown in vitro that cofilin/ADF knockout leads to a reduction in the G-actin 
: F-actin ratio (Hotulainen et al. 2005).  
 
1.3.2.5 Rho GTPases 
The Rho family of small GTPases includes RhoA, Cdc42 and Rac1 and performs 
several essential cellular functions, such as cytoskeletal organisation, regulation of 
cell shape and motility (Etienne-Manneville and Hall 2002; Hanna and El-Sibai 2013; 
Kim et al. 2018; Sit and Manser 2011). The Rho GTPases cycle between two states; 
the active state bound to GTP and the inactive state bound to GDP. The active state 
recognises target proteins, such as Rho-associated protein kinase-1 (ROCK1) and 
ROCK2 to generate a cellular response until GTP hydrolysis to GDP returns the 
GTPases to their inactive state (Etienne-Manneville and Hall 2002).  
 
1.3.3 The podocyte cytoskeleton 
The podocyte cytoskeleton is extremely complex and critical for glomerular function 
(Blaine and Dylewski 2020; Schell and Huber 2017; Welsh and Saleem 2012). 
Phalloidin staining, which is the gold standard to reveal F-actin (Melak, Plessner, and 
Grosse 2017), of isolated glomeruli from adult rats displayed an intense F-actin 
signal in podocyte foot processes, with a weaker signal in the cell body (Cortes et al. 
2000), demonstrating that the foot processes are the main site of F-actin in 
podocytes. Electron microscopy immunogold labelling of adult rat podocyte F-actin in 
vivo further characterised this network as a thick F-actin cable that runs longitudinal 
along the foot processes parallel to the GBM and cortical actin fibres which occupy 
the cytoplasm around the cable (Ichimura, Kurihara, and Sakai 2003) (Figure 1.5a).  
 
It has been suggested that the thick, central actin cable could be involved in 
generating the tensional forces, whereas the cortical actin purely provides the unique 
pyramidal structure of the foot processes (Ichimura, Kurihara, and Sakai 2007). 
Recent studies have supported this hypothesis. Super-resolution microscopy to 
visualise BALB/c adult mouse glomeruli suggested that the foot process network is 
non-contractile due to the absence of myosin IIa and that the contractile actin fibres 
are located in the cell body and major processes (Suleiman et al. 2017). The authors 
went on to suggest that the contractile fibres in the cell body and primary processes  
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Figure 1.5 – Comparison of podocyte foot processes in health and injury. (a) Lateral 
view of the glomerular filtration barrier in healthy podocytes. Ultrafiltrate can freely filter 
through into the urinary space while albumin is excluded due to charge and size. F-actin is 
arranged with a thick central cable and cortical F-actin. (b) Example of how F-actin could be 
disorganised in podocytopathies. Albumin is lost to urinary space through bare areas of 
GBM and podocyte pseudocyst formation. F-actin is disorganised to a mat adjacent to the 
GBM. Black dashed arrows indicate direction of albumin and green dashed arrows indicate 
direction of ultrafiltrate. Original figure. 
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generate tension to the foot processes that strengthen the focal adhesion complexes 
in order to maintain the SD.  
 
There are certain proteins in podocyte foot processes that have a role in F-actin 
organisation. Synaptopodin is a proline-rich actin binding protein in podocytes that 
promotes F-actin stress fibres formation and organisation, and cell motility (Asanuma 
et al. 2006; Mundel, Heid, et al. 1997). Mice lacking synaptopodin have no renal 
phenotype, but the effect of glomerular injury is exacerbated in vivo (Ning, Suleiman, 
and Miner 2020). The authors also showed by immunofluorescent staining and 
scratch wound assays that podocytes lacking synaptopodin in vitro displayed 
reorganisation of F-actin, increased adhesion molecules and impaired motility (Ning 
et al. 2020). Mechanistically, synaptopodin promotes the formation of stress fibres in 
podocytes by inhibiting ubiquitination and proteasomal degradation of RhoA and the 
activation of Rac1 (Asanuma et al. 2006; Buvall et al. 2013, 2017; Wong et al. 2012).  
 
Synaptopodin works in conjunction with another important foot process actin binding 
protein, a-actinin. The most well defined feature of a-actinin is its ability to bundle 
and cross link F-actin filaments, creating a more resilient structure (Asanuma et al. 
2005; Honda et al. 1998) (Figure 1.3). It has been demonstrated in vitro and in vivo 
that synaptopodin directly interacts with and regulates the activity of a-actinin-4 in 
the foot processes, leading to elongation of actin filaments and improved plasticity of 
the actin filaments, meaning a lower chance of the filaments breaking (Asanuma et 
al. 2005). More recently, it has also been shown that mutations to the gene encoding 
a-actinin-4, which are present in some forms of focal segmental glomerulosclerosis 
(FSGS), lead to exacerbated podocyte detachment and irreparable F-actin damage 
in response to mechanical stress in vitro (Feng et al. 2018; Kaplan et al. 2000), 
demonstrating the importance of a-actinin to podocytes.  
 
The basal membrane of the foot processes adhere to the GBM through focal 
adhesions. These focal adhesions are mostly composed of a3b1 integrin and ab 
dystroglycan molecules, which bind to laminin and agrin in the GBM and are linked 
to the cytoskeleton through linker proteins (Korhonen et al. 1990; Pozzi et al. 2008; 
Raats et al. 2000; Regele et al. 2000) (Figure 1.3). Integrins link to the cytoskeleton 
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via a complex of a-actinin-4, talin, vinculin and integrin linked kinase (ILK) 
(Drenckhahn and Franke 1988; Faul et al. 2007; Otey et al. 1993; Yamaji et al. 
2004), whereas dystroglycan links the cytoskeleton to the GBM via utrophin (Raats 
et al. 2000). The focal adhesion complexes can also initiate intracellular signalling in 
response to stimuli, such as mechanical stress (K. Endlich, Kliewe, and Endlich 
2017; Friedland, Lee, and Boettiger 2009; Vogtländer et al. 2009).  
 
Disorganisation of the foot process actin network in vivo has been associated with 
foot process effacement, SD destruction and albuminuria (Faul et al. 2007; 
McClatchey and Fehon 2009; Perico et al. 2016; Suleiman et al. 2017; Welsh and 
Saleem 2012; Yu et al. 2013). When the foot processes efface and retract into the 
primary processes, the cell body can adhere to the GBM and the F-actin network can 
disorganise into a mat of F-actin running parallel to the GBM. This is accompanied 
by widespread myosin IIa expression and an increase in F-actin, a-actinin and 
synaptopodin expression (Figure 1.5b) (Shirato et al., 1996; Shirato, 2002; Suleiman 
et al., 2017; Ning, Suleiman and Miner, 2020). The exact mechanisms and 
disorganisation of F-actin in podocyte injury will be discussed later in this 
introduction.  
 
 Chronic kidney disease 
1.4.1 Prevalence of chronic kidney disease 
The term CKD refers to a group of highly heterogenous diseases affecting the 
structure and function of the kidney (Levey and Coresh 2012). Some patients with 
CKD will progress to ESKD, requiring life-long dialysis or a kidney transplant 
(Eckardt et al. 2013). CKD affects approximately 5.6 million people in the U.K. with 
many cases remaining undiagnosed, and the mean age of ESKD diagnosis is 72.2, 
suggesting that progression to ESKD occurs in older patients (Bikbov et al. 2020; 
Hirst et al. 2020; Nguyen et al. 2018). Sadly, some patients with ESKD can succumb 
to the condition. It was estimated that in 2017, 6766 people in the U.K. died of CKD 
(Bikbov et al. 2020). However, the prevalence and death rate of CKD in the U.K. per 
100,000 people fell 11.4% and 14.5% respectively from 1990 to 2017 (Bikbov et al. 
2020). However, even though the prevalence per 100,000 people has declined, the 
absolute number of people with CKD in the U.K. has risen, as population has 
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increased between 1990-2017 (the time frame analysed by Bikbov et al.), therefore 
the pressure on the NHS from CKD is still increasing. 
 
It has been estimated that in 2009-2010 the cost to NHS England of CKD was 
between £1.44-1.45 billion, equating to ~1.3% of all NHS spending that year. Renal 
replacement therapy (dialysis or transplant) alone was responsible for over half of 
this amount, but only 2% of CKD patients required it (Kerr et al. 2012). According to 
NHS Kidney Care, the cost of CKD is more than breast, colon, lung and skin cancer 
combined. The same report states that between ages of 65 and 74, 1 in 5 men and 1 
in 4 women have CKD and that recipients could wait up to 3 years for a transplant 
(Kerr et al. 2012).  
 
CKD is not only a significant issue in the U.K. It is estimated that CKD affects up to 
750 million people worldwide, which is a global prevalence of 9.1% (Bikbov et al. 
2020). The global prevalence per 100,000 people increased 1.2% from 1990 - 2017, 
demonstrating that CKD diagnosis globally is rising with time. In 2017 it was 
estimated that globally 1,230,168 people died of CKD, an increase of 2.8% per 
100,000 since 1990 (Bikbov et al. 2020). The prevalence and death rate of CKD is 
much higher in countries with lower GDPs and less developed health care systems 
(Bikbov et al. 2020) that may not be able to afford as many dialysis machines, drugs 
or highly trained surgeons. Death by CKD is expected to rise to 4 million globally in a 
worst-case scenario by 2040 (Foreman et al. 2018) underlying the urgent need for 
novel, widely accessible therapies.  
 
1.4.2 Risk factors of CKD 
The prevalence of CKD increases with age and poor life-style choices. Diets with low 
nutritional value, high caloric intake, high animal protein, saturated fat, sodium and 
phosphorous intake are all related to higher CKD incidence (Crews et al. 2014; 
Gutiérrez 2015). Physical inactivity leads to greater chance of cardiovascular 
disease, and CKD can develop as a co-morbidity, through endothelial dysfunction 
and hypertension (Bharakhada et al. 2012; Stengel et al. 2003; Stump 2011). It is a 
well-established fact that physical activity improves cardiovascular health. The 
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kidneys and heart have an intimate relationship, with pathogenesis in one organ 
being linked to pathogenesis in the other (Chrysohoou et al. 2010).  
 
A major risk factor for CKD is diabetes. It is thought that between 20% and 40% of 
patients with diabetes will develop diabetic nephropathy, and advanced diabetic 
nephropathy is the leading cause of glomerulosclerosis and ESKD worldwide 
(Dronavalli, Duka, and Bakris 2008). The interaction between hyperglycaemia-
induced metabolic and haemodynamic changes, as well as genetic predispositions, 
are major mechanisms by which diabetic nephropathy occurs (Ziyadeh 2004).  
 
Tobacco smoking is another factor associated with CKD onset. One study of a 
population in Wisconsin, America, stated that tobacco smokers had almost a 2-fold 
higher chance of developing CKD than non-smokers (Shankar, Klein, and Klein 
2006). Another study based in America has shown that smokers have on average a 
1.63 higher chance of developing CKD, and heavier tobacco use was associated 
with a higher chance of CKD. The study also made distinctions between CKD 
groups, and hypertensive nephropathy (2.85 higher chance) and diabetic 
nephropathy (2.24 higher chance) showed an increased incidence compared to non-
smokers, whereas there was no increased risk of developing glomerulonephritis 
(Yacoub et al. 2010). 
 
Illicit and pharmacological drug use is a risk factor for decline in kidney function. 
Cocaine and opiate use was associated with a 1.2 and 1.8 higher chance of 
albuminuria development and estimated glomerular filtration rate (eGFR) decline 
respectively in a study of a population in Baltimore, Maryland, U.S.A (Novick et al. 
2016). Heroin use has also been associated with acute kidney injury, immune-
complex membranoproliferative glomerulonephritis, FSGS, amyloidosis and chronic 
interstitial nephritis (Sethi 2018). Non-steroidal anti-inflammatory drugs (NSAIDs) 
that inhibit cyclo-oxygenase mediated formation of prostaglandins, such as 
ibuprofen, are also linked to decline in kidney function via damage to the 
mesangium, GBM and podocytes (Gooch et al. 2007; Nasrallah et al. 2013). 
 
It has been thought that high alcohol intake is also associated with declining kidney 
function and CKD development, which was more apparent at younger ages 
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compared with older people (Pan et al. 2018; Shankar et al. 2006), however, 
conflicting reports are now emerging. One report showed that alcohol drinkers were 
actually 30% less likely to develop CKD than non-drinkers in a 10 year follow up 
study (Bundy et al. 2018) and another report associated heavy alcohol consumption 
with an inverse risk of developing CKD (Koning et al. 2015). This is an area of 
research that requires further investigation, especially due to how common alcohol 
consumption is worldwide.  
 
1.4.3 Current treatment for CKD  
Pharmacological intervention aims to slow CKD progression. Angiotensin converting 
enzyme (ACE) inhibitors are widely used to supress the progression of CKD to 
ESKD. ACE inhibitors reduce proteinuria, rate of renal function loss, blood pressure 
and protect against the cardiovascular comorbidities in CKD (Chiurchiu, Remuzzi, 
and Ruggenenti 2005; Turner et al. 2012). ACE inhibitors interfere with renin 
angiotensin aldosterone system (RAAS) activity by reducing the production of 
angiotensin II and aldosterone. This leads to vasodilation of renal vessels, in 
particular, efferent arterioles, and reduction of systemic, renal and glomerular blood 
pressure (Sidorenkov and Navis, 2014). ACE inhibitors can however lead to adverse 
effects, such as reduction in renal function, hypotension, hyperkalaemia, elevated 
bradykinin levels and hepatotoxicity (Sidorenkov and Navis 2014).  
 
Patients begin dialysis once they are diagnosed with ESKD, because there is a 
build-up of waste products in the blood, such as urea and creatinine (Aronson, 
Mittleman, and Burger 2004). Dialysis was first conceptualised by John Jacob Abel 
in 1912 and the first dialysis performed on humans was in 1943 (Crowther, 
Reynolds, and Tansey 2010; Eknoyan 2009). Haemodialysis involves an intravenous 
needle attached to a tube that transports the patient’s blood into the dialysis 
machine. The dialysis machine works in a similar way to the kidney – there is a 
semipermeable membrane where molecules that are small enough to pass through 
will, and other larger molecules, e.g. blood cells, will not pass through the 
membrane. The filtered blood is then transported back into the patient (Mallick and 
Gokal 1999). There are alternatives to haemodialysis, such as peritoneal dialysis, 
which involves inserting a tube into the abdominal cavity and using the peritoneal 
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membrane as the partially permeable membrane (Gokal and Mallick 1999). Since 
metabolism causes a regular build-up of waste products, dialysis must be performed 
3-4 times per week, which can have an impact on the patient’s quality of life 
(Daugirdas, Blake, and Ing 2007). 
 
Current and emerging treatment options are tailored to specific types of CKD. Many 
forms of CKD are immune mediated, so immunosuppressive drugs such as steroids 
are used to suppress the immune reaction (Berg and Nilsson-Ehle 1996; Hanamura 
et al. 2012). Adenosine-3′,5′-cyclic monophosphate (cAMP) inhibitors, such as 
tolvaptan are sometimes prescribed to PKD patients in attempts to lower total kidney 
volume (Torres et al. 2012). Finerenone, a non-steroidal mineralocorticoid receptor 
agonist (Kolkhof et al. 2014), is emerging as a candidate to treat diabetic kidney 
disease as it has reduced albuminuria in randomised clinical trials (Bakris et al. 
2015; Filippatos et al. 2016; Licette, Liu, and Schutte 2015). The novel use of SGLT-
2 inhibitors is also growing traction in the clinical field for treatment of CKD patients. 
SGLT-2 inhibitors block the reabsorption of glucose into the blood during filtration in 
order to reduce hyperglycaemia in diabetic kidney disease patients (Scheen 2015) 
and have been shown to decelerate loss in eGFR and reduce proteinuria in patients 
(Heerspink et al. 2020; Neuen et al. 2019; Sugiyama et al. 2019).  
 
The final option for ESKD patients is a kidney transplant. Humans can live with only 
one kidney, so it is possible to receive a transplant from a living or deceased donor. 
If the transplant is successful, the patient would have their life extended by 10-15 
years on average in comparison to a patient solely on dialysis (Wolfe et al. 1999). 
However, there are complications with transplantation, such as organ rejection. The 
patient’s antigens must be the same in order for rejection not to occur, and 
immunosuppressive drugs used post-operatively that lower the risk of rejection may 
pose a higher risk of infection (Zou et al. 2007). There may also a long waiting time 
before a compatible donor becomes available. Kidney transplantation is the option 
that all CKD patients will desire, as it offers the best clinical outcome. However, this 
is a highly invasive procedure and requires recovery following the surgery. Also, 
available organs for transplant are in short supply, highlighting the need for novel, 
non-invasive interventions.  
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1.4.4 CKD pathophysiology 
CKD in humans and other mammals can be a result of defects in any component of 
the nephron. Glomerular injury is regarded as damage to one more component of 
the glomerulus that hinders its ability to perform ultrafiltration of the blood. This can 
manifest in a diverse range of phenotypes, such as mesangial matrix expansion, 
podocyte detachment, thickening of the GBM, macrophage infiltration, podocyte foot 
process effacement, podocyte motility and glomerulosclerosis (Butt et al. 2020; 
Gross et al. 2004; Reiser et al. 2004; Samnegård et al. 2005; Vasilopoulou et al. 
2016; M.-S. Zou et al. 2010). This section will focus on the pathophysiology of 
glomerular diseases in humans, and particularly FSGS and glomerulonephritis (GN).  
 
1.4.4.1 Pathophysiology of FSGS 
FSGS, by definition, is sclerosis of a compartment (not the whole glomerulus) of 
some (but not all) glomeruli in the kidneys. FSGS is characterised as an increase in 
sclerotic and mesangial matrix in the glomeruli, which causes capillary loop collapse 
and a dysfunctional glomerular filtration barrier (Reidy and Kaskel 2007). The 
glomerular compartment the sclerotic region is found in defines the classification of 
FSGS. Sclerosis at the vascular pole is classified as the perihilar variant. The cellular 
variant of FSGS is associated with hypercellularity in the capillary lumen. The tip 
variant is sclerosis near the tubular pole of the glomeruli and the collapsing variant is 
one or more glomeruli with global or segmental capillary loop collapse (Reidy and 
Kaskel 2007). There are two types of FSGS based on their origins: primary and 
secondary FSGS. Primary FSGS involves direct podocyte injury that contributes to 
capillary loop collapse and sclerosis. Secondary FSGS is mediated by external 
factors, such as drug toxicity, obesity, hypertension or viral infections (Lim et al. 
2016). Both primary and secondary FSGS normally cause an increase in proteinuria 
and are typically diagnosed by kidney biopsy (Rosenberg and Kopp 2017).  
 
Podocyte injury is one of the earliest observable features in human FSGS. A number 
of genetic defects in podocytes have been identified to contribute to the 
pathogenesis of FSGS. NPHS1, NPHS2, CD2AP and ACTN4 are all transcripts 
which encode podocyte SD proteins, and mutations in these genes can result in 
FSGS (Boute et al. 2000; Gigante et al. 2009; Kaplan et al. 2000; Kestilä et al. 
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1998). Alterations to one or more of these transcripts induces morphological and 
functional changes to the foot processes and SD, resulting in a defective glomerular 
filtration barrier. Mutations in WT1 (Wilms tumour 1) can also cause FSGS. WT1 is a 
podocyte transcription factor which regulates NPHS1 transcription, therefore WT1 
mutations can have detrimental effects to nephrin expression and SD integrity 
(Wagner et al. 2004).  
 
There is also evidence that circulating factors may contribute to podocyte injury in 
FSGS patients. Electron microscopy studies have identified that within minutes of 
blood reperfusion to healthy transplanted kidneys in FSGS patients, podocyte foot 
process effacement is initiated (Chang et al. 2012). One serum factor possibly 
involved in the pathogenesis of FSGS is soluble urokinase receptor (suPAR). suPAR 
is a receptor for urokinase that can act as a signalling orchestrator by associating 
with other transmembrane receptors, such as integrins (Wei et al. 2011). suPAR was 
increased by 2-fold in the serum of patients with recurrent FSGS compared to 
healthy patients (Wei et al. 2011), suggesting that suPAR may be an important 
circulating factor causing FSGS. However, circulating suPAR increase has also been 
identified in other glomerular diseases, such as lupus nephritis (Qin et al. 2015). 
Therefore, more investigation is required into the role of suPAR, and other circulating 
factors, in FSGS.  
 
Podocyte loss is one mechanism of FSGS pathophysiology. Viable cells have been 
collected from the urine of patients with FSGS. The cells were then cultured in vitro 
and immunostained for podocalyxin, a SD protein found in podocyte foot processes, 
strongly suggesting that FSGS causes podocyte detachment (Vogelmann et al. 
2003). Cytoskeletal disorganisation has also been implicated in the pathogenesis of 
FSGS by super resolution microscopy. The authors used synaptopodin as a marker 
for podocyte foot process F-actin, and myosin IIa as a marker for contractile F-actin. 
In healthy kidney biopsies, synaptopodin was restricted to the foot processes and 
myosin IIa was localised to the podocyte cell bodies. In FSGS, myosin IIa was found 
to co-localise with synaptopodin in the foot processes, which resembled sarcomere 
like structures (Suleiman et al. 2017). This suggests that in FSGS, there is a shift of 
contractile F-actin from the cell body to the foot processes, which could result in 
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conformational changes to the podocytes and glomerular filtration barrier.  
 
1.4.4.2 Pathophysiology of GN 
GN is a term that describes a group of conditions where an autoimmune response is 
generated against components of the glomerulus, resulting in nephrotic syndrome. 
There are five main sub-groups of diseases classed as GN: post-infectious GN; 
immunoglobulin A (IgA) nephropathy; anti-GBM nephritis; anti-neutrophil cytoplasm 
antibodies (ANCA)-positive GN and lupus nephritis (Couser 2012). GN typically 
results in proteinuria, glomerular crescent formation and high levels of glomerular 
inflammation (Couser 2012).  
 
Post-infectious GN occurs as the result of an infection and is generally not thought of 
as an autoimmune response. Circulating immune complexes, composed of 
pathogenic antigens and IgG antibodies to them, can get trapped in the glomeruli 
(Couser 2012). This complex results in complement activation, resulting in neutrophil 
activation and recruitment to the glomeruli, where oxidants and proteases are 
released causing glomerular injury. The classical and alternative complement 
pathways are important mediators of glomerular injury. Patients with complement 
deficiencies often have long-term post-infectious glomerulonephritis, compared with 
childhood patients who normally recover (Sethi et al. 2013).  
 
IgA nephropathy is the most common form of glomerular injury worldwide and is a 
result of an autoimmune response against the glomeruli (Cattran et al. 2009). Over 
100 gene mutations that are associated with IgA nephropathy have been identified in 
patients (Magistroni et al. 2015). It is likely that IgA nephropathy is triggered by a 
genetically predisposed autoimmune reaction following exposure to toxins (Couser 
2012). Staphylococcus aureus antigens have been identified in the mesangium of 
IgA nephropathy patients, causing deposition of IgA and IgG in the glomerular tuft 
(Nasr and D’Agati 2011; Worawichawong et al. 2011). Immunoglobulin deposition 
results in complement activation and sub lytic C5b-9 attack on mesangial cells and 
endothelial cells (Daha and van Kooten 2016). The mesangial cells then become 
activated and proliferate, and also release cytokines to recruit neutrophils and 
macrophages, causing the immune response against the glomeruli (Couser 2012).  
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The antigen that is mostly targeted in anti-GBM GN is a 14 amino acid fragment of 
type IV collagen, and some immunoreactivity has also been seen in type III collagen 
(Pedchenko et al. 2010). These antigens have been shown to have an almost 
identical structure to some pathogen associated molecular patterns in some bacteria, 
such as Clostridia botulinum (Arends et al. 2006). The antigens in collagen have to 
undergo confirmational changes in order to become exposed, but it is unclear what 
the cause of these conformational changes are (Pedchenko et al. 2010). IgG 
antibodies bind to the exposed antigens activating the classical complement pathway 
and recruitment of T helper cells. The innate and adaptive immune response then 
causes damage to the glomeruli, such as what is seen in IgA nephropathy and post-
infectious GN (Couser 2016).  
 
ANCA-associated vasculitis is a group of autoimmune diseases that target antigens 
on the endothelial cells in the glomerular capillaries. In vitro studies have shown that 
cytokines released in response to some infections can prime neutrophils and 
upregulate adhesion molecules in glomerular endothelial cells and neutrophils, that 
could result in neutrophil localisation to the glomeruli (Nagao et al. 2007; Radford, 
Savage, and Nash 2000). Primed neutrophils trapped in the glomeruli express 
ANCA-specific antigens on their cell surface, which ANCAs bind to causing over 
activation of neutrophils (Nakazawa et al. 2019). Excessive neutrophil activation 
induces abnormal cytokine production, release of lytic enzymes and reactive oxygen 
species that damage the glomerular endothelial cells and can cause endothelial cell 
death (Nakazawa et al. 2019). 
 
Lupus nephritis is a complication that can occur in patients with systemic lupus 
erythematosus (SLE) (Almaani, Meara, and Rovin 2017). Viral infections that initiate 
interferon-a signalling pathways can trigger lupus nephritis (Gatto et al. 2013). 
Defects in clearing of apoptotic cells can lead to nucleosome, containing DNA, 
presenting on the surface of cells, and sometimes histones containing DNA can 
escape into the blood stream (Liu and Anders 2014). It is theorised that the 
negatively charged components of the glomerulus (podocyte foot processes and 
endothelium) can bind to the cationic histones in circulation (Couser 2016). Deposits 
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of IgG are formed inside the glomeruli and the glomerular injury is primarily mediated 
by activation of the classical complement response (Birmingham and Hebert 2015). 
Complement C5b-9 induces cell lysis of glomerular cells and recruits leukocytes to 
the glomeruli which release reactive oxygen species and proteases, causing 
glomerular tissue damage (Birmingham and Hebert 2015).  
 
Although the triggers and targets differ between forms of GN, some of the basic 
mechanisms are similar. Glomerular deposits of IgG result in complement activation, 
neutrophil and macrophage accumulation (Couser 2012). Macrophages trigger the 
release of pro-inflammatory cytokines and chemokines to promote the inflammatory 
response (Couser 2016). Neutrophils release proteases, reactive oxygen species 
and other factors that damage and lyse glomerular cells (Nagao et al. 2007; Radford 
et al. 2000). The collective result of the autoimmune response is damage to the 
glomerular filtration barrier and nephrotic syndrome, which can result in CKD 
progression (Couser 2016).  
 
 Glomerular and podocyte injury 
Experimental models of rodent diseases have been developed to mimic some of the 
phenotypes observed in human glomerular disease models. These experimental 
models of rodent kidney disease allow deeper investigation into the cellular and 
molecular mechanisms that occur in kidney injury. Podocytopathies are a common 
mechanism of glomerular injury in humans and mice (Bierzynska, Soderquest, and 
Koziell 2014), therefore, this section will aim to explain some causes and underlying 
mechanisms in podocyte injury, with a focus on the cytoskeleton. Some of the 
features of glomerular and podocyte injury can be found in Figure 1.6. 
 
1.5.1 Adriamycin nephropathy 
1.5.1.1 Overview of Adriamycin nephropathy 
Adriamycin (ADR), also known as doxorubicin hydrochloride, is an anthracycline 
chemotherapeutic drug. It has been historically used in combination with other 
chemotherapeutic drugs to treat leukaemia, breast cancer, lung cancer, myelomas, 
bladder cancer and Hodgkin’s lymphoma, among other forms of cancer (Lankelma et 
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al. 1999; Lipshultz et al. 2010; Von Der Maase et al. 2005; Myrehaug et al. 2008; 
Orlowski et al. 2007; Piscitelli et al. 1993). ADR prevents cancer cell proliferation  
by DNA intercalation to prevent transcription and translation of RNA and replication 
of DNA (Cutts et al. 1996; Raje, Pandav, and Barthwal 2020). ADR also inhibits 
topoisomerase-II activity, an enzyme which cleaves double stranded DNA for repair, 
therefore promoting apoptosis (Berger et al. 1996; Deffie, Batra, and Goldenberg 
1989; Walker et al. 1991). However, it has been documented that some patients 
receiving ADR chemotherapy experience nephrotoxic side effects, such as 
decreased creatinine clearance and podocyte foot process effacement (Burke et al. 
1977; Klastersky et al. 1985; Wollina, Graefe, and Karte 2000).  
 
ADR can be used to cause podocyte injury in vitro and in rodents in vivo to replicate 
some of the characteristics of FSGS in humans (Bertani et al. 1986; Chen et al. 
1998; Lee and Harris 2011). While most strains of rat are susceptible to ADR 
nephropathy, this is not the case with mice (Pippin et al. 2009). The mouse strains 
FVB/NJ, CAST/EiJ and the widely used C57BL/6 strain are all resistant to ADR 
nephropathy, whereas BALB/c and 129/SvJ are both susceptible to ADR injury 
(Pippin et al. 2009). The difference in sensitivity is due to the presence of protein 
kinase, DNA activated, catalytic subunit (PRKDC), a protein responsible for the 
protection of the mitochondrial genome (Papeta et al. 2010). Genome-wide analysis 
of a range of mouse strains localised the ADR susceptibility locus to chromosome 
16A1-B1 (Zheng et al. 2005) and identified the Prkdc gene. To confirm that Prkdc 
was responsible, the authors obtained a C57BL/6-Prkdc global knockout mouse 
strain (Kurimasa et al. 1999) and found that the level of glomerulosclerosis was 
comparable to BALB/c mice after 10 mg/kg intravenous ADR administration. It was 
also found that podocytes express Prkdc in vitro by Western blot, and 
overexpression of Prkdc prevented any loss in cell survival after 0.1 µg/ml and 0.2 
µg/ml ADR treatment (Papeta et al. 2010). Mitochondrial genome damage is a major 
mechanism for toxicity in senescent cells (Suliman et al. 2007), such as podocytes, 
therefore the authors analysed the mitochondrial genome after ADR injury. There 
was a significant reduction in the mitochondrial DNA to nuclear DNA ratio in BALB/c 
mice compared to wild-type C57BL/6 mice, demonstrating a potential mechanism for 
ADR susceptibility in BALB/c mice (Papeta et al. 2010). Therefore,  
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Figure 1.6 – Glomeruli and podocytes in health and disease. (a) Comparison of glomeruli 
in health and disease. Green dashed arrow indicates foot process effacement. Blue dashed 
arrow indicates podocyte migration. Black dashed arrow indicated podocyte mitotic 
catastrophe. Red dashed line indicates loss of podocytes to urine. (b) Comparison of 
podocytes in health and disease. Dashed line indicates barrier between health and disease. 
Original diagram. 
 31 
the majority of in vivo studies employing ADR as a glomerular injury model use 
BALB/c or 129/SvJ mice.  
 
One of the first studies to associate rodent administration of ADR with nephrotoxicity 
was in the 1980’s (Bertani et al. 1982). The authors administered 7.5 mg/kg of ADR 
to rats and found proteinuria, foot process effacement and loss of sialic acid residues 
on foot processes at 13 and 28 days after administration (Bertani et al. 1982). Since 
then, ADR has become a widely used podocyte cytotoxin and the histologic and 
molecular events have been documented (Lee and Harris 2011; Okuda et al. 1986; 
Pereira et al. 2015; Wang et al. 2000, 2015; Yang et al. 2018). The standard dosing 
for ADR in mice is 10 mg/kg, but this can be fine-tuned to increase or reduce disease 
severity. There are standard biochemical and histological features that scientists 
employing the ADR injury model can expect. Mice will experience a drop in body 
weight from which they do not recover (Lee and Harris 2011; Wang et al. 2000). 
After 5 days, albuminuria will be significantly increased and can peak after 1 week 
before remaining steadily high up to 6 weeks after induction (Lee and Harris 2011; 
Wang et al. 2000). Serum albumin concentration and creatinine clearance will drop 
after 1 week and 4 weeks respectively (Lee and Harris 2011; Wang et al. 2000). 
Histologically, glomerulosclerosis will begin to occur after 2 weeks and steadily 
progress (Lee and Harris 2011; Wang et al. 2000). Podocyte foot processes will 
begin to fuse after 1 week. Podocyte detachment from the GBM and tubular protein 
casts will be visible after 2 weeks (Lee and Harris 2011; Wang et al. 2000). Some 
macrophage and immune cell interstitial accumulation may occur in the later stages 
of injury (Lee and Harris 2011). ADR nephropathy is a model that causes a low 
degree of mortality, with a high degree of tissue damage, however, mortality may 
occur after over dosing (Lee and Harris 2011; Wang et al. 2015).  
 
1.5.1.2 Cytoskeletal reorganisation 
Cytoskeletal disorganisation in podocytes has been associated with foot process 
effacement and albuminuria in vivo (Shirato et al., 1996; Welsh and Saleem, 2012; 
Yu et al., 2013; Suleiman et al., 2017; Blaine and Dylewski, 2020). In BALB/c mice 
injured with 14 mg/kg of ADR for 9 days where synaptopodin and myosin IIa were 
used as surrogates for F-actin staining, there was a shift from non-contractile actin to 
 32 
contractile actin in podocyte foot processes. There was also an increase in the 
thickness and distance between synaptopodin clusters in the foot processes, 
indicative of actin spreading in effaced foot processes (Suleiman et al. 2017). 
Another recent study administered mice with a C57BL/6 background 12 and 18 
mg/kg of ADR and assessed the glomerular F-actin cytoskeleton with FITC-
phalloidin after 4 weeks. This study stated that there is a reorganisation of F-actin in 
the glomeruli from a capillary loop pattern to a collapsing pattern, accompanied by 
an increase in F-actin fluorescence intensity (Woychyshyn et al. 2020). Podocytes, 
endothelial cells and mesangial cells all express F-actin (Cortes et al. 2000), so the 
alterations to F-actin organisation and fluorescence intensity cannot be deemed 
podocyte specific as there was no double labelling performed. C57BL6/J mice are 
also inherently less sensitive to ADR nephropathy (Papeta et al. 2010), so the F-
actin phenotype in this study may not be representative of human FSGS.  
 
One study using mouse immortalised podocytes exposed them to 0.125 µg/ml ADR 
and quantified F-actin reorganisation by FITC-phalloidin staining. In this study, the 
authors found that the predominant form of F-actin in healthy podocytes was 
cytoplasmic stress fibres, and administration of ADR caused cortical F-actin 
accumulation and lamellipodia formation (Marshall et al. 2010). Another study 
treated mouse immortalised podocytes with 0.27 µg/ml of ADR, visualised F-actin 
with FITC-phalloidin, and quantified stress fibre percentage and mean fluorescence 
intensity over time. After 12 hours of ADR treatment, the stress fibre prevalence fell 
from 100% to 75%, which steadily decreased to 20% at 24 hours. From the 
representative images, the stress fibres formed a “mat” of unorganised F-actin 
throughout the cell body, with no clear arrangements following ADR treatment, 
however, this would be clearer if quantification was performed by the authors. The 
mean fluorescence intensity also fell by over 50% at 12 hours and remained at this 
level until 24 hours after ADR treatment (Liu et al. 2012). There was also a 3-fold 
increase in a-actinin-4 mRNA and protein expression, which is responsible for actin 
bundling (Asanuma et al. 2005). The authors postulated that an increase of a-




In another study, mouse immortalised podocytes in vitro were treated with a higher 
dose of 0.5 µg/ml of ADR and the cytoskeleton was visualised with FITC-conjugated 
phalloidin 12 hours later (Ni et al. 2018). The authors did not quantify the F-actin 
changes, but they could be observed from the representative images displayed. The 
non-treated podocytes showed a mix of cytoplasmic stress fibres and cortical stress 
fibres, however, treatment with ADR decreased the F-actin fluorescence shown in 
representative images. It was not clear if the distribution of F-actin changed following 
ADR treatment, as this was not quantified. This was accompanied by a reduction in 
synaptopodin and Wilms tumour 1 (WT-1) expression, as quantified by Western blot 
(Ni et al. 2018).  
 
One of the most recent papers exploring the effect of ADR on the podocyte 
cytoskeleton comprehensively quantified F-actin reorganisation in primary podocytes 
isolated from BALB/c mice injected with 8 mg/kg of ADR via the retro-orbital sinus 
(Ning et al. 2020). The authors classified F-actin organisation into cytoplasmic or 
cortical F-actin arrangements and found that there was over 20% reduction in stress 
fibre prevalence in ADR treated mice compared to saline treated mice. Incidentally, 
this loss of stress fibres was aggravated by synaptopodin knockout, demonstrating 
the crucial role of synaptopodin in slowing disease progression (Ning et al. 2020). 
The deficiency in synaptopodin also decreased RhoA activation, which is responsible 
for stress fibre formation (Asanuma et al. 2006), and a-actinin-4 did not co-localise 
with stress fibres, suggesting loss of synaptopodin meant crucial actin regulating 
signalling cascades did not occur.  
 
WT-1 is a nuclear transcription factor that is specific to podocytes in the glomerular 
tuft and crucial for proper podocyte development and function (Guo et al. 2002; 
Morrison et al. 2008). In BALB/c mice treated with 10.5 mg/kg ADR, Wt1 mRNA was 
significantly downregulated in kidneys compared to untreated controls. This was 
accompanied by a 2-fold upregulation of the microRNA miR-206, which was shown 
to target the 3’ untranslated region of WT-1. Furthermore, the characteristics of ADR 
were mimicked by upregulating miR-206 in podocytes in vitro, including a significant 
reduction in synaptopodin and a reorganisation of podocyte cytoplasmic stress fibres 
to cortical stress fibres (Guo, Guo, and Su 2016). The wide range of published 
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literature demonstrate that F-actin reorganisation is a common feature of ADR 
podocytopathy in vitro and in vivo.  
 
1.5.1.3 Podocyte motility 
Two different types of cellular motility have been described – translocative motility 
and stationary motility (Haemmerli, Arnold, and Sträuli 1983). Translocative motility 
was described as motility in the X, Y or Z plane, whereas stationary motility was 
described as cellular motility without any directional migration. An example of 
stationary motility in podocytes is the theory proposed that the foot processes are 
slightly motile in vivo in order to “clean” the sub-cellular space between the GBM and 
the foot processes of proteins that have been trapped there during ultrafiltration 
(Welsh and Saleem 2012). This theory has been supported by the evidence of a 
sub-podocyte space between podocyte cell bodies, podocyte foot processes and the 
GBM in healthy rat and human samples as visualised and quantified by electron 
microscopy (Arkill et al. 2014). Rat and zebrafish glomeruli imaged with high 
powered, time lapse, multi-photon microscopy revealed that healthy podocytes show 
very little translocative motility (Endlich et al. 2014; Peti-Peterdi and Sipos 2010). 
The authors theorised that the low number of podocytes showing translocative 
motility was due to these podocytes becoming activated and damaged in the healthy 
kidney by an unknown cause. Therefore, the available evidence and theory currently 
is that healthy podocytes display high levels of stationary motility and low levels of 
translocative motility in order to maintain a functioning filtration barrier.  
 
Multiphoton microscopy using fluorescently tagged cells is the main way to assess 
podocyte motility in vivo as it is the only technique that allows serial imaging of intact, 
living tissue (Larson 2011). One study, using podocin-Cre mice of a C57BL6/J, 
crossed with R26R-Confetti construct expressing mice, to fluorescently label 
podocytes different colours, assessed podocyte motility in ADR nephropathy (Hackl 
et al. 2013). The study revealed that glomerular injury caused podocyte clustering 
and the podocyte processes seemed to overlap and form bridges with the parietal 
epithelial cell layer and the glomerular tuft. This effect was also mimicked in the early 
stages (<6 days) of ADR nephropathy. Critically, the study used confetti mice to label 
individual podocytes different colours in order to track the fate of individual 
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podocytes to confirm their findings (Hackl et al. 2013). Since both the C57BL6/J and 
FvB mice are both resistant to ADR nephropathy, the results shown here may not 
fully mimic the human FSGS phenotype, nevertheless, this study shows that 
podocytes that are subjected to ADR injury show increased motility. 
 
1.5.1.4 Podocyte loss 
Podocyte adhesion to the GBM is critical for a functioning glomerulus and podocytes 
face strong hydrostatic force from the capillary blood flow, which pushes them away 
from the capillary wall towards the urinary space (Kriz et al. 1994; Kriz, Gretz, and 
Lemley 1998). One of the classical features of ADR administration is podocyte loss 
(Kubo et al. 2020). Sprague-Dawley rats injected with 10 mg/kg of ADR displayed a 
1/3 decrease in podocyte number per glomerulus and the protein level of a3b1 
integrin and a + b dystroglycan, the major podocyte adhesion molecules, in the 
glomeruli was also markedly decreased. BALB/c mice injected with a slightly lower 
dose of ADR (8 mg/kg) showed ~45% decrease in podocyte number at 14 days 
which increased to ~55% decrease at 28 days (Hosoe-Nagai et al. 2017). (M.-S. Zou 
et al. 2010). Primary podocytes cultured from 129S5 background mice and treated 
with 1 µmol/ml of ADR showed a 50% decrease in cell adhesion to the matrix. The 
cells also showed a 90% decrease in a3 integrin and 50% decrease in b1 protein 
levels with a ~2 fold increase in ILK (Dai et al. 2019). ILK activation has been shown 
to be a downstream effector in the onset of proteinuria and blockade of ILK activation 
in puromycin aminonucleoside (PAN) nephrosis prevented podocyte detachment by 
protection of cell adhesion molecules (Kretzler et al. 2001; De Paulo Castro Teixeira 
et al. 2005). 
 
Intermediate filaments are normally found in the podocyte cell bodies and primary 
processes, with no presence in the podocyte foot processes (Zou et al. 2006). 
Immortalised mouse podocytes treated with 0.25 µg/ml of ADR showed increase in 
transcript levels of Nefh, a type IV intermediate filament, at 6 and 24 hours (Wang et 
al. 2018). The authors then explored the role of NEFH in cell detachment. Wild type 
cells treated with ADR showed ~30% cellular detachment, which was increased to 
~40% when in NEFH knockdown cells, whereas NEFH overexpression showed no 
increase in detachment when compared to the wild type (Wang et al. 2018). This 
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finding implies that the intermediate filaments of podocytes may play a role in cellular 
adhesion, however, more investigation is required. There have been direct links 
shown between intermediate filaments and molecules involved in cellular adhesion, 
such as a-actinin-4, vinculin and utrophin (Leube, Moch, and Windoffer 2015), which 
are all expressed in podocytes.  
 
Podocytes are terminally differentiated cells that do not replicate under normal 
conditions, and mitosis in podocyte injuries can lead to podocyte loss (Liapis, 
Romagnani, and Anders 2013). ADR has been shown to cause mitosis prior to 
podocyte loss in BALB/c mice injected with 13 mg/kg of ADR (Mulay et al. 2013). 
Murine double minute-2 (MDM-2) inhibits p53 dependent cell cycle arrest and 
apoptosis, therefore promoting mitosis (Haupt et al. 1997) and inhibiting MDM-2 in 
ADR-treated treated mice suppressed podocyte mitosis and detachment. Podocyte 
mitosis was confirmed by tubulin immunostaining (to identify mitotic spindle), 
analysis of nuclei shape (bi-nucleated or mini-nucleated cells) and histone-3 
immunostaining (marker for metaphase) (Mulay et al. 2013). Furthermore, presence 
of the cyclin-dependent kinase inhibitor p21 has been shown to prevent podocyte 
loss in ADR injury in C57BL/6 mice injected with 12 mg/kg of ADR (Marshall et al. 
2010). Overall, ADR administration to rodents is an ideal candidate to inflict damage 
targeted to podocytes.  
 
1.5.2 Nephrotoxic serum nephritis 
1.5.2.1 Induction of nephrotoxic serum nephritis 
Nephrotoxic serum (NTS) nephritis is an inducible model of rodent glomerular injury 
that mimics some of the pathological features of human autoimmune 
glomerulonephritis (Pippin et al. 2009). It is one of the oldest models of rodent 
glomerular injury and studies can be found as early as the 1930’s (Smadel 1937). 
NTS nephritis has the advantage over ADR injury in that it can be used in C57BL/6 
mice, which makes using transgenic mice much more accessible (Pippin et al. 2009). 
NTS nephritis can be induced in two forms; an acute form and a chronic form, which 
depends on the addition or omittance of a pre-immunisation step (Chen et al. 2002; 
Hoppe and Vielhauer 2014). Pre-immunisation of the experimental animal with 
sheep IgG in complete Freund’s adjuvant, which normally occurs 5 days before NTS 
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administration primes the immune system to recognise the NTS antibodies, therefore 
accelerating the onset of the autologous phase (Chen et al. 2002; Hoppe and 
Vielhauer 2014). 
 
To create the nephrotoxic serum, glomerular extracts from the experimental species 
(normally mouse or rat) are homogenised and injected into a secondary species 
(normally rabbit or sheep) in incomplete Freund’s adjuvant (Hoppe and Vielhauer 
2014). The secondary species will then create an immune response and polyclonal 
antibodies against the glomerular structures, such as the GBM, podocytes and 
endothelial cells. The serum and said antibodies are then extracted. There are two 
phases of NTS injury – the heterologous and autologous stages (Hoppe and 
Vielhauer 2014). The heterologous stage is initiated within minutes of injection of 
NTS, where the polyclonal antibodies will bind to their respective glomerular 
structures. The binding of the antibodies can also sometimes interfere with podocyte 
integrin molecules causing foot process effacement (Shirato et al., 1996). Glomerular 
injury is mediated by complement activation and neutrophil inflammation in the 
heterologous stage (Assmann et al. 1985; Hébert et al. 1998). Podocytes and 
endothelial cell toll like receptor molecules can also be stimulated which activates 
the production of cytokines and chemokines, accelerating macrophage accumulation 
and NTS nephritis onset (Hoppe and Vielhauer 2014).  
 
The heterologous phase then develops into the autologous phase within 1 week 
which is the development of the systemic, adaptive immune response against the 
anti-glomerular antibodies (Chen et al. 2002; Hoppe and Vielhauer 2014). T-cells are 
released that promote macrophage accumulation to the glomerulus (Tipping and 
Holdsworth 2006). Furthermore, the T-cells stimulate B-cell activation to promote the 
production of autologous antibodies against the sheep anti-glomerular antibodies, 
which are deposited in the glomerulus (Hoppe and Vielhauer 2014). This glomerular 
deposition of autologous antibodies exacerbates glomerular injury by forming large 
immune complexes of IgG (Chen et al. 2002; Hoppe and Vielhauer 2014). This 
glomerular deposition of IgG is reflective of IgG build up in human vasculitis patients 
(Jennette and Falk 1997). 
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1.5.2.2 Expected renal outcomes of NTS nephritis 
Since NTS nephritis is a widely used glomerular injury model, the renal 
manifestations are well characterised. One study documented the course of NTS 
nephritis 7, 14 and 21 days after NTS induction in C57BL/6 mice. Urinary albumin to 
creatinine ratio rose at 7 days, then then further rose at 14 days and finally rose even 
more at 21 days, suggesting progressive glomerular filtration barrier degradation 
(Hoppe and Vielhauer 2014). Serum protein concentration was decreased, but 
serum cholesterol and urea concentration were sharply increased after 21 days. 
There was also severe glomerular crescent formation and sclerosis, and monocyte, 
T cell and macrophage accumulation at 21 days (Hoppe and Vielhauer 2014).  
 
Further studies have confirmed and expanded on these characteristics. One study 
pre-immunised male wild type C57BL/6 mice with 200 µg of sheep IgG 5 days prior 
to intravenous injection of 150 µl of NTS per 20 g of body weight (Tham et al. 2020). 
The urinary albumin to creatinine ratio rose sharply after 7 days, suggesting a high 
level of damage to the glomerular filtration barrier. Damage to the glomerular 
filtration barrier was further confirmed where serum creatinine levels doubled after 7 
days. Histologically, over 35% of glomeruli assessed showed crescent formation and 
signs of thrombosis, as analysed by light microscopy. Immunofluorescent 
experiments also revealed a high level of neutrophils and IgG deposition within the 
glomerular tuft, confirming the role of the immune system in this model of NTS 
nephritis (Tham et al. 2020).  
 
In another study, C57BL/6 mice injected with sheep IgG prior to administration of 
sheep NTS were examined 21 days after disease induction (Vasilopoulou et al. 
2016). Both urinary albumin concentration and the albumin to creatinine ratio of NTS 
injected mice increased significantly. This was accompanied by glomerulosclerosis 
and increased glomerular Col4a1 expression. There was also an increase in 
glomerular IgG1 and IgG2a protein expression, as determined by enzyme linked 
immunosorbent assay (ELISA), demonstrating that the disease induction was in the 
autologous phase by 21 days post NTS injection. Interestingly, there was an 
increase in TUNEL positive (apoptotic) glomerular cells which were not WT-1 
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positive (podocytes) indicating there was significant apoptosis of either mesangial 
cells or capillary endothelial cells (Vasilopoulou et al. 2016).  
 
It has been shown in the non-accelerated NTS nephritis model (omitting pre-
immunisation) that CD1 mice are more sensitive to intravenous NTS injection than 
C57BL/6 mice (Ougaard et al. 2018). Albuminuria was exacerbated in CD1 mice 2 
and 16 days after NTS injection, but interestingly, albumin excretion returned to 
basal levels after 42 days (Ougaard et al. 2018). There was also an increase in 
complement 3 and monocyte chemoattractant protein 1 (MCP-1) gene expression in 
kidney lysates at 7, 21 and 42 days (Ougaard et al. 2018). 
 
One major mediator of glomerular and kidney injury is the innate immune response, 
and in particular, macrophages. This has been proven in a study injecting mice of a 
FVB/N background intravenously with NTS, where macrophages were conditionally 
ablated using diphtheria toxin (Duffield et al. 2005). The authors found that ablating 
macrophages protected the glomerular filtration barrier, as serum creatinine 
concentration and the urinary protein to creatinine ratio were both reduced compared 
to non-ablated mice after 15 and 20 days of NTS treatment.  Furthermore, 
suppressing macrophages reduced glomerulosclerosis and crescent formation, and 
there were less apoptotic and proliferative cells within glomerular crescents (Duffield 
et al. 2005). This key study demonstrated that macrophages significantly contributed 
to the pathogenesis of NTS nephritis.  
 
Another of the key mediators of kidney injury is the adaptive immune response. 
C57BL/6 mice were pre-immunised with 200 µg of rabbit IgG and then injected with 
rabbit anti-mouse GBM antiserum 3 days later and the authors assessed the effect 
of stimulating glucagon-like peptide-1 receptor (Glp1r), a receptor found in the pre-
glomerular vascular smooth muscle cells and juxtaglomerular cells (Moschovaki 
Filippidou et al. 2020). Glp1r is known to have anti-inflammatory properties, including 
inhibiting cytotoxic T-cell proliferation and increasing the number and function of 
regulatory T-cells in mice and humans (Hadjiyanni et al. 2010). Treatment with the 
Glp1r agonist Liraglutide ameliorated some of the effects of NTS nephritis, including 
increase in the albumin to creatinine ratio, number of glomerular crescents, 
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expression of Col1a1, and macrophage and T-cell accumulation (Filippidou et al., 
2020).  
 
Another feature of NTS nephritis is glomerular cell proliferation. Mice with a mixed 
129/Sv and C57BL/6 background were pre-immunised with sheep IgG and then 6 
days later injected with NTS. Ki-67 immunostaining revealed a significant increase in 
glomerular proliferative cells compared with vehicle injected mice, although the exact 
cell type was not identified. Interestingly, NTS also induced an increase in the 
parietal epithelial cell marker claudin-1 in the glomerular tuft, suggesting that there 
may be parietal epithelial migration into the glomerular tuft (Dai et al. 2017). Another 
study administered Wistar-Kyoto rats with 1 ml/kg body weight of sheep anti-rat NTS 
and studied glomerular proliferation 14 days after NTS nephritis induction by Ki67 
immunohistochemistry (IHC). The authors found there was a 7.1 fold increase in 
Ki67 positive glomerular nuclei compared to saline treated rats, however, there was 
no double labelling so it was unclear which glomerular cells were proliferating 
(Succar et al. 2014).  
 
1.5.2.3 NTS and the podocyte cytoskeleton 
Studies have also attempted to quantify changes to the F-actin cytoskeleton in NTS 
nephritis. One study in the 1990’s associated F-actin disorganisation in the foot 
processes in vivo with foot process effacement (Shirato et al., 1996). NTS nephritis 
was induced in Sprague-Dawley rats with rabbit anti-rat-GBM serum and F-actin was 
visualised in the foot processes by immunogold electron microscopy. The authors 
described an increase in podocyte foot process F-actin accumulation at day 3, 10 
and 28 after NTS injection. Interestingly, the F-actin expression in the mesangium 
was markedly decreased at days 1 and 3 (Shirato et al., 1996). The cytoskeletal 
disorganisation in the foot processes correlated with foot process effacement, 
suggesting this is a key underlying mechanism in the pathogenesis of NTS nephritis.  
 
C57BL/6 mice injected with NTS per g body weight were culled after 9 days, and 
kidneys cryosections were immunostained to visualise synaptopodin and F-actin 
(Kvirkvelia et al. 2013). NTS induction decreased the glomerular fluorescence 
intensity of synaptopodin and F-actin. There was also a reorganisation of the 
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staining, where the glomeruli of control mice would display a “fine linear” expression 
of F-actin and synaptopodin which was reorganised to a thicker expression. This 
thicker expression in disease in the study by Kvirkvelia et al., may be representative 
of the accumulation of F-actin described by Shirato et al. The authors also attempted 
an in vitro model of NTS injury, where they incubated mouse immortalised podocytes 
with 6% NTS in media for 5 hours. The synaptopodin in untreated cells was spread 
throughout the whole podocyte cell, but NTS administration led to peri-nuclear 
accumulation of synaptopodin. Untreated cells also showed a cortical arrangement 
of F-actin, which was reorganised to accumulation of cytoplasmic stress fibres in 
NTS treated cells (Kvirkvelia et al. 2013). This in vitro model does not fully represent 
the in vivo effects of NTS to podocytes, as the injury is due to a mix of multi-cellular 
actions in vivo, however, is a reasonable starting point and may provide some insight 
into the earlier mechanisms of podocyte injury.  
 
A different study attempted to replicate the conditions of NTS nephritis in vitro by 
incubating podocytes with macrophage conditioned media. This media had been 
generated by incubation of macrophages in Dulbecco’s modified eagle medium 
(DMEM) with 5 mg/ml of lipopolysaccharide (LPS) to activate the macrophages for 
48 hours and is a good in vitro model of NTS nephritis. The macrophages and LPS 
were then extracted by filtration followed by the addition of the DMEM to mouse 
immortalised podocytes for 6, 24, 48 and 96 hours (Succar et al. 2016). The 
untreated podocytes showed cortical F-actin stress fibres, which did not change over 
time. The macrophage conditioned media treated cells showed an increase in stress 
fibre accumulation and fragmentation of F-actin filaments to form unorganised F-
actin structures, with 90% of podocytes displaying disorganised F-actin by 96 hours 
(Succar et al. 2016). This was accompanied by an increase in ZO-1 disorganisation 
and mRNA expression, a marker for tight junctions and is present in the SD of 
podocytes connected to the cytoskeleton (Huber et al. 2003). Perhaps cytoskeletal 
disorganisation could be prevented by modulating ZO-1 transcript levels. Although 
these conditions do not fully replicate NTS nephritis in vivo, this study does provide 
interesting insight into the role of macrophages in podocyte health, and the 
conditions of this experiment could be improved by co-culturing with macrophages. 
Macrophage-induced podocyte cytoskeletal disorganisation has been attributed to 
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the secretion of tumour necrosis factor a (TNF-a) (Ikezumi et al. 2008), which may 
potentially be the active pathway in this study.  
 
Another protein expressed by mesangial cells and podocytes during the 
inflammatory response in NTS nephritis is heparin-binding epidermal growth factor 
(HB-EGF) (Feng et al. 2000). HB-EFG is a growth factor that is involved in cellular 
development and inflammatory processes (Miyata et al. 2012), and is not normally 
found in healthy glomeruli (Nakagawa et al. 1997). HB-EGF mRNA and protein was 
upregulated after NTS induction in 129S2 mice, as determined by in situ 
hybridisation and immunofluorescent assays. Therefore, the authors then incubated 
mouse immortalised podocytes with 30 nM of HB-EGF for 48 hours and then 
visualised F-actin with phalloidin. HB-EGF led to a 60% increase in the formation of 
F-actin ring-like structures in the podocytes, with the accumulation of membrane F-
actin ruffles, similar to lamellipodia (Feng et al. 2000). Ring-like F-actin structures 
have been associated with mitosis induction in other cell types (Lu et al. 2014), 
which is detrimental to podocytes and may be occurring here, however the authors 
did not assess proliferation.  
 
Overall, the diverse effects to the glomeruli and podocytes make NTS nephritis a 
prime candidate to explore potential therapeutic agents.  
 
 Thymosin b4 
1.6.1 Discovery of TB4 and early characterisation 
Thymosin b4 (TB4) was first isolated in 1981 from calf thymus through a combination 
of ion-exchange chromatography and gel filtration, and the authors originally thought 
it to be a thymic hormone that induces terminal deoxynucleotidyl transferase activity 
in thymocyte populations (Low, Hu, and Goldstein 1981). After its isolation from the 
thymus, it was discovered by high performance liquid chromatography (HPLC) that 
TB4 was ubiquitous in mouse and rat tissues, including the spleen, thymus, brain, 
lung, liver and heart muscles and that TB4 was composed of 43 amino acids and 4.9 
kDa in size (Hannappel et al. 1982; Low and Goldstein 1982). The same study found 
that in rats, TB4 was most abundant in the spleen, with the brain, kidney, liver and 
testis contained 10 – 20% of splenic levels, and the heart and muscles containing 5 
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– 10% (Goodall, Hempstead, and Morgan 1983). This was the first study to identify 
TB4 in the kidney. The same year, synthetic TB4 was generated for the first time in 
Staphylococcus aureus using isolated rat splenic mRNA and validated using co-
immunoprecipitation (Filipowicz and Horecker 1983), paving the way for in vitro and 
in vivo studies using synthetic and recombinant TB4. The secretion of TB4 has been 
confirmed in the thymus of rats (Wise et al. 1992). 
 
Nine years after the isolation of TB4 from calf thymus, an actin sequestering peptide 
was isolated from human platelets using a combination of nondenaturing 
polyacrylamide gel electrophoresis and N-(iodoacetyl)-N’-1-sulfo-5-
naphthylethylenediamine actin labelling. The authors described the peptide as 
“binding to the bulk of the unpolymerized actin in platelets and preventing it from 
polymerising” and designated the protein “Fx” (Safer, Golla, and Nachmias 1990). 
They found this peptide bound stoichiometrically to muscle G-actin and the authors 
investigated the amino acid composition of Fx by HPLC. However, they did not link 
the Fx amino acid composition and the TB4 amino acid sequence discovered 
previously until a year later, when the actin binding and sequestering abilities of TB4 
and Fx were compared by nondenaturing polyacrylamide gel electrophoresis. The 
amino acid sequence of Fx was deciphered by HPLC and compared to the amino 
acid sequence of TB4 as published in 1981. The authors found that Fx and TB4 
were identical, and therefore the same peptide (Safer, Elzinga, and Nachmias 1991).  
 
1.6.2 TB4 and the actin cytoskeleton 
TB4 is a member of the actin binding b-thymosin family and is the major G-actin 
sequestering protein in mammalian cells (Cassimeris et al. 1992; Nachmias 1993; 
Safer et al. 1991). One of the first studies to fully investigate the actin binding 
properties of TB4 determined that TB4 would not bind to isolated muscle and platelet 
F-actin, only G-actin, and that TB4 suppressed the rate of actin polymerisation. The 
authors also determined that the dissociation constant of G-actin : TB4 complexes 
was between 2 – 3 µM (Weber et al., 1992). Since then, the actin binding properties 
of TB4 have been investigated in detail. Using muscle actin and TB4 purified from 
sheep spleen by HPLC, it was shown that TB4 binds to ATP-G-actin with a much 
higher affinity than ADP-G-actin. The former produced a dissociation constant of 1.7 
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– 2 µM, whereas the latter gave a dissociation constant of 80 – 85 µM (Carlier et al. 
1993). The difference in the affinity is most likely due to alteration of the TB4 binding 
site on actin due to the nucleotide that is bound to it, as shown by HPLC (Carlier et 
al. 1993). 
 
Around the same time, TB4 was found to decrease the rate in which the barbed end 
of F-actin grew (Yu et al., 1993), prolong the nucleation phase of actin and decrease 
the rate of initial elongation of actin filaments (Sanders et al. 1992). This occurs 
when the concentration of the intracellular pool of G-actin falls below the critical 
concentration of actin polymerisation (0.1 µM) so actin polymerisation stalls. The 
mechanism was proposed that once G-actin disassociates from the ends of the 
filaments in vivo, TB4 binds to the G-actin monomers and blocks these monomers 
from re-polymerising (Sanders et al. 1992) (Figure 1.7). TB4 primarily binds to 
subdomain 2 on G-actin molecules and the binding of TB4 causes conformational 
and steric changes to the G-actin molecule, as determined by mass spectrometry 
(Enrique M. De La Cruz et al. 2000). It was also shown by circular dichroism that 
TB4 binds preferentially to Mg-G-actin than to Ca-G-actin (De La Cruz et al., 2000), 
suggesting that actin dynamics can be controlled by the ratio of Mg and Ca in the 
cell. A recent in vitro study that overexpressed fluorescently labelled TB4 and profilin 
in COS-7 cells (fibroblast-like cells derived from monkey kidney tissue), and 
observed no effect on the rate of polymerisation or density of actin filaments when 
either protein was overexpressed (Zhang et al. 2017). The authors suggested that 
this was due to most of the G-actin being naturally sequestered by each molecule 
respectively, so overexpression had no effect. TB4 forms 4 cross links with 
subdomains 1, 2 and 3 of G-actin. It is also proposed that a ternary complex of 
DNase1 and cross-linked actin-TB4 is formed when DNase 1 binds (De La Cruz et 
al., 2000). G-actin acts as an inhibitor to the activity of DNase 1 (Lazarides and 
Lindberg 1974), which degrades DNA in nuclei (Choi et al. 2020), and it has been 
shown that the dissociation of G-actin from DNase 1 leads to increased chromatin 
degradation (Eulitz and Mannherz 2007), suggesting that the binding of G-actin to 




A recent study has explored the role of TB4 in the F-actin cytoskeleton in the 
developing epidermis and eyes. The study found that embryonic Tmsb4x  
knockdown by lentiviral short hairpin RNA transfection prevented eyelid closure of 
neonatal mice, which is an essential morphogenetic process (Padmanabhan et al. 
2020). Eyelid closure is often hindered by mutated planar cell polarity genes (Curtin 
et al. 2003; Wang and Nathans 2007), defects in planar cell polarity were seen in 
Tmsb4x knockdown in the form of improper hair follicle alignment and orientation of 
papillary dermal cells in embryos. Planar cell polarity is required for the correct 
orientation of cells, embryogenesis and embryonic physiological functions 
(Papakrivopoulou et al. 2021). The embryos also showed a lower fluorescence 
intensity of F-actin in the epidermis, which can be directly correlated to defective 
adherens junction formation and stability, as shown by an increased thickness in E-
Figure 1.7 – Mechanism of G-actin sequestering. Simplified diagram depicting how TB4 
sequesters G-actin that detaches from F-actin. Original diagram. 
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cadherin immunostaining. The decrease in F-actin was mirrored by a decrease in G-
actin in keratinocytes in vitro and the authors suggested that the defect in adherens 
junction formation was via the loss of the G-actin pool that would normally be 
available in wild type mice (Padmanabhan et al. 2020).  
 
The actin binding ability of TB4 has been shown to protect the actin cytoskeleton 
from disorganisation. One study explored the interaction of advanced glycosylation 
end products (AGE) and their receptors (RAGE) in human umbilical vein epithelial 
cells (HUVEC) in vitro, two molecules which are known to disrupt the cytoskeleton 
(Kim and Kwon 2015). AGE caused a reduction in cell viability, RAGE expression, 
increased the F-actin to G-actin ratio. The authors found that increasing 
concentrations of exogenous TB4 (0.01 – 0.5 µg/ml) protected AGE induced 
increase in F-actin to G-actin ratio. TB4 siRNA was used to decrease the expression 
of endogenous TB4, and it was shown that loss of endogenous TB4 exacerbated the 
effects of AGE on HUVECs, demonstrating the importance of endogenous and 
exogenous TB4 in cytoskeletal protection (Kim and Kwon 2015). Another in vitro 
study using Henrietta Lacks (HeLa) cells found a reduction in F-actin filaments and 
lamellipodia when endogenous TB4 was overexpressed by transfection with the 
opposite effect seen in TB4 downregulation by siRNA. It was also shown in this 
study that TB4 inhibits the cofilin-stimulated F-actin-ATPase, therefore slowing the 
progression of F-actin depolymerisation (Al Haj et al. 2014).  
 
Cell migration is modulated by the F-actin cytoskeleton (Svitkina 2018) and 
endogenous TB4 has been shown to prevent migration in podocytes (Vasilopoulou 
et al. 2016), but increase migration in other cell types, such as colon cancer cells 
(Tang et al. 2011). TB4 has been shown to interact with the kinase domain of 
integrin linked kinase (ILK) in endothelial cells by surface plasmon resonance (Fan et 
al. 2009) and the increase in migration in colon cancer cells was attributed to TB4 
overexpression enhancing the ILK activation. This ILK activation, in turn, caused an 
upregulation of IQGAP1 (Brown and Sacks 2006), an activator of Rac1, which 
indeed caused an increase in Rac1 signalling and cell migration, as shown by 
Transwell assay (Tang et al. 2011). Since an increase in cancer cells is known as 
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metastasis, which is detrimental to disease progression, this is one potential 
drawback of using exogenous TB4 as a therapy. 
 
1.6.3 TB4 and inflammation 
The suppression of inflammation is vital in preventing disease progression in a wide 
range of pathologies. TB4 has moonlighting abilities, meaning it can perform multiple 
cellular functions (Husson et al. 2010; Tompa 2005; Xue and Robinson 2016).  
 
One of the first studies to implicate a therapeutic role of TB4 in inflammation was 
published in 1999. Through reverse-phase HPLC, it was identified that an alternative 
form of TB4, called TB4 sulfoxide (TB4-SO), is formed by oxidation of methionine-6 
residue. By live cell tracking, it was shown that TB4-SO, but not TB4, caused altered 
motility of neutrophils, where the neutrophils migrated in a more disperse manner 
compared with untreated cells. Furthermore, scratch wound assay of neutrophils 
revealed that TB4-SO improved wound closure compared to both TB4 and untreated 
cells. The authors then transitioned to an in vivo study, and induced footpad swelling 
by carrageenin-induced inflammation. Daily intraperitoneal injection of 1 µg TB4-SO, 
but not an equivalent dose of TB4, was found to significantly reduce swelling in the 
footpads compared to untreated cells (Young et al. 1999).  
 
Thirteen years later, TB4-SO was examined in inflammation using zebrafish larvae 
(Evans et al. 2013). TB4-SO absorbed into latex beads were injected into the larvae, 
causing inflammation. Imaging after 3 and 6 hours revealed a significantly lower 
number of macrophages proximal to the TB4-SO bead compared to vehicle beads, 
suggesting TB4-SO induced macrophage dispersion. Next, the authors used laser 
and needle-induced injuries in the cardiac tissue of the zebrafish larvae. At both 3 
and 6 hours, administration of TB4-SO resulted in a reduced number of leukocytes in 
the injury area compared to vehicle treated fish. The authors then examined the 
effects of exogenous TB4 or TB4-SO (6 mg/kg every 2 days) in a murine model 
myocardial infarction, while also using TB4 global knockout mice to examine the role 
of endogenous TB4 in inflammation and observe the effects of exogenous TB4 
administration in the absence of endogenous TB4. Exogenous TB4 attenuated 
neutrophil and macrophage infiltration into injured tissue at 4 and 7 days respectively 
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compared to vehicle treated mice, but the number of immune cells in TB4 knockout 
mice, without exogenous TB4, was exacerbated. TB4 administration also resulted in 
lower levels of TNFa, interleukin (IL)-6 and IL-10 cytokines compared to vehicle 
treated mice, which TB4 knockout also exacerbated. Flow cytometry determined that 
TB4-SO reduced the number of macrophages and monocytes 28 days after 
infarction. Serial magnetic resonance imaging (MRI) determined that TB4 and TB4-
SO reduced infarct volume and reduced fibrosis in the heart (Evans et al. 2013). This 
study showed that when TB4 is oxidised in would sites, immune cells are resolved, 
which promotes reparative wound healing and anti-inflammation. 
 
The anti-inflammatory effects of exogenous TB4 have been examined extensively in 
eye injuries. Topical administration of TB4 to treat corneal wounds in rats showed 
that 1 µg/µl of TB4 induced closure of the corneal wounds 12 and 24 hours after 
administration. The study then went on to investigate this further in vitro using 
primary human corneal epithelial cells (HCECs), where it was found that 50 – 1000 
ng/ml of TB4 induced cell migration in a dose dependent manner (Sosne et al. 
2001). A year later, the therapeutic role of TB4 was further characterised in corneal 
alkali injury in 129 Sv mice, which showed increased corneal re-epithelialisation and 
suppression of inflammatory genes, such as MCP-1, IL-1, IL-2 and MIP1&2 (Sosne 
et al. 2002). This was then further expanded in BALB/c mice inflicted with alkali 
corneal injury. The authors found using quantitative polymerase chain reaction 
(qPCR) and ELISA that TB4 inhibited neutrophil infiltration, decreased chemokine 
expression and modulated corneal matrix metalloproteinase (MMP) levels, which are 
involved in promotion of cell motility (Sosne et al. 2005). Furthermore, using TNF-a 
injured HCEC culture in vitro it was demonstrated with ELISA and 
immunofluorescence that TB4 administration prevented NFkB phosphorylation and 
translocation to the nucleus, therefore suppressing the TNF-a induced activation of 
the NFkB pathway, one of the earliest signalling events in the inflammatory response 
(Sosne, Qiu, Christopherson, et al. 2007).  
 
The extensive studies of TB4 in the eye prompted investigation into the inflammatory 
response of other cell/tissue types. LPS administration to rodents, which mimics 
some phenotypes of septic shock in humans (Amura, Silverstein, and Morrison 
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1998), led to a sharp decrease in blood TB4 concentration, indicating that TB4 was 
being metabolised in response to the early inflammatory response (Bongiovanni et 
al., 2015). Intraperitoneal administration of 100 µg of synthetic TB4 dramatically 
improved survival rate compared to LPS alone. Use of adeno associated virus (AAV) 
expressing Tmsb4x improved LPS induced systemic inflammation by prevention of 
pericyte loss and perivascular leakage protection. TB4 also prevented the 
haemodynamic effects, such as drop in blood pressure, that are normally seen in 
murine sepsis models (Bongiovanni et al., 2015). A reduction of circulating TB4 
concentration was also seen in patients that had been admitted to an intensive care 
unit with septic shock (Badamchian et al. 2003). 
 
Interestingly, it was also found that TB4 was increased in the sera of inflammatory 
bowel disease (IBS) patients (Mutchnick et al. 1988). Rodent models of colonic 
inflammation were suppressed after TB4 overexpression, in the form of reduced 
inflammatory cell infiltration, suppression of colonic epithelial cell apoptosis, 
prevention of oxidative damage and modulation of pro-inflammatory cytokines 
(Zheng et al. 2017). The anti-inflammatory properties of TB4 have also been 
demonstrated in the lungs of male C57BL/6 mice injected with bleomycin, which 
mimics some of the characteristics of human pneumonitis (Yoshimi et al. 2008). 
Intraperitoneal injection of 6 mg/kg of TB4 suppressed polymorphonuclear leucocyte 
infiltration, lung oedema and collagen deposition (Conte et al. 2013). Mice of a 
C57BL/6 background with chronic granulomatous disease, which is an autoimmune 
disorder that targets phagocytes (Holland 2010), were challenged with a fungal 
infection of Aspergillus fumigatus and treated daily intraperitoneally with 5 mg/kg of 
exogenous TB4. TB4 was shown to suppress the inflammatory response and 
granuloma formation in these mice (Renga et al. 2019).   
 
1.6.4 TB4 in angiogenesis and cardiac injury 
Another well documented property of TB4 is its protection of the heart muscle and 
vasculature. TB4 has been detected as early as embryonic day 10 in the hearts of 
murine embryos on a 129 background (Smart et al. 2002) indicating that TB4 may 
play a role in development of the heart. Mice in which TB4 was knocked down in 
cardiomyocytes using short hairpin RNA were developmentally hampered and there 
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was a clear lack of neovascularisation and evidence of ischaemia (Smart et al. 
2007). The effect of exogenous TB4 in myocardial infarction in C57BL/6 mice was 
then explored (Smart et al. 2011). Mice were primed with daily intraperitoneal 
injection of 12 mg/kg of TB4 for 10 days and myocardial infarction was induced 3 
days later. Priming with exogenous TB4 significantly improved cardiac functional 
parameters after 28 days compared to vehicle treated mice, such as reducing infarct 
volume and improving diastolic and systolic volumes. Exogenous TB4 also reduced 
cardiac scar volume, with increased left ventricular mass at 28 days, as determined 
by MRI (Smart et al. 2011).   
 
In a model of acute myocardial infarction in C57BL/6 mice, treatment with 1.6 
mg/kg/day of TB4 via an osmotic mini pump (OMP) reduced death by cardiac rupture 
by 30% compared with vehicle treated mice. TB4 treated mice also showed less 
cardiac inflammatory cell infiltration, cardiac TUNEL+ (apoptotic) cells and increased 
angiogenesis after 1 week (Peng et al. 2014). More recently, it has been shown that 
endothelial progenitor cells in vitro treated with 10 ng/ml of TB4 formed tubules more 
readily (mimicking angiogenesis) than untreated cells, and increased the expression 
of angiogenic growth factors, such as platelet derived growth factor (2b subunits) 
(PDGF-BB), insulin-like growth factor 1 (IGF-1) and vascular endothelial growth 
factor (VEGF). The authors then transplanted these cells to diabetic fatty rats in vivo 
after myocardial infarction and saw increased angiogenesis, and increased 
recruitment of endogenous cardiac progenitor cells, therefore an improvement in 
cardiac function (Poh et al. 2020). A study using the hind limb ischaemia model in 
mice suggested that TB4 may actually enhance the NKkB pathway to promote 
angiogenesis (Lv et al. 2020), which is in contrast to the inflammatory studies that 
stated TB4 suppresses this pathway (Sosne et al. 2001).  
 
TB4 has been shown to be involved in other pathways that affect angiogenesis. TB4 
competes with myocardin-related transcription factor A (MRTF-A) for the binding of 
G-actin. Once MRTF-A is released from G-actin, it translocates to the nucleus, 
activating serum response factor (SRF) target genes. This was shown by Luciferase 
activity in HeLa cells (Morita and Hayashi 2013). MRTF-A signalling upregulates the 
expression of cysteine-rich angiogenic protein 61 (CCN1) and cellular 
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communication network factor 2 (CCN2), two molecules which drive angiogenesis 
and vessel stabilisation (Hanna et al. 2009; Hinkel et al. 2014). Using AAV vectors, 
upregulating TB4 and MRTF-A resulted in a significant upregulation in angiogenesis 
in a model of ischaemia in the hindlimbs of rabbits, suggesting that the MRTF-A 
release, modulated by TB4 binding to G-actin, could be responsible for TB4s role in 
angiogenesis (Ziegler et al. 2018). 
 
It was also shown in rat cardiomyocytes in vitro that addition of 10 ng/µl of TB4 
promoted cell migration and survival and increased the beating frequency of rat 
neonatal cardiomyocytes 2 and 4 weeks after explant through ILK and Akt activation. 
The most physiological significant finding of the paper was that TB4 was able to 
protect heart function in mice after myocardial infarction, as represented by a higher 
volume of blood ejection and increased cardiac contraction 4 weeks after infarction 
(Bock-Marquette et al. 2004; Srivastava et al. 2007).  
 
It is clear from the extensive literature that TB4 plays a major role in protection of the 
heart, however, it is emerging that it also plays a role in the vasculature in other 
organs, such as the brain (Morris, Zhang, and Chopp 2018). Stroke refers to a 
number of conditions that cause haemorrhage or blockage of the blood vessels that 
supply the brain (Lo, Dalkara, and Moskowitz 2003). In a model of acute stroke in 
aged Wistar rats, where the middle cerebral artery was occluded, daily treatment 
with 12 mg/kg of TB4 intraperitoneally reduced vascular lesion volume (Morris et al. 
2017). The same model was also undertaken in younger Wistar rats, where 
exogenous TB4 improved neurological outcome, promoted myelination and 
oligodendrocyte progenitor cell proliferation (Morris et al. 2014).  
 
1.6.5 TB4 in the kidney 
The role of TB4 in the kidney is a relatively new and unexplored area compared to 
other organs. A study from 2010 analysed the expression of TB4 in human foetal 
kidneys using IHC. The authors found TB4 expression in the developing and adult 
kidney was restricted to the tubules and ducts and was absent from the glomeruli 
(Nemolato et al. 2010). Endogenous Tmsb4x transcripts have also been identified in 
the kidney by qPCR, where Tmsb4x was found to be enriched in the glomeruli of 
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adult mice compared to the rest of the kidney and glomerular Tmsb4x transcripts 
could be detected at embryonic day 16.5. By embryonic day 18, some TB4 
expression also co-localised with nephrin, a major SD protein found in the podocyte 
foot processes, as confirmed by immunocytochemistry (Vasilopoulou et al. 2016). 
The discrepancies in glomerular TB4 positive immunostaining between these two 
studies are likely due to different antibodies used, different techniques used 
(immunofluorescent versus IHC), and different stages of kidney development. 
Another study used in situ hybridisation and immunocytochemistry on C57BL/6 mice 
kidney sections. Tmsb4x was present throughout the kidney, but more extensively in 
the cortex. The authors stated that TB4 peptide immunoreactive cells had small cell 
bodies and long branched processes, and were clearly in direct contact with the 
Bowman’s capsule and lined the tubules (Paulussen et al. 2009). However, the exact 
cell types expressing TB4 were not identified. 
 
A recent study that assessed the amniotic fluid of patients with developmental kidney 
disease found that TB4 was upregulated and positively correlated with the severity of 
disease (Klein et al. 2020). The study used ELISA to quantify the amniotic fluid 
concentration of TB4 where it was shown that TB4 was upregulated 2-fold in 
compromised renal outcome patients compared to healthy patients. The authors 
performed IHC on human foetal kidney formalin fixed, paraffin embedded (FFPE) 
sections, and showed that in healthy foetuses, TB4 was expressed mainly in the 
tubules, with no glomerular staining, which did not change with disease. The 
absence of glomerular staining is likely due to the developmental stage (foetal), as 
other studies have reported a lack of TB4 expression in developing glomeruli 
(Nemolato et al. 2010). Finally, they generated mutant zebrafish larvae using 
CRISPR/CAS-9 to form a truncated TB4 protein. TB4 knockout lead to defective 
development of the tubular components of the developing zebrafish kidney, but no 
change to the glomeruli (Klein et al. 2020). This is the first study to implicate TB4 in 
the progression of developmental defects to the human kidney. Another recent study 
in human adult CKD patients showed by mass spectrometry that urinary TB4 was 
upregulated 44.3-fold in ESKD patients compared to healthy patients (Kim et al. 
2021). These studies combined suggest that TB4 may have a role in the progression 
of CKD in humans.  
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The expression and function of TB4 in kidney disease has been further investigated 
in rodent models (Vasilopoulou, Riley, and Long 2018). One study quantified the 
expression of TB4 in CKD using the 5/6 nephrectomy model of FSGS in rats, which 
involves removing 1 kidney and 2/3 of the other kidney. In this model, the authors 
performed mass spectrometry and showed that TB4 expression was increased 3-fold 
in non-sclerotic glomeruli and 4-fold in sclerotic glomeruli of 5/6 nephrectomy rats 
compared with sham operated rats, with the expression predominantly in the 
endothelial cells (Xu et al. 2005). A later study employing mass spectrometry in the 
same 5/6 nephrectomy model of kidney injury in rats also reported a 4-fold 
upregulation of TB4 peptide in whole kidney tissues compared to sham operated rats 
(Kim et al. 2021).  
 
The first study to explore the role of endogenous Tmsb4x was published by 
Vasilopoulou et al. Global knockout of TB4 was achieved by deleting exon 2 of the 
Tmsb4x locus in mice of a C57BL/6 background. Interestingly, global knockout of 
Tmsb4x in these mice had no renal phenotype – the albuminuria and blood urea 
nitrogen (BUN) concentrations were equivocal to their wild type littermates. There 
was also no glomerulosclerosis or foot process effacement, exhibiting that 
endogenous Tmsb4x is expendable for healthy glomeruli and kidneys. However, this 
was not the case in the context of glomerular injury. The authors employed NTS 
nephritis in order to create an immune mediated glomerular injury, which mimics 
some of the features seen in human glomerulonephritis (Pippin et al. 2009). Loss of 
endogenous Tmsb4x exacerbated the effects of NTS nephritis at 21 days after 
disease induction, including a further 5-fold enhancement of albuminuria in Tmsb4x 
knockout mice with NTS nephritis compared to wild type mice with NTS nephritis, 
indicating glomerular filtration barrier leakage. Loss of Tmsb4x caused a significant 
decrease in creatinine clearance and an increase in BUN when compared with wild-
type mice with NTS injury. Tmsb4x knockout also led to exacerbated glomerular 
histological damage, in the form of enhanced crescent formation and hyaline 
deposits. The distribution of podocytes was further analysed by WT-1 
immunofluorescence. NTS did not cause changes to the number of WT-1 positive 
cells inside the glomerular tuft or in the parietal epithelium in wild type mice, 
however, Tmsb4x knockout caused a reduction of glomerular tuft WT-1 positive cells 
and increase in parietal WT-1 expression. The total number of renal corpuscle WT-1 
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positive cells did not change (Vasilopoulou et al. 2016), suggesting that the 
podocytes may be migrating from the glomerular tuft towards the parietal epithelium, 
which has previously been seen in podocyte injury in vivo (Brähler et al. 2016; 
Burford et al. 2014; Hackl et al. 2013).  
 
Next, the authors looked at glomerular inflammation at 21 days after disease 
induction by IHC. There were no statistical changes to the number of CD3 cells (T 
cell marker (Call et al. 2002)) or F4/80 positive cells (macrophage marker (Austyn 
and Gordon 1981)) inside or outside the glomerular tuft in wild type NTS nephritis 
compared with vehicle treated mice. Lack of Tmsb4x, however, caused a significant 
increase in the number of glomerular CD3 positive cells, glomerular F4/80 positive 
cells and F4/80 positive peri-glomerular cells compared to wild type littermates 
treated with NTS. The final in vivo component analysed was fibrosis, which was 
assessed by IHC and qPCR. NTS nephritis led to significant fibrosis in wild type 
mice, which was presented as collagen IV deposition inside and around the 
glomerular tuft and increased whole kidney Col4a gene expression compared with 
vehicle treated mice. NTS nephritis in Tmsb4x knockout mice caused an 
exacerbated increase in whole kidney Col4a and Acta2 (a-SMA) gene expression 
compared with wild-type mice with NTS nephritis. The in vivo data taken as a whole 
demonstrates a potential role of endogenous Tmsb4x in limiting onset of glomerular 
disease.  
 
To further explore the role of endogenous TB4 specifically in podocytes, the authors 
transfected mouse immortalised podocytes (Mundel, Reiser, et al. 1997) with siRNA 
that targeted Tmsb4x. A greater than 95% reduction in Tmsb4x mRNA levels 
following siRNA transfection was confirmed by qPCR. Three aspects were analysed: 
cell viability (MTT assay); cell migration (scratch wound) and F-actin (phalloidin 
staining and Rho GTPase activity). There was no change to podocyte viability 24, 48 
or 72 hours after Tmsb4x siRNA transfection. Knock-down of endogenous Tmsb4x 
led to a 50% increase in podocyte migration in vitro. This may be a potential 
mechanism to explain the effects of NTS nephritis in vivo, podocyte migration has 
been associated with foot process effacement and proteinuria in vivo (George et al. 
2012; Harris et al. 2013; Kriz et al. 2013). Finally, the analysis of the cytoskeleton 
showed an increase in cytoplasmic stress fibres in Tmsb4x knock-down podocytes, 
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with an upregulation of RhoA activity. RhoA activation has been shown to increase 
the formation of stress fibres in podocytes (Asanuma et al. 2006), so is likely to 
contribute to the mechanism by which this reorganisation of the actin cytoskeleton 
occurred.  
 
Two of the major properties of TB4 are G-actin regulation and suppression of 
inflammation. The disorganisation of podocyte F-actin in vitro provides evidence that 
this could be the mechanism of exacerbated albuminuria in vivo. The podocyte 
cytoskeleton is critical for the unique shape of the foot processes and its 
disorganisation leads to albuminuria (Shirato et al., 1996; Blaine and Dylewski, 
2020). It is possible that the absence of the actin binding properties of endogenous 
TB4 from podocytes caused exacerbated damage to the glomerular filtration barrier 
leading to an increase in albuminuria in NTS nephritis. The anti-inflammatory 
properties of TB4 also clearly played a role in the enhanced progression of injury in 
this model of immune mediated glomerular disease as shown by the increased 
macrophage accumulation in Tmsb4x knockout with NTS nephritis. It would be 
interesting to explore if the anti-inflammatory effect of TB4 was mediated by changes 
in the expression and activity of TNF-a and NFkB, as shown in the eye (Sosne, Qiu, 
Christopherson, et al. 2007).  
 
Angiotensin II administration to rodents is a model of renal injury that mimics some of 
the effects of hypertension in humans (Johnson et al. 1992). A study explored the 
effects of globally knocking out Tmsb4x and inducing hypertension in mice of a 
C57BL/6 background (Kumar et al., 2018). Tmsb4x knockout exacerbated 
albuminuria ~26-fold and reduced Nphs1 mRNA levels compared with wild type 
hypertensive mice, suggesting significant damage to the SD and glomerular filtration 
barrier. Macrophage infiltration and expression of ICAM-1, a pro-inflammatory 
protein, were also exacerbated in Tmsb4x knockout along with interstitial fibrosis 
(Kumar et al., 2018). Interestingly, loss of Tmsb4x did not exacerbate the increase in 
blood pressure, suggesting that the protective effects of endogenous TB4 were not 
involved in blood pressure regulation.  
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Further studies investigated the use of TB4 as a therapeutic agent in renal injury. 
One of the first studies used the unilateral ureteral obstruction (UUO) model in 
C57BL/6 mouse kidneys to induce interstitial fibrosis, tubular dilation, tubular atrophy 
and interstitial collagen deposition. Endogenous expression of TB4 in interstitial and 
tubular cells increased as disease progressed in UUO mice compared with control 
mice. Administration of 150 µg/day of TB4 intraperitoneally reduced interstitial 
fibrosis by 33% 14 days after obstruction as determined by Sirius red staining (Zuo 
et al. 2013). Another study employed the UUO model in Sprague Dawley rats to 
induce tubular interstitial fibrosis and a low dose (1 mg/kg/day) and high dose (5 
mg/kg/day) of TB4 were administered via intragastric lavage (Yuan et al. 2017). The 
low dose suppressed the onset of UUO-induced proteinuria, and the effect was more 
pronounced when the high dose was used. UUO also increased the relative area of 
fibrotic interstitial tissue, as determined by Sirius red staining, which both the low and 
high dose of TB4 prevented. TB4 also prevented UUO induced glomerulosclerosis, 
tubular lumen dilation and apoptosis of tubular epithelial cells. Transforming growth 
factor b (TGF-b) is a cytokine that promotes fibrosis and can induce tubular epithelial 
cells and mesangial cells to transform into fibroblast cells (Qiao et al. 2013; Yang 
and Liu 2001) and TB4 suppressed whole kidney expression of TGF-b and a-SMA in 
UUO mice, suggesting a potential mechanistic pathway. Interestingly, TB4 
administration in UUO also preserved E-cadherin expression in tubulointerstitial 
tissue, providing more evidence of its role in adherens junction preservation 
(Padmanabhan et al. 2020). The authors expanded on their in vivo findings by 
challenging tubular epithelial cells in vitro with TGF-b and treating with exogenous 
TB4. Exogenous TB4 prevented alterations to the gene transcripts and protein levels 
of E-cadherin and a-SMA. TB4 also prevented the TGF-b-induced increase in 
tubular apoptotic cells and markers, such as cleaved caspase-3, Bax and Bcl2 in 
tubular cells in vitro (Yuan et al. 2017). Combined, these two studies of the UUO 
model of kidney injury demonstrate that TB4 has a potential therapeutic role in this 
model of fibrosis.  
 
KK Cg-Ay mice of a C57BL/6 background are commonly used as a model of 
glomerular injury that reflects some of the features of human type 2 diabetic 
nephropathy (O’Brien et al. 2013). A study in these mice has explored the role of 
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exogenous TB4 via intraperitoneal administration of 100 ng/10 g body weight daily. 
TB4 decreased blood glucose levels and suppressed the urinary albumin 
concentration by 33%. TB4 also suppressed glomerular hypertrophy and mesangial 
matrix expansion seen in the KK Cg-Ay mice, suggesting that TB4 decelerates the 
onset of early-stage diabetic nephropathy (Zhu et al. 2015). There were no 
mechanistic assays undertaken in this study so the improvement of renal function 
could be associated with the reduction in blood glucose seen following TB4 
administration. The injury model induced in KK Cg-Ay mice is less severe than in the 
more widely used db/db mouse strain (Kitada, Ogura, and Koya 2016), and perhaps 
it would have been a more informative study to explore the role of exogenous TB4 in 
a more severe form of diabetic nephropathy. 
 
Exogenous TB4 has also been explored in the ischaemia reperfusion injury (IRI) 
model of kidney injury. Sprague-Dawley rats injected intravenously with 10 mg/kg of 
exogenous TB4 showed decreased inflammatory and apoptotic markers than sham 
control rats (Aksu et al. 2019). TB4 also suppressed the increase in BUN and blood 
creatinine concentration seen in IRI, indicating TB4 was protective of kidney function 
(Aksu et al. 2019). This work could have been taken further by showing the 
localisation of the inflammatory and apoptotic markers by IHC experiments, to 
identify if these markers were located in the medulla or cortex. 
 
All together, the in vitro and in vivo data strongly demonstrate that endogenous TB4 
is crucial in the progression of glomerular disease in mice, providing further rationale 
to explore the role of exogenous TB4 in glomerular disease models.  
 
1.6.6 Clinical applications of TB4 
The World Health Organisation has recently declared that the international non-
proprietary name for use of TB4 in clinical settings is Timbetasin (World Health 
Organisation 2018) and the company RegenRx is heavily involved in the clinical 
application of TB4. A number of clinical trials have investigated the safety and 
efficacy of administering exogenous TB4 to humans in 3 main forms; RGN-137, 
RGN-259 and RGN-352, all manufactured by RegeneRx. RGN-137 is a topical gel 
containing TB4 that was designed to be applied to external skin wounds, RGN-259 
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comes in the form of sterile TB4 containing eye drops and RGN-352 is a solution 
containing TB4 that was designed to be administered intravenously (Anon 2021) 
 
The earliest clinical trials of TB4 were in skin conditions. Venous stasis ulcers can 
develop on the ankle or lower leg of patients with chronic vascular diseases (Olin et 
al. 1999). A phase 2 clinical trial applied 0.01%, 0.03% and 0.1% of TB4 in the form 
of RGN-137 to patients experiencing these ulcers. There were no major adverse 
events when using any doses, showing that TB4 was safe to use and 0.03% of 
RGN-137 led to a 45% decrease in wound closure time compared to placebos 
((Guarnera, DeRosa, and Camerini 2010; RegeneRx - NCT00832091 2010) all 
references containing NCTXXXXXXXX refer to the clinical trial identification number 
on www.clinicaltrials.gov). Epidermolysis bullosa is a genetic group of skin conditions 
that can cause blistering of the skin in response to mechanical trauma (Pai and 
Marinkovich 2002) which can be due to the absence or functional loss of laminin-
332, type XVII collagen or integrin a6b4 (Keith et al. 2020). TB4 has been shown to 
synthesise laminin-332 (Sosne et al. 2004), making it an attractive therapy for 
epidermolysis bullosa. A previous phase 2 clinical trial using RGN-137 in 
epidermolysis bullosa was established between 2006 – 2012, however this was 
terminated due to lack of patient enrolment (RegeneRx - NCT00311766 2012). In 
mid-2019 patient recruitment re-started to study the efficacy and safety of RGN-137 
in patients with junctional and dystrophic epidermolysis bullosa, with the aim to apply 
RGN-137 topically to wounds once a day for up to 84 days. The primary outcome is 
to achieve a 50% reduction in the area of the wounds in less than 84 days 
(RegeneRx - NCT03578029 2019).  
 
Exogenous TB4 to treat disorders of the eye has almost fully completed the journey 
from lab bench to bedside in the form of RGN-259 (Sosne 2018). The stage two 
clinical trials for dry eye syndrome were successful. There was a statistical difference 
in mean ocular discomfort, tear film break up time and corneal fluorescein scores 
(marker for inflammation) (Nichols, Evans, and Karpecki 2020) in patients treated 
with RGN-259 groups compared to the vehicle groups, with a very low percentage of 
adverse events (RegeneRx - NCT01393132 2015; Sosne et al. 2013; Sosne and 
Ousler 2015). Stage three trials are currently ongoing. According to the RegenRx 
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website, as of August 2020 there had been 600 patients recruited to the current 
stage 3 clinical trials of RGN-259 in dry eye syndrome (Anon 2021; RegeneRx - 
NCT03937882 2020). RGN-259 is also currently in the third stage of phase 3 trials to 
treat neurotrophic keratopathy, which is a disease of the eye that causes corneal 
epithelial breakdown, impairment of healing and development of corneal ulceration, 
melting and perforation (Sacchetti and Lambiase 2014). The phase 2 trials 
performed in neurotrophic keratopathy were in four patients that all showed a 
reduction in epithelial defects with no discomfort when administered RGN-259 (Dunn 
et al. 2010). There was also an early clinical trial to examine the effect of RGN-259 in 
corneal wounds of diabetic patients following vitrectomy surgery, however this trial 
was terminated due to slow recruitment (RegeneRx - NCT00598871 2010). 
 
Doses of 42 mg, 120 mg, 420 mg and 1260 mg of RGN-352 have been tested in 
phase 1 clinical trials for their safety and efficacy when administered intravenously. 
There were no toxic or adverse events to patients given RGN-352 as a single dose 
or daily for 14 days (Ruff et al. 2010). RGN-352 was designed to be an interventional 
treatment for patients with myocardial infarction and other vascular and neurological 
disorders, such as multiple sclerosis and stroke (Anon 2021). Phase 2 trials hoped to 
improve cardiac function in a 28-day time frame by a single injection of 1200 mg or 
daily injection of 450 mg (for 3 three days) and then weekly injections of 450 mg. 
Unfortunately, the recruitment of patients was suspended in 2015 due to RegeneRx 
not being good manufacturing practice (GMP) compliant (exact reason unknown) 
(RegeneRx - NCT01311518 2015).  
 
It is also worth noting that TB4 has recently begun clinical trials sponsored by a 
Chinese company called Beijing Northland Biotech. Co., Ltd under the name of 
NL005 (Beijing Northland Biotech. Co. Ltd. 2021). These trials are similar to RGN-
352, where they have completed phase 1 clinical trials of recombinant human TB4 in 
an injectable form to study the safety at doses of 0.5 µg/kg, 2.0 µg/kg, 2.5 µg/kg, 5.0 
µg/kg, 12.5 µg/kg and 25 µg/kg of TB4 in healthy patients. The phase 1a and 1b 
trials were completed In late 2020 (Beijing Northland Biotech. Co. Ltd. - 
NCT04555850 2020; Beijing Northland Biotech. Co. Ltd - NCT04555824 2020) but 
no results have been posted to the clinical trial data base (www.clinicaltrials.gov).  
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However, the company website states that the phase 1 trials were successful and 
that they are currently in phase 2a clinical trials to study NL005 in patients with 
ischaemia-reperfusion injury caused by myocardial infarction (Beijing Northland 
Biotech. Co. Ltd. 2021).  
 
Overall, the safety data from the clinical trials is promising, and paves the way for 
TB4 to be explored in other tissue pathologies, such as CKD.  
 
1.6.7 AcSDKP 
In vivo, TB4 is metabolised relatively quickly as demonstrated by a time course study 
injecting synthetic TB4 into Swiss-Webster mice (Mora et al. 1997). Synthetic TB4 
(400 µg) was injected intraperitoneally and serum was collected via cardiac puncture 
at 2 minutes, 2 hours, 6 hours and 24 hours after administration and TB4 
concentration assessed by ELISA. Serum TB4 concentration peaked after 2 hours 
and returned to baseline after 6 hours, indicating that TB4 is metabolised during this 
time (Mora et al. 1997). One of the peptides that TB4 is metabolised to is a 
tetrapeptide termed N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is 
ubiquitous throughout mammalian cell types and also present in the plasma and 
urine (Junot et al. 1999; Le Meur et al. 2001; Pradelles et al. 1991). AcSDKP is 
located at the N terminus of TB4 and is generated through stepwise hydrolysis, 
involving meprin-a and prolyl oligopeptidase (POP) (Kumar et al. 2016). AcSDKP 
has anti-inflammatory and anti-fibrotic benefits in animal models of hypertension, 
stroke, myocardial infarction, autoimmune diseases and CKD, by reducing organ 
macrophage infiltration, cytokine and chemokine expression, NFkB activation, TGF-b 
expression and collagen deposition (Cavasin et al. 2007; Ding et al. 2014; Kumar 
and Yin 2018; C. Li et al. 2019; Yang et al. 2004). This section will focus on the role 
of AcSDKP in CKD models.  
 
The plasma concentration of AcSDKP in patients with CKD increases proportionally 
with disease severity and ACE inhibitors further enhance AcSDKP plasma 
concentration (Azizi et al. 1999; Le Meur et al. 2001). ACE is known to degrade 
AcSDKP, therefore the exacerbated increase in plasma concentration is likely due to 
ACE inhibition (Nagai et al. 2015). Diminished AcSDKP in Sprague-Dawley rats, as 
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achieved by inhibiting prolyl oligopeptidase via OMP secretion of buprenorphine, 
causes increased collagen formation around the glomeruli and vasculature, and 
glomerulosclerosis, as determined by IHC (Cavasin et al. 2007). This occurred 
without any disease induction, suggesting that endogenous AcSDKP is essential for 
regulation of renal collagen.  
 
The role of exogenous AcSDKP in the UUO model of renal fibrosis and inflammation 
has been explored in detail. Administration of 0.4 mg/kg/day of AcSDKP by OMP to 
Wistar rats was initiated on the day of UUO induction, which led to decreased 
fibrosis and inflammation in the obstructed kidney after 14 days. AcSDKP 
suppressed macrophage infiltration, lowered activation of NFkB and suppressed 
expression of TGF-b, aSMA and MCP-1 (Wang et al. 2010). In mice of a C57BL/6 
background, 1.6 mg/kg/day of AcSDKP was administered via OMP and the effects 
were assessed 5 and 14 days after UUO induction. AcSDKP decreased fibrosis at 
both time points, which was determined by a reduction in Sirius red IHC. There was 
also a decrease in fibronectin, plasminogen activator inhibitor-1 (PAI-1) and TGF-b 
signalling compared to UUO mice without AcSDKP (Zuo et al. 2013). Finally, in 
BALB/c mice, 1 mg/kg/day of AcSDKP via OMP suppressed tubulointerstitial fibrosis 
and collagen deposition in the cortex in UUO mice. Surprisingly, there was no 
reduction of macrophage accumulation after AcSDKP administration, which could be 
due to different doses and strains of mice (Chan et al. 2015).  
 
Exogenous AcSDKP has also shown therapeutic benefits in glomerulonephritis 
models. Wistar-Kyoto rats were administered with 1 mg/kg/day AcSDKP by 
subcutaneous OMP 2 weeks after the induction of anti-GBM glomerulonephritis 
(Omata et al. 2006). Exogenous AcSDKP suppressed the onset of 
glomerulosclerosis, interstitial collagen deposition and fibrosis 42 days after disease 
induction, as determined by IHC. Albuminuria increase and BUN development were 
prevented and levels of fibronectin, collagen I and collagen III were all suppressed 
with AcSDKP administration. TGF-b, a signalling protein that induces fibrosis, was 
also suppressed 42 days after disease induction (Omata et al. 2006).  
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Systemic lupus erythematosus (SLE) is another autoimmune disorder in which the 
body generates autoantibodies that target the glomerulus (Almaani et al. 2017). A 
study used transgenic MRL/MpJ-Faslpr/2J mice, which develop renal phenotypes that 
simulate SLE (Wu et al. 2016), that were treated with 800 ug/day of AcSDKP via 
OMP (Liao et al. 2015). Protein array analysis, Western blot and IHC revealed that 
AcSDKP suppressed glomerular complement levels and ICAM-1 expression as well 
as attenuated macrophage and T cell infiltration to the kidney. The suppression of 
these inflammatory compounds proved beneficial to kidney function, as AcSDKP 
significantly improved eGFR, albuminuria, and glomerulosclerosis. Furthermore, 
AcSDKP suppressed interstitial collagen formation, demonstrating its anti-
inflammatory and anti-fibrotic effects (Liao et al. 2015).  
 
AcSDKP is detectable in the urine of diabetic patients and urinary concentration 
increases as eGFR declines (Nitta et al. 2019). The role of exogenous AcSDKP has 
been explored in rodent models of type 1 and type 2 diabetic nephropathy, which 
were achieved by injection of streptozotocin and using db/db transgenic mice 
respectively (Wu and Yan 2015). Sprague-Dawley rats, 8 weeks after streptozotocin 
injection, were treated with 1 mg/kg/day of AcSDKP by OMP. While there was no 
improvement in renal function, AcSDKP improved fibrosis and diabetes-induced loss 
of glomerular nephrin (Castoldi et al. 2013). Further studies explored AcSDKP co-
administration with the ACE inhibitor Imidapril in type 1 diabetic nephropathy. 
AcSDKP (0.5 mg/kg/day via OMP) and Imidapril co-treatment of CD1 mice 16 weeks 
after streptozotocin injection was maintained for 8 weeks. Mesangial expansion, 
fibrosis and aSMA positive cells were all reduced with commination treatment 
compared to ACE inhibitor treatment alone (Nagai et al. 2014). AcSDKP was also 
found to restore the expression of the anti-fibrotic microRNAs miR-29 and miR-let-7 
in diabetic kidneys. To further elucidate potential mechanisms, the authors cultured 
human dermal microvascular endothelial cells and found that AcSDKP blocked 
endothelial to mesenchymal transition, which has been shown to contribute to 
glomerulosclerosis in diabetic nephropathy (Li, Qu, and Bertram 2009; Nagai et al. 
2014). More recently, type 1 diabetic CD1 mice were also treated with 0.5 mg/kg/day 
of AcSDKP via OMP, in co-treatment with Imidapril 16 weeks after disease induction. 
It was shown that co-treatment of Imidapril and AcSDKP prevent endothelial to 
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mesenchymal transition, collagen 1 and fibronectin deposition in the kidney. 
AcSDKP and ACE inhibition disrupted the metabolic reprograming in diabetic 
nephropathy by restoring the protein levels of SIRt3, CPT1a and PGC1a, while 
suppressing the diabetic-induced increased protein levels of GLUT1, PKM2 and 
PDK4 (Srivastava et al. 2020). AcSDKP has also been administered (1 mg/kg/day 
via OMP) in a model of type 2 diabetes in db/db mice of a C57BL/6 background. 
Although AcSDKP was not able to prevent the increase in albuminuria, it was able to 
supress the increase in glomerular mesangial matrix expansion and plasma 
creatinine concentration. AcSDKP also alleviated the upregulation of fibronectin in 
db/db mice, and collagen IV, through suppression of TGF-b expression (Shibuya et 
al. 2005).  
 
Finally, AcSDKP has been shown to be therapeutic in hypertension related CKD 
rodent models. C57BL/6 mice treated with DOCA-salt, which reproduces some of the 
effects of hypertension in humans, saw a reversal of detrimental effects when treated 
with 800/kg/day AcSDKP by OMP. AcSDKP suppressed kidney monocyte and 
macrophage infiltration, reduced glomerulosclerosis and mesangial matrix expansion 
and furthermore, prevented albuminuria and glomerular nephrin loss. The protective 
effects of AcSDKP were independent of blood pressure regulation, as the systolic 
blood pressure of treated mice remained high (Rhaleb et al. 2011). More recently, 
exogenous 1.6 mg/kg/day of AcSDKP has been administered to Zucker Obese rats 
via OMP that develop hypertension upon consuming a high salt diet. The rats also 
developed diabetes-like symptoms, as glucose intolerance and urine volume rose. 
IHC revealed that the Zucker obese rat kidneys had more Cd68 positive 
macrophages on the high salt diet compared to the normal salt diet, which AcSDKP 
prevented. AcSDKP also prevented the high salt induced development of cortical 
and medullary fibrosis, as quantified by Sirius red staining. Zucker obese rats 
developed glomerulosclerosis compared to the Zucker lean rats, which was 
exacerbated by the high salt, but AcSDKP prevented this exacerbation (Maheshwari 
et al. 2018). Overall, the protective effects of AcSDKP are well documented in rodent 
models of kidney injury, in particularly demonstrating anti-inflammatory and anti-
fibrotic effects.  
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 Gene therapy using AAVs 
1.7.1 What is AAV?  
TB4 is metabolised rapidly when administered to mice. Therefore, some previous 
studies have used AAV encoding Tmsb4x as a therapeutic strategy in experimental 
models of animal injury to induce a persistent, systemic upregulation of TB4. 
AAV.Tmsb4x has been shown to induce neovascularisation and vessel maturation in 
a model of ischaemia in rabbit hind limbs (Hinkel et al. 2014). AAV.Tmsb4x also 
improved the cardiac output of pigs 56 days after myocardial infarction when used as 
a preventative strategy, as determined by increased ejection fraction, reduced blood 
pressure and improved myocardial contractile capability (Ziegler et al. 2018). These 
studies have shown that AAV.Tmsb4x can provide a beneficial effect in experimental 
models.  
 
AAV is a non-pathogenic single stranded DNA parvovirus with potential as a 
therapeutic tool (Schultz and Chamberlain 2008). AAV normally require a helper 
virus, such as an adenovirus, for replication and assembly in vitro (Muzyczka 1992), 
hence the name AAV. The first documented production of genetically modified AAV 
particles that could infect and transduce mammalian cells in vitro was in the mid-
1980’s (Hermonat and Muzyczka 1984; Tratschin et al. 1984). Since then, AAV gene 
vectors are emerging as serious candidates to induce long term gene expression in 
scientific and clinical settings. The viral genome is ~4.7 kilobases that contains two 
open reading frames (ORFs) – the rep (replication proteins) and cap (capping 
proteins) regions (Vincent, Piraino, and Wadsworth 1997). The capsule is composed 
of 3 types of proteins; Virion protein 1 (VP1), VP2 and VP3, which assemble to form 
a spherical shell composed of ~60 subunits in a 1:1:10 ratio (Li and Samulski 2020; 
Xie et al. 2002).  
 
The viral genome is flanked by inverted terminal repeats (ITRs) which can be 
manipulated to package recombinant DNA into the viral particles (Zhou et al. 2017). 
Since the viral particles are so small in size, the recombinant transgene must be 
smaller than ~5 kilobases in length (Muzyczka 1992). The transgene is inserted into 
the ITR between a promotor and a poly (A) tail (Gao et al. 2002). One common 
method to engineer the transgene into the cassette is by triple transfection of host 
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cells in vitro (Nass et al. 2018). Commonly used host cells are human embryonic 
kidney (HEK) cells, due to the human-like post translational modifications and high 
transfection efficiency (Feng et al. 2007; Hu et al. 2018; Senís et al. 2014). The 
recombinant transgene, equipped with the ITR of choice and a promotor (commonly 
cytomegalovirus (Gorman et al. 1989)), are transfected into the host cells in vitro with 
cis-plasmid adenovirus helper plasmids along with a second plasmid in trans 
containing the viral cap and rep genes (Gao et al. 2002). The third plasmid contains 
the adenoviral helper plasmid, which assists the formation of the viral particles in the 
host cells. The host cellular machinery then generates the viral proteins and, along 
with the helper plasmid, assembles them into the viral particles (Sonntag et al. 
2011). Once the viral assembly has occurred, cells are harvested and the virus is 
purified (Gao et al. 2002).  
 
Although there are hundreds of serotypes and pseudo-serotypes of AAVs, 12 main 
primate isolated serotypes have been described (AAV 1-12) (Chiorini et al. 1997, 
1999; Gao et al. 2004; Mori et al. 2004; Muramatsu et al. 1996; Rutledge, Halbert, 
and Russell 1998; Schultz and Chamberlain 2008; Srivastava, Lusby, and Berns 
1983; Xiao et al. 1993). The capsid subunits each contain 9 variable regions that 
determine tissue tropism and intracellular trafficking (Li and Samulski 2020; Xie et al. 
2002). Researchers can also generate hybrids of two different serotypes to tailor the 
viral characteristics to their needs. For example, AAV 2/7 can be generated by the 
triple transfection method on the trans plasmid to produce a hybrid virus that 
contains the reproduction genome of serotype 2 and the capsid of serotype 7 
(Hildinger et al. 2001). Therefore, the tissue tropism of this hybrid virus would be the 
same as serotype 7.  
 
AAVs are commonly used in rodents as a vector to upregulate genes of interest (Li 
and Samulski 2020; Schultz and Chamberlain 2008), but the appropriate serotype 
must be used depending on the target organ. Tissue tropism means that the virus 
will bind to a receptor on a cell type located in said tissue, be internalised and take 
effect. An excellent study assessed the tissue tropism of AAV serotypes 1-9 in 
BALB/c mice by loading each serotype with luciferase (Zincarelli et al. 2008). The 
AAVs were injected via the tail vain (1x1011 viral particles). D-Luciferin substrate was 
then injected intraperitoneally before the whole mouse was imaged in a light-tight 
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chamber that detected photons emitted by luciferase binding to its substrate. The 
injection of D-luciferin took place 7, 14, 29, 59 and 100 days after AAV administration 
(Zincarelli et al. 2008). AAV serotypes 1, 6, 7, 8 and 9 luciferase activity could be 
detected at day 7, serotypes 4 and 5 at day 14 and serotypes 2 and 3 at day 29. 
Serotypes 2, 3, 4 and 5 were deemed low expression due to the number of photons 
emitted. AAV1, 6 and 8 were deemed medium expression and AAV7 and 9 were 
deemed to cause high expression (Zincarelli et al. 2008). The authors then isolated 
the heart, liver, lung, hamstring, gastrocnemius muscle, quadricep, brain, testes and 
kidney to measure luciferase activity. The heart contained high luciferase levels from 
serotypes 1-4 and 6-9, but AAV5 luciferase was not present. The liver was also 
transduced by a wide range of serotypes and only AAV3 luciferase expression was 
not present. Luciferase from AAV4, 6, 7, 8 and 9 were present in the lung and 
luciferase from all serotypes (AAV1-9) were present in the hamstring. The 
gastrocnemius muscle was transduced by AAV1, 3, 6, 7 8 and 9 and the quadricep 
was transduced by AAV 3, 6, 7, 8 and 9. The brain showed transduction of only AAV 
8 and 9 and the testes only AAV9. There was no signal from the kidneys, suggesting 
AAV transduction had not occurred. However, all serotypes were detected in all 
tissue types analysed by qPCR (Zincarelli et al. 2008). The serotypes could have 
infected the cells but not have been packaged and transported to the nucleus so that 
transcription and translation of the transgene could occur. Another more recent study 
has confirmed this theory and found that while most AAV serotypes can infect cells 
in most organ systems, some were unable to express their respective transgenes at 
the RNA level (Westhaus et al. 2020). The mechanism is not fully understood; 
however, a working theory is that although AAV serotypes can enter the cells, they 
require helper viruses to express their transgene.  
 
The ability of AAV for effective gene transduction to the kidney is currently unclear, 
as researchers face challenges targeting the kidney in animal studies. Studies are 
beginning to emerge that altered AAV capsids and administration methods may have 
improved tropism to the kidney in experimental models (Kevany et al. 2019; C. Yang 
et al. 2020), A synthetic AAV has recently been generated, serotype Anc80, that has 
shown high efficiency to transduce adult kidney mesenchymal cells and 
myofibroblast progenitors (Ikeda et al. 2018). Furthermore, engineering of AAV 
serotypes with alternative promotors to target the kidney has also shown effective 
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transduction of kidney cells (Schievenbusch et al. 2010). Alternatively, transduction 
with AAVs that encode secreted peptides presents another way to deliver viral 
peptides to the kidney. 
 
1.7.2 Mechanisms of cellular entry and transgene expression 
For the transgene to be upregulated, the AAV needs to gain entry to the host cell 
and translocate to the nucleus (Figure 1.8). A glycosylated cell surface AAV receptor 
(AAVR) was identified in host cells through genome-wide screening for genes 
essential for signal transduction (Pillay et al. 2016). The authors then used 
CRISPR/Cas9 to genetically alter AAVR to block the binding to AAV1, 2, 3, 5, 8, and 
9 in HeLa cells and showed no serotype could enter the cells. Furthermore, they 
then created AAVR knockout mice with an FVB background and demonstrated by 
luciferase assay that AAVR knockout mice were resistant to AAV infection (Pillay et 
al. 2016). Finally, they also demonstrated through immunofluorescence in vitro in 
HeLa cells that binding of AAV to AAVR causes endocytosis of AAVR which then 
traffics AAV to the Golgi-apparatus (Pillay et al. 2016). However, another study 
emerged that showed some AAV serotypes are able to enter cells independently of 
AAVR (Dudek et al. 2018). The authors demonstrated in AAVR knockout cells of 
different cell lines (HeLa, Huh7 and A549) that AAV4 was able to gain entry to the 
cells in a comparable manner to wild type cells. Furthermore, they proved that AAV4 
was unable to bind to AAVR, even in the presence of adenovirus helpers, 
demonstrating multiple entry mechanisms for different virus serotypes (Dudek et al. 
2018).  
 
It is thought that the AAV particles are delivered to the nucleus via endosomes and 
lysosome trafficking, in which the cytoskeleton is implicated (Li and Samulski 2020; 
Wang, Tai, and Gao 2019). The theory is that after internalisation the virus is 
encapsulated in an early endosome that is coated in clathrin. The clathrin coated 
endosome is then tracked to the peri-nuclear area, carried by the microtubule 
cytoskeleton, as demonstrated by disruption of microtubules in HeLa cells where 
AAV2 was unable to translocate to nuclei (Xiao and Samulski 2012). The intact virus 
inside the endosome will be exposed to an increasingly acidic environment, as the 
early endosome (pH 6) transitions to the late endosome (pH 5) and then the 
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Figure 1.8 – Mechanism of AAV entry and transgene expression. Diagram depicting 
AAV transduction. Viral particles can enter cell via AAVR and endocytosis. AAVs are 
translocated to nucleus in an endosome/lysosome before escape. AAVs are either degraded 
by proteosome or enter the nucleus. The capsid is uncoated, and the transgene undergoes 
second strand synthesis and circularisation. The episomal DNA is then converted to mRNA, 
exits the nucleus and the viral protein is synthesised by the cell. The viral protein is then 
either secreted by the cell or it undertakes its cellular duties. ssDNA, single stranded 
deoxyribonucleic acid; ER, endoplasmic reticulum; AAV, adeno associated virus; AAVR, 
adeno associated virus receptor. Original diagram. 
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lysosome (pH4) (Sonntag et al. 2006). The AAV then escapes from the lysosome (or 
late endosome) as the membrane is degraded (Sonntag et al. 2006).  
 
The virus can then follow 1 of 2 paths – it can either enter the nuclear pores 
(successful gene delivery) (Kelich et al. 2015; Xiao et al. 2002), or it can be 
ubiquitinated and degraded by proteasomes into peptides (unsuccessful gene 
delivery) (Zhong, Li, et al. 2008). If the gene delivery is successful, the AAV capsid is 
uncoated in the nucleus and the viral single stranded DNA is exposed (Thomas et al. 
2004). However, this single stranded DNA molecule must undergo second strand 
synthesis to form double stranded DNA, a rate limiting step in gene transduction 
(Ferrari et al. 1996; Fisher et al. 1996). Second strand synthesis is initiated at the 
self-primed 3’ end of the ITR (Zhong, Zhou, et al. 2008; Zhou et al. 2008). The 
transduction window can be shortened by utilising a mutated ITR to form self-
complementary genome configurations. This can also be achieved by strand 
annealing, where 5’ and 3’ genomes are packaged into separate viral particles and 
when the capsid degradation occurs, the two strands pair inside the nuclear 
envelope (McCarty et al. 2003; Nakai, Storm, and Kay 2000). The genome is then 
circularised to increase the stability (Duan et al. 1998). It is important to note that in 
most AAV transduction, the viral gene is not integrated into the host genome (Li and 
Samulski 2020). The AAV genome is classed as episomal DNA, as it is located in 
the nucleus, but not in the hosts chromatin (Wang et al. 2019). This is particularly 
important, as it means that the expression of the trans gene persists even after 
mitosis (Wang et al. 2019).  
 
The transgene then undergoes transcription, translation and post-translational 
modifications like any other protein innately synthesised by the host cell. The viral 
protein will then undertake its natural cellular tasks, or it can be secreted into the 
blood stream to reach off site targets (Streck et al. 2005; Subbarayan et al. 2020; 
Yoshioka et al. 2004). The persistence of AAV transgenes can be months or years 
depending on the host or virus serotype. One study injected rhesus monkeys with 
AAV9 and AAV2/8 that carried a firefly luciferase cassette and measured the 
transgene expression monthly and found stable expression up to 2 years after first 
injection (Tarantal et al. 2017). This was taken further and the levels of AAV1 and its 
transgene erythropoietin were assessed 5 years after administration to Macaca 
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fascicularis (Guilbaud et al. 2019). The authors found that there was a peak in 
erythropoietin levels throughout the first year but the level remained steadily higher 
than control animals after 5 years (Guilbaud et al. 2019).  
 
Transgene persistence studies in mice take place over considerably less time than 
non-human primates due to differences in life span. One early study injected Swiss 
Webster mice with 3x106 viral particles of AAV-LacZ (study does not state serotype) 
and immunostained various muscles with anti-b-galactosidase antiserum 8 months 
after injection. The study found stable expression of b-galactosidase at 8 months 
post injection and the level of positive immunostaining was comparable to mice 
analysed after 7 days (Xiao, Li, and Samulski 1996). Luciferase encoding AAV 1-9 
administration in BALB/c mice demonstrated luciferase activity 9 months after the 
injections of each respective AAV and found that only AAV2 transgene expression 
was not sustained (Zincarelli et al. 2008).  
 
Gene therapy strategies have been trialled in clinical settings since the first clinical 
trial in 2012 that restored lipoprotein lipase deficiency in order to prevent pancreatitis 
attacks (Ylä-Herttuala 2012). Since the success of this trial, more clinical trials have 
been approved. AAV therapy has been successfully trialled in haemophilia A and B 
by restoring Factor VII and Factor IX (George et al. 2017; Nathwani et al. 2011, 
2014). Clinical trials have also been undertaken and well tolerated in a range of eye 
disorders with some success, however a large amount of variability between patients 
(Jacobson et al. 2015; Li and Samulski 2020; Moore et al. 2018). AAV therapy has 
also been explored in heart disease, however, with limited success. AAV therapy 
was well tolerated with no adverse effects, but failed induce a therapeutic benefit (Li 
and Samulski 2020). Currently, there are no clinical trials listed to treat any kind of 




 Aims and hypothesis 
Ten percent of the world have CKD. In some patients, CKD can be catastrophic, 
leading to ESKD, requiring lifelong dialysis or kidney transplant. Identification and 
analysis of molecules that can slow the progression of CKD to ESKD has the 
potential to save lives. Prevention of podocyte cytoskeletal disorganisation is thought 
to be a mechanism that can slow the development of ESKD by protection of the 
glomerular filtration barrier. Therefore, manipulation of actin regulating molecules is 
an attractive target to alleviate glomerular disease. To investigate this, this thesis 
examined the role of TB4, a molecule which sequesters G-actin (Sanders et al. 
1992), in animal and cell culture models of glomerular a podocyte injuries. 
 
The hypothesis of this thesis was that administration of exogenous TB4 would 
prevent the onset of podocyte and glomerular damage via its actin modulating and 
anti-inflammatory properties.  
 
The aims of this thesis were to: 
• Develop an in vitro model to assess the therapeutic effect of exogenous TB4 
on healthy and ADR-injured mouse immortalised podocytes. 
• Explore the protective role of exogenous TB4 in cytotoxic ADR injury in vivo.  




Chapter 2: Exogenous thymosin b4 prevents Adriamycin 
induced cytoskeletal disorganisation in vitro 
 Introduction 
CKD is a devastating condition that affects around 5.6 million people in the U.K. 
(Bikbov et al. 2020). Screening studies revealed many cases of CKD remain 
undiagnosed (Hirst et al. 2020) causing a number of CKD patients to progress to 
ESKD. The current therapies for CKD patients include lifestyle changes, lifelong 
dialysis, pharmacological intervention (such as ACE inhibitors) or kidney 
transplantation (Chen, Knicely, and Grams 2019). However, these therapies are not 
sufficient to stop the progression of CKD to ESKD. One of the main causes of ESKD 
is the breakdown of the glomerular filtration barrier (Gorriz and Martinez-Castelao 
2012), which consists of capillary endothelial cells, the GBM and epithelial cells 
named podocytes (Patrakka and Tryggvason 2010). Podocytes project finger like 
extensions called foot processes, which wrap around the glomerular capillaries. The 
unique shape of healthy podocytes is maintained by the actin cytoskeleton (Faul et 
al. 2007; Welsh and Saleem 2012), a dynamic structure found in most eukaryotic 
cells (Gunning et al. 2015). The responsibilities of F-actin include maintenance of 
cellular architecture (Clarke and Spudich 1977), cell motility (Mitchison and Cramer 
1996), focal adhesion (Parsons et al. 2010) and vesicular transport (Schuh 2011). 
Regulation of F-actin architecture in podocytes is essential for a functioning filtration 
barrier and is maintained by a number of actin regulating proteins, including TB4 
(Paavilainen et al. 2004). During podocyte injury, the foot process network of F-actin 
can become disorganised, leading to foot process effacement and proteinuria (Faul 
et al. 2007; Welsh and Saleem 2012).  
 
The cellular role of TB4 is to sequester G-actin monomers in the cytosol (Sanders et 
al. 1992) to maintain a cellular reservoir of G-actin that is readily available for 
polymerisation. Expression of TB4 peptide, and its mRNA precursor Tmsb4x, have 
been found in embryonic mouse and human kidneys as well as mature mouse, rat 
and human podocytes (Guinobert et al. 2005; Vasilopoulou et al. 2016, 2018; Xu et 
al. 2005). Loss of podocyte Tmsb4x mRNA leads to reorganisation of cortical actin 
stress fibres to cytoplasmic stress fibres and an increase in podocyte migration in 
vitro (Vasilopoulou et al. 2016). As it is thought that F-actin reorganisation and 
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podocyte migration in vitro represents foot process effacement in vivo (N. Endlich, 
Siegerist, and Endlich 2017; Suleiman et al. 2017). This data demonstrates the 
critical role of endogenous TB4 in maintaining the cytoskeletal structure and function 
in podocytes. The same study showed that while a loss of global Tmsb4x transcripts 
in C57BL/6 mice had no effect on healthy glomeruli, it exacerbated nephrotoxic 
serum nephritis, with an increase in albuminuria, glomerulosclerosis accompanied by 
podocyte loss (Vasilopoulou et al. 2016). These in vivo findings indicate that 
endogenous TB4 may play an important role in the progression of CKD, however, 
the effects of exogenous TB4 on podocytes are not known. 
 
Due to the critical role that the presence of TB4 plays in maintaining the function of 
the podocyte cytoskeleton, it was postulated that treatment with exogenous TB4 may 
have a therapeutic role in a podocyte injury model that directly targets the 
cytoskeleton. ADR, an anti-cancer drug (Kim and Kim, 1972; Momparler et al., 1976; 
Mirski, Gerlach and Cole, 1987) that has been associated with nephrotoxic side 
effects in some patients (Burke et al. 1977; Klastersky et al. 1985; Wollina et al. 
2000), was used to induce podocyte injury in this chapter. ADR mimics some of the 
characteristics of human FSGS (Wang et al. 2000) when administered to rodents, 
and has previously been shown to lead to podocyte damage in vitro and in vivo 
(Huang et al. 2016; Marshall et al. 2010; Xie et al. 2019). The specific characteristics 
of ADR-injury in vitro include F-actin rearrangements, a loss of cytoplasmic and 
cortical actin stress fibres (Chen et al. 2017; Liu et al. 2012; X. Liu et al. 2018), and a 
decrease in podocyte viability, either by apoptosis (Karger et al. 2016; Xu et al. 
2018) or detachment from the matrix (Dai et al. 2019; Wang et al. 2018). These 
detrimental effects to podocytes make ADR an ideal injury model to employ in this 
study.  
 
 Aims and Hypothesis 
The hypothesis of this section of the thesis is that exogenous TB4 prevents ADR-
induced podocyte cytoskeletal reorganisation, changes to motility and loss of cell 
viability in vitro. The first aim of this section is to assess the effects of TB4 on healthy 
podocytes by analysis of the F-actin cytoskeleton, motility and viability. Secondly, 
this section aims to determine the optimal concentration of ADR to induce podocyte 
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injury. The final aim of this chapter is to assess the effect of exogenous TB4 on 
ADR-injured podocyte F-actin organisation, cellular motility, and cell viability.  
 
 Materials and methods 
Unless stated otherwise, all materials were obtained from ThermoFisher Scientific, 
MA, U.S.A. 
 
2.3.1 Immortalised mouse podocyte cell culture 
The flasks used for mouse podocyte cell culture were coated in 0.1 mg/ml of 
collagen I (Merck U.K., Dorset, U.K.) for 1 hour in a 37 °C incubator. The collagen I 
solution was extracted from the flasks, which were then washed twice with 
Dulbecco’s phosphate buffered saline (D-PBS) before adding the cells. The media 
used to culture mouse podocytes was Roswell Park Memorial Institute – 1640 
(RPMI-1640) cell culture media with 10% foetal calf serum (FCS) and 1% 
penicillin/streptomycin (P/S). All reagents were prewarmed to 37 °C prior to use 
unless stated otherwise. 
 
To study the therapeutic effect of exogenous TB4 on podocytes, an immortalised cell 
line was used, kindly provided by Dr Peter Mundel, Harvard Medical School (Mundel, 
Reiser, et al. 1997). The cell line was generated from isolated glomeruli of kidneys 
from adult H-2Kb-tsA58 mice. The mice harbour the gene transcript for simian virus 
40 (SV40) under the control of the mouse major histocompatibility complex H-2Kb 
promoter. SV40 is a large T antigen on the surface of the cell which, when exposed 
to interferon gamma (IFN-g) at 33 °C, allows cells to freely proliferate (Jat et al. 
1991). When cells are then deprived of IFN-g and thermo-switched to 37 °C, the 
SV40 large T antigen is inactivated, inducing cell growth arrest and cellular 
senescence leading to podocyte differentiation (Mundel, Reiser, et al. 1997).  
 
Undifferentiated mouse podocyte cells were thawed rapidly from -80 °C in a 37 °C 
water bath, added to 9 ml of media and centrifuged at 1200 rpm for 5 minutes. The 
cell pellet was resuspended in 5 ml of media and the cell suspension added to a 
collagen I-coated T25 flask along with 50 U/ml of IFN-g. The flask was then placed in 
a 33 °C incubator with 5% CO2. Once the cells reached 90% confluence, the media 
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was extracted, and the cell layer washed with D-PBS. Next, the cell layer was 
disrupted with 1 ml of 0.25% Trypsin-EDTA at 33 °C for no more than 5 minutes. 
Trypsinisation was halted by diluting in 9 ml of media before centrifuging for 5 
minutes at 1200 revolutions per minute (rpm). Fresh collagen-1 T75 flasks were 
washed with D-PBS prior to addition of cells. After centrifugation, the cell pellet was 
resuspended in 10 ml of RPMI-1640 media. To achieve 1:10 dilution, 1 ml of the cell 
suspension was added to the flask and the remaining 9 ml was discarded. Finally, 9 
ml of RPMI-1640 was added to the new flask containing the cells, with 50 units per 
ml (U/ml) of IFN-g. The cells were then returned to 33 °C for maintenance of the 
undifferentiated cell line. Fresh media/IFN-g changes occurred every 2 days. 
 
The protocol for induction of podocyte differentiation was similar to the maintenance 
of the undifferentiated cell line. After trypsinisation and centrifugation, the cells were 
once again diluted 1:10 before addition to a collagen coated T75 flask. Differentiated 
podocytes were cultured in the absence of IFN-g and were thermoswitched to 37 °C 
for 14 days. Media changes occurred every 2 days. For experimental studies, all 
cells were used between passage 15 and 30.  
 
2.3.2 Counting and plating of differentiated mouse podocytes 
All plates were coated with 1% of Matrigel basement matrix membrane (Corning, NY, 
USA) in RPMI-1640 for 40 minutes at 37 °C. Matrigel contains a high concentration 
of cell matrix proteins, such as laminin and collagen IV, to facilitate cell adhesion. 
The Matrigel solution was then removed, and the plates were washed twice with D-
PBS before adding the differentiated cells. The cells were harvested by 
trypsinisation, media was added to the disrupted cells and the suspension was 
centrifuged at 1200 rpm for 5 minutes. The supernatant was then discarded, and the 
pellet resuspended in 2 ml of media. To determine cell number, 10 µl of the cell 
suspension was mixed with 10 µl of 0.4% Trypan Blue and transferred to a 
haemocytometer. The average cell number of 4 fields of view was calculated and it 
was ensured there were no more than 10% of dead cells present in the suspension. 
For 6 well plate assays, 50,000 cells were plated, for 4 well chamber slides, 5,000 
cells were plated and for 96 well plates, 2,000 cells were plated per well. The cells 
were then placed back in 37 °C for a further 24 hours before each assay.  
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2.3.3 Administration of TB4 or ADR to mouse podocytes 
Synthetic TB4 was obtained in a stock solution of 1.5 mg/ml dissolved in D-PBS 
(ReGeneRx Biopharmaceuticals Inc, USA). Working doses were achieved by serial 
dilution; 66.67 µl of the 1.5 mg/ml TB4 stock was diluted in 9.93 ml of RPMI-1640 
media for a concentration of 10,000 ng/ml TB4. The 10,000 ng/ml TB4 solution was 
then further diluted 1:100 to achieve the working concentration of 1000 ng/ml TB4. 
Further 1:10 serial dilutions achieved the three doses of 10 and 100 ng/ml TB4. The 
final doses of 10, 100 and 1000 ng/ml were chosen due to their occurrence in 
previous studies using exogenous TB4 in vitro (Sosne et al. 2004; Sosne, Qiu, 
Christopherson, et al. 2007; Zhang et al. 2008). RPMI-1640 media alone was used 
as the control for all cell culture experiments. A wide range of ADR concentrations 
have previously been used to induce podocyte injury (Cormack-Aboud et al. 2008; 
Dai et al. 2010; Nijenhuis et al. 2011; Schneider et al. 2017). Therefore, dose 
response assays were undertaken to determine the appropriate concentration to 
induce podocyte injury. Concentrations of 0, 0.0125, 0.125, 0.25, 0.5, 1.0 or 2.5 
µg/ml of ADR (Merck U.K.) were achieved by serial dilutions before addition to the 
cell culture media. Finally, to determine the effect of exogenous TB4 on ADR injured 
podocytes, concentrations of 0.0125 µg/ml and 0.125 µg/ml ADR were chosen with 
or without all three doses of 10 ng/ml, 100 ng/ml and 1,000 ng/ml TB4 used 
previously. A summary of the experimental set up can be found below (Figure 2.1).  
 
Day -15 Day -1 Day 0 Day 1/2/3
Maintaining cells 
at 33oC in the 
presence of IFN-ɣ
Thermo-switch 








Figure 2.1 - Experimental design for in vitro assays. Schematic of the in vitro 
experimental design. Immortalised, undifferentiated mouse podocytes were grown at 33 °C 
before thermoswitching to 37 °C for 14 days. The differentiated podocyte cells were then 
plated onto the appropriate dish for 24 hours before assays were undertaken. 
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2.3.4 Cell viability 
Cell viability was determined by methyltetrazolium (MTT) assay 24, 48 and 72 hours 
after RPMI-1640/TB4/ADR treatment to 2,000 mouse immortalised podocytes in a 96 
well plate (Greiner Bio-One, Kremsmünster, Austria). At the desired end point, 10% 
(v/v) MTT reagent (3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium Bromide) 
(Merck U.K.) (dissolved in 5 mg/ml in PBS) was added to the media of each well for 
3 hours at 37 °C. After 3 hours, the media was aspirated and 100 µl of dimethyl 
sulfoxide (DMSO) (Merck U.K.) was added to each well for 15 minutes in the dark. 
Absorbance of 4 replicates was read at 565 nm on a plate reader (Tecan Infinite 
M200 Pro, Männedorf, Switzerland). Due to variability of the assay, the results were 
normalised to the 24-hour RPMI-1640 only values of their respective independent 
experiments. Experiments were repeated independently at least 3 times. 
 
2.3.5 Scratch wound assay 
To assess podocyte migration, a scratch wound assay was used. Mouse podocytes 
were plated onto 6 well plates and treated with RPMI-1640 alone or containing TB4 
and/or ADR as described in 2.3.2 and 2.3.3. After 24 hours, the scratch wound was 
generated by dragging a 200 µL pipette tip along the cell surface so that the cells 
detached from the plate, creating a wound. The wells were washed with 2 ml of 
warmed media, so that there were not detached cells left in the well. Cells were 
treated with 2 ml of media alone or the media containing ADR/TB4 were added to 
each well. Four fields of view of the cells were imaged at 0, 6 and 24 hours at 10x 
magnification. The images were taken on the brightfield mode of an Olympus IX71 
inverted Tissue Culture scope (Olympus, Tokyo, Japan). The number of cells that 
migrated into the wound area were counted at 6 and 24 hours after wound induction. 
The average of 4 fields of view were calculated and the experiments were repeated 
independently at least 3 times.  
 
2.3.6 Phalloidin staining of mouse podocytes 
F-actin organisation and amount was analysed after staining and visualisation with 
Acti-stainTM 488 Phalloidin (Cytoskeleton Inc., USA). Cells were plated onto 4 well 
chamber slides and administered with RPMI-1640 alone or TB4 and/or ADR as 
described in 2.3.2 and 2.3.3. After 24 hours, media was aspirated, and the cells were 
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treated with the desired dose of TB4/ADR for 24 hours at 37 OC. The cells were then 
washed with D-PBS and fixed with 5% PFA and 5% sucrose in PBS for 20 minutes. 
After fixation, cells were washed in PBS and permeabilised in 0.5% Triton X-100 in 
PBS for 10 minutes. The cells were then washed in 0.1% Triton X-100 in PBS and 
incubated in block solution (10% FCS, 1% BSA and 0.1% Triton X-100 in PBS) for 
60 minutes. Directly after blocking, the cells were incubated with 100 nM of Acti-
stainTM 488 Phalloidin for 30 minutes in the dark to stain for F-actin. After another 
washing stage in PBS, the cells were incubated in 10 µg/ml Hoechst 33342 to stain 
nuclear chromatin for 10 minutes in the dark. The slide was then mounted on a 
coverslip with SlowFade fluorescent mounting media prior to imaging with an air 40x 
objective on an Eclipse 50i upright fluorescent microscope (Nikon Instruments, 
Melville, USA). Hoechst 33342 was excited with a DAPI filter cube and imaged at 
405 nm. Acti-stainTM 488 Phalloidin was excited with a Nikon filter B-2A and imaged 
at 520 nm. Fifty cells were imaged per dose in each experiment.  
 
The composite images of nuclei and F-actin were opened in Fiji ImageJ software 
(Schindelin et al. 2012) and the channels were split. Only the F-actin channel was 
used for analysis. The doses were made blind to the scorer to eliminate any form of 
bias. The circumference of the cell was traced and measured, obtaining the area of 
the podocyte cells, mean grey value and integrated density of podocyte F-actin. An 
area of the background adjacent to the cell was also measured. Corrected total cell 
fluorescence (CTCF), which is proportional to the fluorescence of F-actin in the cell 
was calculated by the following formula: CTCF = Integrated density – (cell area x 
mean grey area of background). The F-actin arrangements were then classed 
according to their arrangements. Cortical F-actin stress fibres were defined as the 
majority of the F-actin accumulated around the cortex of the cell. Cytoplasmic stress 
fibres were defined as F-actin filaments that traversed the cell body in parallel 
organisation. Unorganised F-actin filaments showed no recognisable organisation 
and resembled a “mat” of unorganised F-actin across the whole cell. Cell area and 
CTCF were normalised by dividing each dose by 0 ng/ml TB4 and 0 µg/ml of ADR of 
the same experiment due to variability between experiments. Experiments were 
repeated independently at least 3 times.  
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2.3.7  mRNA extraction 
To determine mRNA levels of gene in different conditions, mRNA was extracted from 
podocytes. Mouse podocytes were plated onto 6 well plates and exposed to either 
RPMI-1640 alone or containing TB4 and/or ADR as described in in 2.3.2 and 2.3.3. 
After 24 hours mRNA was extracted using an RNeasy mini kit (Qiagen, Düsseldorf, 
Germany). The media was aspirated and 350 µL of buffer RLT with 1% b-
mercaptoethanol was used to disrupt and lyse the cell layer. The cell suspension 
was then vortexed for 1 minute before mechanical homogenisation with a blunt 20-
guage RNAse-free syringe and needle. An equal homogenous mixture with 70% 
ethanol was then created with the cell lysate by pipetting. The homogenous cell 
lysate-ethanol mixture was then transferred to a spin column attached to a collection 
tube and centrifuged at 8000 x g for 15 seconds. Genomic deoxyribonucleic acid 
(gDNA) was digested by incubation for 15 minutes at room temperature in RNase 
free DNase 1 (Qiagen). Buffer RW1 (350 µl) was added to the column which was 
then centrifuged at 8000 x g for 15 seconds. The flow through was discarded in each 
of the following steps after centrifugation. The collection tube was reused and 700 µl 
of buffer RW1 was added to the spin column and centrifuged for a further 15 
seconds at 8000 x g. Next, 500 µL of buffer RPE (diluted to 20% buffer RPE in 100% 
ethanol) was added twice to the spin column and centrifuged at 8000 x g for 15 
seconds and 2 minutes for the first and second addition respectively. The collection 
tube was then discarded, and the spin column placed in an RNAse free Eppendorf 
tube before 50 µl of RNAse free water was added to the column membrane and 
centrifuged at 8000 x g for 1 minute. The resulting flow through contained purified 
mRNA which was stored at -80 °C until ready for further use.  
 
2.3.8 cDNA synthesis 
mRNA was converted to cDNA prior to qPCR. The following protocol used the iScript 
cDNA synthesis kid (Biorad, CA, USA). Prior to cDNA synthesis, the purity and 
concentration of mRNA was determined using a Nanodrop machine. To assess 
purity, the absorbance at 260 nm and 280 nm was read. An A260/A280 ratio between 
1.8 – 2.1 is indicative of highly purified mRNA. mRNA concentration was calculated 
by the Nanodrop automatically using the Beer-Lambert law (𝐴 =	∈ 𝐶𝑙), which predicts 
a linear change in absorbance with concentration, where A is absorbance at 260 nm, 
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∈ = extinction coefficient of mRNA (0.025 mg/ml)-1cm-1, 𝐶 =	concentration of mRNA 
and 𝑙	= path length of the chamber.  
 
The amount needed for 0.1 µg mRNA was added to a PCR tube (Greiner Bio-One) 
and made up to 15 µl with RNase free water. A master-mix was prepared with 4 µl of 
5x iScript reaction mix and 1 µl of iScript reverse transcriptase per sample. Negative 
controls were also prepared, one without reverse transcriptase and one without 
mRNA. The PCR tubes containing the mRNA were then mixed with 5 µl of the 
master-mix (excluding reverse transcriptase negative control, which contained 
mRNA plus 5 µl of reaction mix alone). The PCR tubes were then placed into a PCR 
Thermocycler (Eppendorf, Stevenage, U.K.) and the following program was started: 
25 °C – 5 minutes (primer annealing) 
42 °C – 30 minutes (reverse transcription) 
85 °C – 5 minutes (removal of mRNA template) 
4 °C – hold 
The samples were then stored at -20 °C until further analysis undertaken.  
 
2.3.9 Primer design 
Primers for qPCR experiments were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and Primer3 
(https://primer3.ut.ee/). The details of the primers used are listed (Table 2.1). The b- 
thymosin family of peptides was examined to determine if ADR leads to a loss of 
actin sequestering molecules. TB4 is predicted to bind to Schip1 (Miyamoto-Sato et 
al. 2010), a protein in the ezrin complex that preserves cortical F-actin arrangements 
in podocytes in vitro (Perisic et al. 2015). Other members of the ezrin complex were 
examined to see if they were altered by potential interactions. Other actin regulating 
proteins, such as synaptopodin, destrin, cofilin and profilin were examined to 
determine changes following ADR injury.  
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Table 2.1 – Primer details 
Target gene/translated protein 
(annealing temp, °C) 
Primer sequence (5' to 3') 




Fwd: ATGTCTGACAAACCCGATATGGC Bp 76 - 200. Exon 1 
– 2 (125) Rvs: CCAGCTTGCTTCTCTTGTTCA 
Tmsb10/Thymosin β10 (60) 
Fwd: CAGCTTCGATAAGGCCAAGC Bp 264 - 337. Exon 
3 – 4 (74). Rvs: CAATGGTCTCTTTGGTCGGC 
Tmsb15a/Thymosin β15a (64) 
Fwd: CCAGACTTGTCGGAAGTGGAG Bp 153 - 260. Exon 
2 – 3 (108). Rvs: CTCCTTCTCTTGCTCGATGGT 
Tmsb15b/Thymosin β15b (64) 
Fwd: AGCGATAAACCAGACTTGTCAGA Bp 125 - 231. Exon 
2 – 3 (107). Rvs: TGCTGGATAGTTTCATTCGACG 
Tmsb15l/Thymosin β15-like (60) 
Fwd: TGAGCGATAAACCAGACTTGTCA Bp 88 - 196. Exon 1 
– 2 (109). Rvs: TGCTGGATAGTTTCCTTCGAC 
Schip1/Schip1 (60) 
Fwd: GCACACAGAACAAGATGCCA Bp 1337 - 1557. 
Exon 7 – 8 (221). Rvs: GCTCGGACGTTACCAATGAC 
Slc9a3r2/Nherf2 (58) 
Fwd: TGCTGGTAGTCGATCCTGAG Bp 829 - 967. Exon 
4 – 6 (139). Rvs: CACACAGAGCCACCATTGAG 
Podxl/Podocalyxin (58) 
Fwd: GCCTGTGGATTCTTCACCGA Bp 808 - 959. Exon 
2 – 3 (152). Rvs: CTTCAGAGGTGCCCAATGGT 
Ezr/Ezrin (64) 
Fwd: AAGTGTGGTACTTCGGCCTG Bp 259 - 936. Exon 
3 – 8 (678). Rvs: AGTCAGGTGCCTTCTTGTCG 
Clic5/CLIC5a (58) 
Fwd: TCTACACAACCTGGCTCCTG Bp 998 - 1123. Exon 
6 (126). Rvs: AGTTTGGGGTACTTCTCGGG 
Nf2/Neurofibromin 2 (60) 
Fwd: AAAAGGTCTACTGCCCTCCC Bp 945 - 1033. Exon 
4 – 5 (89). Rvs: GTGCACAGAGGGGTCATAGT 
Dstn/Destrin (60) 
Fwd: TCTCCTGCTTTTGCTACCCG Bp 227 - 329. Exon 
1 – 2 (103). Rvs: AACTCCTGAGGCCATGTTCG 
Synpo/Synaptopodin (62) 
Fwd: ACCCAATCAGAACCTCTCGG Bp 1735 - 1879. 
Exon 2 (145). Rvs: TGAAGGCAGGGACATGGTAG 
Cfl1/Cofilin 1 (58) 
Fwd: AGACAAGGACTGCCGCTATG Bp 373 - 460. Exon 
2 (88). Rvs: GGCCCAGAAGATGAACACCA 
Pfn1/Profilin 1 (60) 
Fwd: GTGGAACGCCTACATCGACA Bp 623 - 786. Exon 
3 (164). Rvs: TTGACCGGTCTTTGCCTACC 
Pfn2/Profilin 2 (60) 
Fwd: GCTACTGCGACGCCAAATAC Bp 346 - 537. Exon 
1 – 2 (192). Rvs: TGTCCATTGTGCAGTCACCA 
Gapdh/Glyceraldehyde-3-
phosphate dehydrogenase 
(same as gene of interest) 
Fwd: TGCCCCCATGTTTGTGATG 
Bp 801 - 951. Exon 




qPCR experiments used cDNA that was prepared as in 2.3.8. A master-mix was 
prepared containing the necessary components for the reaction and included per 
sample:  
 
10 µl of 2x SYBR Green supermix (PCR Biosystems, London, U.K.) 
0.5 µl of forward primer (10 µM) (Fisher Scientific, NH, USA) 
0.5 µl of reverse primer (10 µM) (Fisher Scientific) 
8 µl nuclease-free water (Qiagen). 
 
Following this, 1 µl of cDNA samples was added to each well of a 96 well plate 
(Roche, Basel, Switzerland) in duplicate for the gene of interest and also 
glyceraldehyde-3-phosphate deydrogenase (Gapdh) (housekeeping gene) along 
with 19 µl of the master-mix. The plate was then sealed with transparent film 
(Roche), and vortexed and then added to the real-time PCR Light Cycler 480 
(Roche), the experiment was started using a previously determined protocol (below), 
where X refers to annealing temperature of primers (Table 2.1).  
 
95 °C  - 3 mins 
    95 °C  - 30 secs 
    X °C  - 30secs  x45 cycles 
    72 °C  - 30secs   
    65 °C  - 15secs 
    95 °C  - 15secs  
 
The average Ct value for each duplicate was calculated for the target gene and the 
housekeeping gene. The difference in the Ct values (DCt) of the target gene and 
Table 2.1 – Primer details. Details of all primers used for in vitro experiments, including 
target gene and its translated protein; the nucleotide sequences; the size of the amplicons; 
the location of the amplicon on the target gene and the annealing temperature used in 
quantitative PCR experiments. Tmsb4x, Thymosin b4, TB4; Schip1, Schip1, Schwannomin 
interacting protein 1; Slc9a3r2, Nherf 2, Sodium-hydrogen exchange regulatory cofactor 2; 
fwd, forward; rvs, Reverse; temp, temperature. Bp, base pairs. 
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housekeeping gene was calculated. The average DCt value for RPMI-1640 alone 
was calculated and then subtracted from the DCt value of the treated cells giving the 
DDCt.  
 
The formula 2-DDCt was used to determine fold changes in mRNA levels. Negative 
controls omitting cDNA or reverse transcriptase were included on each plate to 
identify potential contamination. Melt curves with a single peak were generated to 
confirm primer specificity. Experiments were repeated independently at least 4 times. 
Expression of Gapdh was unaltered by ADR/TB4 treatment, confirming the validity of 






Figure 2.2 – Effect of ADR/TB4 on Gapdh expression. The threshold values of Gapdh 
were unaffected by ADR/TB4 treatment compared to media alone. Each data-point 
represents 1 experiment showing the mean ±SEM of 2 replicate wells. Experiments were 
repeated independently at least 4 times. 






















2.3.11 Statistical analysis 
All statistical analysis was performed using GraphPad Prism 9.00 for Mac, GraphPad 
Software, La Jolla California USA, www.graphpad.com. All data were plotted as the 
mean value ±SEM. Normal distribution was assessed by Shapiro-Wilk test. If data 
were not normally distributed, they were either log10 or square root transformed or 
normalised to RPMI-1640 only treated values to achieve normality before statistical 
tests were used.  
 
For experiments with just 1 variable, for example TB4 dose response cytoskeleton 
analysis, one-way analysis of variance tests (ANOVA) with Dunnett’s multiple 
comparison tests were used to compare experimental doses with RPMI-1640. For 
experiments with two variables, such as TB4 and ADR co-treatment experiments, 
two-way ANOVA with Tukey’s multiple comparison test was used to compare 
statistical difference between all values.  
 
 Results 
2.4.1  Exogenous TB4 has no effect on podocyte viability, migration or 
cytoskeleton  
It has been previously shown that loss of endogenous Tmsb4x mRNA and TB4 
peptide leads to increased podocyte motility and cytoskeletal disorganisation in vitro 
(Vasilopoulou et al. 2016). It is not known if exogenous TB4 has any effect to 
podocytes, therefore the first section of the chapter aims to identify any effects of 
TB4 to podocyte viability, migration, and the cytoskeleton.   
 
2.4.1.1 Exogenous TB4 has no effect on podocyte viability 
Podocyte viability was assessed by MTT assay as per 2.3.4. There was no statistical 
significance between any value, indicating exogenous TB4 did not affect podocyte 
viability at 24, 48 or 72 hours after treatment (Figure 2.3).  
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2.4.1.2 Exogenous TB4 does not alter podocyte migration 
Podocyte migration was assessed by scratch wound assay as described in 2.3.5. 
Images were taken at 0, 6 and 24 hours after wound formation, with representative 
images of each time point provided in Figure 2.4a, b, c. All doses of TB4 and media 
only treated cells showed increase in cell migration between 6 and 24 hours (P<0.01 
for 0 ng/ml, 100 ng/ml, 1000 ng/ml; P<0.001 for 10 ng/ml), however, there was no 
statistical difference between cells treated with TB4 compared to media treated cells 
alone at 6 or 24 hours (Figure 2.4d). Therefore, exogenous TB4 does not alter 






























Figure 2.3 – TB4 has no effect on podocyte viability. Differentiated immortalised mouse 
podocytes were treated with 0 - 1000 ng/ml of TB4 and cell viability was assessed by MTT 
assay 24, 48 and 72 hours after TB4 treatment. Each data point represents the average of 4 
replicates. Individual experiments were repeated at least 5 times. Data has been normalised 
to 0 ng/ml of TB4 to reduce variability and achieve normal distribution. Data shown as the 




























Figure 2.4 – Exogenous TB4 does not alter podocyte migration. Differentiated 
immortalised mouse podocytes were treated with 0 - 1000 ng/ml of TB4 and cell migration 
assessed by scratch wound assay. Representative images of podocytes treated with 0 ng/ml 
of TB4 at (a) 0 hours, (b) 6 hours and (c) 24 hours imaged with x10 magnification. The black 
line indicates the boundaries of the wound which was transferred from 0h to images of 
subsequent time points. Each data point represents the average of 4 fields of view of 1 




2.4.1.3 Exogenous TB4 does not alter the podocyte cytoskeleton 
To analyse the podocyte cytoskeleton cells were fixed and stained with Acti-StainTM 
488 Phalloidin and analysed as described in 2.3.6. Podocyte F-actin arrangements 
were sorted into three sub-types: cortical actin stress fibres (Figure 2.5a); 
cytoplasmic stress fibres (Figure 2.5b) or unorganised actin fibres (Figure 2.5c). 
Cortical actin stress fibres displayed as an F-actin network around the periphery of 
the cell. Unorganised actin fibres did not show any specific actin arrangement. 
Cytoplasmic stress fibres displayed as organised F-actin filaments traversing the cell 
body perpendicular to adjacent fibres.  
 
The results show that the predominant F-actin organisation in podocytes is cortical 
actin stress fibres, with a prevalence of 53.5 ± 2.2% (Figure 2.5d), whereas the 
prevalence of cytoplasmic stress fibres was 26.4 ± 2.5 (Figure 2.5e) and 
unorganised actin was 12.4 ± 2.0% (Figure 2.5f). Exogenous TB4 had no effect on 
the proportion of cells displaying each type of F-actin organisation, total F-actin 
fluorescence in podocytes (Figure 2.5g) or the cell area (Figure 2.5h).  
 
Collectively, the results presented in this subsection provide evidence that 
exogenous TB4 had no effects on healthy podocyte cells in vitro. Next, the effect of 
ADR on podocyte cells in vitro was examined to determine appropriate doses to 












   
   
   
   
   
   




























































































































































Figure 2.5 – Exogenous TB4 does not alter podocyte F-actin organisation. 
Differentiated immortalised mouse podocytes were treated with 0 - 1000 ng/ml of TB4, fixed 
after 24 hours and stained with phalloidin conjugated to Actin-stain 488 to examine F-actin. 
Nuclei were stained using Hoechst 33342. Representative images of cells with (a) cortical 
actin stress fibres, (b) unorganised actin fibres and (c) cytoplasmic actin stress fibres at 40x 
magnification. White arrowheads indicate stress fibres. Scale bar = 10 µm. Quantification of 
the effect of exogenous TB4 on the percentage of cells with (d) cortical actin stress fibres, 
(e) unorganised actin fibres, (f) cytoplasmic stress fibres, (g) the normalised F-actin 
fluorescence and (h) total area of the cell. (g) and (f) have been normalised to media only 
treated cells to reduce variability. Each data point represents the average of 50 cells. Data 
are shown as mean ±SEM of 5 independent experiments.  
 
 89 
2.4.2 Characterisation of ADR-induced podocyte injury in vitro 
ADR was identified as a candidate to induce podocyte damage, however, a range of 
0.125 µg/ml – 2.5 µg/ml have been used previously (Cormack-Aboud et al. 2008; Dai 
et al. 2010; Nijenhuis et al. 2011; Schneider et al. 2017). Therefore, dose response 
experiments were conducted in order to determine appropriate concentrations to use 
in co-treatment experiments with TB4.  
 
2.4.2.1 ADR reduces podocyte viability  
Firstly, a dose response experiment was carried out to determine the effect of ADR 
on podocyte viability by MTT assay as described in 2.3.4. Treatment of podocytes 
with doses equivalent to or higher than 0.125 µg/ml of ADR caused between 60-70% 














































Cell viability - 24 hours
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Cell viability - 72 hours
*** *** *** *** *** ***
Figure 2.6 – ADR reduces cell viability. 
Differentiated immortalised mouse 
podocytes were treated with 0 – 2.5 µg/ml 
of ADR and assessed by MTT assay at 
(a) 24 hours, (b) 48 hours and (c) 72 
hours after ADR treatment. All statistical 
annotations are in comparison to 0 µg/ml 
of ADR. Data have been normalised to 
24-hour media treated only values to 
reduce variability and achieve normal 
distribution. Each data point represents 
the average of 4 replicate values. All data 
are shown as mean ±SEM of 4 individual 




0.0125 µg/ml of ADR reduced podocyte viability by 60% (P<0.01 versus media 
treated cells) and 0.125 – 2.5 µg/ml of ADR decreased cell viability by 90% (P<0.001 
vs media treated cells for both time points) (Figure 2.6b c). 
 
2.4.2.2 Effect of ADR on podocyte migration 
Next, the effect of ADR on podocyte migration was assessed by a scratch wound 
assay as described in 2.3.5 at 0, 6 and 24 hours after ADR treatment (Figure 2.7a, 
b, c). ADR did not cause changes to podocyte migration after 6 hours (Figure 2.7d). 
As expected, the cells treated with media only showed a significant increase in 
wound closure between 6 and 24 hours (P<0.01).  
 
The representative images display cells treated with 1 µg/ml of ADR, where there is 
a significant loss of cells at 24 hours (Figure 2.7a, b, c). Comparing this data with 
the representative image of untreated cells 24 hours after scratch wound (Figure 
2.6d), where 0.125 µg/ml and above caused a loss in podocyte viability after 24 
hours, the conclusion can be drawn that doses above this concentration are 
inappropriate for scratch wound analysis due to significant loss of viability.  
 
The number of cells migrating into the wound was reduced when podocytes were 
treated with ADR compared to cells treated with media alone; this was significant at 
doses of 0.25 µg/ml ADR and above (Figure 2.7e). Between 6 and 24 hours, 0.0125 
– 0.5 µg/ml ADR showed no difference in cell number compared with and 1 – 2.5 





Figure 2.7 – Assessment of cell motility after ADR treatment. Differentiated immortalised 
mouse podocytes were treated with 0 – 2.5 µg/ml ADR and cell migration was assessed by 
scratch wound assay at (a) 0, (b) 6 and (c) 24 hours after wound induction. (d) 
Representative image of untreated cells 24 hours after scratch wound. Black line indicates 
borders of wound area. Images taken at 10x magnification. (e) Quantification of cells that 
migrated into wound at 6- and 24-hour time points. Each data point represents the average 





















































2.4.2.3 ADR causes podocyte cytoskeletal disorganisation 
To determine which concentrations lead to significant cytoskeletal changes in these 
laboratory conditions, a comprehensive analysis of a wide range of doses was 
undertaken. Cells were treated with 0 – 2.5 µg/ml ADR and stained with Acti-StainTM 
488 Phalloidin as described in 2.3.6. Podocyte cytoskeletal organisation was sorted 
into the same three sub-groups as the TB4 dose response experiment (Figure 2.5a, 
b, c) after 24 hours of ADR treatment.  
 
The lowest dose of 0.0125 µg/ml of ADR caused a 21 ± 0.7% reduction in cortical 
stress fibres (P<0.01 versus untreated cells), 0.125 µg/ml caused a 50 ± 2.9% 
decrease in cortical stress fibres (P<0.001 versus untreated cells). Treating cells with 
2.5 µg/ml ADR caused a 42 ± 1.1 % reduction in cortical stress fibres compared with 
untreated cells (P<0.001). Both doses of 0.5 µg/ml and 1 µg/ml ADR caused a 41 ± 
2.9 % reduction in cortical stress fibre prevalence compared with untreated cells 
(P<0.001 for both doses). The highest dose of 2.5 µg/ml caused a 44 ± 1.2% 
reduction in cortical stress fibres compared with untreated cells (P<0.001) (Figure 
2.8a). No dose of ADR altered cytoplasmic stress fibre prevalence compared with 
untreated cells (Figure 2.8b). The low dose of 0.0125 µg/ml of ADR lead to 3.5 ± 
0.4-fold increase in unorganised actin filaments (P<0.001 versus untreated cells). 
Cells treated with 0.125 µg/ml ADR showed 5.3 ± 0.1-fold increase in unorganised 
actin prevalence (P<0.001 versus untreated cells). Podocytes treated with 0.25 
µg/ml ADR showed a 5.7 ± 0.1-fold increase in unorganised actin prevalence 
(P<0.001 versus untreated cells). In cells treated with 0.5 µg/ml ADR, there was a 6 
± 0.1-fold increase in unorganised actin compared with untreated cells (P<0.001). In 
cells treated with 1 µg/ml and 2.5 µg/ml ADR, there was a 5.4 ± 0.1 and 6.3 ± 0.1-
fold increase in unorganised F-actin respectively (P<0.001 in both doses versus 
untreated cells) (Figure 2.8c). 
 
Next, the podocyte cell area and total F-actin fluorescence were also analysed. 
Doses of 0.0125 µg/ml 0.125, 0.25 and 0.5 µg/ml of ADR did not significantly alter F-
actin fluorescence. Doses of 1 (P<0.05) and 2.5 (P<0.001) µg/ml of ADR lead to a 
55 ± 0.23% and 82 ± 0.06% decrease in podocyte F-actin fluorescence respectively 



















































































































































































































Figure 2.8 - ADR induces podocyte cytoskeletal disorganisation. Differentiated 
immortalised mouse podocytes were treated with 0 – 2.5 µg/ml of ADR, fixed after 24 hours 
and stained with phalloidin conjugated to Actin-stain 488 to assess F-actin. Nuclei were stain 
with Hoechst 33342. Quantification of the effect of ADR on the percentage of cells with (a) 
cortical actin stress fibres, (b) unorganised actin fibres, (c) cytoplasmic stress fibres, (d) the 
normalised podocyte F-actin fluorescence and (e) total area of the cell. All statistical 
annotations are in comparison to 0 µg/ml of ADR. Data points represent the average of 50 
podocytes. Data are shown as the mean ±SEM of 3 independent experiments. *P≤0.05, 
**P≤0.01, ***P≤0.001. 
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Finally, the podocyte cell area was examined. Cells treated with 0.0125 µg/ml, 0.125 
µg/ml, 0.25 µg/ml or 0.5 µg/ml ADR did not show significantly altered cell size 
compared with untreated cells. Cells treated with 1 µg/ml ADR showed a 49 ± 0.1% 
reduction in F-actin fluorescence compared with untreated cells (P<0.05). Cells 
treated with 2.5 µg/ml ADR showed a 63 ± 0.1% reduction in F-actin fluorescence 
compared with untreated cells (P<0.01) (Figure 2.8e).  
 
2.4.2.4  ADR alters actin associated gene levels 
After 24 hours, the lower dose of 0.0125 µg/ml ADR did not cause a loss of viability 
(but loss of viability was seen at 48 and 72 hours), podocyte cell area or F-actin 
fluorescence but did cause cytoskeletal disorganisation. Since foot process F-actin 
disorganisation leads to foot process effacement in vivo (Suleiman et al. 2017) and 
which can precede podocyte loss in vivo (Ichimura et al. 2019), it was concluded that 
0.0125 µg/ml ADR in vitro mimics the early stages of ADR injury in vivo. In contrast, 
the higher dose of 0.125 µg/ml ADR led to a decrease in viability at 24, 48 and 72 
hours, decrease of podocyte cell area and F-actin fluorescence, while also causing a 
higher degree of cytoskeletal disorganisation. Therefore, it was decided that these 
two doses would be used to study the effect of treating the cells with exogenous TB4 
in ADR-induced podocyte injury; one dose where there is minor damage to the 
cytoskeleton but initially not effect on cell viability, and another dose where there was 
significant podocyte damage associated with a reduction in cell number after 24 
hours of ADR exposure.  
 
After the working doses of ADR had been determined, the mRNA expression of 
Tmsb4x, Cfl1 and Schip1 were examined by qPCR after ADR injury. The translated 
proteins (TB4, cofilin-1 and Schip1) of these transcripts have been shown to 
modulate podocyte actin (Garg et al. 2010; Perisic et al. 2015; Vasilopoulou et al. 
2016), therefore a small number of actin regulating protein transcript expression 
were screened to determine if ADR induces changes.  
 
The low dose of 0.0125 µg/ml ADR slightly reduced podocyte Tmsb4x expression by 
15 ±0.1%, however this was not significant compared to media only treated cells. 
The higher dose of 0.125 µg/ml led to an exacerbated loss of 65 ± 0.1% Tmsb4x  
 95 

















































Figure 2.9 – ADR reduced actin associated mRNA expression. Differentiated 
immortalised mouse podocytes were treated with 0, 0.0125 and 0.125 µg/ml of ADR and 
mRNA was extracted after 24 hours. Expression of (a) Tmsbx4, (b) Cfl1 and (c) Schip1 was 
quantified by qPCR and Gapdh was used as a housekeeping gene. Statistical annotations 
are in comparison to 0 µg/ml of ADR. Each data point represents the average of duplicate 
assays from the same independent experiment. Data are shown as the mean ±SEM of at 
least 4 individual experiments. *P≤0.05, **P≤0.01. 
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expression compared to the control (P<0.01) (Figure 2.9a). This observation 
alongside the finding of cytoskeletal disorganisation provides a strong rationale for 
replenishing ADR-injured podocyte TB4 levels with exogenous TB4.  
 
Cofilin-1 is a major actin regulating protein in eukaryotic cells (Bernstein and 
Bamburg 2010) that contributes to actin severing and treadmilling (Al Haj et al. 2014; 
De La Cruz 2009). Endogenous TB4 suppresses the expression of Cfl1 
(Vasilopoulou et al. 2016) therefore the effect of ADR on Cfl1 was examined. The 
low dose of 0.0125 µg/ml ADR caused a 19 ± 0.2% reduction in Cfl1 compared to 
media only treated cells, but this was not statistically significant. The higher dose of 
0.125 µg/ml ADR reduced Cfl1 expression by 44 ± 0.1% (P<0.05) compared to 
media only treated cells (Figure 2.9b).  
 
Schip1 is expressed in podocytes and associates with the membrane-ezrin-
cytoskeleton complex playing a role in actin dynamics by promoting cortical F-actin 
accumulation (Perisic et al., 2015). The human homologue, which shares 98.77% 
sequence similarity with the mouse homologue, is predicted to interact with TB4 
(Miyamoto-Sato et al. 2010). There was no statistical difference between media 
treated cells and cells treated with 0.0125 µg/ml ADR. Podocyte Schip1 expression 
was decreased by 45 ± 0.8% in cells treated with 0.125 µg/ml of ADR (P<0.05) 
compared with media only treated cells (Figure 2.9c). 
 
These results suggest that there is a loss of actin regulating protein gene expression 
in podocytes in ADR-injury. This may provide insight into why cytoskeletal 
disorganisation in podocytes is occurring (2.4.2.3). The next subsection of this thesis 
chapter will explore the effect of ADR and TB4 on podocyte actin regulating gene 
expression in more detail.  
 
2.4.3 The effect of exogenous TB4 on ADR-injured podocytes  
The data so far in this chapter has shown that exogenous TB4 does not induce 
changes to healthy podocyte viability, migration or cytoskeletal organisation. 
Subsequently, ADR-induced podocyte injury has been characterised at a wide range 
of doses and 0.0125 µg/ml ADR and 0.125 µg/ml ADR were selected to study the 
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effect of exogenous TB4 on injured podocytes. These two doses allowed the effect 
of exogenous TB4 to be studied in: (i) cells that have a constant expression of 
Tmsb4x with only damage to the cytoskeleton at 24 hours and (ii) cells with depleted 
expression of Tmsb4x, loss of viability at all time points and higher damage to the 
cytoskeleton. This part of the thesis therefore proceeded to investigate the effect of 
exogenous TB4 on ADR-injured podocytes.  
 
2.4.3.1 Exogenous TB4 does not prevent ADR-induced loss of podocyte viability 
While exogenous TB4 did not alter podocyte viability, 0.0125 µg/ml reduced 
podocyte viability at 48 and 72 hours and 0.125 µg/ml reduced cell viability at all 3 
time points (2.4.2.1). It was hypothesised that TB4 would prevent ADR-induced 
podocyte viability loss, therefore, cell viability was assessed by MTT assay as 
described in 2.3.4.  
 
The lower dose of 0.0125 µg/ml ADR did not alter cell viability after 24 hours 
compared with untreated cells, but reduced cell viability by 45 ± 6.4% at 48 hours 
(P<0.001 versus untreated cells) and 51 ± 10% at 72 hours (P<0.001 versus 
untreated cells) respectively. The higher dose of 0.125 µg/ml ADR caused a 49 
±7.8% reduction of cell viability at 24 hours compared to media only treated cells 
(P<0.01). Furthermore, 0.125 µg/ml ADR caused a 87 ± 3.5% reduction at 48 hours 
(P<0.001 versus untreated cells) and 93 ± 1.5% decrease at 72 hours (P<0.001 
versus untreated cells). Exogenous TB4 was unable to prevent this loss of viability at 
either dose or time point (Figure 2.10a, b, c). 
 
These results indicate that while ADR causes a decrease in podocyte viability at all 
3-time points studied, this could not be prevented by doses of 10, 100 and 1000 
ng/ml of exogenous TB4.  
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2.4.3.2 Exogenous TB4 prevents ADR-induced F-actin disorganisation 
Both doses of ADR caused cytoskeletal rearrangements in podocytes, namely a 
reduction in cortical actin stress fibre frequency and an increase in the prevalence of 
unorganised actin filaments. Due to its actin sequestering and regulating properties 
(Safer et al. 1991; Sanders et al. 1992) it was hypothesised that exogenous TB4 
treatment would be able to prevent these cytoskeletal rearrangements.  
 
Figure 2.10 – Exogenous TB4 does not protect ADR-induced loss of podocyte 
viability. Differentiated immortalised podocytes were treated with 0 – 0.125 µg/ml ADR and 
0 – 1000 ng/ml exogenous TB4 and viability was assessed by MTT assay at (a) 24, (b) 48 
and (c) 72 hours after treatment. Data have been normalised to media only treated cells of 
respective experiments to achieve normal distribution and reduce variability. Each data point 
represents the average of 4 replicates of 1 individual experiment. Data are shown as the 
























































































Podocytes were treated with TB4 and/or ADR and stained with Acti-StainTM 488 
Phalloidin as described in 2.3.6. Podocytes injured with 0.0125 µg/ml ADR reduced 
their cortical actin stress fibre prevalence from 61 ± 2.2% to 33 ± 2.3% (P<0.001), 
while increasing the prevalence of unorganised actin from 12 ± 2% to 31 ± 3.2% 
(P<0.001) compared with media only treated cells. The higher dose of 0.125 µg/ml 
ADR exacerbated this effect, decreasing cortical actin stress fibre prevalence to 25 ± 
2.1% (P<0.001) and increasing the prevalence of unorganised fibres to 50 ± 4.2% 
(P<0.001) compared with media treated cells (Figure 2.11a, c).  
 
Cells exposed to 10 ng/ml of exogenous TB4 suppressed reduction of cortical actin 
stress fibre prevalence at 0.0125 µg/ml ADR (47 ± 3.7%, P<0.001 compared with 
0.0125 µg/ml ADR only) and 0.125 µg/ml ADR (40 ± 2.4%, P<0.01 compared with 
0.125 µg/ml ADR only) while supressing the unorganised fibre formation at 0.125 
µg/ml (35 ± 3.7%, P<0.01 compared with 0.125 µg/ml ADR only) (Figure 2.11a, c).  
 
Treatment of podocytes with 100 ng/ml of exogenous TB4 fully prevented the 
reduction of cortical actin stress fibres at both doses of 0.0125 µg/ml (63 ± 1.3%, 
P<0.001 compared to 0.0125 µg/ml ADR alone) and 0.125 µg/ml (57 ± 2.6%, 
P<0.001 compared to 0.125 µg/ml ADR). This was accompanied by the suppression 
of unorganised actin prevalence at 0.0125 µg/ml ADR (20 ± 2.6%, P<0.05 compared 
with 0.0125 µg/ml ADR) and 0.125 µg/ml ADR (24 ± 4.2%, P<0.001 compared with 
0.125 µg/ml ADR) (Figure 2.11a, c). ADR injured cells exposed to 1000 ng/ml of 
TB4 also displayed cytoskeletal stability. Cortical stress fibre prevalence was 
preserved at both 0.0125 µg/ml (63 ± 1.8%, P<0.001 compared to 0.0125 µg/ml 
ADR) and 0.125 µg/ml ADR (51 ± 2.2%, P<0.001 compared to 0.125 µg/ml ADR). 
Unorganised actin fibre prevalence was suppressed at 0.0125 µg/ml (12 ± 2.5%, 
P<0.001 compared with 0.0125 µg/ml ADR) and 0.125 µg/ml ADR (24 ± 2.8%, 
P<0.001 compared with 0.125 µg/ml ADR) (Figure 2.11a, c).  
 
Neither dose of ADR altered cytoplasmic stress fibre prevalence compared to media 
treated cells. At the lower dose of 0.0125 µg/ml ADR, 100 ng/ml and 1000 ng/ml of 
exogenous TB4 reduced the prevalence of cytoplasmic stress fibres (P<0.01  
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Figure 2.11 – Exogenous TB4 prevents ADR-induced cytoskeletal disorganisation. 
Differentiated immortalised mouse podocytes were treated with 0, 0.0125 or 0.125 µg/ml of 
ADR and 0, 10, 100 or 1000 ng/ml of TB4, fixed after 24 hours and stained with phalloidin 
conjugated to Actin-stain 488 to examine F-actin. Nuclei were stained with Hoechst 33342. 
Quantification of the effect of exogenous TB4 on the percentage of cells with (a) cortical 
actin stress fibres, (b) unorganised actin fibres, (c) cytoplasmic stress fibres, (d) the 
normalised corrected total cell fluorescence and (e) total area of the cells that have been 
injured with ADR. (d) and (e) have been normalised to achieve normal distribution and 
reduce variability. Each data point represents the average of 50 cells from an individual 






























































































































































































compared with 0.0125 µg/ml ADR alone) (Figure 2.11b). The low dose of 0.0125 
µg/ml ADR did not affect podocyte F-actin fluorescence or cell area. Podocytes 
treated with 0.125 µg/ml ADR showed a 35% decrease in F-actin fluorescence 
(P<0.01) and 25% decrease in cell area (P<0.05), which exogenous TB4 was unable 
to prevent (Figure 2.11d, e).  
 
Taken together, these results demonstrate that exogenous TB4 prevented ADR 
induced podocyte cytoskeletal rearrangements.  
 
2.4.3.3 TB4 had no effect on ADR-altered gene expression 
The data presented so far suggest that doses of 100 ng/ml and 1000 ng/ml 
exogenous TB4 exhibited similar effects in ADR injury, specifically, the level of 
cytoskeletal preservation was comparable. The lowest possible beneficial dose of 
exogenous TB4 was desired, therefore, 100 ng/ml of exogenous TB4 was selected 
to assess the effect of TB4 on ADR-injured podocytes. 
 
Gene levels are analysed by qPCR 24 hours after treatment. Firstly, the effect of 
ADR and exogenous TB4 were examined on the b-thymosin family of actin 
sequestering genes. Tmsb4x encodes TB4 and Tmsb10 encodes thymosin b-10, a 
homologue of TB4 with identical actin sequestering properties, but with a 5 fold 
higher affinity for G-actin (F.-X. Yu et al. 1993; Yu et al. 1994). Thymosin b-15 has 
three isoforms; thymosin b-15a (Tmsb15a), thymosin b-15b (Tmsb15b) and thymosin 
b-15-like (Tmsb15l) peptide which bind to G-actin with a 2.4x higher stability than 
TB4 (Eadie et al. 2000). 
 
Cells treated with 0.0125 µg/ml ADR showed no statistical difference in expression 
of Tmsb4x and Tmsb10 compared with media treated cells. The higher dose of 
0.125 µg/ml led to a 61 ± 5% reduction in Tmsb4x and a 52 ± 13% reduction in 
Tmsb10 expression compared to media treated cells. Exogenous TB4 was unable to 
prevent the reduction in either transcript (Figure 2.12a, b). While 0.0125 µg/ml ADR 
had no effect on podocyte Tmsb15a, 0.125 µg/ml ADR caused 3.3-fold (± 0.4)  
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Figure 2.12 – Exogenous TB4 does not prevent ADR-induced b-thymosin mRNA level 
alterations. Differentiated immortalised mouse podocytes were treated with 0, 0.0125 and 
0.125 µg/ml of ADR with 0-1000 ng/ml of TB4 and mRNA was extracted after 24 hours. 
Expression of (a) Tmsbx4, (b) Tmsb10, (c) Tmsb15a (d) Tmsb15b and (e) Tmsb15l was 
quantified by real time PCR and Gapdh was used as a housekeeping gene. Each data point 
represents the average of replicates of a single experiment. All data are shown as the mean 
±SEM of 4 individual experiments. *P≤0.05, **P≤0.01. Tmsb4x, TB4; Tmsb10, Thymosin β-





























































































upregulation in Tmsb15a compared to media treated cells (P<0.01) which 
exogenous TB4 did not prevent (Figure 2.12c). There were no alterations to  
Tmsb15b or Tmsb15l in any treatment group compared to media treated cells 
(Figure 2.12d, e).  
 
Collectively, these results demonstrate that ADR alters the mRNA level of some of 
the b-thymosin family, suggesting there could be changes to the balance of the actin-
regulating molecules within the cell.  
 
Consistent with 2.4, 0.0125 µg/ml ADR did not alter Schip1 or Cfl1 expression but 
0.125 µg/ml ADR lead to a 50 ±0.4% reduction in both genes compared to media 
treated cells (P<0.01). However, cells treated with 0.0125 µg/ml ADR and 1000 
ng/ml exogenous TB4 showed an increase of 44 ±0.1% in Schip1 levels compared 
with cells treated with 0.0125 µg/ml ADR (P<0.05). Exogenous TB4 was unable to 
prevent the reduction in Cfl1 expression (Figure 2.13a, b). 
 
Dstn encodes destrin/ADF, an F-actin regulating protein that promotes actin severing 
and depolymerisation (Vartiainen et al. 2002) and Pfl1 and Pfl2 encode Profilin 1 and 
profilin 2 respectively. Profilin has been shown to promote actin polymerisation in the 
presence of TB4 (Pantaloni and Carlier 1993). Profilin 1 and profilin 2 have opposing 
effects on the actin cytoskeleton – profilin 1 promotes actin bundling whereas profilin 
2 supresses actin bundling (Ding and Roy 2013). There were no alterations to Dstn, 
Pfl1 or Pfl2 levels after exogenous TB4 administration compared to media treated 
cells or either dose of ADR (Figure 2.13c, d, e).  
 
Synpo encodes synaptopodin, a podocyte actin regulating serine/threonine kinase 
(Mundel, Heid, et al. 1997). Treatment of podocytes with 0.0125 µg/ml of ADR 
showed no change in the level of Synpo compared with media treated cells. 
Treatment with 0.125 µg/ml of ADR showed a 4-fold (± 0.9) increase in Synpo 
expression in comparison to untreated podocytes (P<0.01). Exogenous TB4 had no 
effect on Synpo expression at any dose of ADR (Figure 2.13f). 
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Ezrin and Nherf2 link the cytoskeleton to the SD plasma membrane via interactions 
with podocalyxin (Takeda 2003), a SD molecule coated with sialic acid residues that  
   
Figure 2.13 – The effect of ADR and exogenous TB4 on podocyte actin associated 
genes. Differentiated immortalised mouse podocytes were treated with 0, 0.0125 and 0.125 
µg/ml of ADR with 0-1000 ng/ml of TB4 and mRNA was extracted after 24 hours. Expression 
of (a) Schip1 (b) Cfl1, (c) Pfl1 (d) Pfl2, (e) Dstn and (f) Synpo was quantified by qPCR and 
Gapdh was used as a housekeeping gene. Each data point represents the average of 
replicate values of 1 individual experiment. Data are shown as the mean ±SEM of 4 
independent experiments. **P≤0.01. Schip1, Schwannomin interacting protein 1; Cfl1, 










































































































































































































Figure 2.14 – ADR and TB4 do not alter 
transcript levels of the podocalyxin 
complex. Differentiated immortalised mouse 
podocytes were treated with 0, 0.0125 and 
0.125 µg/ml of ADR with 0-100 ng/ml of TB4 
and mRNA was extracted after 24 hours. 
Expression of (a) Podxl, (b) Ezr, (c) Slc9a3r2 
(d) Clic5 and (e) Nf2 was quantified by real 
time PCR and Gapdh was used as a 
housekeeping gene. Each data point 
represents the average of replicates of an 
individual experiment. All data are shown as 
the mean ±SEM of 4 individual experiments. 
Podxl, podocalyxin; Ezr, Ezrin; Slc9a3r2, 
Nherf2; Clic5, Chloride intracellular channel 5; 
Nf2, neurofibromatosis 2. 
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promotes charge exclusion of negatively charged plasma molecules from the 
ultrafiltrate (Nielsen and Mcnagny 2009). Adjacent to this complex is the chloride 
intracellular channel 5a (CLIC5a), which phosphorylates ezrin (Wegner et al. 2010), 
stimulating the essential process of ezrin binding to F-actin, leading to coupling of 
podocalyxin to the cytoskeleton (Orlando et al. 2001; Takeda et al. 2001).   
 
Treatment with 0.0125 µg/ml or 0.125 µg/ml ADR did not alter podocyte levels of 
Podxl, Ezr, Slc9a3r2 or Clic5 compared with untreated cells. Exogenous TB4 also 
did not alter the levels of these transcripts in any condition compared with the media 
treated only cells, suggesting that this complex may not be involved in the TB4 
mediated podocyte cytoskeletal protection (Figure 2.14a, b, c, d).  
 
Nf2 encodes the protein neurofibromin 2, a protein that has only been shown 
previously to be expressed in glial cells, linking the cortical cytoskeleton to the  
plasma membrane (Cole et al. 2008) and interacting with Schip1 (Goutebroze et al. 
2000). It was not known previously if Nf2 was expressed by podocytes, however Nf2 
was detected at Ct values between 19-24, showing relatively high expression. Again, 
neither ADR nor exogenous TB4 altered the expression of Nf2 (Figure 2.14e). 
 
 Discussion 
This chapter of the thesis has demonstrated that exogenous TB4 has no effect on 
healthy podocyte viability, migration or the podocyte cytoskeleton. Subsequently, a 
strategy was employed to explore the effect of exogenous TB4 on podocytes 
damaged by ADR. A dose response experiment identified two appropriate 
concentrations of ADR to induce (i) cytoskeletal disorganisation without a significant 
loss of cell viability at 24 hours after ADR and (ii) cytoskeletal disorganisation 
accompanied by significant reduction in podocyte viability and reduced Tmsb4x. 
Importantly, this chapter has provided strong evidence that exogenous TB4 
prevented ADR-induced cytoskeletal disorganisation but has no effect on ADR-
altered cell viability.  
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2.5.1 The effect of exogenous TB4 on healthy podocytes 
To date, no studies have examined exposure of healthy podocytes to exogenous 
TB4 in vitro. Therefore, this chapter has provided the first evidence that exogenous 
TB4 does not alter healthy podocyte viability, migration or the F-actin cytoskeleton. 
The only study to date examining TB4 in podocytes showed that TB4 was expressed 
in mouse podocytes and then subsequently investigated the effects of knocking 
down endogenous TB4 by siRNA (Vasilopoulou et al. 2016). Loss of endogenous 
TB4 did not alter podocyte viability, suggesting that endogenous TB4 is expendable 
for podocyte survival (Vasilopoulou et al. 2016). In accord with the findings in 
podocytes, exogenous TB4 does not alter cell viability in other cell types. Healthy 
human corneal epithelial cells cultured with 1 µg/ml of exogenous TB4 showed no 
change in viability after 24 hours of exposure as measured by MTT assay (Ho et al. 
2007). Similarly, exogenous TB4 (100 ng/ml – 5000 ng/ml) also did not affect cell 
viability of adipose derived stem cells compared to untreated cells when assessed by 
trypan blue staining 24 hours after treatment (Jeon et al. 2013). Therefore, the data 
presented in this thesis have provided further evidence that exogenous TB4 has no 
effect on cell viability of healthy cells grown in culture.  
 
Whilst endogenous TB4 knockdown did not affect cell viability, there was a 
reorganisation of cortical stress fibres to cytoplasmic stress fibres and an increase in 
cell migration (Vasilopoulou et al. 2016). It was subsequently postulated that since a 
lack of endogenous Tmsb4x caused an increase in podocyte migration, exogenous 
TB4 may reduce migration of healthy podocytes, however this proved not to be the 
case. 
 
There was ~10-fold increase in migration between 6 and 24 hours in healthy 
untreated podocytes reported in this thesis. Other studies examining podocyte 
migration indicate that healthy podocytes do undergo motility in culture. One study 
that utilised the scratch wound method found that healthy primary podocytes from 
C57BL/6 mice showed 50% wound closure after 24 hours (Cechova et al. 2018). 
Another study using the same scratch wound assay with mouse immortalised 
podocytes found at least 20 cells had migrated into the wound after 72 hours, and 
live imaging revealed these cells travelled at 0.1 µm/min (Kruger et al. 2018). 
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Furthermore, human immortalised podocytes showed complete wound closure after 
just 17 hours (Yu et al. 2020). Therefore, there is significant evidence that healthy 
podocytes do display a migratory phenotype in vitro, but different culture conditions 
and cell lines influence rates of migration.  
 
Exogenous TB4 has been shown to induce migration in healthy cultured cells. 
Exogenous TB4 (100 ng/ml) induced a 4-fold increase in healthy embryonic mouse 
myocardial cell migration (Bock-Marquette et al. 2004). HCECs exposed to 1 µg/ml 
exogenous TB4 showed increased scratch wound healing 24 and 48 hours after 
wound induction compared to untreated cells, which was dependent on the presence 
of MMP4 (Qiu, Kurpakus-Wheater, and Sosne 2007). Additionally, 100 ng/ml of 
exogenous TB4 stimulated HUVEC migration as shown by a Boyden chamber assay 
after 4 hours (Philp et al. 2003). The results presented in this thesis chapter provide 
contrasting results to these other cell types, as no alterations to motility compared to 
untreated cells were present. There could be multiple explanations as to why the 
effects on podocytes differ from other cell types. It would not be due to the dose of 
TB4, as the previous doses used were the same as in this thesis. The culture 
conditions and type of assay used may have caused the variations. Myocardial cells 
were exposed to TB4 for 24 hours longer than in this thesis, which allowed more 
time for migration to occur. The HUVEC cells were examined by Boyden chamber 
assay, which may facilitate migration more than scratch wound assay. In fact, the 
cells on the wound line in the scratch wound assay may have been damaged by the 
wound induction, which could have affected their health and motility. Boyden 
chamber assay does not inflict a wound on the cell; therefore, the cells have less 
chance to be damaged. The natural migratory behaviour of each cell type may have 
influenced the variations; podocytes may not be as naturally motile as HUVEC or 
myocardial cell types. 
 
Endogenous TB4 is responsible for cytoskeletal stability in healthy podocytes in vitro, 
as loss of TB4 resulted in a reorganisation from cortical actin fibres to cytoplasmic 
stress fibres (Vasilopoulou et al. 2016). However, the effect of exogenous TB4 on 
podocyte F-actin has not been examined, and this chapter has provided evidence 
that the amount and organisation F-actin is unaffected by exogenous TB4 in healthy 
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podocytes in vitro. The actin regulating properties have influenced actin dynamics in 
other healthy cell types. Increasing concentrations (10 ng/ml – 500 ng/ml) of 
exogenous TB4 reduced the F-actin to G-actin ratio in HUVECs, indicating that a 
higher degree of G-actin was sequestered in these cells (Kim and Kwon 2015). A 
reduction in the F-actin to G-actin ratio was also identified in human cerebral 
endothelial cells exposed to 10 ng/ml – 500 ng/ml of TB4. However, the 
representative images of the cells stained with phalloidin to visualise F-actin seem 
identical to untreated cells, and quantification was not undertaken indicating no 
change to overall F-actin organisation (Song et al. 2020). Changes to F-actin 
organisation could be expected if there were reductions to the F-actin to G-actin 
ratio, as there could be less F-actin fibres in certain cellular compartments such as 
the cortex or centre of the cell. Further studies could examine the F-actin to G-actin 
ratio in healthy podocytes to determine if exogenous TB4 is indeed causing further 
G-actin sequestration as seen in other cell types.  
 
There could be due to a number of reasons why exogenous TB4 does not alter the 
F-actin cytoskeleton in podocytes. Healthy podocytes have an innate level of 
endogenous TB4 peptide that is already sequestering the majority of G-actin, 
therefore saturating the cells with exogenous TB4 and causing further G-actin 
sequestering would be unlikely to alter F-actin organisation stability. Cell motility is 
dependent on actin polymerisation (Mogilner and Oster 1996), which could explain 
why Tmsb4x knockdown in podocytes displayed increased migration (loss of G-actin 
sequestering leading to actin polymerisation) (Vasilopoulou et al. 2016), but not in 
podocytes with increased levels of TB4. Furthermore, treatment with exogenous TB4 
did not alter the mRNA transcript levels of some members of the b-thymosin family 
or other known actin regulating proteins, such as cofilin-1, profilin and destrin. The 
lack of alterations to other actin sequestering and regulating molecules induced by 
exogenous TB4 suggests that intracellular actin regulation is unaffected and TB4 is 
the only molecule that is present in excess.  
 
A potential caveat of our experiment using exogenous TB4 is that the internalisation 
of TB4 into the cells has not been examined. Internalisation of exogenous TB4 has 
been proven in HUVECs by an increase in intracellular TB4 immunostaining (Grant 
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et al. 1999). The effects of exogenous TB4 treatment and transfection of Tmsb4x to 
cardiac endothelial cells were comparable, suggesting that exogenous TB4 was also 
internalised in this cell type (Bock-Marquette et al. 2004). Furthermore, 
internalisation of TB4 was confirmed in human corneal endothelial cells by utilising a 
His-tagged TB4 peptide, as the intracellular immunofluorescent staining of Histidine 
dramatically increased 2 hours after treatment (Ho et al. 2007). The exact 
mechanisms of TB4 internalisation are not well understood, however, due to the 
small size (4.9 kilodaltons) it is likely that TB4 enters cells via active or passive 
transport. Other mechanisms of internalisation have not been explored, but TB4 has 
been shown to bind to two extracellular purinergic receptor classes, P2X and P2Y 
classes (Freeman, Bowman, and Zetter 2011), which are expressed on podocytes 
(Forst et al. 2016; Szrejder et al. 2020). TB4 induced purinergic signalling has been 
associated with corneal epithelial cell migration (H. M. Yang et al. 2020), 
demonstrating that this TB4-induced stimulation of this pathway does have 
intracellular effects, even though there was no alterations to motility in healthy 
podocytes in this thesis. To confirm internalisation of exogenous TB4 to podocytes, 
future studies could utilise previously reported methods, such as using His-tagged 
TB4, to quantify an increase in intracellular TB4 amount by immunofluorescence. 
Additionally, co-immunoprecipitation assays to detect TB4/purinergic receptor 
binding could be utilised to identify if there is an increase in binding after treatment 
with exogenous TB4. Finally, podocyte transfection to overexpress Tmsb4x mRNA 
could also be undertaken to see if similar effects are observed.  
 
2.5.2 Optimising an in vitro model of ADR-induced podocyte injury 
ADR is a widely used podocyte injury model, that leads to decreased podocyte 
viability and cytoskeletal rearrangements (Marshall et al., 2010; Liu et al., 2012). 
Previously, a wide range of concentrations between 0.125 µg/ml, to 20 µg/ml ADR 
have been used to induce loss of cell viability and cytoskeletal disorganisation in 
vitro (Chen et al. 2017; Liu et al. 2012; X. Liu et al. 2018; Maimaitiyiming, Zhou, and 
Wang 2016; Marshall et al. 2010). It was therefore important to identify the optimum 
dose to induce podocyte damage in the available laboratory conditions.  
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Doses of 0.0125 µg/ml and 0.125 µg/ml ADR were selected for subsequent 
experiments utilising exogenous TB4, as 0.0125 µg/ml did not reduce cell viability at 
24 hours, but 0.125 µg/ml did. The doses above 0.125 µg/ml all induced the same 
extent of cell viability reduction and cytoskeletal reorganisation. In fact, doses above 
0.125 µg/ml caused such an extreme loss of cell viability (>90%) that there were few 
cells left to analyse in subsequent assays. Other studies have examined cell viability 
following ADR exposure in podocytes. Human immortalised podocytes treated with 
20 µg/ml of ADR (160-fold higher concentration than 0.125 µg/ml) showed 15% 
prevalence of apoptotic cells, one cause of reduced cell viability, and a loss of F-
actin cortical fibres to unorganised F-actin after 24 hours (Maimaitiyiming et al. 
2016). In contrast to this, immortalised mouse podocytes (the same cell line used in 
this study), exposed to 0.2 µg/ml, 0.3 µg/ml and 0.4 µg/ml ADR led to 15 – 20% 
prevalence of apoptotic cells (Xie et al. 2017; Yi et al. 2017). It is clear from previous 
studies that external factors influence the extent by which ADR induces podocyte 
damage. These factors may include culture conditions, the matrix the cells are grown 
on, the source of the cell line used, and the batch of ADR used. This has been 
confirmed in a study using different lines of human, mouse and rat immortalised 
podocytes exposed to ADR. The mouse and human cells displayed similar 
reductions in cell viability when exposed to 0.05 µg/ml, 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml 
and 2.5 µg/ml ADR, whilst the rat immortalised podocytes did not experience a loss 
in cell viability at any concentration (Chittiprol et al. 2011). Therefore, it is important 
for researchers to identify appropriate doses to induce desired outcomes when 
performing experiments with podocytes exposed to ADR.  
 
The doses of 0.0125 µg/ml and 0.125 µg/ml ADR (and also higher concentrations) 
led to F-actin disorganisation. The podocyte cytoskeleton is critical for maintaining 
the glomerular filtration barrier in vivo (Welsh and Saleem 2012) with the majority of 
podocyte F-actin in vivo is located in the foot processes (Shirato et al., 1996). 
Therefore, molecules that induce changes in podocyte F-actin in vitro are likely to 
alter F-actin in vivo. F-actin disorganisation which presents as  a “mat” of 
disorganised actin parallel to the GBM has been associated with ADR-induced foot 
process effacement in vivo (Kriz et al. 2013; Suleiman et al. 2017), therefore, highly 
regulated cytoskeletal organisation and structure is critical for maintaining the unique 
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architecture of podocytes. Alterations to F-actin in vitro and in vivo have been 
demonstrated in Ste20-like kinase (SLK) knockout mice exposed to ADR, where 
glomerular phalloidin mean fluorescence increased and there was an increased 
prevalence of an F-actin mat juxtaposed to the GBM, rather than F-actin bundles 
lining capillary walls. SLK knockdown podocytes with ADR in vitro conversely 
showed a decrease in phalloidin staining and loss of F-actin cytoplasmic fibres 
(Woychyshyn et al. 2020). Even though the effects on F-actin fluorescence were 
contrasting, alterations did indeed occur in vitro and in vivo, therefore, the changes 
to F-actin reported in this thesis chapter are likely to translate to podocytes in vivo.  
 
One of the most interesting results of the ADR dose response study is the loss of 
podocyte Tmsb4x after 24 hours of 0.125 µg/ml ADR exposure. To date, there have 
been no studies associating a lack of Tmsb4x with glomerular disease. An increase 
in interstitial TB4 prevalence was reported in the UUO model of kidney injury, but it 
was confirmed that the increased TB4 was from macrophages (F4/80 co-labelling) 
and myofibroblasts (aSMA co-labelling) (Zuo et al. 2013). Since lack of Tmsb4x 
accelerates glomerular injury in vivo and leads to podocyte cytoskeletal 
reorganisation in vitro (Vasilopoulou et al. 2016), this finding provides rationale that 
restoring the level of TB4 in podocytes with exogenous TB4 may prevent the 
cytoskeletal disorganisation that is observed in ADR-injury in vitro (Marshall et al., 
2010; Liu et al., 2012, 2018; Chen et al., 2017) and prevent albuminuria in vivo. 
 
Due to the significant reduction in podocyte viability after ADR-treatment, assessing 
migration in this model is a challenge. There is a limited amount of research into 
ADR-induced motility in vitro, however some authors have succeeded. Mouse 
immortalised podocytes treated with 0.27 µg/ml ADR for 18 hours showed a 50% 
increase in wound closure compared to untreated cells when measured by scratch 
wound assay (Gao et al. 2010). The short ADR exposure time used in this 
experiment may have contributed to the fact that the researchers were able to 
assess migration before cell detachment. Another study utilised the scratch wound 
assay with mouse immortalised podocytes exposed to 0.25 µg/ml ADR for 24 hours 
and saw a 25% increase in wound closure compared to untreated cells, 
accompanied by an increased assembly and disassembly of podocyte focal 
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adhesions (Xu et al. 2014). Podocyte viability was not examined in this study, so it is 
unclear how ADR-induced loss of viability was accounted for. It is possible that in the 
laboratory conditions the cells were assessed in, ADR did not reduce cell viability at 
this dose, due to variable factors mentioned previously. Future studies employing 
ADR as an injury model could therefore identify a suitable end point where podocyte 
loss does not occur to enable the assessment of migration. Alternatively, live cell 
imaging is another assay that could be utilised to track the distance that individual 
cells travel before detaching.  
 
These dose response assays in this thesis provided valuable information for 
subsequent assays in this study. The two doses of 0.0125 µg/ml and 0.125 µg/ml of 
ADR were deemed appropriate to analyse the therapeutic potential of TB4 in co-
treatment experiments. The dose of 0.0125 µg/ml caused a high degree of 
cytoskeletal disorganisation without a loss of Tmsb4x or cell viability at 24 hours, 
allowing the effect of exogenous TB4 to be studied at a level of moderate podocyte 
injury. The higher dose of 0.125 µg/ml of ADR allowed the effect of exogenous TB4 
to be studied in podocytes which express lower levels of endogenous Tmsb4x, have 
a greater extent of cytoskeletal disorganisation, a significant decrease in cell viability 
at 24, 48 and 72 hours and thus more severe podocyte injury. 
 
2.5.3 Assessing the effect of exogenous TB4 on ADR-injured podocytes 
A key finding of this chapter is that exogenous TB4 prevented ADR-induced 
disorganisation of the podocyte F-actin cytoskeleton. Specifically, TB4 prevented the 
loss of cortical actin stress fibres and the increase in the prevalence of unorganised 
actin fibres that was caused by ADR. TB4 is protective of cytoskeletal 
disorganisation in other cell types. Exogenous TB4 was shown to prevent 
uncontrolled F-actin polymerisation and loss of cell viability in HUVECs challenged 
with AGE in vitro (Kim and Kwon 2015). Uncontrolled F-actin polymerisation was 
also reported in human cerebral cells injured with scrapie prion protein, which 
exogenous TB4 completely prevented (Song et al. 2020). The findings presented in 
this chapter provide further evidence of the cytoskeletal stabilising effect of 
exogenous TB4. Since exogenous TB4 can prevent ADR-induced cytoskeletal 
disorganisation in vitro, it is postulated that TB4 may also be able to prevent the 
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cytoskeletal disorganisation seen in vivo. Cytoskeletal reorganisation is a common 
factor in many podocyte injury models in rodents and cultured cells, including PAN, 
ADR and diabetic nephropathy (Marshall et al., 2010; Liu et al., 2012; Wang et al., 
2016; Ling et al., 2018). There have been no reported studies specifically examining 
the F-actin cytoskeleton in healthy human samples, or FSGS patients, potentially 
due to difficulty obtaining cryo-samples of human kidney tissue. Phalloidin staining, 
the gold-standard for labelling F-actin, only works on cryo-sections, therefore FFPE 
sections are unsuitable.  
 
The protection of F-actin by exogenous TB4 may be mediated by other podocyte 
actin-associated proteins, such as a-actinin-4 and integrins. Mouse immortalised 
podocytes transfected to overexpress the actin-focal adhesion cross linking protein 
plectin showed almost complete prevention of ADR-induced reduction of podocyte F-
actin fluorescence (Ni et al. 2018). The cytoskeletal protection was mediated by 
suppression of a6b4 integrin and maintenance of a3b1 integrin, focal adhesion 
kinase and p38 activation (Ni et al. 2018). Exogenous TB4 has been shown to 
increase a1, a2 and a3 integrin mRNA levels in human dental pulp cells (Lee et al. 
2013). A3 integrins are the dominant type in healthy podocytes (Shirato 2002), and 
changes in integrin balance can alter cytoskeletal organisation (Defilippi et al. 1999). 
The shift of ADR-induced integrin expression may warrant further investigation to 
determine if changes in integrin subunit expression are occurring in this injury model 
which TB4 could be preventing. Increased a-actinin-4, an actin bundling protein 
found in podocytes (Asanuma et al. 2005), was shown to be involved in the 
formation of unorganised actin in mouse immortalised podocytes exposed to 0.27 
µg/ml ADR (Liu et al. 2012), the same phenotype observed in this study. 
Dexamethasone, a glucocorticoid, was able to fully prevent the ADR-induced actin 
disorganisation via modulation of a-actinin-4 (Liu et al. 2012). Dexamethasone has 
been shown to preserve the F-actin to G-actin ratio in injured mouse hippocampi (N. 
Yang et al. 2020), suggesting that de novo formation of F-actin from G-actin could be 
associated with the actin bunding properties of a-actinin-4. Since TB4 is a G-actin 
sequestering peptide (Safer et al. 1991) future studies could examine the effect of 
exogenous TB4 on a-actinin-4 levels to determine if this could be a potential 
mechanism of protection of F-actin organisation. The F-actin to G-actin ratio could 
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also be examined to determine if the protective effects induced by exogenous TB4 
were via G-actin sequestering.  
 
It was hypothesised that due to its anti-apoptotic properties, such as the inhibition of 
caspase-3 activation (Moon, Song, and Yang 2007), and prevention of oxidative 
stress (Ho et al. 2008; Kumar and Gupta 2011), exogenous TB4 would be able to 
prevent ADR-induced loss of cell viability, however this was not the case. ADR has 
been shown to induce apoptosis by activation of NFkB pathway (Karger et al. 2016). 
TB4 prevented activation of the NFkB pathway in HCECs treated with TNF-a, 
therefore preventing apoptosis (Sosne, Qiu, Christopherson, et al. 2007). ADR also 
leads to detachment of podocytes from the matrix via integrin loss facilitated by 
activation of ILK (Dai et al. 2019; Wang et al. 2018). Studies in other cells types have 
shown that TB4 binds to and activates the ILK pathway (Bock-Marquette et al. 2004), 
which may contribute to reduction in cell viability. However, the decrease in podocyte 
viability following ADR injury was not affected by exogenous TB4 treatment, so this 
was unlikely to be the case in the context of podocyte injury mediated by ADR.  
 
Exogenous TB4 has previously been shown to improve cell viability in other 
damaged cell types. Tmsb4x knockdown in human cerebral endothelial cells and 
then subsequently treated with 500 ng/ml exogenous TB4 were injured with 
damaged with prion protein (106-126). Cell viability was improved compared to non-
exogenous TB4 treated cells, as assessed by MTT assay 24 hours after treatment 
(Song et al. 2020). This data showed that exogenous TB4 was protective of the 
human cerebral cells, even in TB4 knockdown cells. In endothelial progenitor cells 
challenged with AGE to induce oxidative stress, 0.5 µg/ml of exogenous TB4 fully 
prevented a reduction in cell viability as measured by MTT assay 24 hours after 
treatment (Q. Chen et al. 2019). Exogenous TB4 (2,500 ng/ml and 5,000 ng/ml) also 
prevented H2O2-induced reduction in neural stem/progenitor cell viability in vitro. This 
was associated with prevention of reactive oxygen species and inflammatory 
cytokine (interleukin -1b and -6, and toll like receptor 4) production (Li et al., 2019). 
There are significant differences between these studies and the experimental set up 
of this thesis chapter; the first is the cell type used. Different cell types have varying 
intracellular signalling patterns and proteins, which may have worked in parallel with 
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TB4 to prevent the loss of cell viability. The previous studies also used a higher 
dosage of TB4 than this thesis chapter: 500 ng/ml, 2,500 ng/ml and 5,000 ng/ml 
compared to 1000 ng/ml in this thesis. It is possible that the higher dosage of TB4 
provided further protection than the doses used in this thesis and follow up studies 
could attempt to prevent ADR-induced cell viability in podocytes with increased 
concentrations of TB4.  
 
Thymosin b10 and thymosin b15 are TB4 homologues which also bind to and 
sequester G-actin (Yu et al., 1993; Yu et al., 1994; Eadie et al., 2000). This thesis 
has provided the first evidence that Tmsb10 and Tmsb15a, Tmsb15b and Tmsb15l 
transcripts are localised to podocytes. Tmsb10 mRNA levels were reduced and 
Tmsb15a transcript levels were upregulated in response to ADR-injury. There is 
relatively little known about thymosin b10 and thymosin b15 in the kidney compared 
to TB4. Thymosin b10 is expressed in the human kidney in development, and 
localised to the proximal and distal tubules (Gerosa et al. 2010), suggesting that it 
has a role in nephrogenesis. Tmsb10 transcripts have been detected in human adult 
kidneys by Southern blot analysis (Hall 1994) and adult C57BL/6 mice by qPCR 
(Vasilopoulou et al. 2016). The human protein atlas (www.proteinatlas.org) identifies 
Tmsb10 transcripts in human kidneys, but only localised to proximal tubular cells, 
distal tubular cells, collecting duct cells and immune cells, with no mention of any 
glomerular specific cell. The protein atlas also states the three isoforms of Tmsb15 
are present in very low levels in the kidney compared to Tmsb10, with some 
expression only seen in collecting duct cells, T cells and some proximal tubular cells. 
However, it seems from the website that glomerular cell types have not been 
examined in any context, so it is possible that the mRNA transcripts are present in 
human glomeruli. Further studies using in situ hybridisation of FFPE kidney sections 
or single cell RNA sequencing (scRNAseq) could confirm this. Thymosin b15 is 
expressed in the mouse adult kidney, but it hasn’t been localised to specific cells. 
Future studies could explore the effects of knocking down Tmsb10 or Tmsb15a in 
podocytes in vitro to see if similar cytoskeletal disorganisation occurs. The loss of 
both Tmsb4x and Tmsb10 mRNA in ADR injury is interesting and warrants further 
exploration. Future studies could perhaps treat ADR-injured podocytes with a 
combination of exogenous TB4 and thymosin b10 to examine if this synergistic 
 117 
approach is able to maintain cell viability and further prevent cytoskeletal 
disorganisation. 
 
To date, there have been no reports on the effect of ADR on cofilin-1, profilin-1 or -2, 
therefore this thesis has provided the first evidence that the transcripts of these 
actin-regulating proteins are unchanged in ADR nephropathy. Collectively, the 
effects of ADR on actin modulating genes were not altered by TB4, except for 
Schip1. Previous studies have shown that in whole kidney homogenates, lack of 
Tmsb4x upregulates Cfl1 levels (Vasilopoulou et al. 2016). It has been suggested 
that TB4 promotes cofilin-1 activity, by disassociating G-actin:cofilin-1 complexes, 
therefore allowing cofilin-1 to sever F-actin (Al Haj et al. 2014). The steady mRNA 
expression of Pfl1 and Pfl2, proteins that promote actin polymerisation (Mouneimne 
et al. 2012), coupled with the loss of Tmsb4x, Tmsb10 and Cfl1 in ADR-injury may 
provide an explanation of the ADR-induced F-actin disorganisation, as collectively 
there is significantly reduced expression of factors that negatively regulate F-actin 
polymerisation. 
 
Synaptopodin is a mature podocyte actin-associated protein (Mundel, Reiser, et al. 
1997) that has previously been shown to orchestrate cytoskeletal organisation 
through RhoA signalling (Asanuma et al. 2006) and regulating the actin-bundling 
activity of a-actinin (Asanuma et al. 2005). The results presented in this study show 
that Synpo was upregulated 4-fold in response to ADR-injury. This data is in contrast 
to previously reported Synpo levels in ADR injury. Mouse immortalised podocytes 
treated with 0.25 µg/ml ADR showed a 50% reduction in Synpo mRNA expression 
and synaptopodin protein expression as measured by qPCR and Western blot 
respectively (Wang et al. 2018). It is possible that the higher concentration of ADR 
induced a different effect on Synpo levels in podocytes in this study. This would have 
to be confirmed by repeating the experiment in the same laboratory conditions as 
this thesis and treating with an increased dose of ADR. Previous studies have shown 
that when Tmsb4x is downregulated, the expression of Synpo remains constant 
(Vasilopoulou et al. 2016). ADR induced a reduction of Tmsb4x in this thesis, so the 
upregulation of Synpo is unlikely to be directly due to the reduction of Tmsb4x, but 
other intracellular effects of ADR. Endogenous Synpo expression has been recently 
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shown to decelerate ADR nephropathy in vivo through suppression of Rac1 activity 
and activation of RhoA (Ning et al. 2020). Although this study did not quantify Synpo 
mRNA expression after ADR exposure, perhaps podocytes upregulate Synpo as a 
protective mechanism in ADR injury.  
 
One gene of interest that exogenous TB4 affected the levels of was Schip1. Schip1 
is a member of the complex linking the cytoskeleton to podocalyxin (Perisic et al., 
2015), a protein that is essential for charge based filtration of the blood (Kerjaschki et 
al. 1984). Schip1 overexpression was shown to prevent the loss of the podocyte 
cortical actin cytoskeleton and formation of cytoplasmic stress fibres in response to 
PDGF-BB (Perisic et al., 2015) and TB4 is predicted to bind to the human 
homologue of Schip1 (Miyamoto-Sato et al., 2010). The other members of the 
podocalyxin-cytoskeleton complex were unaltered, except Schip1, meaning that if 
this complex breaks down in ADR injury, the loss of Schip1 is likely to be the cause. 
Neurofibromin 2 has mostly been characterised in glial cells, linking the cortical 
cytoskeleton to the membrane (Cole et al. 2008) and Schip1 has been shown to bind 
to Neurofibromin 2 (Goutebroze et al. 2000), however the significance of this binding 
is not yet clear. The presence of Neurofibromin 2, a member of the ERM family of 
proteins that organise membrane-cytoskeletal interactions (Fehon, McClatchey, and 
Bretscher 2010; McClatchey and Fehon 2009) in podocyte cells, may be significant 
in the future of understanding cytoskeletal-membrane interactions and receptor 
organisation in podocytes.  
 
 Conclusions  
The results demonstrated in this thesis chapter show that in ADR-injury there is a 
clear downregulation of endogenous Tmsb4x expression. ADR causes a disruption 
of the F-actin cytoskeleton, unravelling the highly organised cortical actin stress 
fibres to unorganised F-actin. Exogenous TB4 has a protective role of the podocyte 




Figure 2.15 - Diagram depicting the function of TB4 in ADR injury. ADR causes a 
reduction in podocyte Tmsb4x expression and actin cytoskeletal disorganisation. Treatment 
with exogenous TB4 prevented ADR-induced disorganisation of the actin cytoskeleton. 
Original diagram. 
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Chapter 3: Systemic thymosin b4 delivery alleviates 
Adriamycin-induced glomerular injury 
 Introduction 
The results presented in the previous chapter of this thesis demonstrate that 
exogenous TB4 prevents ADR-induced F-actin disorganisation in cultured 
podocytes. However, it is imperative to explore the role of exogenous TB4 in vivo. 
The in vitro model allows exploration into cell specific mechanisms, however, using 
in vivo models of glomerular injury provides insight into the therapeutic potential of 
molecules in a living system, which encompasses blood flow, a key component 
missing from culture systems.  
 
So far, there have been a limited number of studies that have used exogenous TB4 
as a therapeutic agent in kidney injury. In the UUO model, a model of renal fibrosis, 
C57BL/6 mice were treated with 150 µg/day of TB4, resulting in a 33% reduction of 
interstitial fibrosis compared to sham mice. Administration of either 1 mg/kg or 5 
mg/kg of synthetic TB4 to UUO injured Sprague-Dawley rats reduced 24h proteinuria 
and histopathological changes (Yuan et al. 2017). Daily injection of synthetic TB4 
(100 ng/g/day) to C57BL6 mice attenuated albuminuria and histopathological 
changes in the diabetic nephropathy model (Zhu et al. 2015). Furthermore, Sprague-
Dawley rats injured with the acute ischaemia reperfusion kidney model and injected 
intravenously with 10 mg/kg synthetic TB4 showed reduced inflammatory and 
apoptotic markers and improved kidney function (Aksu et al. 2019). These studies 
show that exogenous TB4 may have a protective role in acute and CKD models, 
however, the effect of exogenous TB4 in glomerular injury is unknown. 
 
It is estimated that in the U.K., around 0.8 in 100,000 individuals are diagnosed with 
FSGS but many cases do not respond to the current treatment of steroids to slow the 
progression to ESKD (Hogg, Middleton, and Vehaskari 2007), highlighting the urgent 
need for novel therapies that can circumvent steroid resistance. ADR mimics some 
of the characteristics of human FSGS when administered to rodents (Bertani et al. 
1986; Lee and Harris 2011; Wang et al. 2015), including albuminuria, foot process 
effacement, glomerulosclerosis, podocyte detachment and cytoskeletal 
disorganisation (Guo et al., 2008; Heikkilä et al., 2010; Zou et al., 2010; Lee and 
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Harris, 2011; Suleiman et al., 2017). The previous chapter showed that exogenous 
TB4 is able to prevent ADR-induced cytoskeletal reorganisation in vitro, suggesting 
that exogenous TB4 may have beneficial effects in ADR injury in vivo.  
 
To examine this, a systemic gene therapy strategy was undertaken. TB4 is 
metabolised relatively quickly when the recombinant peptide is administered in vivo, 
and the concentration of circulating TB4 returns to basal levels within 6 hours (Mora 
et al. 1997). Therefore, an AAV construct encoding Tmsb4x was used (Bongiovanni 
et al., 2015) to achieve systemic, long-term upregulation of TB4. AAV 2/7 has the 
capsule of AAV 7, which displays strong tissue tropism for the liver and brain (Van 
Der Perren et al. 2011). AAV infects liver cells before inducing transgene expression 
via transcription and translation (Schultz and Chamberlain 2008). Specific targeting 
of the kidney is a challenge that renal scientists employing AAV therapy face, due to 
low tissue tropism of known serotypes (Zincarelli et al. 2008). Therefore, this thesis 
chapter employed a systemic upregulation of TB4 with AAV.Tmsb4x (the mRNA 
precursor of TB4), as it has been proven that TB4 is a secreted peptide (Mora et al. 
1997). AAV infection is also slow and can take over 1 week for full infection and 
replication to occur (Davidoff et al. 2005), so AAV.2/7 was used as a preventative 
therapy, rather than an intervention after disease had been induced. 
 
 Aims and hypothesis 
It was hypothesised that exogenous TB4 would prevent ADR-induced glomerular 
injury by protection of the podocyte cytoskeleton. The first aim of this chapter is to 
examine if endogenous TB4 is downregulated in glomeruli and podocytes in ADR 
injury in vivo. The second aim of this chapter is to confirm that AAV.Tmsb4x can 
infect liver cells and induce systemic upregulation of TB4. The final aim of this 
chapter will aim to investigate if exogenous TB4 can prevent ADR-induced 
glomerular injury and to determine if ADR or TB4 affect the podocyte cytoskeleton in 
vivo.  
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 Materials and methods 
3.3.1 Analysis of single cell RNA sequencing data 
Analysis of scRNAseq data from a recently published study (Chung et al. 2020) was 
performed in collaboration with Mr Daniyal J. Jafree and Mr Gideon Pomeranz, from 
University College London Great Ormand Street Hospital Institute of Child Health. 
scRNAseq analysis was performed using RStudio for Macintosh (RStudio Inc., 
v1.2.5042) using R (v4.0.2).   
 
3.3.1.1 Data acquisition 
The raw scRNAseq dataset used in this analysis was acquired from a study 
characterising the single-cell transcriptome of murine ADR nephropathy using the 
10X Genomics platform (Chung et al. 2020). Matrices of gene counts per droplet, 
generated after alignment of reads to genes, were acquired from the National Center 
for Biotechnology Information Gene Expression Omnibus (GSE146912) and are 
available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146912. 
 
3.3.1.2 Quality control, data processing and integration 
All of the following analyses were performed using the Seurat toolkit (Butler et al. 
2018). The count matrices from n = 2 control samples (8,412 cells) and n = 2 
samples with ADR nephropathy (8,296 cells) were merged into a single object. 
Genes expressed in two or fewer droplets were excluded and droplets with < 200 
and > 4000 detected genes and > 10% of features mapping to the mitochondrial 
genome were excluded. The data were then normalized using the NormalizeData 
function and the data scaled by all detected genes using the ScaleData function 
before principal component analysis (PCA), using the top nine components for 
downstream analyses. Integration and matching of cell types between experimental 
conditions was performed using the Harmony package for R (Korsunsky et al. 2019).  
 
3.3.1.3 Clustering, cell type identification and counting 
Shared nearest neighbour graphing was performed using the FindNeighbors 
function. Unsupervised clustering was performed with the FindClusters function 
using the Louvain algorithm and a resolution of 0.4, generating 14 transcriptionally 
distinct clusters of cells, before dimension reduction using Uniform Manifold 
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Approximation and Projection (UMAP). Cell type identification was performed by 
assessing the top ten differentially expressed genes per cluster calculated using the 
FindAllMarkers function and canonical markers for glomerular cell types were 
compared from previous scRNAseq studies (Chung et al. 2020; Fu et al. 2019; 
Karaiskos et al. 2018). Ten glomerular cell types were subsequently identified and 
assigned. The number of cell types by experimental condition was exported and 
graphed in Prism (GraphPad, v9.0.0) 
 
3.3.1.4 Comparison of Tmsb4x expression 
The FindAllMarkers function was used to compare the scaled expression of Tmsb4x 
between ADR nephropathy and control datasets. The average log fold change was 
calculated for podocytes or all glomerular cell types (glomerular endothelial cells, 
mesangial cells, and podocytes) between experimental conditions. Wilcoxon Rank 
Sum tests was used to assess statistical significance. 
 
3.3.2 Experimental animals and procedures 
ADR nephropathy was induced in BALB/c mice, as they harbour low levels of 
PRKDC, rendering them sensitive to ADR-induced glomerular injury (Papeta et al. 
2010). All procedures described were approved by the Home Office. All materials 
listed below were obtained from Merck U.K unless stated otherwise. All incubations 
were at room temperature unless stated otherwise.  
 
Male BALB/c mice aged between 7 – 10 weeks were housed in cages of three, 
exposed to constant temperature (22 °C) and light cycle (12 hours light, 12 hours 
dark), and provided with standard laboratory chow and tap water ad libitum. Blood 
and urine were collected prior to the mice being injected with 5x1012 viral particles of 
either AAV.LacZ serotype 2/7 or AAV.Tmsb4x serotype 2/7 via the tail vein. The AAV 
constructs were a kind gift from the lab group of Professor Christian Kupatt 
(Bongiovanni et al., 2015). Three weeks later (day 0 in Figure 3.1), mice were 
weighed and then injected with 10 mg/kg of ADR or vehicle (0.9% saline) via the tail 
vein and culled 14 days later. The final treatment groups to be compared were 
administered (i) AAV.LacZ and vehicle (control group) (LacZ/saline), (ii) AAV.LacZ 
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and 10 mg/kg ADR (glomerular injury group) (LacZ/ADR) and (iii) AAV.Tmsb4x and 
ADR (glomerular injury and treatment group) (Tmsb4x/ADR).  
 
Mice were weighed at day 0, 2, 7 and 14 after ADR/vehicle administration. Blood 
(collected in MicroVette EDTA coated capillary action tube, SARSTEDT, Nümbrecht, 
Germany) and urine were collected at day 2 and mice were culled by CO2 
asphyxiation at day 14 after ADR administration for kidney and liver collection, 
following overnight urine collection in metabolic cages. Death was confirmed by 
exsanguination. A 25G needle was used for blood collection via the lateral 
saphenous vein while the mice were alive and via cardiac puncture post-mortem. 
The collected blood was centrifuged for 15 minutes at 3000 rpm. The separated 
plasma was extracted and stored at -80 °C until further use. Urine was centrifuged at 
10,000 rpm for 5 minutes and the supernatant was stored at -80 °C until further use. 
An overview of the experimental set up can be found (Figure 3.1). 
 
3.3.3 Tissue processing 
Left kidneys and part of the liver were immediately snap frozen on dry ice after 
extraction from the mice. Right kidneys were weighed to obtain kidney weight to 
body weight ratio and then cut in half with a scalpel medially along the basal side. 
The kidney halves along with the liver were fixed in 4% PFA in dH2O overnight at 4 
°C while rotating. After fixation, one half of the kidney was cryo-preserved and the 
other half, along with the liver and heart, was embedded in paraffin wax. 
 
For cryo-preservation, the tissue was incubated in 30% sucrose in dH2O overnight 
following fixation at 4 °C while rotating. The kidney was then rinsed in OCT medium 
(Agar Scientific, Stansted, U.K.) before cryo-preservation in OCT medium on dry ice, 












Mice culled, kidneys and 
liver collected, urine 
and plasma collected
Figure 3.1 – Experimental design for in vivo ADR experiment. A graphic displaying the 
chronological experimental design for the in vivo experiment. Day 0 was designated as the 
day of ADR/vehicle administration. 
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with the cut side of the kidney face down, and stored at -80 °C until further use. Cryo-
sections were cut on a cryostat (Clinicut 60, Bright Instruments, Huntingdon, U.K.) to 
8 µm, adhered to SuperFrost Plus microscope slides (VWR International, PA, U.S.A) 
and stored at –20 °C until further use. For paraffin wax embedding, the tissue was 
prepared by a series of dehydration and washing steps. The tissues were 
dehydrated by 1-hour subsequent incubations in 70%, 80%, 90% and 100% ethanol. 
The tissues were then cleared by 2 one-hour incubations in Histoclear II (National 
Diagnostics, GA, USA). The Histoclear II was drawn out from the tissues by 
incubation in a 1:1 solution of Histoclear II and paraffin wax at 80 °C for 1 hour. 
Finally, the tissues were washed in paraffin wax for 2 one-hour incubations at 80 °C. 
Tissues were then embedded in fresh wax with cut side face down until solidified. 
The wax blocks were then sectioned to 5 µm on a microtome (RM2255, Leica 
Biosystems, Milton Keynes, U.K.) and adhered to SuperFrost Plus microscope 
slides. 
 
3.3.4 Antibodies used  







Polyclonal sheep IgG a-
human TB4 
1:200 (IHC, IF) 
1:4000 (ELISA) 
Proteinase K R&D Systems, MN, USA, 
AF6796 
Goat a-mouse albumin 
(capture) 
1:100 (ELISA) N/A Bethyl Laboratories, TX, 
USA, A90-134A 
Polyclonal guinea pig 
a-mouse synaptopodin 
1:200 (IF) N/A 2B Scientific, Oxfordshire, 
U.K., 163-004-SY 
Monoclonal rabbit a-mouse 
WT-1 
1:200 (IHC) Tris-EDTA Abcam, Cambridge, U.K., 
AB89901 
Monoclonal rat a-mouse 
F4/80 
1:1000 (IHC) Trypsin Bio-Rad, CA, USA, 
MCA497R 
Polyclonal rabbit a-mouse 
Ki67 
1:400 (IF) N/A Abcam, Cambridge, U.K., 
AB15580 
Table 3.1 – List of primary antibodies used. a, anti; IgG, immunoglobulin G; WT-1, 
Wilms tumour 1; F4/80, EGF-like module containing mucin-like hormone receptor-like 1; 
Ki67, antigen Ki67; IHC, immunohistochemistry; IF, immunofluorescence; ELISA, enzyme 
linked immunosorbent assay; N/A, not applicable; EDTA, ethylenediaminetetraacetic acid.  
acid.  
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 Table 3.3.2 – List of secondary antibodies used in in vivo experiments 
 
3.3.5 TB4 ELISA 
To determine if TB4 was upregulated in the mice treated with AAV.Tmsb4x 
compared with AAV.LacZ treated mice, plasma concentration of TB4 was measured 
by a customised ELISA, which was refined based on a previously used protocol 
(Mora et al. 1997). Standards using synthetic TB4 (ReGeneRx Biopharmaceuticals 
Inc), diluted in incubation buffer (pH 7.4, Na2HPO4 (0.01M), NaCl (0.15M), Tween-20 
(0.055 % v/v), BSA (1 % v/v)), were prepared by serial dilutions to obtain the 
following concentrations: 10,000 ng/ml, 5,000 ng/ml, 2,500 ng/ml, 1,250 ng/ml, 625 
ng/ml, 312.5 ng/ml, 156 ng/ml, 78 ng/ml, 39 ng/ml, 0 ng/ml. A 1:1 homogenous ratio 
of standards/samples and incubation buffer was added to a sterile borosilicate tube 
(Scientific Laboratory Supplies, Nottingham, U.K.). Sheep anti-serum to TB4 (Table 
3.1) was diluted 1/4000 in incubation buffer and 100 µl was added to each tube of 
standard/sample. The tubes were sealed, vortexed and incubated at 4 °C overnight. 
The ELISA plate (Greiner Bio-One, 96 well, flat transparent) was coated with 100 µl 




Goat a-mouse albumin HRP 
conjugate (detection) 
1:40,000 (ELISA) Bethyl Laboratories, TX, USA, 
A90-134P-7 
Goat a-sheep HRP conjugate 1:2000 (ELISA) Dako, Ely, U.K., P0450 
Goat a-guinea pig Alexa Fluor 488 
conjugate 
1:200 (IF) ThermoFisher Scientific, MA, USA, 
A11073 
Goat a-guinea pig Alexa Fluor 594 
conjugate 
1:200 (IF) ThermoFisher Scientific, MA, USA, 
A11076 
Donkey a-sheep Alexa Fluor 594 
conjugate 
1:200 (IF) ThermoFisher Scientific, MA, USA, 
A11016 
Rabbit a-rat IgG HRP conjugate 1:200 (IHC) Agilent, CA, USA P0450 
Rabbit a-sheep IgG HRP conjugate  1:200 (IHC) ThermoFisher Scientific, MA, USA, 
61-8620 
Donkey a-rabbit IgG Alexa Fluor 594 
conjugate 
1:200 (IF) Abcam, Cambridge, U.K., 
AB89901 
Table 3.2 – List of secondary antibodies used. a, anti; IgG, immunoglobulin G; IHC, 
immunohistochemistry; IF, immunofluorescence; ELISA, enzyme linked immunosorbent 
assay. 
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H2O). Negative control wells with coating buffer only were also prepared and the 
ELISA plate was incubated at 4 °C overnight.  
 
The plate was washed 5 times with washing buffer (pH 7.4, Na2HPO4 (0.01M), NaCl 
(0.15M), CaCl2 (1 mM), MgCl2 (0.5 mM), Tween-20 (0.55% v/v)) (all subsequent 
washes were 5x with washing buffer) and blocked with 200 µl of blocking buffer (5 % 
dry fat milk in incubation buffer) for 1 hour. After washing, 100 µl of the 
standards/samples were added to the ELISA plate wells and left to incubate for 2 
hours. The plate was then washed and 100 µl of goat anti-sheep HRP-conjugated 
(Table 3.2) secondary antibody, diluted 1/2000 in incubation buffer was added to 
each well. The plate was left for 1 hour to incubate and then washed again. 
Substrate solution (containing equal parts stabilised H2O2 and stabilised 
tetramethylbenzidine) was prepared (R&D Systems, Stansted, U.K.) and 100 µl was 
added to each well of the plate, which was left to incubate for 15 minutes in the dark. 
The reaction was stopped with the addition of 50 µl of 2M sulphuric acid per well and 
absorbance (Abs) was read at 450 nm using a plate reader.  
 
A blank value (incubation buffer only) was subtracted from each Abs450 value before 
a standard curve of the log10 values vs Abs450 was generated on Graph Pad Prism 
9.0 (Figure 3.2). Sample log10 transformed values were compared to the standard 
curves to determine sample TB4 concentration.  
 























Figure 3.2 - TB4 ELISA standard 
curve. Example of a standard curve 
used to calculate plasma TB4 
concentration. r2 value indicates how 
well points align to line of best fit 
(0.9999 = perfect fit). 
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3.3.6 Albumin ELISA 
To measure albuminuria, a commercially available ELISA kit was used (Bethyl 
Laboratories, TX, USA). Tris Buffered Saline (TBS) (5 x 50 mM), pH 8.0 in H2O was 
prepared; using Tris Base (44.37 mM), Tris HCl (0.21 M), NaCl (0.69 M) and KCl 
(13.42 mM). The wash solution (pH 8.0, 1 x TBS in H2O and 0.05 % (v/v) Tween-20), 
postcoat solution (pH 8.0, 1 x TBS in H2O and 0.1 % BSA (v/v) and sample diluent 
(postcoat solution and 0.05 Tween-20 (v/v)) were also prepared prior to the start of 
the experiment. 
 
Goat a-mouse albumin antibody (Table 3.1) was diluted 1/100 in coating buffer, 
added to each well of the ELISA plate and left to incubate for 1 hour. After 
incubation, the ELISA plate was washed 3x with wash buffer (all subsequent washes 
were 3x in wash buffer) and blocked by adding 200 µl of PostCoat solution to each 
well for 30 minutes. Standards of mouse albumin were prepared by serial dilutions to 
obtain concentrations of: 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 
15.625 ng/ml and 7.8 ng/ml in sample diluent. Urine samples were either diluted 
1/1,000 or 1/10,000 in incubation buffer depending on the amount of urinary albumin 
present. The plate was then washed before the standards/samples were added to 
the appropriate wells and left to incubate for 1 hour. The plate was washed and 100 
µl of the goat a-mouse albumin antibody conjugated to HRP (Table 3.2) diluted in 
sample diluent for a final dilution of 1:100 was added to each well. After washing 
again, 100 µl of substrate solution (containing equal parts H2O2 and 
tetramethylbenzidine) (R&D Systems) was added to each well for 15 minutes in the 
dark. The reaction was halted with 50 µl of 2M sulphuric acid and the Abs was read 
at 405 nm. All standards and samples were assessed in duplicate.  
 
The average Abs405 – blank (sample diluent only) values, were transferred to Graph 
Pad Prism 8.0 where a standard curve of Abs405 vs log10 was plotted. The sample 
albumin concentrations (ng/ml) were determined based on comparison of their 
Abs450 values with the standard curve (Figure 3.3). The concentration was then 
multiplied by the volume of urine produced by the mouse at each time point to give 
the amount of albumin in the urine (ng). The final value of µg of albumin over a 24-
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hour period was calculated by the following formula: amount of albumin (ng)/time in 
metabolic cage (hours) X 24 (hours)/1000. 
 
3.3.7 Creatinine assay 
Creatinine is a muscle metabolite that freely filtered through the glomerular filtration 
barrier and used to adjust urinary albumin amount for body weight (Wyss et al. 
2000), so urinary creatinine levels were quantified using a commercially available kit 
(Cayman Chemicals, MI, USA). Creatinine standards were serially diluted in distilled 
H2O: 0 mg/dl, 2 mg/dl, 4 mg/dl, 6 mg/dl, 8 mg/dl, 10 mg/dl, 12 mg/dl, 15 mg/dl, and 
the urine samples were diluted 1/10 in distilled H2O. Next, 15 µl of the diluted sample 
was added to the assay plate in duplicate. The reaction was started by the addition 
of 150 µl of alkaline picrate solution, the plate was sealed and incubated on a shaker 
for 10 minutes. The Abs was then read at 495 nm, designated initial Abs (Iabs), and 5 
µl of acid solution was added to each well and left to incubate for 20 minutes on a 
shaker. The Abs495 was once again read, designated final Abs (Fabs).  
 
The average Iabs and Fabs of duplicate values were calculated and the corrected Abs 
was calculated by subtracting Fabs from Iabs. The change in Abs of the standard 0 
mg/dl was subtracted from itself and all other standards and the standard curve was 
generated from these values. The concentration of creatinine in mg/dl was calculated 
by the formula - ((Sample absorbance – standard curve y intercept)/slope of 
standard curve) X sample dilution. Sample creatinine concentration was converted 
Albumin ELISA standard curve





















Figure 3.3 – Albumin ELISA 
standard curve. Example of a 
standard curve used to calculate 
urinary albumin amount. 
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from mg/dl to µmol/l by multiplying by 88.4 (creatinine molecular weight is 113.12) 
and then to µmol/µl by division by 1,000,000. This value was then converted to µmol 
by multiplication with the urine volume of each sample. Conversion to mg was 
achieved by multiplying the µmol value by 113.12 (creatinine molecular weight) and 
dividing by 1000. Albumin to creatinine ratio was determined by dividing this value by 
the amount of albumin (µg) in the urine as calculated in 3.3.6. 
 
3.3.8 BUN assay 
BUN assay was used as a measure of plasma urea concentration and was assessed 
using a commercially available kit (BioAssay Systems, CA, USA). Blood was 
collected and plasma was prepared as described in 3.3.2. Standards were prepared 
of 50 mg/dl, 10 mg/dl, 5 mg/dl, 2.5 mg/dl, 1 mg/dl, 0.5 mg/dl and 0 mg/dl of urea in 
distilled H2O. The 96 well plate wells were filled with 5 µl of water (blank), standards 
or plasma samples in duplicate and 200 µl of the working reagent was added before 
tapping to mix. Abs was read at 520 nm after 20 minutes of incubation. A standard 
curve was generated of Abs520 against concentration of urea standard (mg/dl). 
Sample urea concentration was calculated with the following formula: [urea (mg/dl)] 
= (Abs520 of sample – Abs520 of blank)/ (Abs520 of standard – Abs520 of blank) x 
concentration of standard. Urea concentration was then converted to BUN by 
division by 2.14. BUN reflects only the nitrogen content of urea (molecular weight 
28), but urea measurement reflects the whole molecule (molecular weight 60). 
Hence, urea is 2.14 x (60/28 =2.14) that of BUN.  
 
3.3.9 Glomerular extraction 
Glomerular extraction was undertaken by Dr Eugenia Papakrivopoulou of the 
Clinique Saint Jean, Brussels (Eugenia Papakrivopoulou et al. 2018) in male BALB/c 
mice administered 10 mg/kg ADR intravenously. The mice were anesthetised and 
perfused with 1x108 Dynabeads (Invitrogen, Paisley, U.K.) through the left ventricle 
of the heart. The kidneys were removed, decapsulated, minced and digested. The 
glomeruli containing Dynabeads were extracted by a magnetic particle concentrator 




Snap frozen tissues were thawed and mechanically homogenised (PRO Scientific 
Inc, PRO 200, Oxford, U.K.) in 700 µl of buffer RLT (RNEasy Mini kit, Qaigen, USA). 
One volume of 70% ethanol in dH2O was added to the lysate and mRNA extraction 
was undertaken as described in 2.3.7. cDNA synthesis was performed as described 
in 2.3.8 and qPCR was performed as described in 2.3.10 using primers previously 
listed to examine Tmsb4x, Tmsb10, Tmsb15a, Tmsb15b, and Tmsb15l (Table 2.1).  
 
3.3.11 IHC 
IHC was performed on FFPE sections, prepared as described in 3.3.3. Sections 
were dewaxed twice for 5 minutes in Histoclear II (National Diagnostics) and 
rehydrated by sequential incubations in 100% ethanol (twice for 5 minutes), 70% 
ethanol (5 minutes) and distilled H2O (5 minutes). For immunoreactivity to occur, 
antigen retrieval must take place. The antigen retrieval methods used in this thesis 
are listed below:  
 
• Proteinase K – slides were incubated in 20 µg/ml Proteinase K diluted in 
distilled H2O for 20 minutes at 37 °C.  
• Trypsin – 1 mg tablet was dissolved in 1 ml distilled H2O. Slides were 
incubated in trypsin for 15 minutes at 37 °C.  
• Tris-EDTA (pH 9.0) – 10 mM Tris-buffer (Fisher Scientific) 1 mM EDTA, 
0.05% Tween-20 dissolved in distilled H2O was prepared. The buffer was 
heated in a microwavable container for 10 minutes on high power. Slides 
were placed in the heated buffer and then heated for another 25 minutes on 
medium power. Slides were allowed to cool before proceeding.   
 
After antigen retrieval, the slides were washed in dH2O before incubation in 1.6% 
hydrogen peroxide diluted in 1xPBS, to quench any endogenous peroxidase on the 
tissue. The sections were washed in dH2O and a hydrophobic ring was drawn 
around the tissues using a PAP pen (Vector Laboratories, Inc, Peterborough, U.K.). 
The slides were rinsed in 0.1% PBS-Tween 20 and then incubated in block solution 
(10% FCS, 1% BSA in 0.1% PBS-Tween 20 in dH2O) for 1 hour in a humidified  
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Dewaxing and rehydration of tissues
Antigen retrieval
Block non-specific antibody binding
Primary antibody incubation
Incubation in secondary antibody 
conjugated to HRP
Amplification of signal with 




Dehydration of stained tissue
Mounting of slides
Figure 3.4 – Flow diagram of IHC protocol. Simplified protocol of IHC experiments to aid 
in the explanation of the procedure. HRP, horse radish peroxidase; DAB, 3,3’-
Diaminobenzidine. 
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chamber. Immediately after blocking, the primary antibody (Table 3.1), diluted in 
block solution was applied to the sections before overnight incubation at 4 °C in the 
humidified chamber.  
 
The primary antibody was then washed off in 0.1% PBS-Tween 20 in dH2O. In cases 
where the primary antibodies were not raised in rabbit, an additional HRP-
conjugated secondary antibody (raised in rabbit) step (Table 3.2), diluted in block 
solution, was undertaken for 1 hour to display a rabbit epitope. The sections were 
washed in 0.1% PBS-Tween 20 for three times for 5 minutes and incubated in either 
a-rabbit EnVision (Dako, Ely, U.K.) or a-rabbit ImmPRESS (Vector Laboratories) for 
40 minutes in the humidified chamber to amplify positive staining. The slides were 
then washed in PBS and incubated in 3,3’-Diaminobenzidine (DAB) for up to 5 
minutes to reveal positive staining. After another washing stage of 5 minutes in tap 
water, counterstaining with Mayer’s haematoxylin for 30 seconds to 1 minute to 
visualise nuclei took place. Subsequently, the sections were thoroughly washed in 
running tap water for 10 minutes. The slides were then rehydrated in 70% 
ethanol (5 minutes), 100% ethanol (twice for 5 minutes) before washing in Histoclear 
II (National Diagnostics) (twice for 5 minutes). Finally, the sections were mounted 
with Histomount (National Diagnostics) and stored at room temperature. A flow 
diagram simplifying this protocol can be found in Figure 3.4. Negative controls were 
also generated by omitting the primary antibody to confirm antibody specificity. 
Immunohistochemically stained sections were imaged on a Leica DM5500 B 
histological microscope (Leica Biosystems) with either the 20x or 40x objective.  
 
3.3.12 Immunofluorescence 
All washing steps were three times for 5 minutes unless stated otherwise. To 
fluorescently label proteins, cryo-sections were prepared as described in 3.3.3 and 
the slides were defrosted in PBS before a hydrophobic ring was drawn around the 
tissue with a PAP pen. The sections were then permeabilised for 10 minutes in 0.3% 
PBS-Triton X-100 before incubation in block solution (10% FCS, 1% BSA, 0.3% 
PBS-Triton X-100) for 1 hour in a humidified chamber. The primary antibody (Table 
3.1) was diluted in block solution and applied to the section, which was then 
incubated overnight at 4 °C in a humidified chamber.  
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The primary antibody was then washed off with 0.3% PBS-Triton X-100 before 
incubation with the appropriate fluorophore conjugated secondary antibody (Table 
3.2) diluted in block for 1 hour in the humidified chamber. The antibody was then 
washed off in 0.3% PBS-Triton X-100, and the slides incubated in 0.1% Sudan black 
(in 70% ethanol) for 20 minutes to suppress tissue autofluorescence and then 
washed again in PBS. The tissues were then incubated in 10 µg/ml Hoechst 33342 
diluted in PBS for 10 minutes to stain nuclei and washed in PBS. The slides were 
then dabbed dry, mounted with SlowFade then a coverslip was placed over the 
tissue and sealed with nail varnish. The slides were kept at 4 °C until further use. 
Negative control sections were also generated that omitted the primary antibody to 
confirm antibody specificity.  
 
3.3.13 Confocal microscopy 
Fluorescent images were obtained using a Laser Scanning 880 confocal microscope 
(Zeiss, Oberkochen, Germany) with the 63x 1.4 objective lens with immersion oil 
(Zeiss). ZEN Black software (Zeiss) was used for image acquisition set up. The 
images were captured with a diode (405 nm), an Argon (488 nm) and a Helium-Neon 
laser (594 nm). A negative control slide was prepared as described in 3.3.12, 
omitting either the 488 nm fluorophore or the 594 nm fluorophore so that channel 
bleed through and exposure could be assessed. The glomerulus with the brightest 
fluorescence was located on a control section and the gain was adjusted to 
maximise the fluorescence visualisation without inducing saturation (Figure 3.5a, b, 
c). The selected gain for each channel was adjusted so that any bleed through in the 
488 nm channel (Figure 3.5d, e, f) and the 594 nm channel (Figure 3.5g, h, i) was 
minimised. The “best signal” mode of image acquisition was selected, and the 
emission spectra (Figure 3.6) generated by ZEN black software indicated 
approximately 3% bleed through from the 405 nm channel into the 488 nm channel, 
however it was clear from the control images (Figure 3.5) that this did not affect the 
image acquisition.  
 
The image was acquired unidirectionally to reduce the number of scan lines the laser 
undertook, therefore reducing the time taken for image capture. The frame size was  
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Figure 3.5 - Confocal microscopy experimental set up. Single stain sections were 
prepared using either Acti-Stain 488 Phalloidin or Alexa Fluor 594 nm conjugated secondary 
antibodies. The gain was adjusted for the (a) 405 nm, (b) 488 nm and (c) 594 nm laser to 
the maximum gain that would not saturate the images. Representative images of the first 
section, omitting Acti Stain 488 nm Phalloidin, was imaged with the (d) 405 nm, (e) 488 nm 
and (f) 594 nm lasers. Representative images of the second section, omitting the Alexa 
Fluor 594 nm conjugated secondary antibody was imaged with the (g) 405 nm, (h) 488 nm 
and (i) 594 nm lasers. 










































set to the optimal setting, which was 1304x1304 pixels for 63x magnified images. 
The scan speed was set to 4 (out of 10), which increased pixel dwell time to reduce 
noise compared to the fastest scan speed (10) but did not cause bleaching of the 
pixels compared to the slowest scan speed (1). The line average time was set to 4, 
which caused the laser to scan each line 4 times and the pixel values were 
averaged. The images were saved as 16-bit images, which contained higher grey 
levels (bit depth) in comparison to 8-bit images. Finally, the pinhole was set to 1 Airy 
unit, which allowed the optimal ratio of light to resolution.  
 
3.3.14 Image analysis  
All image analyses were conducted on Fiji ImageJ software (Schindelin et al. 2012). 
Fifty glomeruli per sample were analysed unless stated otherwise. WT-1 is specific 
to podocyte nuclei in the glomerular tuft (Wagner et al. 2004), therefore to assess 
podocyte loss, WT-1 immunostained tissue images were acquired. For each 
glomerulus, the area was measured and the number of WT-1 positive nuclei in the 
tuft were assessed. This number was normalised to the tuft area. For each group, an 
average of 50 glomeruli was calculated for each sample. Additionally to the number 
in each glomerulus, the number of WT-1 positive nuclei in the parietal epithelium 
were counted.  
 
Figure 3.6 – Emission spectra of the wavelengths used in confocal microscopy 
studies. (a) The cross talk between each laser used in image acquisition. (b) Individual 
wavelengths of each track used. Track 1, red, 594 nm, synaptopodin; track 2, blue, 405 nm, 
nuclei; Track 3, green, 488 nm, F-actin. 
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Previous studies have identified through intravital multiphoton imaging that in 
disease, podocytes will cluster together before migration away from the glomerular 
tuft towards the Bowman’s capsule (Burford et al. 2014; Hackl et al. 2013). To 
assess podocyte clustering, a minimum of 30 glomeruli stained for WT-1 were used 
per mouse. The vascular pole of the glomeruli was designated the “lower” pole and 
the tubular pole was designated the “upper” pole. The glomerulus was divided into 
quarters and the number of WT-1 positive glomeruli in each quarter of the 
glomerulus was counted. 
 
To quantify renal inflammation, IHC sections were immunostained with F4/80 
antiserum which visualised macrophages. Images were captured on a Leica 
DM5500 B histological microscope with the 40x objective. The number of F4/80+ 
cells inside and out of the glomerular tuft in a constant region of interest were 
counted in each glomerulus.  
 
To assess glomerular F-actin alterations in vivo, cryosections were stained with 
phalloidin and images captured on a confocal microscope. The mean grey value of 
the background was subtracted from the images to remove background staining. The 
circumference of the glomerulus was traced, and the mean glomerular fluorescence 
was measured. The images were then thresholded to a value that caused the 
software to detect the lowest fluorescence but would not oversaturate the brightest 
fluorescence. The total area (µm2) and percentage area of the glomerulus covered 
by the F-actin was calculated using Fiji ImageJ. This experiment was repeated on 
sections immunostained to visualise synaptopodin. 
 
To determine alterations to podocyte F-actin in vivo, cryosections were 
immunostained with synaptopodin antiserum and phalloidin. A macro, that was 
designed by Dr Dale Moulding of GOSHICH, was used to automate image analysis. 
The circumference of the glomerulus was traced and measured, and the area 
outside of the glomerular tuft was cleared. A Gaussian blur with a Sigma (radius) 
value of 2.0 was applied to each channel to create a solid mask that defined the area 
of each individual protein (synaptopodin or F-actin) before each channel was 
thresholded. The mean fluorescence of F-actin within the synaptopodin positive area 
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was measured. The total area (µm2) of F-actin in the synaptopodin positive regions 
was also measured before normalising to the area of synaptopodin (percentage area 
of podocytes covered of F-actin). 
 
3.3.15 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 9.00 for Mac, 
GraphPad Software, La Jolla California USA, www.graphpad.com. Normal 
distribution was assessed by Shapiro-Wilk test. Where data was not normally 
distributed, values were log10 transformed, and parametric statistical analysis was 
undertaken on the transformed values. For experiments where two groups were 
compared, an unpaired t-test was performed. Where 3 treatment groups were 
assessed, one-way ANOVA with Tukey’s multiple comparison tests were used to 
compare statistical significance between all three groups. For experiments with two 
variables, two-way ANOVA with Tukey’s multiple comparison test was used to 
compare statistical difference between all values.  For data that analysed individual 
glomeruli (at least 250 glomeruli per group), normal distribution of the data could not 
be achieved through any transformation. In this case, a Kruskal-Wallis test, the non-
parametric equivalent of one-way ANOVA, was performed with Dunn’s multiple 
comparison test to compare statistical significance between all three groups. 
 
 Results 
3.4.1 Glomerular and podocyte Tmsb4x levels in ADR injury 
Firstly, the levels of Tmsb4x were examined in Dynabead extracted glomeruli from 
mice injected with ADR by qPCR. There was a tendency for a reduction in 
glomerular endogenous Tmsb4x mRNA after 7 days of 10 mg/kg ADR injection, 
compared with saline injected mice, however, this was not statistically significant 
(P=0.072). By 14 days, the level of Tmsb4x mRNA had increased compared with 7 





To investigate the expression of Tmsb4x in specific glomerular cells following ADR 
injury, a recently published scRNAseq dataset obtained from glomeruli isolated by 
Dynabeads of healthy or ADR-injured C57BL/6J mice 14 days after ADR or vehicle 
administration was analysed (Chung et al. 2020). Using unsupervised clustering 
analysis, ten transcriptionally distinct cell types were found (Figure 3.8) which were 
identified using established markers of differentiated kidney cell types (Karaiskos et 
al. 2018) (Figure 3.9). All cell types of the glomerulus were present in control and 
ADR-injured glomeruli (Figure 3.10a). This strategy detected a podocyte cluster 
which expressed both Nphs1 and Nphs2, components of the podocyte SD (Figure 
3.10b). As previously described (Chung et al. 2020), there was a reduction in the 
proportion of podocyte cells in the ADR injured glomeruli compared with controls 
(Figure 3.11a). ADR injury was associated with significant downregulation of 
Tmsb4x in the glomerular tuft, assessed by grouped analysis of glomerular 
endothelial, mesangial and podocyte cells (Figure 3.11b; 0.14 log fold change; 




















Effect of ADR on glomerular 
Tmsb4x expression
0.104
Figure 3.7 – The effect of ADR on glomerular Tmsb4x levels. Glomeruli were extracted 
by Dynabead perfusion and cDNA was synthesised from the extracted mRNA. mRNA level 
examination revealed the expression of glomerular Tmsb4x was altered at 7 days in ADR 
nephropathy. Gapdh was used as a housekeeping gene. Each data point represents the 
average of duplicates from the same individual experiment. Data are shown as the mean 
±SEM of at least 4 mice in each group. N=5 for saline group, N=5 for 7 days group and 
N=4 for 14 days group. 
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P<0.05). When podocyte cells were analysed individually, a larger 0.37 log fold 
reduction in Tmsb4x was observed in those obtained from ADR-injured compared 
with healthy glomeruli (Figure 3.11c; P<0.05).  
 
Figure 3.8 - Identification of transcriptionally different cell clusters. (a) Uniform 
manifold approximation and projection (UMAP) from single cell RNA sequencing data of 
8,412 glomerular cells from two wildtype (control) mice and 8,296 glomerular cells from 
mice with ADR nephropathy. After analysis and cell type assignment, ten 
transcriptionally distinct cell populations were discriminated including arterial endothelial 
cells (AEC), glomerular endothelial cells (GEC), macrophages (MΦ), mesangial cells, 
monocytes (Mono), parietal epithelial cells (PEC), podocytes, smooth muscle cells 
































































































Figure 3.9 – Canonical markers between cell types. Dotplot showing enrichment of 
canonical markers between cell types within the single cell RNA sequencing dataset. The 
markers include endomucin (Emcn) and Eps15 homology domain-containing protein 3 
(Edh3) for glomerular endothelial cells (GEC), pleiotrophin (Ptn) and platelet-derived growth 
factor receptor beta (Pdgfrb) for mesangial cells, Wilms' tumour 1 (Wt1) and podocin 
(Nphs2) for podocytes, Emcn and fibulin 2 (Fbln2) for arterial endothelial cells (AEC), protein 
tyrosine phosphatase receptor type C (Ptprc) and campath 1 antigen (Cd52) for monocytes 
and macrophages, paired box gene 8 (Pax8) for parietal epithelial cells (PEC), actin alpha 2 
(Acta2) and myosin heavy chain 11 (Myh11) for smooth muscle cells (SMC), E-cadherin 
(Cdh1) and aquaporin 2 (Aqp2) for tubular epithelial cells (TEC) and T cell surface 































































































Collectively, these findings demonstrate that ADR injury is associated with reduced 
Tmsb4x expression in the glomerulus and specifically in podocytes. 
 
  
Figure 3.10 – Comparison of cells in healthy glomeruli and in ADR nephropathy and 
identification of podocytes from Chung et al., 2020. (a) Uniform manifold approximation 
and projection (UMAP) grouped by experimental condition in the scRNAseq dataset. The 
UMAP corresponds to Figure 1A, showing concordance of cell types between ADR and 
control. (b) Bar graphs comparing the proportions of cell types between ADR and control. In 
the control dataset, n = 4,402 GECs, n = 1,302 mesangial cells, n = 1,486 podocytes, n = 
477 AECs, n = 218 macrophages, n = 143 PECs, n = 118 SMCs, n = 34 monocytes, n = 47 
TECs and n = 69 T cells were detected. In the ADR dataset n = 3,895 GECs, n = 1,239 
mesangial cells, n = 378 podocytes, n = 1,207 AECs, n = 245 macrophages, n = 505 PECs, 
n = 290 SMCs, n = 271 monocytes, n = 256 TECs and n = 36 T cells were detected. (b) 
Feature plots showing expression of nephrin (Nphs1) and podocin (Nphs2), canonical 
























































































































Figure 3.11 – ADR reduced glomerular and podocyte levels of Tmsb4x. (a) Bar graphs 
comparing the proportions of cell types between ADR and control. In the control dataset, n = 
4,402 GECs, n = 1,302 mesangial cells, n = 1,486 podocytes, n = 477 AECs, n = 218 
macrophages, n = 143 PECs, n = 118 SMCs, n = 34 monocytes, n = 47 TECs and n = 69 T 
cells were detected. In the ADR dataset n = 3,895 GECs, n = 1,239 mesangial cells, n = 378 
podocytes, n = 1,207 AECs, n = 245 macrophages, n = 505 PECs, n = 290 SMCs, n = 271 
monocytes, n = 256 TECs and n = 36 T cells were detected. (b) Violin plot comparing the 
scaled expression of Tmsb4x of all glomerular cells (podocytes, GECs, mesangium) 
between ADR (n = 5,602 cells) and control (n = 7,190 cells) An average log fold decrease of 
0.13 was detected in ADR compared to control (*: adjusted p value < 0.0001). (c) Violin plot 
comparing the scaled expression of Tmsb4x of podocytes between ADR (n = 378 cells) and 
control (n = 1,486 cells). An average log fold decrease of 0.36 was detected in ADR 
compared to control (*: adjusted p value < 0.0001). Each data point represents 1 cell. Data 








































































































3.4.2 AAV.2/7 upregulated TB4 in the circulation in mice with ADR nephropathy 
Since the levels of glomerular Tmsb4x were decreased in the early stages of ADR 
nephropathy, it was hypothesised that replenishing the supply of TB4 peptide may 
alleviate some of the phenotypes of ADR injury. TB4 has a relatively short half-life 
and plasma concentration returns to basal levels just 6 hours after injection of 
synthetic TB4 (Mora et al. 1997). Therefore, to induce a persistent upregulation of 
TB4, mice were treated with AAV.2/7 with a Tmsb4x (TB4) transgene, or LacZ (b-
galactosidase) transgene as a control.  
 
Firstly, to confirm that intravenous AAV.2/7 infected the liver of ADR injured mice, 
one of the organs that AAV.2/7 displays tissue tropism for (Zincarelli et al. 2008), 
liver mRNA levels of Tmsb4x were assessed by qPCR. There was a 10-fold increase 
in liver Tmsb4x levels in Tmsb4x/ADR mice compared to LacZ/ADR treated mice 5 
weeks after injection of AAV to healthy mice (P<0.001) (Figure 3.12a), 
demonstrating efficient transduction of Tmsb4x by AAV.2/7. To determine if the 
system was efficient in producing TB4 peptide, liver FFPE sections were 
immunostained to visualise TB4 expression. The livers of AAV.LacZ treated mice 
showed low expression of TB4 peptide (Figure 3.12c, d) compared to high 
expression of TB4 peptide in AAV.Tmsb4x treated mice livers (Figure 3.12e). The 
antibody was specific for TB4, as determined by the negative control omitting the 
primary antibody (Figure 3.12f). 
 
TB4 is a secreted peptide (Wise et al. 1992), therefore, it was hypothesised that the 
circulating plasma concentration of TB4 would be increased in AAV.Tmsb4x treated 
mice compared to LacZ treated mice. A custom ELISA protocol was designed based 
on a previously used method (Mora et al. 1997) to determine the concentration of 
TB4 in the plasma 14 days after ADR/vehicle injection. ADR had no effect on the 
plasma concentration of TB4, with levels in LacZ/saline and LacZ/ADR treated mice 
of 1.2 ± 0.3 ng/ml and 1.9 ± 0.3 ng/ml respectively. Tmsb4x/ADR treated mice had a 
plasma TB4 concentration of 3.4 ± 0.5 ng/ml, which was significantly increased 
compared with both LacZ/saline (P<0.01) and LacZ/ADR (P<0.05) treated mice 

















































Figure 3.12 – AAV.2/7 upregulated TB4 in circulation of mice with ADR nephropathy. 
Mice were injected with AAV.2/7 and 5 weeks later when the mice were culled, the livers 
were snap frozen on dry ice. (a) mRNA was extracted from the livers and cDNA synthesised 
before analysis for Tmsb4x by qPCR. Gapdh was used as a housekeeping gene. Each data 
point represents the average of replicates from individual mouse livers. (b) Blood was 
harvested by cardiac puncture 5 weeks after AAV injection and plasma TB4 concentration 
was determined by ELISA. Each data point represents a single experiment with plasma from 
individual mice. Representative images of FFPE livers immunostained to visualise TB4 from 
(c) LacZ/saline, (d) LacZ/ADR and (e) Tmsb4x/ADR treated mice. (f) Negative control 
omitting the primary antibody. Data are shown as the mean ±SEM of at least 5 mice.  N=9 in 
LacZ/saline group, N=6 in LacZ/ADR and N=5 in Tmsb4x/ADR. *P≤0.05, **P≤0.01, 
***P≤0.001 between groups. 
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3.4.3 ADR altered the kidney mRNA levels of some members of the b-thymosin 
family 
qPCR was performed to determine if ADR with or without TB4 gene therapy affected 
kidney levels of TB4 and other members of the b-thymosin family transcripts. ADR 
with or without TB4 gene therapy did not alter the levels of Tmsb4x (Figure 3.13a), 
Tmsb15a (Figure 3.13c) or Tmsb15l (Figure 3.13e) compared with healthy mice. 
 
 ADR induced a 3.5-fold increase in kidney Tmsb10 expression compared to 
LacZ/saline treated mice (P<0.001). The added TB4 suppressed the ADR-induced 
increase in Tmsb10 expression (P<0.05), however, Tmsb4x/ADR mice still showed a 
significant 2.27-fold increase in kidney Tmsb10 levels compared with LacZ/saline 
mice (P<0.01) (Figure 3.13b).  
 
Conversely, ADR caused a tendency for kidney expression of Tmsb15b levels to be 
reduced compared to LacZ/saline mice (P=0.078, LacZ/saline vs LacZ/ADR), and 
Tmsb4x/ADR mice showed a 44 ± 5% reduction of Tmsb15b compared with 




















































































































































Tmsb15l Figure 3.13 – Effect of ADR nephropathy 
with/without TB4 gene therapy on kidney 
levels of b-thymosin family. Whole kidney 
mRNA levels were examined by qPCR. 
Levels of (a) Tmsb4x, (b) Tmsb10, (c) 
Tmsb15a, (d) Tmsb15b and (e) Tmsb15l in 
ADR nephropathy with or without TB4 
therapy. Each data point represents the 
average of replicate values from the same 
mouse. All data are shown as the mean 
±SEM of at least 5 individual mice. N=9 in 
LacZ/saline group, N=6 in LacZ/ADR and 
N=5 in Tmsb4x/ADR.  *P≤0.05, **P≤0.01, 
***P≤0.001 between groups. Tmsb4x, TB4; 
Tmsb10, Thymosin β-10; Tmsb15a, 
Thymosin β15a; Tmsb15b, Thymosin β-15b; 
Tmsb15l, Thymosin β-15-like.  
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3.4.4 TB4 was expressed in glomeruli and podocytes in all three mouse groups 
To assess the expression of TB4 in healthy BALB/c mice and ADR injured BALB/c 
mice with or without TB4 gene therapy, 8 µm cryosections were prepared and 
immunostained with a-TB4 antibody (Table 3.1) and fluorescent secondary antibody 
(Table 3.2). Co-localisation with synaptopodin was used to evaluate podocyte TB4 
expression.  
 
The expression of synaptopodin was consistent between healthy mice and mice with 
ADR nephropathy with and without TB4 gene therapy. Synaptopodin covered large 
proportions of the glomeruli in patterns which were consistent with podocyte cell 
bodies and processes. This stable synaptopodin expression between the groups 
allowed TB4 expressed to be examined in podocytes and non-podocyte areas of the 
glomeruli (Figure 3.14a, b, c).  
 
TB4 was expressed in the podocyte cell bodies (white arrows) and podocyte 
processes (white arrowheads) of the glomeruli in healthy mice. TB4 was also 
expressed in non-podocyte areas, which could either be mesangial cells or 
glomerular capillary endothelial cells (black and white arrowheads) in healthy mice. 
TB4 was also expressed in podocytes and glomeruli in ADR-injured mice with and 
without TB4 gene therapy (Figure 3.14a, b, c). Antibody specificity was confirmed by 





































Figure 3.14 - Kidney TB4 expression in ADR nephropathy with or without TB4 gene 
therapy. Cryosections were stained with antibodies to label synaptopodin and TB4. TB4 
was expressed in glomeruli and podocytes of mice in the (a) LacZ/saline, (b) LacZ/ADR and 
(c) Tmsb4x/ADR groups. (d) Negative control omitting primary antibody. Scale bar = 20 µm.  
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3.4.5 Mouse body and kidney weights were reduced after ADR and TB4 
treatment 
Body weight is an indicator of general well-being and a decrease in body weight is 
indicative of poor health (Ullman-Culleré and Foltz 1999). Healthy mice and mice 
exposed to ADR with and without TB4 gene therapy were weighed on the day of 
ADR/vehicle injection, 2, 7 and 14 days later. There was no statistical difference 
between body weights on the day of ADR/vehicle administration (Figure 3.15b).  
 
LacZ/saline treated mice lost 1.4 ± 0.4% of body weight after 2 days compared with 
day 0 of vehicle administration. However, this steadily increased back to baseline 7 
days after ADR/vehicle injection and further increased by another 2.7 ± 0.7% at 14 
days. In mice with ADR nephropathy without TB4 gene therapy, the weight loss at 2 
days was exacerbated, and mice lost 4.5 ± 0.3% of body weight compared to the day 
of ADR administration, which was significantly lower compared with LacZ/saline mice 
(P<0.001). This weight loss was sustained at 3.7 ± 0.5% and 3.2 ± 0.7% below their 
weight at day 0 at both 7 days (P<0.01 vs LacZ/saline) and 14 days after ADR 
injection respectively (P<0.001 vs LacZ/saline). ADR treated mice with TB4 therapy 
experienced a similar pattern of weight loss to ADR-only mice, as there was no 
significant difference between these two groups at any time point. The Tmsb4x/ADR 
group lost 4.9 ± 0.6% of body weight 2 days after ADR injection (P<0.01 vs 
LacZ/saline). The weight loss persisted, and mice weighed 2.5 ± 0.4% less and 1.8 ± 
1.1% less at 7 and 14 days respectively (P<0.05 in both cases vs LacZ/saline) 
compared with their weights on the day of ADR administration (Figure 3.15a).  
 
The left kidneys were weighed and normalised to body weight 14 days after 
ADR/vehicle administration. Mice treated with LacZ/saline had a kidney weight of 
0.306 ±0.02g, which was 0.011 ±0.001 grams per gram of body weight. 
Administration of ADR without TB4 gene therapy slightly, but not significantly 
reduced these values, as their kidney weight was 0.25 ±0.01 g and 0.01 grams per 
gram of body weight. ADR administration with TB4 gene therapy significantly 
reduced both kidney weight (0.23 ±0.02 g) and kidney weight to body weight ratio 
(0.009 ±0.001 g/g) compared with LacZ/saline treated mice (P<0.05 in both cases) 
(Figure 3.15c, d). 
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Figure 3.15 – Body weights of ADR-injured mice with or without TB4 gene therapy at 
day 0, 2, 7 and 14 days after ADR/vehicle injection and kidney weights at 14 days after 
ADR/vehicle administration. (a) Mice were weighed at day 0, 2, 7 and 14 after 
ADR/vehicle administration. Statistical annotations using @ refer to comparison between 
LacZ/saline and LacZ/ADR. Statistical annotations using # refer to comparison between 
LacZ/saline and Tmsb4x/ADR (b) Mouse weights at day 0. (c) Left kidney weight and (d) 
kidney weight to body weight ratio 14 days after ADR/vehicle administration. Each data point 
represents 1 mouse. All data are shown as the mean ±SEM of at least 5 individual mice. 
N=9 in LacZ/saline group, N=6 in LacZ/ADR and N=5 in Tmsb4x/ADR.  *P≤0.05, **P≤0.01, 
***P≤0.001 between groups. 
a
b c





































































































































3.4.6 Urine excretion 2 and 14 days after administration of ADR 
To determine if any changes to urine excretion were occurring following ADR 
administration with or without TB4 gene therapy, the urine volumes were measured 
at day 0, 2 and 14 by using metabolic cages. LacZ/saline treated mice excreted 500 
± 126 µl of urine/24 hours on the day of vehicle administration. Addition of ADR 
caused mice to urinate 255 ± 90 µl/24 hours without TB4 gene therapy, and 324 ± 85 
µl/24 hours with TB4 gene therapy on the day of ADR administration. At day 2 of 
vehicle exposure, mice treated with saline urinated 687 ± 96 µl/24 hours. Mice 
treated injected with ADR without TB4 gene therapy urinated 637 ± 101 µl/24 hours 
of urine 2 days after ADR exposure, which was unchanged after addition of TB4 (872 
± 107 µl of urine/24 hours). At 14 days, mice injected with LacZ/saline excreted 657 
± 93 µl of urine/24 hours. Addition of ADR with or without TB4 gene therapy did not 
change urine excretion, as each group urinated 756 ± 87 µl/24 hours and 804 ± 105 
µl/24 hours. There were no significant differences between any groups at any time 
point measured (Figure 3.16). 
 
  
Figure 3.16 – Urine excretion at 2- and 14-days post-ADR injection. Urine was collected 
overnight in metabolic cages at day 0, 2 and 14 after ADR/vehicle injection and values were 
extrapolated to 24 hours. Each data point represents 1 mouse. Data are shown as mean 
±SEM of at least 5 individual mice. N=9 in LacZ/saline group, N=6 in LacZ/ADR and N=5 in 





























3.4.7 Exogenous TB4 prevented ADR-induced albuminuria, but there were no 
alterations to BUN 
Albumin cannot pass through the glomerular filtration barrier in the healthy kidney. 
Therefore, an increase in the amount of urinary albumin is a hallmark of damage to 
the glomerular filtration barrier (Suh and Miner 2013). ELISA was undertaken to 
examine albuminuria after ADR with and without TB4 gene therapy (3.3.6).  
 
Prior to either ADR or vehicle injection, LacZ/saline mice excreted 94.7 ± 16 µg of 
albumin/24 hours, LacZ/ADR mice excreted 41 ±16 µg/24 hours and Tmsb4x/ADR 
treated mice 60 ± 31 µg/24 hours. There was no significant difference between the 
groups. Two days following the injection of ADR or vehicle, there were no significant 
differences in urinary albumin concentration between any group. LacZ/saline mice 
excreted 103 µg/ml ± 20 µg/24 hours, LacZ/ADR mice 65 ± 10 µg/24 hours and 
Tmsb4x/ADR treated mice 73 ± 7 µg/24 hours. Fourteen days after either ADR or 
vehicle injection the LacZ/saline mice urinary albumin value was 107 ± 21 µg/24 
hours. The albuminuria values of the LacZ/ADR treated mice were to 1448 ± 115 
µg/24 hours, which was significantly more than LacZ/ADR treated mice (P<0.001). 
TB4 gene therapy prevented the increase in urinary albumin excretion, with an 
albuminuria value of 214 ± 43 µg/24 hours (P<0.01 vs LacZ/ADR), providing 
evidence that TB4 prevented albumin excretion (Figure 3.17a).  
 
The albumin to creatinine ratio (ACR) was examined 14 days after ADR or vehicle 
injection to normalise albuminuria to mouse body weight. LacZ/saline treated mice 
had an ACR of 153 ± 18.2 µg/mg. ADR administration without TB4 gene therapy 
caused an ACR of 2473 ± 229 µg/mg, which was significantly more than LacZ/saline 
treated mice (P<0.001). TB4 gene therapy prevented the ADR induced increase in 
ACR, as mice had an ACR of 249 ± 37 µg/mg (P<0.001) (Figure 3.17b).  
 
BUN is a measure of circulating plasma urea concentration and was measured by 
colourimetric assay 14 days after ADR or vehicle injection. LacZ/saline treated mice 







































































































Albuminuria to creatinine 
ratio - Day 14
Figure 3.17 – TB4 prevents ADR-induced albuminuria, but there were no changes to 
BUN. Urine was collected overnight in metabolic cages and urinary albumin concentration 
was determined at baseline, 48 hours and 14 days post saline/ADR injection by ELISA. (a) 
Quantification of urinary albumin concentration. Urine creatinine concentration was 
determined by colourimetric assay and then the (b) urinary albumin (µg) to urinary creatinine 
(mg) ratio was determined at 14 days. BUN was assessed by colourimetric assay of the 
plasma at 14 days and (c) quantified. Each data point represents the average of replicate 
values from a single mouse. Data are shown as the mean ±SEM of at least 5 mice.  N=9 in 
LacZ/saline group, N=6 in LacZ/ADR group and N=5 in Tmsb4x/ADR group. **P≤0.01, 
***P≤0.001 between groups.  
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without TB4 gene therapy had a BUN concentration of 18.8 ± 1.2 mg/DL and 
addition of TB4 gene therapy did not change BUN concentration (20.9 ± 1 mg/DL). 
There were no significant differences between any groups (Figure 3.17c). 
 
3.4.8 ADR did not cause glomerular inflammation 
One of the major properties of TB4 is its anti-inflammatory action (Vasilopoulou et al. 
2016, 2018). Therefore, it was postulated that if inflammation was occurring in this 
model of ADR injury that contributed to glomerular injury, the mechanism by which 
TB4 may protect the glomerulus could be due to suppression of inflammation. To 




























































































Macrophage count in 
glomerular tuft
Figure 3.18 – ADR did not induce an immune response at 14 days. FFPE kidneys were 
cut into 5 µm sections and incubated with a rat anti-mouse F4/80 primary antibody followed 
by a goat anti-rat secondary antibody conjugated to 488 nm fluorophore.  Representative 
images of (a) LacZ/saline, (b) LacZ/ADR and (c) Tmsb4x/ADR treated glomeruli. (d) 
Negative control omitting the primary antibody. Arrowheads indicate positive F4/80 staining. 
White dashed line indicates glomerular tuft. Scale bar = 20 µm. F4/80 positive cells were 
counted (e) in the glomerular tuft and (f) outside the glomerular tuft. Each data point 
represents the average of 50 glomeruli from each mouse. Data are shown as the mean 
±SEM of at least 5 mice. N=9 in LacZ/saline group, N=6 in LacZ/ADR group and N=5 in 
Tmsb4x/ADR group. 
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Representative images are presented in Figure 3.18a, b, c, with antibody specificity 
confirmed by omitting the primary antibody (Figure 3.18d). ADR administration with 
and without TB4 gene therapy did not induce a glomerular immune response, as 
there were no significant alterations to macrophage numbers inside or outside the 
glomerular tuft compared with LacZ/saline treated mice. (Figure 3.18e, f). Therefore, 
it can be concluded that inflammation was unlikely to be contributing to glomerular 
damage in this mouse model. 
 
3.4.9 TB4 prevented ADR-induced podocyte loss 
To count the number of podocytes per glomerulus, mouse kidney sections were 
immunostained using a-WT-1 antibody, which is specifically expressed in podocyte 
nuclei in the adult glomerulus (Lefebvre et al. 2015). Representative images of WT-1 
immunostaining from all three treatment groups can be found in Figure 3.19a, b, c, 
and antibody specificity was confirmed by omitting the primary antibody (Figure 
3.19d). 
 
Firstly, the area of each glomerular cross section was measured. The average area 
of LacZ/saline treated glomerular cross sections was 2658 ± 54 µm2. Administration 
of ADR lead to an increase of glomerular cross section area to 3846 ± 92 µm2, which 
was significantly larger than LacZ/saline treated mice (P<0.001). Treatment with 
exogenous TB4 dampened the ADR-induced increased in glomerular cross section, 
as the average glomerular cross section was 3278 ± 95 µm2. This value was 
significantly smaller than the LacZ/ADR treated mice (P<0.001), but significantly 
larger than the LacZ/saline treated mice glomeruli (P<0.001), showing that 
exogenous TB4 dampened the ADR-induced increase in glomerular cross section 
(Figure 3.19j).  
 
Next, the number of WT-1 positive cells were counted per glomerulus. Fourteen days 
after injection of either ADR or vehicle, LacZ/saline treated mice had 10.9 ± 1 
podocytes per glomerular cross section. There was a reduction with ADR treatment, 
where each mouse showed on average 8.9 ± 1.6 podocytes per glomerular cross 
section, but this reduction was not significant compared to LacZ/saline treated mice. 
Tmsb4x/ADR treated mice had an average of 10.4 ± 1.4 podocytes on each 
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glomerular cross section (Figure 3.19e). Since ADR with and without TB4 gene 
therapy altered the glomerular cross-sectional area, the number of WT-1 positive 
cells were normalised to glomerular area (podocyte density). LacZ/saline treated 
mice had a podocyte density of 6.6 x10-3 ± 0.3 x10-3 podocytes/µm2. Again, the 
average podocyte density of LacZ/ADR treated mice was reduced to 5.3 x10-3 ± 1 
x10-3 podocytes/µm2, however not statistically significant compared to LacZ/saline 
treated mice. Mice treated with Tmsb4x/ADR showed an average podocyte density 
of 6.6 x10-3 ± 0.8 x10-3 podocytes/µm2 (Figure 3.19f), but this was not significantly 
different to LacZ/saline or LacZ/ADR treated mice.   
 
ADR is a rodent model of FSGS (Chen et al. 1998), which is defined as scarring to a 
part of (segmental) some, but not all (focal) glomeruli in the kidney, meaning that 
some glomeruli will be more damaged than others within the same individual mouse 
(Jefferson and Shankland 2014). It was postulated that the healthier glomeruli may 
be “masking” the more damaged glomeruli when the average of 50 glomeruli was 
calculated in each mouse, therefore, individual glomeruli from each group were 
examined. A separate analysis using each individual glomerulus from each group 
was performed.  
 
When glomeruli were analysed as individual values 14 days after ADR or vehicle 
injection, ADR nephropathy without TB4 gene therapy reduced the average number 
of WT-1 positive cells in the glomerular tuft and podocyte density count compared 
with LacZ/saline treated mice (P<0.001 in both data sets). Mice treated with ADR 
and TB4 gene therapy prevented the reduction in podocyte number and density 
compared with ADR without TB4 gene therapy (P<0.001 in both data sets) (Figure 
3.19g, h).  
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Figure 3.19 – Exogenous TB4 prevents ADR-induced podocyte loss. FFPE kidneys 
were incubated with a rabbit anti-mouse WT-1 primary antibody followed by donkey anti-
rabbit conjugated to 594 nm fluorophore (ThermoFisher). Representative images of (a) 
LacZ/saline, (b) LacZ/ADR and (c) Tmsb4x/ADR glomeruli. Arrowheads indicate positive 
WT-1 staining. White dashed line indicates glomerular tuft boundary. (d) Negative control 
omitting primary antibody. Scale bar = 20 µm. WT-1 positive cells were (e) counted inside 
the glomerular tuft and (f) normalised to the glomerular tuft area (podocyte density). Each 
data point represents the average of 50 glomeruli from each individual mouse. Data are 
presented as the mean ±SEM of 5 individual mice. N=9 for LacZ/saline group, N=6 for 
LacZ/ADR group, N=5 for Tmsb4x/ADR group. (g) Podocyte count and (h) and podocyte 
density, (i) WT-1 positive nuclei outside the glomerular tuft and (j) glomerular cross-sectional 
area were plotted as individual data points. Data are presented as the mean ±SEM of at 
least 250 individual glomeruli. N=450 for LacZ/saline group, N=300 for LacZ/ADR group, 
N=250 for Tmsb4x/ADR group. *P≤0.05, ***P≤0.001 between groups. 
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The number of WT-1 positive cells were counted in the parietal epithelium and 
analysed per individual glomerulus. There were 2.3 ± 0.1 WT-1 positive cells in the 
parietal epithelium in LacZ/saline treated mice. Treatment of mice with ADR without 
TB4 gene therapy did not alter parietal WT-1 count compared to LacZ/saline treated 
mice, as each glomerulus had on average 2.6 ± 0.3 WT-1 positive cells outside 
glomerular tuft. Treatment with ADR and TB4 gene therapy did not alter parietal WT-
1 count compared to LacZ/saline treated mice, as each glomerulus had on average 
2.6 ± 0.2 WT-1 positive cells outside glomerular tuft (Figure 3.19i). 
 
3.4.10 ADR or TB4 did not alter podocyte distribution 
Podocyte clustering has been observed in animal models of kidney injury, where 
podocytes appeared to cluster together prior to migration towards the parietal 
epithelium in response to stress (Burford et al. 2014; Hackl et al. 2013). Therefore, 
the WT-1 immunostained images were used to investigate if podocytes were 
clustering in the ADR model of glomerular injury (3.3.14). Only images where visible 
vascular and tubular poles of the glomeruli were used. It was hypothesised that 
podocytes in a healthy glomerulus would be evenly distributed throughout the 
glomerulus, with approximately 25% of the total podocyte number located in each 
quadrant of the glomerulus and that alterations to their distribution could suggest 
further podocyte injury. 
 
Podocyte clustering was defined as more than 50% of all podocytes occupying 25% 
of total glomerular space, as it was thought that this would be a sufficient threshold 
to define podocyte clustering. A representative image of a glomerulus displaying 
podocyte clustering is provided in Figure 3.20a. LacZ/saline treated mice had on 
average 12.1 ± 3% of glomeruli displaying podocyte clustering. Treatment with ADR 
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Figure 3.20 – ADR or TB4 did not alter podocyte distribution. FFPE kidneys were 
incubated with a rabbit anti-mouse WT-1 primary antibody followed by anti-rabbit EnVision 
conjugated to HRP and then positive staining was visualised by 3,3′-Diaminobenzidine 
incubation. Mayer’s haematoxylin was used to stain nuclei. (a) Representative image of a 
LacZ/ADR treated glomerulus displaying podocyte clustering (>50% of podocytes in 1 
quadrant of the glomerulus). Black dashed line indicates glomerular tuft circumference, 
yellow dashed line indicates glomerular quartiles. White star indicates the lower hemisphere 
(vascular pole), and white circle indicates upper hemisphere (tubular pole). Black arrow 
indicates quadrant of glomerulus with clustering. Quantification of (b) the percentage of 
glomeruli displaying podocyte clustering, (c) the number of podocytes in each hemisphere of 
the glomerulus and (d) the number of cells in each glomerular hemisphere as a percentage 
of total podocyte number. Scale bar = 20 µm. Each data point represents the average of at 
least 30 glomeruli. n=33 for LacZ/saline, n=31 for LacZ/ADR and n=30 for Tmsb4x/ADR. 
Data are shown as the mean ±SEM of at least 5 mice. ***P≤0.001 between groups. 
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was not significantly different than LacZ/saline treated mice. Mice treated with ADR 
with TB4 gene therapy displayed on average 17.1 ± 5.8% of glomeruli with podocyte 
clustering. There were no significant differences between any group (Figure 3.20b). 
Since the glomerulus is spherical, it was not possible to definitively determine which 
was the “left” and “right” side of the glomerulus on a 5 µm cross section. The one 
parameter that could be determined was the upper and lower hemispheres of the 
glomeruli. The upper hemisphere was designated as the pole closest to the proximal 
tubule and the lower hemisphere was designated the as the vascular pole. 
LacZ/saline treated mice had on average 6.1 ± 0.6 podocytes in the lower 
hemisphere and 7.4 ± 0.6 podocytes in the lower hemisphere of their glomeruli. Mice 
treated with ADR without TB4 gene therapy had an average of 5.2 ± 0.8 podocytes 
in the lower hemisphere and 6.1 ± 1 podocytes in the upper hemisphere of the 
glomeruli. ADR treated mice with TB4 gene therapy had an average of 6.1 ± 0.9 
podocytes in the lower hemisphere and 7.3 ± 1 podocytes in the upper hemisphere 
of the glomeruli. There were no differences between any groups (Figure 3.20c).  
 
The number of podocytes in each hemisphere of the glomeruli were then calculated 
as a percentage of the total number of podocytes in the glomeruli. LacZ/saline 
treated mice had an average of 44.2 ± 0.9% of podocytes in the lower hemisphere 
and 55.8 ± 0.9% of podocytes in the upper hemisphere of the glomeruli. In ADR 
treated mice without gene therapy, this value was unchanged. The mice had an 
average of 44.9 ± 0.7% of podocytes in the lower hemisphere, and 55.1 ± 0.7% of 
podocytes in the upper hemisphere. Mice treated with ADR with TB4 gene therapy 
had an average of 45.5 ± 0.6% of podocytes in the lower hemisphere and 54.5 ± 
0.6% of podocytes in the upper hemisphere. There were no significant differences 
between the treatment groups, however, in all three groups it was found that there 
was a significant difference in the number of podocytes in each hemisphere of the 
glomeruli (P<0.001 in all treatment groups) (Figure 3.20d).  
 
3.4.11 TB4 prevented ADR-induced reduction of glomerular F-actin 
Next, the F-actin content of the glomeruli was examined, as F-actin alterations to the 
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Figure 3.21 – TB4 prevents ADR-induced alterations to glomerular F-actin. Kidney 
cryosections were stained with phalloidin to visualise glomerular F-actin. Representative images 
of (a) LacZ/saline, (b) LacZ/ADR and (c) Tmsb4x/ADR treated glomeruli. White dashed line 
indicates glomerular tuft. Scale bar = 20 µm. (d) Negative control omitting phalloidin. 
Quantification of (e) area of glomerulus covered by F-actin (µm2), (f) percentage area of 
glomerulus covered by F-actin and (g) glomerular mean F-actin fluorescence. Each group 
contained at least 50 glomeruli per mouse. Data are shown as the mean ±SEM of at least 
250 glomeruli from at least 5 mice. N=450 for LacZ/saline group, N=300 for LacZ/ADR 
group, N=250 for Tmsb4x/ADR group.  ***P≤0.001 between groups. 
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foot process effacement and albuminuria (Oh, Reiser, and Mundel 2004; Suleiman et 
al. 2017; Yu et al. 2013). Glomerular F-actin content was examined by phalloidin 
staining of cryosections. Representative images of glomeruli from all three treatment 
groups stained with phalloidin are provided in Figure 3.21a, b, c and specificity was 
confirmed by omitting phalloidin Figure 3.21d. Individual glomeruli were quantified 
from all three treatment groups, 14 days after ADR or vehicle administration.  
 
In LacZ/saline treated mice, F-actin covered on average 1660 ± 33 µm2 of the 
glomerular cross section, which equated to 50 ± 0.9% of the total glomerular cross 
section. Administration of ADR with TB4 gene therapy caused a loss of glomerular F-
actin coverage to 776 ± 40 µm2 (P<0.001 vs LacZ/saline), equivalent to 31 ± 0.1% of 
the total glomerular cross section (P<0.001 vs LacZ/saline). Treatment with TB4 
gene therapy prevented this loss of F-actin, and Tmsb4x/ADR treated mice showed 
a glomerular F-actin coverage of 1781 ± 54 µm2 (P<0.001 vs LacZ/ADR), which 
equated to 49 ± 1.3% of glomerular cross-sectional area (P<0.001 vs LacZ/ADR) 
(Figure 3.21e, f). ADR also caused a reduction in mean glomerular F-actin 
fluorescence (P<0.001 vs LacZ/saline) which TB4 prevented (P<0.001 vs LacZ/ADR) 
(Figure 3.21g). Collectively, these results suggest that TB4 protects glomerular F-
actin in ADR nephropathy.  
 
3.4.12 Examination of podocyte synaptopodin content 
Following analysis of glomerular F-actin content, the amount of the podocyte 
cytoskeletal protein synaptopodin was quantified in individual glomeruli by 
immunofluorescence 14 days after ADR or vehicle injection. Representative images 
of glomeruli immunostained for synaptopodin from all three treatment groups are 
provided in Figure 3.22a, b, c. The specificity of the staining was confirmed by 
omitting the primary antibody (Figure 3.22d).  
 
Synaptopodin covered 336.1 ±15.7 µm2 of LacZ/saline treated glomeruli, and 
treatment with ADR without TB4 gene therapy significantly increased this amount to 
514.7 ±27.6 µm2 (P<0.001 vs LacZ/saline). Treatment with TB4 gene therapy 



















































































































































Figure 3.22 – The effect of ADR and TB4 on synaptopodin. Kidneys cryosections were 
immunostained with guinea-pig anti-mouse synaptopodin followed by goat anti-guinea pig 
secondary antibody conjugated to 488 nm fluorophore. Representative images of (a) 
LacZ/saline, (b) LacZ/ADR and (c) Tmsb4x/ADR treated glomeruli. White dotted line refers 
to the boundaries of the glomerular tuft. (d) Negative control omitting the primary antibody. 
Quantification of the (e) total area covered by synaptopodin of glomeruli (µm2), (f) the 
percentage area of glomeruli covered by synaptopodin and (g) mean glomerular 
synaptopodin fluorescence. Scale bar = 20 µm. Each group contained at least 50 glomeruli 
per mouse. Data are shown as the mean ±SEM of at least 250 glomeruli from at least 5 
mice. N=450 for LacZ/saline group, N=300 for LacZ/ADR group, N=250 for Tmsb4x/ADR 
group. *P≤0.05, **P≤0.01, ***P≤0.001 between groups. 
 165 
average 371.5 ±23.8 µm2 of the glomerular cross section (P<0.001 vs LacZ/ADR) 
(Figure 3.22e).  
 
The total area of synaptopodin was then normalised to glomerular cross-sectional 
area. Synaptopodin covered on average 12.5 ± 0.5% of glomeruli when treated with 
LacZ/saline, and an average of 12.6 ± 0.5% of glomeruli treated with ADR with TB4 
gene therapy. There was no significant difference between these two groups.  
Treatment with ADR with TB4 gene therapy reduced synaptopodin coverage to 10.7 
± 0.5% compared with the ADR without TB4 gene therapy group (P<0.05), but this 
value was not significantly different to LacZ/saline group (Figure 3.22f). The mean 
fluorescence of synaptopodin in the glomeruli was also measured as an alternative 
measure of synaptopodin content. LacZ/saline treated mice had an average 
glomerular synaptopodin fluorescence of 12.1 ± 0.4 arbitrary units (AU). Mice treated 
with ADR without TB4 gene therapy had an average glomerular synaptopodin 
fluorescence of 11.8 ± 0.6 AU. ADR treated mice with TB4 gene therapy had an 
average glomerular synaptopodin fluorescence of 10.1 ± 0.4, which was significantly 
less than ADR treated mice without TB4 gene therapy (P<0.01) (Figure 3.22g).  
 
3.4.13 Analysis of podocyte F-actin 
It was postulated that the alterations observed to glomerular F-actin content could be 
localised to the podocytes. Therefore, kidney cryosections were immunostained to 
visualise F-actin and synaptopodin, as a marker for podocytes. Representative 
images of glomeruli from all three treatment groups can be found in Figure 3.23a, b, 
c. The staining was specific for synaptopodin and F-actin, as seen in the negative 
controls omitting the primary antibody or phalloidin (Figure 3.23d). 
 
In LacZ/saline treated mice, there was on average 356 ± 21 µm2 F-actin in 
synaptopodin positive areas. Treatment with ADR reduced the area of F-actin to 280 
± 19 µm2 in synaptopodin positive regions, but this was not significantly different to 
LacZ/saline. Tmsb4x/ADR treated mice showed an average 318 ± 30 µm2 of F-actin 
in synaptopodin positive regions, which was not significantly different to either of the 




Figure 3.23 – Visualisation of podocyte F-actin. Kidney cryosections were 
immunostained with a-synaptopodin antibody to visualise synaptopodin and phalloidin to 
visualise F-actin. Nuclei were immunostained with Hoechst 33332. Representative images of 
(a) LacZ/saline, (b) LacZ/ADR and (c) Tmsb4x/ADR treated glomeruli. (d) Negative control 
omitting primary antibody and phalloidin. White arrows indicate F-actin in synaptopodin 
positive areas. Scale bar = 20 µm. Images have been altered to exclude positive phalloidin 




































































































































































Figure 3.24 – ADR or TB4 do not alter amount of podocyte F-actin. Quantification of (a) 
total area of F-actin in synaptopodin positive area (µm2), (b) the percentage of synaptopodin 
positive area covered by F-actin and (c) mean F-actin fluorescence in synaptopodin positive 
areas. Each group contained at least 50 glomeruli per mouse. Data are shown as the mean 
±SEM of at least 250 glomeruli from at least 5 mice. N=450 for LacZ/saline group, N=300 for 
LacZ/ADR group, N=250 for Tmsb4x/ADR group. 
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content was altered in ADR treatment with and without TB4 gene therapy, therefore 
to account for this, F-actin area was normalised to synaptopodin area. F-actin 
covered 63.4 ±1.2% of the synaptopodin positive area in LacZ/saline treated mice, 
which was unchanged with administration of ADR (64.4 ±1.4%) or TB4 (65.8 ±1.5%) 
(Figure 3.24b). The mean fluorescence of F-actin in synaptopodin positive regions 
was also examined as a surrogate for the amount of F-actin. LacZ/saline treated 
mice F-actin had a mean fluorescence of 26.6 ±0.65 in synaptopodin positive 
regions. Again, this result was unchanged after treatment with ADR with TB4 gene 
therapy (27.5 ±0.9) or with TB4 gene therapy (27.8 ±1.1) (Figure 3.24c). Taken 
together, these results suggest that there was no change to the amount of F-actin in 
podocytes after ADR/TB4 treatment.  
 
3.4.14 TB4 prevented formation of vesicles induced by ADR 
Recently, a mechanism of albuminuria has been shown using a combined use of 
focused-ion beam/scanning electron microscopy (FIB/SEM) in PAN nephrosis. 
Vesicles (approximately 500 nm to 1 µm in diameter) form at the basal side of the 
foot processes, travel through the cytoplasm and then open at the apical membrane 
as a vector for albumin to travel from the bloodstream to urinary space in nephrotic 
podocytes (Burford et al. 2017; Ichimura et al. 2019; Schießl et al. 2016). While 
examining the F-actin and synaptopodin images used in 3.4.13, small structures in 
the F-actin regions were observed that resembled the shape of vesicles identified 
previously (Ichimura et al. 2019). These vesicles were F-actin positive, but not all 
seemed to be encapsulated by synaptopodin, suggesting that they were formed of F-
actin (Figure 3.25a, b, c).  
 
The diameter of the vesicle labelled in Figure 3.25b were between 1 and 1.3 µm, 
suggesting that these structures could be the vesicles described by Ichimura et al., 
as they were described as up to approximately 1 µm in diameter (Ichimura et al. 
2019). Therefore, the identity of each mouse was blinded to the observer, and the 
number of vesicles were counted on each glomerulus to determine if this could be 




Figure 3.25 – TB4 prevents ADR-induced podocyte suspected vesicle formation. 
Kidney cryosections were immunostained with a-mouse synaptopodin and phalloidin to 
visualise synaptopodin and F-actin. Nuclei were stained with Hoechst 33342. 
Representative images of (a) synaptopodin, (b) F-actin and (c) the composite including 
nuclei from a LacZ/ADR treated glomerulus. White arrows indicate vesicles. Quantification 
of (d) the number of vesicles per glomerulus and (e) the vesicle density of each 
glomerulus. Each group contained at least 50 glomeruli per mouse, with at least 250 
glomeruli in each group. n=450 for LacZ/saline group, n=300 for LacZ/ADR group, n=250 
for Tmsb4x/ADR group. Data are shown as the mean ±SEM of at least 250 glomeruli from 
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When counting the number of vesicles per glomerulus, LacZ/saline treated mice had 
an average of 5.3 ± 0.3 vesicles per glomerulus. This number rose to 7.2 ± 0.3 
vesicles per glomerulus after treatment with ADR without TB4 gene therapy, which 
was significantly more than LacZ/saline treated mice (P<0.001). Treatment with 
exogenous TB4 prevented this increase, as each glomerulus displayed an average 
of 5.6 ± 0.3 vesicles per glomerulus, which was significantly lower than the 
LacZ/ADR treated group (P<0.01) (Figure 3.25d). Since glomerular area was altered 
in ADR nephropathy (3.4.9), the number of vesicles were normalised to glomerular 
area (vesicle density). LacZ/saline glomeruli had an average vesicle density of 2.3 
x10-3 ± 0.1 x10-3 vesicles per µm2. Again, this value increased to 2.7 x10-3 ± 0.1 
vesicles per µm2 after ADR treatment without TB4 gene therapy, which was 
significantly greater than LacZ/saline glomeruli (P<0.001). Tmsb4x/ADR treated 
glomeruli had 2.2 x10-3 ± 0.1 x10-3 vesicles per µm2, which was significantly less that 
LacZ/ADR treated mice (P<0.05) (Figure 3.25e). These results suggest that vesicle 




This chapter of the thesis has shown that ADR administration to mice results in a 
reduction in the levels of glomerular and podocyte Tmsb4x mRNA. To restore the 
levels of TB4 in ADR-induced glomerular injury, the novel strategy of AAV gene 
therapy was utilised. AAV.Tmsb4x infected and transduced cells in the liver. This 
transduction caused a significant increase in systemic TB4 compared to AAV.LacZ 
treated mice, which persisted throughout the experiment. Systemic upregulation of 
exogenous TB4 in ADR treated mice prevented albuminuria and podocyte loss 
compared to mice treated with ADR without TB4 gene therapy. Collectively, this 
thesis chapter has provided the first evidence that exogenous TB4 prevents ADR-
induced glomerular injury via protection of podocytes.  
 
This thesis chapter used novel analyses of published scRNAseq data (Chung et al. 
2020), and also qPCR, to show that glomerular and podocyte levels of Tmsb4x were 
downregulated in ADR nephropathy. The reduction in podocyte Tmsb4x levels in 
ADR nephropathy provided rationale to administer mice with TB4 as a therapeutic 
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agent. Global loss of endogenous Tmsb4x in C57BL/6 mice resulted in exacerbated 
proteinuria, podocyte loss and inflammation in NTS nephritis (Vasilopoulou et al. 
2016). Furthermore, healthy podocyte specific knockdown of Tmsb4x caused an 
increase in podocyte migration and F-actin reorganisation, demonstrating that loss of 
endogenous Tmsb4x has detrimental effects to podocytes (Vasilopoulou et al. 2016). 
Therefore, one of the main hypotheses of this thesis chapter, after the reduction in 
podocyte Tmsb4x was confirmed, was that restoring the levels of TB4 would 
alleviate the phenotypes of ADR nephropathy and damage to podocytes.  
 
Analysis of scRNAseq data is a novel method of analysis that an increasing number 
of researchers are utilising to identify potential targets in pathological settings. 
scRNAseq can also reveal hidden differences in gene expression. For example, in 
this thesis, it was shown from the scRNAseq data that podocyte Tmsb4x was 
downregulated 14 days after ADR injection. qPCR examination of mRNA from 
glomerular extracts showed no difference between saline treated mice and 14-day 
ADR treated mice, only at 7 days. It is possible that another cell type in the 
glomerulus was masking the reduction of Tmsb4x levels in podocytes by showing 
increased levels of Tmsb4x. To confirm if this was the case, the same pipeline could 
be used to analyse the scRNAseq data from Chung et al., but instead of examining 
the podocyte cluster, the endothelial cell cluster would be analysed. However, the 
scRNAseq data analysed from Chung et al., does have limitations. Firstly, the mouse 
strain used was C57BL/6, which is thought to be resistant to ADR nephropathy, due 
to the presence of the mitochondrial genome protector PRKDC (Papeta et al. 2010). 
The scRNAseq study attempted to circumvent this issue by administering the mice 
with 20 mg/kg ADR (Chung et al. 2020), double the dose used in this thesis. While 
the study did not provide albuminuria data, interrogation of the data in this thesis 
showed that there was a lower proportion of podocytes in ADR treated mice 
compared with the vehicle treated mice, suggesting damage to the glomeruli 
occurred. This also means that the most damaged podocytes might have been lost 
in the urine, and unusable for analysis. Another limitation is the sample size of the 
scRNAseq data. The authors only included 2 mice in each treatment group, however 
the general protocol undertaken in many scRNAseq experiments has a low sample 
number (Fu et al. 2019; Lu et al. 2017; Ransick et al. 2019), due to the high cost of 
scRNAseq experiments. On the other hand, the argument could be made that the 
 172 
cell numbers examined was very high, as there were at least 8296 cells in each 
group of the scRNAseq data analysed in this experiment. Undoubtedly, as the 
technology advances, the experiments will become cheaper, allowing a higher 
number of mice to be analysed. The data does provide valuable insight of cellular 
genetics at in situ single cell resolution, which is normally unattainable with 
conventional qPCR.  
 
After the downregulation of Tmsb4x in glomeruli and podocytes was confirmed, this 
thesis chapter provided further evidence that AAV therapy is a suitable method of 
systemically upregulating secreted proteins to deliver therapies for kidney disease. 
This study to utilised AAV.Tmsb4x gene therapy in a rodent model of kidney injury, 
and it was demonstrated that AAV2/7 induces a systemic upregulation of TB4. AAV 
vectors have been previously used to deliver molecules to alleviate podocyte and 
glomerular injury. Treatment of C57BL/6 mice with AAV to systemically upregulate 
myeloid-derived growth factor (MYDGF) suppressed increased albuminuria, 
podocyte foot process effacement, nephrin loss and glomerular hypertrophy in a 
model of diabetic nephropathy (He et al. 2020). Glomerular transduction by AAV and 
overexpression of Protein S via AAV injection into the renal vein prevented increased 
albuminuria, podocyte loss and mesangial matrix expansion in the OVE26 transgenic 
mouse model of type 2 diabetes (Zhong et al. 2018). Delivery of human tissue 
kallikrein, a serine proteinase that converts kininogen to kinin (Yousef and 
Diamandis 2001), by AAV2 reduced increased albuminuria, glomerulosclerosis and 
reduced creatinine clearance in the surgical 5/6 nephrectomy model of kidney injury 
in rats (Tu et al. 2008). Although glomerular targeted therapy has been 
demonstrated in other models, AAV therapy has not been utilised in ADR 
nephropathy until now. 
 
AAV therapy is an attractive method of inducing long term transgene upregulation 
(Zincarelli et al. 2008) and previous studies have shown high tissue tropism for the 
liver using AAV2/7 (Van Der Perren et al. 2011). AAV infection of highly proliferative 
cells leads to rapid diminishment of viral episomal DNA (Cunningham et al. 2008; 
Halbert et al. 1997). Liver parenchymal cells are mostly senescent (Berasain and 
Avila 2015; Macdonald 1961), meaning that there is a lower chance of viral episomal 
DNA to degrade compared to if AAV infected an organ with a high population of 
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proliferative cells. Furthermore, the liver has a rich blood supply with many blood 
vessels (Mitra and Metcalf 2009). This means that TB4, or other secreted therapeutic 
proteins produced by the cells after AAV transduction, has a high chance of being 




No other study has used AAV therapy to treat mice with TB4 in models of kidney 
disease, but AAV.Tmsb4x has been used in other pathological settings. AAV 
encoding Tmsb4x has been used previously as a therapeutic strategy in animal 







Figure 3.26 – Proposed route of TB4 delivery to glomeruli. Diagram depicting the 
proposed mechanism of how exogenous TB4 reached the glomeruli. rAAV, recombinant 
adeno associated virus; TB4, thymosin b4. Original diagram. 
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particles encoding Tmsb4x to mice has been shown to transduce colonic cells, 
significantly increasing TB4 expression (Zheng et al. 2017). The increased TB4 
expression ameliorated some of the phenotypes of experimental colitis in these mice 
compared with AAV.LacZ injected mice, by attenuating inflammation, apoptosis and 
oxidative damage (Zheng et al. 2017). Tail vein injection of 5x1012 AAV serotype 2/9 
particles encoding Tmsb4x to mice was shown to cause AAV transduction of cells in 
the heart and peripheral muscle, improving some of the phenotypes of LPS induced 
sepsis (Bongiovanni et al., 2015). AAV.Tmsb4x was shown to prevent pericyte loss, 
perivascular leakage, and improved haemodynamics and survival compared to 
AAV.LacZ treated mice (Bongiovanni et al., 2015). Intramuscular injection of 5x1012 
AAV serotype 2/9 particles encoding Tmsb4x to the hindlimb of pigs prevented some 
of the effects of ischaemia. AAV.Tmsb4x increased vessel endothelial cell density, 
pericyte coverage and cardiac function compared with AAV.LacZ treated pigs 
(Ziegler et al. 2018). There are similarities between this thesis chapter and these 
three previous studies. Firstly, AAV.Tmsb4x in this thesis prevented glomerular 
inflammation, and it was shown that AAV.Tmsb4x prevented inflammation in the 
study by Zheng et al., highlighting the anti-inflammatory properties of TB4 (Sosne, 
Qiu, Christopherson, et al. 2007). The anti-inflammatory effects seen by Zheng et al., 
were suppression of TNF-a, IL-1b and IL-10 protein levels, and this thesis chapter 
did not present data to show that TB4 had any effect on these cytokines. 
Macrophage levels were not examined in the study by Zheng et al.. LPS induced 
sepsis is also an experimental model that induces a systemic inflammatory response 
(Schouten et al. 2008), however, Bongiovanni et al., focussed on the haemodynamic 
changes induced by LPS and AAV.Tmsb4x, and inflammation was not measured. 
This thesis chapter used a lower viral dose than the studies by Bongiovanni et al., 
and Ziegler et al., however, all three studies saw a beneficial effect induced by 
AAV.Tmsb4x compared with AAV.LacZ. This suggests that the therapeutic dose 
range of AAV.Tmsb4x can be tailored to the experimental requirements. The main 
difference between this thesis chapter and the three previous studies using 
AAV.Tmsb4x was the tissue that each study was targeting. The previous studies 
targeted the colon, muscle, vasculature, whereas this thesis chapter used 
AAV.Tmsb4x in a model of experimental kidney injury. Therefore, this thesis chapter 
has provided further evidence that AAV.Tmsb4x can be used to target pathologies in 
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multiple tissues. AAV.Tmsb4x circumvents the issue of rapid metabolism of TB4 
after injection of the recombinant peptide, a method which has been used to explore 
the beneficial effects of TB4 in other kidney injury models. TB4 has been 
administered intraperitoneally daily in the UUO model of kidney injury and a model of 
type 2 diabetes in mice (Zhu et al. 2015; Zuo et al. 2013). Exogenous TB4 has been 
administered intravenously in the IRI model of kidney injury (Aksu et al. 2019). 
Intragastric lavage has also been used to administer rats daily with TB4 in the UUO 
model of kidney injury (Yuan et al. 2017). The reason that these studies injected the 
rodents with TB4 daily is because of the short half-life of TB4, as plasma levels of 
TB4 return to basal levels 6 hours after injection (Mora et al. 1997). However, daily 
injection can cause undue stress to rodents, as it has been shown that blood levels 
of corticosterone increase after injection of saline, which could alter the outcomes of 
experimental models of injury (Drude et al. 2011). While the experiments performed 
with daily injections did show positive outcomes, the experiment performed in this 
thesis chapter has an advantage over the studies that injected daily with TB4. Only 
one injection was needed for AAV administration and one was needed for either 
ADR or vehicle administration, which would have reduced the stress caused to the 
mice.  
 
Currently, renal targeted AAV transduction is a challenge. The mean diameter of 
AAV particles is smaller (~22 nm) (Chen 2007) than the glomerular filtration barrier 
pores (~40 nm) (Rodewald and Karnovsky 1974), therefore a large number of 
circulating AAV particles will be lost in the urine. Screening of AAV serotypes 1-9 by 
luciferase assay revealed that even though the viral genome could be detected in the 
kidney, no luciferase protein was detected from any serotype 100 days post injection 
(Zincarelli et al. 2008). Novel administration routes have had some success in 
circumventing this issue. AAV8 induced transgene expression in the kidneys when 
administered by retrograde ureteral and subcapsular injections, with some 
recombinant protein localised to glomerular cells and tubular cells (Rubin et al. 
2019). AAV9 expressing the green fluorescent protein (GFP) transgene injected into 
the renal vein showed a ~12.5-fold increase in glomerular GFP mRNA expression 
and 2-fold increase in glomerular GFP immunostaining compared to non-injected 
kidneys (Zhong et al. 2018). While these routes of administration show promise, they 
are more invasive and stressful than intravenous tail vein injection, hence systemic 
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upregulation of TB4 via a single intravenous injection was chosen in this thesis 
chapter. 
 
Using AAV mediated systemic delivery of TB4, this thesis chapter has shown that 
exogenous TB4 prevents ADR-induced albuminuria 14 days after ADR 
administration. Since the glomerular filtration barrier becomes highly permeable to 
albumin in pathological conditions (Butt et al. 2020), it is likely that exogenous TB4 
prevented ADR-induced damage to the glomerular filtration barrier. The severity of 
ADR-induced albuminuria (1448 µg/24h) was different compared to previous studies. 
BALB/c mice injected with 10 mg/kg ADR excreted approximately 20,000 µg/24 
hours after 14 days in two previous studies (Teramoto et al. 2020; Wang et al. 2000). 
On the other hand, BALB/c mice injected with 10 mg/kg ADR in another study only 
excreted 800 µg/24 hours after 14 days of ADR treatment (X. Liu et al. 2018), half of 
what was observed in this thesis chapter. It is likely that many factors affect 
observed albuminuria levels in the previous studies, as well as this thesis chapter, 
including age of the mice, or the ELISA kit used to measure albuminuria, which could 
explain the discrepancies between these studies and the data presented in this 
thesis chapter. The mice were the same age (all between 7 and 10 weeks) in all 
three previous studies, along with this thesis chapter making the age unlikely to be 
the cause of difference. However, all three studies used different ways to analyse 
albuminuria concentration. The study from Wang et al., Liu et al., and this thesis 
chapter all used ELISA kits from different companies, but Teramoto et al., quantified 
albumin concentration by SDS-PAGE and Coomassie Brilliant Blue staining, making 
the method of quantification a potential source of the discrepancies.  
 
This is the first study to focus on the effect of exogenous TB4 in a specific model of 
glomerular injury. The role of endogenous TB4 has been investigated in glomerular 
injury previously, where it was shown that a loss of endogenous Tmsb4x 
exacerbated an increase in albuminuria in NTS nephritis compared with wild type 
mice injected with NTS (Vasilopoulou et al. 2016). One of the key differences 
between this thesis chapter and the previous study by Vasilopoulou et al., was the 
mechanism of glomerular damage. ADR induces a cytotoxic effect to the podocytes 
(Papeta et al. 2010), whereas NTS causes an autoimmune response against the 
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whole glomerulus (Khan et al. 2005). Wild-type mice treated with NTS excreted 
approximately 20,000 µg/24 hours of albumin after 21 days, but Tmsb4x knockout 
mice injected with NTS excreted 5 to 7-fold more albumin. This was a significantly 
increased amount, highlighting the importance of endogenous TB4 in slowing the 
progression of glomerular injury. Loss of endogenous Tmsb4x was also shown to 
exacerbate albuminuria compared to wild type mice in the angiotensin-II model of 
hypertension (Kumar et al., 2018). One key difference between the injury model 
employed in this study and ADR, is that hypertension affected the whole of the 
kidney and the cardiovascular system, not just the kidney glomeruli, so the increase 
in albuminuria could have been a secondary effect to other alterations induced by 
angiotensin-II. Exogenous TB4 has been shown to prevent secondary-caused 
albuminuria in other models. In a model of diabetic kidney disease in KK Cg-Ay 
mice, exogenous TB4 prevented microalbuminuria compared to vehicle treated mice 
(Zhu et al. 2015). Proteinuria was also prevented by exogenous TB4 in the UUO 
model of kidney injury (Yuan et al. 2017). But these two models are multi-organ 
pathologies, and it is possible that albuminuria occurred as a secondary pathology, 
due to medullary fibrosis. ADR is an injury model that targets primarily the podocytes 
and glomeruli (Lee and Harris 2011). This thesis has provided evidence that 
exogenous TB4 prevents primary glomerular injury, specifically a rodent model of 
primary FSGS.  
 
This thesis has shown that TB4 gene therapy prevented ADR-induced podocyte 
loss, a potential mechanism by which TB4 prevented albuminuria. Podocyte loss 
would have resulted in less coverage of the GBM by podocyte foot processes, 
resulting in naked areas of the GBM, allowing albumin to leak into the urine from the 
blood stream. Endogenous TB4 has been shown to prevent podocyte loss in NTS 
nephritis, as loss of Tmsb4x in mice resulted in a lower number of WT-1 positive 
cells in the glomerular tuft compared with wild type mice treated with NTS 
(Vasilopoulou et al. 2016). Both this thesis chapter and the study by Vasilopoulou et 
al., is that both have shown that TB4 prevents podocyte loss, and this is a 
mechanism that is very likely to have contributed to the prevention of albuminuria in 
both cases. This study also used the same method of quantification as this thesis, 
counting of WT-1 positive cells, making the data more likely to be comparable. There 
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were differences between the Tmsb4x knockout study and this thesis chapter, such 
as WT-1 loss in the glomerular tuft was accompanied by an increase in parietal WT-
1 positive cells. The authors suggested that this could be indicative of podocyte 
migration towards the parietal epithelium in response to injury. There was a slight 
increase in parietal WT-1 expression in ADR treated mice with TB4 gene therapy 
compared to ADR mice without TB4 gene therapy. Parietal cells have been shown to 
express podocyte-like proteins, such as WT-1 (Kaverina et al. 2017; Zhang et al. 
2012), when the glomerulus becomes injured, a potential explanation for the 
increase in WT-1 positive cells induced by ADR with TB4 gene therapy. Exogenous 
TB4 has also been shown to prevent cell loss in other organs. In rats subjected to 
traumatic brain injury, exogenous TB4 prevented hippocampal cell loss compared 
with sham rats (Xiong et al. 2011). The prevention of myocyte loss following 
ischaemic myocardial injury has also been attributed to exogenous TB4 
administration to rats (Bao et al. 2013). In the study by Bao et al., the authors found 
that exogenous TB4 increased Akt phosphorylation in ischaemic tissue compared 
with non-treated ischaemic tissue. Activation of the Akt pathway has been shown to 
increase cell adhesion in cancer cells (Kraus et al. 2002) and human embryonic 
stem cells (Godoy-Parejo et al. 2019) which may provide an explanation for the 
effect of TB4 on podocyte loss in this study. Collectively, this thesis has provided the 
first evidence that exogenous TB4 prevents podocyte loss in glomerular disease.  
 
This thesis chapter has shown that exogenous TB4 prevented the ADR-induced loss 
of glomerular F-actin, a potential mechanism by which TB4 prevented ADR-induced 
albuminuria. This is important, because the podocyte foot processes are enriched in 
F-actin compared with the cell body (Cortes et al. 2000), and disorganisation of foot 
process F-actin has been associated with foot process effacement and albuminuria 
(Shirato et al., 1996; Yu et al., 2013; Suleiman et al., 2017). Although the glomerular 
amount of F-actin was protected by TB4, there were no differences between ADR 
with and without TB4 gene therapy when podocyte specific F-actin was examined 
using synaptopodin as a marker for podocytes. The representative images of 
glomeruli visualising F-actin and synaptopodin provided in this thesis chapter 
showed that a large proportion of the glomerular F-actin was located in synaptopodin 
negative areas. This suggests that much of the F-actin located in glomeruli was not 
localised to podocytes, and that alterations to the amount of F-actin were localised to 
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other glomerular cell types, such as the mesangium or endothelium. To prove this, 
the analysis could be repeated with markers to identify the mesangial cells (Ng2) or 
endothelial cells (endomucin). However, this does not mean that alterations to 
podocyte F-actin were not occurring. Alterations could have occurred to the 
organisation of podocyte F-actin in foot processes without changing the amount, as 
described previously (Shirato et al., 1996). To examine this, access to super 
resolution microscopes would be required, as the resolving power of the confocal 
microscope that the images were taken on was not high enough to see individual F-
actin fibres.  
 
Alterations to glomerular F-actin in ADR nephropathy have been previously 
described using super resolution microscopy. The authors employed stochastic 
optical reconstruction microscopy (STORM) and Airyscan imaging of BALB/c mice 
injected with 14 mg/kg of ADR, and suggested that the actin cytoskeleton in the foot 
processes of podocytes becomes disorganised leading to a mat of contractile F-actin 
filaments in effaced foot processes (Suleiman et al. 2017). The study used 
synaptopodin as a marker of the podocyte cytoskeleton and myosin IIa as a marker 
of contractile actin fibres and found that there was a shift of myosin IIa expression 
from the cell body and primary processes to the foot processes in ADR injury. The 
authors confirmed synaptopodin or myosin IIa and F-actin colocalization in healthy 
podocytes. A higher dose of ADR could have induced more severe F-actin 
disorganisation compared with the data in this thesis chapter, which is why F-actin 
disorganisation could be detected at the podocyte level. The use of myosin IIa as a 
method of quantifying contractile F-actin fibres is an advantage that this study has 
over the quantification performed in this thesis. Future studies could perform this 
type of analysis to investigate if TB4 prevents the ADR induced reorganisation of 
contractile F-actin fibres, as a mechanism of the prevention of albuminuria. Another 
study used C57BL/6 mice injected with 12 mg/kg ADR, and glomerular F-actin 
content was assessed by phalloidin staining to show that ADR induced an increase 
in F-actin fluorescence after 4 weeks (Woychyshyn et al. 2020), which is in contrast 
to the results presented in this thesis chapter. There were differences between this 
study and this thesis chapter, for example the mouse strain (C57BL/6 mice are 
resistant to ADR nephropathy (Papeta et al. 2010)), the dose of ADR used and the 
time of exposure, which could all account for the differences in results. The authors 
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speculated that the increase in F-actin intensity around the capillary loops could be 
due to podocyte foot process F-actin reorganisation to a mat of unorganised actin 
adjacent to the GBM. The analysis performed in this thesis has the advantage over 
this study because synaptopodin was used to segment out podocytes. If 
Woychyshyn et al., had used this method of quantification, they could have 
determined if the increase in F-actin fluorescence around the capillary loops was 
localised to podocytes, and not the endothelium or mesangium.  
 
Although no previous studies have examined F-actin content in the kidney after 
exogenous TB4 treatment, modulation of the F-actin cytoskeleton by TB4 has been 
reported in other pathologies. One study induced burns on the hindlimbs of C57BL/6 
mice and found that 30 mg/kg of exogenous TB4 intravenously accelerated dermal 
wound healing by prevention of uncontrolled F-actin polymerisation up to 7 days 
after burn induction, as shown by quantifying the F-actin to G-actin ratio (Kim and 
Kwon 2017). An ex vivo experiment using embryonic chick hearts found that the 
actin-binding domain on TB4 promoted vessel sprouting and angiogenesis (Philp et 
al. 2003), suggesting that exogenous TB4 mediated angiogenesis after myocardial 
infarction seen previously (Chiu et al. 2012; Poh et al. 2020) is actin-mediated. In 
contrast to this thesis chapter, these two studies did not perform phalloidin staining 
to examine the amount of F-actin, however, the analyses they performed does 
provide information into the mechanism by which TB4 modulated F-actin in the 
respective cell types. Analysing the F-actin to G-actin ratio in podocytes after ADR 
treatment with and without TB4 gene therapy would identify if the main property of 
TB4, G-actin sequestering, was a mechanism by which TB4 prevented ADR-induced 
glomerular and podocyte damage.  
 
While examining the images immunostained to visualise synaptopodin and F-actin, 
structures resembling vesicles were identified, and quantification revealed that TB4 
gene therapy prevented the ADR-induced formation of F-actin buds. The buds were 
F-actin positive, but synaptopodin did not cover all of the buds, suggesting they were 
not dependent on synaptopodin. The size (~1 µm) and location (processes, close to 
the capillaries) of the F-actin is in agreement with previous studies demonstrating 
vesicular transcytosis of albumin with electron microscopy (Ichimura et al. 2019). 
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Vesicular transport of albumin from the basal side of the foot processes through to 
the urinary space is a mechanism that has been proposed and described by a mix of 
electron microscopy (Ichimura et al. 2019) and multiphoton microscopy live imaging 
(Schießl et al. 2016), where fluorescently tagged albumin has been recorded passing 
from the blood stream to the urinary space. It is proposed that the F-actin buds 
observed in this study contained albumin, however, immunofluorescent studies to 
visualise albumin and F-actin are required to confirm this hypothesis. It has been 
shown that F-actin dynamics are required for vesicle formation and transport, as 
HeLa cells treated with Latrunculin A and B (molecules that sequester G-actin) and 
Cytochalasin D (caps F-actin) ceased vesicular formation and intracellular transport 
(Boucrot et al. 2006). Furthermore, vesicles harbouring an F-actin coat have been 
identified in vitro in primary alveolar type II cells from rats (Miklavc et al. 2012), and 
actin coating was inhibited by the actin sequestering molecule Latrunculin B (Miklavc 
et al. 2009). This suggests that vesicular actin coating formation occurs de novo from 
G-actin monomers. It is possible that in this study, exogenous TB4s sequestering of 
G-actin, in the same way as Latrunculin B, prevented podocyte transcytosis of 
albumin via G-actin sequestering. 
 
The podocyte SD, the space between adjacent podocyte foot processes, is the 
gateway in which the ultrafiltrate can escape the blood, but also the barrier which 
prevents loss of proteins, such as albumin (Jarad and Miner 2009; Pavenstädt et al. 
2003). The SD is thought of as a modified adherens junction, and its structure is 
regulated by a complex network of intercellular and extracellular proteins, such as 
nephrin, podocin and cadherins (Patrakka and Tryggvason 2010; Tabatabaeifar et 
al. 2017; Wartiovaara et al. 2004). ADR is known to cause podocyte foot process 
effacement in mice as soon as 1 week after administration (Wang et al. 2000; Zhou 
et al. 2011). Furthermore, ADR caused a reduction in the SD proteins nephrin and 
podocin and increase in P-cadherin compared with vehicle treated rodents (Li, Yuan, 
and Zhang 2003; Wu et al. 2014). These previous studies show that ADR 
significantly disrupts the balance of SD proteins, which likely contributes to foot 
process effacement and albuminuria. Recently, it has been shown that endogenous 
TB4 stabilises adherens junctions, as in Tmsb4x knockdown embryonic mice, the 
pattern of E-cadherin (a major adherens junction protein) was disrupted in basal and 
suprabasal cells in the epidermis, accompanied by alterations to the actin 
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cytoskeleton (Padmanabhan et al. 2020). It is possible that administration of 
exogenous TB4 provided further stability of the SD in podocytes through its 
adherens junction stabilising properties. To confirm this, future studies could 
examine the expression of P-cadherin and other SD proteins in ADR nephropathy 




The results presented in this thesis chapter demonstrated that AAV.2/7 was effective 
in causing transgene upregulation in liver cells and persistent secretion of TB4 into 
the blood stream. Exogenous TB4 prevented ADR-induced damage to the 
glomerular filtration barrier by preventing podocyte loss. Exogenous TB4 also 
prevented alterations to the actin cytoskeleton, by preventing a reduction in the 
amount of glomerular F-actin and inhibiting suspected vesicle formation instigated by 
ADR (Figure 3.27) Collectively, it is proposed that actin modulation is a mechanism 
that underlies the protective action of TB4 in the glomerular filtration barrier, which 






Figure 3.27 – Exogenous TB4 prevents ADR-induced glomerular filtration barrier 
damage. Diagram illustrating the critical results presented in this chapter of the thesis. 
Original diagram. 
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Chapter 4: Exogenous thymosin b4 suppresses 
glomerular damage in NTS nephritis 
 Introduction 
The previous chapters of this thesis have shown that exogenous TB4 protects 
podocytes from ADR injury in vitro (Chapter 2) and in vivo (Chapter 3). One of the 
major beneficial properties of TB4 is its ability to suppress inflammation (Sosne et al. 
2001; Sosne, Qiu, Christopherson, et al. 2007; Vasilopoulou et al. 2016), but the 
model of ADR nephropathy induced in Chapter 3 did not involve an inflammatory 
response. Therefore, to investigate if exogenous TB4 could protect glomeruli in 
immune mediated glomerular injury, NTS nephritis was utilised in this thesis chapter.  
 
NTS nephritis is an inducible rodent model of autoimmune mediated glomerular 
injury that replicates some of the effects of human glomerulonephritis (Pippin et al. 
2009). NTS is generated by injecting glomerular extracts from the experimental 
species (in this case mouse) into a host organism (in this case sheep) (Hoppe and 
Vielhauer 2014). The sheep generates polyclonal antibodies against the epitopes of 
mouse glomerular structures, such as the GBM, endothelial cells and podocytes, 
which are then extracted and purified. The mice are immunised with sheep IgG prior 
to NTS injection to prime the immune system before injection of NTS (Hoppe and 
Vielhauer 2014). When administered, the sheep polyclonal anti-glomerular 
antibodies bind to their respective epitopes on the mouse glomeruli. The mouse then 
creates an autoimmune response against the sheep polyclonal antibodies, mediated 
by complement activation, neutrophil inflammation, T cell activation and macrophage 
accumulation (Assmann et al. 1985; Hébert et al. 1998; Tipping and Holdsworth 
2006). The T cells induce B cell activation, causing glomerular deposition of 
autologous antibodies against the sheep-anti-glomerular antibodies. Large immune 
complexes of IgG are then generated which exacerbate glomerular injury (Hoppe 
and Vielhauer 2014). The chronic immune response occurs typically 1 week after 
NTS injection and can injure glomerular cells causing albuminuria, 
glomerulosclerosis, increased BUN, decreased creatinine clearance and death in 
mice (Chen et al. 2002). 
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Exogenous TB4 has beneficial effects in ADR nephropathy (Chapter 3), diabetic 
nephropathy (Zhu et al. 2015), acute UUO injury (Yuan et al. 2017; Zuo et al. 2013) 
and kidney IRI (Aksu et al. 2019). The beneficial effects of TB4 in the study by Aksu 
et al., was associated with the anti-inflammatory action of TB4. A previous study 
assessed the role of endogenous TB4 in NTS nephritis and found that endogenous 
TB4 slowed the progression of albuminuria, prevented decreased creatinine 
clearance and podocyte loss and inhibited an increase in BUN (Vasilopoulou et al. 
2016). Endogenous TB4 also suppressed glomerular macrophage and T cell 
accumulation, as well as collagen IV and aSMA deposition, demonstrating its anti-
inflammatory and anti-fibrotic properties (Vasilopoulou et al. 2016). It is not yet 
known if exogenous TB4 can alleviate NTS nephritis, therefore, to explore if this is 
the case, AAV.Tmsb4x was administered in this form of glomerular injury.  
 
 Aims and hypothesis 
It was hypothesised that exogenous TB4 would alleviate the phenotypes of NTS 
nephritis through suppression of inflammation. The first aim of this thesis chapter is 
to confirm systemic TB4 upregulation following gene therapy. Secondly, this thesis 
chapter will explore the beneficial potential of exogenous TB4 in NTS nephritis to 
determine if exogenous TB4 prevents NTS induced albuminuria and loss of kidney 
function. The final aim of this thesis chapter is to elucidate potential mechanisms of 
the beneficial effect of TB4 in NTS nephritis.  
 
 Materials and methods 
This laboratory work for this thesis was undertaken during the COVID-19 pandemic, 
which enforced the closure of the laboratory for an extended period. Therefore, some 
of the laboratory work undertaken for this thesis chapter was completed by Dr 
Elisavet Vasilopoulou, who has allowed the data to be used in this thesis chapter. 
The following data was collected by the author of this thesis: assessment of 
podocyte number by WT-1 IHC; quantification of podocyte clustering by WT-1 IHC; 
analysis of glomerular proliferation by Ki67 and synaptopodin staining and 
quantification of glomerular inflammation by F4/80 IHC. All materials used in this 
thesis chapter were obtained from Merck U.K., Dorset, U.K. unless stated otherwise.  
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4.3.1 Experimental animals 
In this experimental procedure, all animals were subjected to NTS-induced 
glomerular injury and all experimental procedures were approved by the Home 
Office. Male C57BL/6 mice aged between 7-10 weeks were housed in cages of 
three, kept at a constant temperature (22 °C) and light cycle (12 hours light, 12 hours 
dark), and provided with standard laboratory chow and tap water ad libitum. The 
mice were injected with 2x1012 viral particles of AAV serotype 2/7 encoding Tmsb4x 
(TB4) or LacZ (b-galactosidase) via the tail vein. Sterile PBS was used as an 
additional control. There was a 4-week transcriptional activation window, before NTS 
injection. The final treatment groups were treated with NTS to induce glomerular 
injury and (i) PBS (PBS/NTS), (ii) AAV.LacZ (LacZ/NTS) or (iii) AAV.Tmsb4x 
(Tmsb4x/NTS).  
 
Urine was collected overnight in metabolic cages and plasma was collected via the 
lateral saphenous vein, which was stored in MicroVette EDTA-coated capillary action 
tubes. To prime the mouse immune system to target the sheep anti-mouse glomeruli 
polyclonal antibodies, mice were then pre-immunised sub-cutaneously with 250 µg 
of sheep IgG diluted in complete Freund’s adjuvant. Five days later (day 0), mice 
were injected with 250 µl of NTS intravenously to induce kidney disease. Urine and 
plasma were collected 7 days later. At day 21 after NTS injection, the mice were 



























Figure 4.1 – Experimental design. Graphic displaying the experimental design for the NTS 
nephritis study undertaken. Adeno associated virus, AAV; Thymosin b4, Tmsb4x; b-
galactosidase, LacZ; phosphate buffered saline, PBS; Intravenous, IV; Sub cutaneously, 
S/C. 
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overnight urine collection in metabolic cages. Blood was collected via cardiac 
puncture and the right kidney and part of the liver were snap frozen on dry ice. The 
left kidney and a separate part of the liver were placed in 4% PFA in dH2O (Figure 
4.1). Blood and plasma were processed as described in 3.3.2 and tissues were 
processed as described in 3.3.3. 
 
4.3.2 qPCR 
mRNA was extracted from kidneys and livers snap frozen in liquid nitrogen 21 days 
after kidney disease induction and qPCR was performed on subsequently generated 
cDNA as described in 3.3.10. The primers used in this chapter can be found in 
(Table 4.1).  
 
Table 4.1 – List of primers 
Target gene/translated 
protein (annealing temp, 
°C) 
Primer sequence (5' to 3') 
Location on 
mRNA (amplicon 
size, base pairs) 
Tmsb4x/TB4 (60) 
Fwd: ATGTCTGACAAACCCGATATGGC Bp 76 - 200. Exon 
1 – 2 (125) Rvs: CCAGCTTGCTTCTCTTGTTCA 
Cd68/CD68 (60) 
Fwd: GGGGCTCTTGGGAACTACAC Bp 481 - 647. 




Fwd: CCCCAAGAAGGAATGGGTCC Bp 316 - 497. 
Exon 2 - 3 (182) Rvs: TGCTTGAGGTGGTTGTGGAA 
Tnfa/Tumour necrosis factor 
a (60) 
Fwd: AGCCGATGGGTTGTACCTTG Bp 509 - 607. 
Exon 2 - 3 (99) Rvs: ATAGCAAATCGGCTGACGGT 
Acta2/a-smooth muscle actin 
(60) 
Fwd: GCCATCTTTCATTGGGATGGA Bp 902 - 1017. 
Exon 7 - 8 (116) Rvs: CCCCTGACAGGACGTTGTTA 
Col4a1/Collagen IV (58) 
Fwd: TTCCTTCGTGATGCACACCA Bp 4970 - 5080. 
Exon 50-51 (111) Rvs: CCGTGGCACTCGATGAATG 
Hprt/Hypoxanthine-guanine 
phosphoribosyltransferase 
(same as gene of interest) 
Fwd: AAGCTTGCTGGTGAAAAGGA Bp 629 - 982. 
Exon 7 - 9 (354) Rvs: GCAAATCAAAAGTCTGGGGA 
 
Table 4.1 – Primer details. Details of all primers used for NTS experiments, including 
target gene and its translated protein; the nucleotide sequences; the size of the amplicons; 
the location of the amplicon on the target gene and the annealing temperature used in 
quantitative PCR experiments. Tmsb4x, Thymosin b4, TB4; Cd68, cluster of differentiation 




4.3.3 TB4 ELISA 
To determine if TB4 was systemically upregulated, the TB4 ELISA described in 3.3.5 
was performed on plasma extracted 21 days after NTS induction. 
 
4.3.4 Kidney function 
Albuminuria was measured at day 0, 7 days and 21 days after NTS injection by 
ELISA as described in 3.3.6, however samples were diluted 1/100,000 as the level of 
albuminuria was much greater than following ADR injury. BUN was analysed at 21 
days after NTS nephritis induction by colourimetric assay as described in 3.3.8.  
 
4.3.5 IHC and immunofluorescence 
Tissues were fixed in 4% PFA in dH2O before FFPE and cryo-sections were 
generated. For FFPE sections, samples were dehydrated in increasing 
concentrations of ethanol, cleared in Histoclear II and embedded in wax and then 
sectioned to 5 µm on a microtome as described in 3.3.3. For cryo-sections, tissues 
were incubated in 30% sucrose overnight, embedded in OCT medium and sectioned 
to 8 µm on a cryostat as described in 3.3.3. Immunohistochemical and 
immunofluorescent experiments of NTS mice kidney sections were undertaken as 
described in 3.3.11 and 3.3.12 respectively. WT-1 positive and F4/80 positive cells 
were revealed by using previously referenced antibodies (Table 3.1). Proliferating 
nuclei were revealed by immunostaining with anti-Ki67 primary antibody (Table 3.1) 
and then incubation with donkey anti-rabbit secondary antibody conjugated to a 594 
nm fluorophore (Table 3.2). Sections were co-stained with a-mouse synaptopodin 
antibody (Table 3.1) and anti-guinea pig antibody conjugated to 594 nm fluorophore 
(Table 3.2) to identify podocytes.  
 
4.3.6 Image and statistical analysis 
All image analysis was performed on Fiji ImageJ software (Schindelin et al. 2012). 
Quantification of the number and distribution of WT-1 positive cells and F4/80 
positive cells was performed as described in 3.3.14. Proliferating cells were 
quantified by counting the number of Ki67 positive nuclei inside the whole glomerular 
tuft and in synaptopodin positive areas. Statistical analyses were performed as 




4.4.1 AAV 2/7 induced systemic upregulation of TB4 
To induce a sustained systemic upregulation of TB4, C57BL/6 mice were treated 
with AAV serotype 2/7 encoding the Tmsb4x transgene. To determine if AAV was 
successfully transducing liver cells, levels of Tmsb4x mRNA in the liver were 
examined by qPCR. Mice injected with AAV.Tmsb4x showed a 2.7 ± 0.3-fold 
increase in Tmsb4x mRNA in the livers, which was significantly higher than PBS 
(P<0.01) and AAV.LacZ (P<0.05) treated mice (Figure 4.2a).  
 
To confirm that the increase in liver Tmsb4x levels caused systemic upregulation of 
TB4, the plasma concentration of TB4, was quantified by ELISA 3 weeks after NTS 
injection. The TB4 plasma concentration in PBS and AAV.LacZ treated mice was 3.4 
± 2.2 µg/ml and 1 ± 0.4 µg/ml respectively. Mice injected with NTS with TB4 gene 
therapy had a plasma TB4 concentration of 11.9 ± 2 µg/ml, which was significantly 
more than both PBS (P<0.05) and LacZ (P<0.05) treated mice, confirming the 
systemic upregulation of TB4 (Figure 4.2b). TB4 gene therapy did not change whole 
kidney levels of Tmsb4x mRNA compared with PBS and AAV.LacZ injected mice 
























































































Figure 4.2 – AAV 2/7 systemically upregulated TB4. 7-10-week-old mice were injected 
with PBS, AAV.LacZ or AAV.Tmsb4x 4 weeks before injection of NTS. Blood was taken by 
cardiac puncture 21 days after NTS injection and assessment of circulating TB4 
concentration was quantified by ELISA. qPCR was performed to assess levels of Tmsb4x in 
livers and kidneys 21 days after NTS injection. (a) Tmsb4x mRNA levels in the liver. (b) 
Quantification of circulating TB4 concentration in the plasma. (c) Expression of Tmsb4x in 
the kidney. Hprt was used as a housekeeping gene for qPCR. Each data point represents 
the mean of duplicate values from 1 individual mouse. Data are shown as the mean ±SEM 
of at least 4 individual mice. N=6 for PBS/NTS, N=4 for LacZ/NTS group and N=10 for 
Tmsb4x/NTS group. *P≤0.05, **P≤0.01 between treatment groups. Tmsb4x, TB4; LacZ, b-




4.4.2 NTS reduced mouse body weight 
To examine the effect of NTS and TB4 on the body weight of mice, mice from all 
three groups were weighed at day 0, day 7 and day 21 after NTS induction. There 
was no significant difference between the body weights of the mice before NTS 
injection (day 0) (Figure 4.3b). 
 
After 7 days, NTS injured mice injected with PBS mice weighed 0.9 ± 1.3% less than 
the day of NTS injection, which was not significantly different, however, the mice 
weighed 6.3 ± 1.2% less 21 days after NTS injection, which was significantly lower 
than the same group at day 0 (P<0.05). Mice treated with LacZ/NTS weighed 4.1 ± 
1.8% less after 7 days, but this was not significant compared to day 0. At day 21 of 
NTS treatment, LacZ/NTS mice weighed 5.3 ± 1.6% less than the day of NTS 
injection, but once again this was not significantly lower than day 0. After 7 days of 
NTS treatment, NTS treated mice with TB4 gene therapy lost 1.2 ± 2.8% of their 
body weight compared to day 0, which was not significant. At day 21, the weight loss 
was increased to 3.7 ± 2.5% but was not significantly lower than day 0 or day 7. 
There were no significant differences between the treatment groups at any time point 
(Figure 4.3a).  
 
To examine if TB4 had any effect of the kidney weights in NTS nephritis, the right 
kidneys were weighed 21 days after NTS injection, and kidney weights were also 
normalised to body weight (g/g). Kidneys from mice treated with PBS and NTS 
weighed on average 0.25 ± 0.01 g, which equated to a kidney weight to body weight 
ratio of 8.6 x10-3 ± 0.3 x10-3 g/g. Kidneys from mice injected with AAV.LacZ and NTS 
weighed on average 0.24 ± 0.01 g, which was equal to 8.2 x10-3 ±0.3 x10-3 g/g. TB4 
gene therapy did not alter kidney weights after NTS injection, as kidneys weighed on 
average 0.22 ± 0.01 g, which equated to 7.9 x10-3 ± 0.2 x10-3 g/g. There were no 







Figure 4.3 - TB4 did not affect body or kidney weight. (a) Mouse body weights were 
recorded at day 0, 7 and 21 after NTS induction. (b) Mice from all three groups weighed the 
same on day 0. (c) There was no difference in the kidney or (d) kidney weight to body 
weight to body weight ratio 21 days after NTS induction. Each data point represents 1 
mouse. All data are shown as the mean ±SEM of at least 4 individual mice. N=6 for 
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 192 
4.4.3 NTS or TB4 did not alter urine volume 
Next, to examine how much urine the mice were excreting throughout the 
experiment, the urine volumes were recorded on day 0, 7 and 21 after NTS injection. 
On day 0, PBS treated mice excreted 778 ± 112 µl/24 hours, which rose to 830 ± 
240 µl/24 hours 7 days later. After 21 days of NTS treatment, PBS treated mice 
excreted 1691 ± 296 µl/24 hours. Mice treated with AAV.LacZ urinated 612 ± 
88 µl/24 hours prior to NTS injection, which rose slightly to 630 ± 293 µl over 24 
hours on day 7 and 1237 ± 314 µl/24 hours on day 21 after NTS injection. Before 
NTS injection, mice treated with TB4 gene therapy urinated 547 ± 161 µl/24 hours, 
and 483 ± 176 µl/24 hours on day 7. After 21 days of NTS nephritis, Tmsb4x/NTS 
mice urinated 1483 ± 333 µl/24 hours. There were no significant differences between 
any groups at any time point or within each group (Figure 4.4).  
 
4.4.4 Exogenous TB4 prevented NTS-induced early albuminuria but there were 
no alterations to BUN 
One of the features of NTS nephritis in C57BL/6 mice is an increase in albuminuria 
(Vasilopoulou et al. 2016), therefore the amount of albumin in the urine was 
assessed by ELISA. Before NTS injection (day 0), PBS treated mice excreted on 
Figure 4.4 – Urine excretion in NTS experiment. Urine volumes were recorded at day 0, 7 
and 21 after NTS injection, and adjusted for 24-hour volume. Each data point represents the 
24-hour urine volume of 1 mouse. All data are shown as the mean ±SEM of at least 4 































average 13 ± 2 µg of albumin in 24 hours, AAV.LacZ treated mice 14 ± 3 µg/24 
hours and mice treated with TB4 gene therapy 10 ± 2 µg/24 hours of albumin with no 
significant differences between the groups. After 7 days of NTS nephritis, PBS and 
AAV.LacZ treated mice urinated on average 8635 ± 3781 µg and 10956 ± 4472 
µg/24 hours respectively, each significantly more than their respective day 0 values 
(P<0.05 vs day 0 in both groups). Mice treated with TB4 gene therapy urinated on 
average 2144 ±1193 µg/24 hours, which was significantly less than both PBS 
(P<0.05) and AAV.LacZ (P<0.05) treated mice. On day 21 after NTS injection, PBS 
treated mice albumin excretion was on average 33494 ± 7151 µg/24, which was 
significantly more than the same group at day 7 (P<0.05). AAV.LacZ treated mice 
urinated 32757 ± 9012 µg albumin per 24 hours, which was significantly more than 
the same group at day 7 (P<0.05). NTS injected mice with TB4 gene therapy 
excreted 33015 ± 6811 µg/24 hours, which was significantly more compared with the 
same mice 7 days post NTS induction (P<0.01). There were no significant 
differences between the mouse groups 21 days after NTS injection (Figure 4.5a). 
 
NTS nephritis has been associated with an increase in BUN (Kvirkvelia et al. 2013), 
therefore BUN was assessed 21 days after NTS injection. PBS and AAV.LacZ 
treated mice had a BUN concentration of 50.8 ± 6.8 mg/DL and 42.3 ± 4.6 mg/DL 
respectively, and there were no significant differences between these two groups. 
Mice treated with TB4 gene therapy had a plasma BUN concentration on 50.7 ± 5.3 
mg/DL, which was not significantly different to either group (Figure 4.5b).  
 
Collectively, these results show that TB4 gene therapy dampened the NTS induced 
increase in albuminuria at day 7 of NTS nephritis, but not at day 21. This thesis 
chapter then proceeded to examine the glomeruli to investigate any potential 























































Blood urea nitrogen - Day 21
Figure 4.5 – Exogenous TB4 suppressed albuminuria but not BUN in NTS nephritis. 
Urinary albumin concentration was determined at day 0, 7 days, and 21 days after NTS 
injection. (a) Amount of urinary albumin excreted over 24 hours by mice on day 0, 7 and 21 
after NTS injection. (b) BUN concentration 21 days after NTS injection. Each data point 
represents the mean of replicate values from 1 individual mouse. All data are shown as the 
mean ±SEM of at least 4 mice. N=6 for PBS/NTS, N=4 for LacZ/NTS group and N=10 for 
Tmsb4x/NTS group. *P≤0.05, **P≤0.01 between groups. 
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4.4.5 Exogenous TB4 increased podocyte number 21 days after NTS induction 
Podocyte loss has been reported as early as day 1 in NTS nephritis (Shirato et al., 
1996; Puelles et al., 2019). Therefore, to determine if exogenous TB4 could prevent 
podocyte loss in NTS nephritis, FFPE sections obtained 21 days after NTS injection 
were stained with a-mouse WT-1 antiserum followed by a HRP conjugated 
secondary antibody. Representative images of glomeruli from all three treatment 
groups immunostained for WT-1, a nuclear marker specific to podocytes in the 
glomerular tuft (Lefebvre et al. 2015) are provided in Figure 4.6a, b, c. Antibody 
specificity was confirmed by omitting the primary antibody (Figure 4.6d). 
 
Firstly, the area of individual glomerular cross sections was measured. PBS treated 
mice had an average glomerular cross section of 3849 ± 194 µm2. AAV.LacZ treated 
mice average glomerular cross-sectional area was 3606 ± 121 µm2. TB4 gene 
therapy did not alter glomerular cross-sectional area, as the average area was 3696 
± 83 µm2. There were no significant differences between the groups (Figure 4.6e).  
 
The number of WT-1 positive cells were then counted in the glomerular tuft and 
measured as an average of 50 glomeruli per mouse and as individual glomeruli. 
When the average of 50 glomeruli per mouse were analysed, PBS treated mice had 
an average of 14.3 ± 1.2 WT-1 positive cells per glomerulus. AAV.LacZ treated mice 
had an average of 15.3 ± 1.1 WT-1 positive cells per glomerulus, and there was no 
significant difference between these groups. Mice treated with NTS and TB4 gene 
therapy had an average of 18.3 ± 0.7 WT-1 positive cells per glomerulus, which was 
significantly more than PBS treated mice (P<0.05) (Figure 4.6f). The number of WT-
1 cells were then normalised to glomerular area (podocyte density). Mice treated 
with PBS and NTS had an average podocyte density of 4.5 x10-3 ± 0.5 x10-3 
podocytes /µm2, and mice treated with AAV.LacZ and NTS had an average podocyte 
density of 4.8 x10-3 ± 0.3 x10-3 podocytes /µm2. There was no significant difference 
between the groups. Treatment of NTS injected mice with TB4 gene therapy caused 
no significant differences to podocyte density compared to both other groups, and 





Figure 4.6 – Exogenous TB4 increased podocyte number in NTS nephritis. 
Representative images of (a) PBS/NTS, (b) LacZ/NTS and (c) Tmsb4x/NTS glomeruli 
immunostained with a-WT-1 antiserum. Mayer’s haematoxylin was used to stain nuclei. 
Arrowheads indicate positive WT-1 staining. (d) Negative control omitting primary antibody. 
Scale bar = 20 µm. (e) Comparison of glomerular cross-sectional area, as assessed by 
individual glomeruli. WT-1 positive cells were counted and analysed as the average of 50 
glomeruli per mouse (f) inside the glomerular tuft and (g) normalised to the glomerular tuft 
area. Each data point represents the average of 50 glomeruli from 1 mouse. Data are shown 
as the mean ±SEM of at least 4 mice. N=6 for PBS/NTS, N=4 for LacZ/NTS group and N=10 
for Tmsb4x/NTS group.  Analysis of (h) WT-1 positive cell count, (i) podocyte density, and (j) 
the number of WT-1 cells in the parietal epithelium when analysed as individual glomeruli. 
Each data point represents 1 glomerulus. Data are shown as the mean ±SEM of at least 200 
glomeruli from at least 4 individual mice. N=300 for PBS/NTS, N=200 for LacZ/NTS group 
























































































































































































































































When individual glomeruli were analysed, there was no significant difference in 
podocyte number or density between PBS and AAV.LacZ treated mice. Mice treated 
with NTS and TB4 gene therapy had significantly increased podocyte number and 
density than both PBS and AAV.LacZ treated mice (P<0.001 vs both groups in both 
data sets) (Figure 4.6h, i). Collectively, these results suggest that exogenous TB4 
prevented podocyte loss in NTS nephritis.  
 
NTS has been associated with an increase in the number of WT-1 positive PECs (Le 
Hir et al. 2001; Vasilopoulou et al. 2016), therefore to determine if exogenous TB4 
could affect parietal WT-1 expression, the number of WT-1 positive cells in the 
parietal epithelium were counted. After 21 days of NTS nephritis, PBS treated mice 
had an average parietal epithelial WT-1 cell count of 8.9 ± 0.3. Mice treated with 
AAV.LacZ had an average of 9.5 ± 0.3 WT-1 positive cells in the parietal epithelium. 
TB4 gene therapy treated mice had average of 9.1 ± 0.2 WT-1 positive cells in the 
parietal epithelium, which was not significantly different to either group 
(Figure 4.6j).  
 
4.4.6 NTS did not induce podocyte clustering 
WT-1 immunostained images were used to quantify if podocyte clustering was 
occurring. Clustering was defined as >50% of total podocyte number occupying 25% 
of the glomerular cross section. However, in this model of NTS nephritis and NTS 
with exogenous TB4 treatment, podocyte clustering was not observed 21 days after 
NTS injection. Mice treated with PBS and AAV.LacZ showed on average 5.3 ± 3.1% 
and 6.7 ± 2.8% of glomeruli with podocyte clustering respectively. Treatment with 
TB4 gene therapy did not alter this number, as mice showed an average of 4.7 ± 
1.2% of glomeruli with podocyte clustering. There were no significant differences 
between the groups (Figure 4.7a).  
 
The distribution of podocytes in the upper (tubular pole) and lower (vascular pole) 
hemispheres of each glomeruli was also examined 21 days after NTS injection. Mice 
treated with PBS had an average of 52.2 ± 0.4% podocytes in the upper hemisphere 
and 47.8 ± 0.4% of podocytes in the lower hemisphere. AAV.LacZ treated mice had 
an average of 53.5 ± 0.8% podocytes in the upper hemisphere and 46.5 ± 0.8% 
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podocytes in the lower hemisphere. TB4 gene therapy did not alter podocyte 
distribution compared with the two other groups, as mice had an average of 53.5 ± 
0.7% of podocytes in the upper hemisphere and 46.5 ± 0.7% podocytes in the lower 
hemisphere. While there were no significant differences in the distribution of 
podocytes between the groups, each groups upper and lower hemisphere values 
were significantly different (P<0.001 within all groups) (Figure 4.7b).  
 
4.4.7 NTS induced glomerular proliferation 
Next, it was determined if the higher number of WT-1 positive cells caused by TB4 
gene therapy was because of podocyte proliferation, which has been observed in 
NTS nephritis (Bruggeman et al. 2011; Henique et al. 2017). Kidney cryosections 
were immunostained with a-Ki67 antiserum, a marker of nuclei undergoing 
proliferation (Polley et al. 2013). Podocytes were identified by co-immunostaining 
with a-synaptopodin antiserum, and the number of Ki67 positive nuclei in 
synaptopodin positive regions were counted per glomerulus. Representative images 
from all three groups are provided in Figure 4.8a, b, c. Antibody specificity was 











































































































Figure 4.7 – Podocyte distribution in NTS nephritis and exogenous TB4 treatment. 
Quantification of (a) the number of glomeruli displaying podocyte clustering (>50% of 
podocytes in 1 quadrant of the glomerulus) and (b) the number of cells in each glomerular 
hemisphere as a percentage of total podocyte number. Each data point represents the mean 
value of at least 30 glomeruli from 1 mouse. n = 30 for PBS/NTS group, n = 32 for LacZ/NTS 
group and n = 31 for Tmsb4x/NTS group. All data are shown as the mean ±SEM of at least 4 
mice. N=6 for PBS/NTS, N=4 for LacZ/NTS group and N=10 for Tmsb4x/NTS group. 
***P≤0.001 between groups.  
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Figure 4.8 – Glomerular proliferation. Kidney cryo-sections were incubated with rabbit 
anti-mouse Ki67 primary antibody, guinea pig anti-mouse synaptopodin primary antibody, 
donkey anti-rabbit secondary antibody conjugated to 594 nm fluorophore and fluorophore 
conjugated secondary antibodies. Nuclei were stained with Hoechst 33342. Representative 
images of (a) PBS/NTS, (b) LacZ/NTS and (c) Tmsb4x/NTS glomeruli. Arrows indicate 
glomerular Ki67 positive nuclei. Arrowhead indicates Ki67 positive podocyte. Negative 
control of (d) 488 nm channel, (e) 594 nm channel and (f) composite of all three channels. 
Scale bar = 20 µm. Ki67 positive cells were counted (g) in the glomerular tuft and (h) in 
synaptopodin positive regions. Each data point represents the average of 50 glomeruli. Data 
are shown as the mean ±SEM from at least 4 mice. N=6 for PBS/NTS, N=4 for LacZ/NTS 
group and N=10 for Tmsb4x/NTS group.  Quantification of (i) proliferating glomerular cells 
and (j) proliferating podocytes when analysed as individual glomeruli. Each data point 
represents 1 glomerulus. Data are shown as the mean ±SEM from at least 200 glomeruli 
from at least 4 mice. N=300 for PBS/NTS, N=200 for LacZ/NTS group and N=500 for 
Tmsb4x/NTS group. *P ≤0.05, **P ≤0.01, ***P ≤0.001 between groups. 
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glomerular cells were analysed as an average of 50 glomeruli per mouse and as 
individual glomeruli.  
 
Firstly, glomerular and podocyte proliferation was examined as an average of 50 
glomeruli per mouse 21 days after NTS injection. Mice treated with PBS had an 
average of 0.9 ± 0.1 Ki67 positive nuclei per glomerulus. AAV.LacZ treated mice had 
an average of 1.5 ± 0.1 Ki67 positive nuclei per glomerulus. TB4 gene therapy 
treated mice had an average of 1.5 ± 0.2 Ki67 positive nuclei per glomerulus. There 
were no significant differences between the groups (Figure 4.8g). The number of 
Ki67 positive nuclei in synaptopodin positive regions was then examined. Mice 
treated with PBS had an average of 0.07 ± 0.02 Ki67 nuclei in synaptopodin positive 
regions. AAV.LacZ treated mice had an average of 0.2 ± 0.05 Ki67 positive nuclei in 
synaptopodin positive regions, which was significantly more than PBS treated mice 
(P<0.05). Treatment with TB4 gene therapy caused 0.01 ± 0.02 Ki67 positive nuclei 
in synaptopodin positive regions, which was significantly lower than AAV.LacZ 
treated mice (P<0.05), but not significantly different to PBS treated mice (Figure 
4.8h).  
 
Next, the glomerular and podocyte Ki67 positive cells were analysed as individual 
glomeruli. LacZ/NTS glomeruli showed an increased number of proliferating 
glomerular cells compared with PBS treated mice (P<0.001 vs PBS/NTS). 
Tmsb4x/NTS treated glomeruli showed a similar number to AAV.LacZ treated mice, 
as the number of proliferating glomerular cells was significantly more than PBS 
treated mice (P<0.001 v PBS/NTS) (Figure 4.8i). The number of Ki67 positive nuclei 
in synaptopodin positive regions were also counted, as a measure of proliferating 
podocytes. Mice treated with AAV.LacZ had significantly more proliferating 
podocytes than PBS/NTS treated mice (P<0.01). Tmsb4x/NTS treated mice had 
significantly fewer proliferating podocytes than LacZ/NTS treated mice (P<0.05) 
(Figure 4.8j). These results suggest that podocyte proliferation was not the cause of 
the increased podocyte number observed in 4.4.5, as there was only a small number 
of proliferating podocytes observed. 
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4.4.8 Whole kidney Inflammatory and fibrotic mRNA levels in NTS nephritis 
were not altered by TB4 
NTS nephritis induces glomerular inflammation, fibrosis and collagen deposition (Le 
Hir et al. 2001; Vasilopoulou et al. 2016). Therefore, the levels of some fibrotic and 
inflammatory mRNA transcripts in whole kidneys were examined by qPCR 21 days 
after NTS injection. 
 
Cluster of differentiation 68 (CD68) is expressed in monocytes and tissue 
macrophages (Holness and Simmons 1993), therefore alterations to Cd68 mRNA in 
whole kidneys could suggest changes in inflammation. Exogenous TB4 did not alter 
Cd68 mRNA expression compared to PBS/NTS and LacZ/NTS treated mice (Figure 
4.9a). MCP-1, also known as C-C motif chemokine 2 precursor (CCL2) is a 
chemokine produced in the inflammatory response (Deshmane et al. 2009), that 
recruits macrophages (Cranford et al. 2016). Macrophages, among other immune 
cells, then produce and secrete TNF-a in the acute inflammatory reaction to promote 
apoptosis and necrosis (Idriss and Naismith 2000).  
 
The mRNA levels of Ccl2 and Tnf-a were examined, however, exogenous TB4 had 
no effect on the levels of either mRNA transcript compared with PBS/NTS and 
LacZ/NTS treated mice (Figure 4.9b, c). a-SMA and collagen IV are markers of 
interstitial fibrosis and mesangial expansion and increased expression of these 
proteins is associated with glomerular injury, including NTS nephritis (Boukhalfa et 
al. 1996; Johnson et al. 1991; Khan et al. 2005). After 21 days of NTS nephritis, 
exogenous TB4 did not alter the mRNA levels of Acta2 or Col4a1 compared with 





































































































































Figure 4.9 – mRNA levels of inflammatory and fibrotic markers in whole kidney 
lysates. Kidneys were harvested 21 days after kidney disease induction and mRNA was 
extracted. Gene expression was assessed by real time PCR. Expression of (a) Cd68 (b) 
Ccl2, (c) Tnf-a, (d) ⍺SMA and (e) Col4a1 21 days after kidney disease induction. Hprt was 
used as a housekeeping gene. Each data point represents the mean of replicate values from 
1 mouse kidney. All data are shown as the mean ±SEM of at least 4 individual mice. N=6 for 
PBS/NTS, N=4 for LacZ/NTS group and N=10 for Tmsb4x/NTS group. CD68, cluster of 
differentiation 68; ⍺SMA, ⍺ smooth muscle actin; Col4a1, Collagen IV; CCL2, monocyte 
chemoattractant protein 1; TNF-⍺, tumour necrosis factor ⍺. 
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4.4.9 Effect of TB4 gene therapy on glomerular inflammation in NTS nephritis 
The previous section of this thesis chapter suggested that exogenous TB4 did not 
alter the mRNA levels of inflammation and fibrosis markers. Although screening of 
whole kidney mRNA levels is informative, it does not always translate to protein 
expression and does not provide information about localised changes in the 
glomerulus. Glomerular inflammation and macrophage accumulation are associated 
with increased albuminuria in NTS nephritis (Chalmers et al. 2015; Kaneko et al. 
2018). Therefore, glomerular inflammation was assessed by IHC for F4/80, a marker 
for macrophages (Austyn and Gordon 1981). Representative images of glomeruli 
from all three groups are presented in Figure 4.10a, b, c. Antibody specificity was 
confirmed by omitting the primary antibody (Figure 4.10d). Data was analysed as an 
average of 50 glomeruli per mouse and as individual glomeruli 21 days after NTS 
injection. 
 
Firstly, the number of F4/80 positive cells were quantified inside and outside the 
glomerular tuft and analysed as an average of 50 glomeruli per mouse. PBS and 
NTS treated mice had an average of 0.1 ± 0.04 F4/80 positive cells in the glomerular 
tuft. AAV.LacZ treated mice had an average of 0.07 ± 0.05 F4/80 positive cells inside 
the glomerular tuft. Mice treated with NTS and TB4 gene therapy had an average of 
0.05 ± 0.02 F4/80 positive cells inside the glomerular tuft. There were no significant 
differences between any groups (Figure 4.10e). The number of F4/80 positive cells 
were then counted outside the glomerular tuft. PBS treated mice had an average of 
27.1 ± 2.5 F4/80 cells outside the glomerular tuft. AAV.LacZ treated mice had an 
average of 13.1 ± 1.9 F4/80 positive cells outside the glomerular tuft, which was 
significantly less than PBS treated mice (P<0.05). Mice treated with TB4 gene 
therapy had an average of 19 ± 2.5 F4/80 positive cells outside the glomerular tuft, 
and this value was not significantly different to either group (Figure 4.10f).  
 
The number of F4/80 positive cells was then analysed as individual glomeruli. 
AAV.LacZ treated mice had significantly less F4/80 positive cells inside the 
glomerular tuft than PBS/NTS treated mice (P<0.05). Mice treated with TB4 gene 
therapy did not have significantly altered F4/80 positive cells in the glomerular tuft 
compared with either PBS/NTS or LacZ/NTS mice (Figure 4.10g). The number of  
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Figure 4.10 – Effect of TB4 gene therapy on glomerular inflammation. FFPE kidneys 
sections were incubated with a rat anti-mouse F4/80 primary antibody, rabbit anti-rat 
secondary antibody conjugated to HRP and anti-rabbit EnVision conjugated to HRP and 
then positive staining was revealed by 3,3′-Diaminobenzidine incubation. Nuclei were 
stained with Mayer’s haematoxylin. Representative images of (a) PBS/NTS, (b) LacZ/NTS 
and (c) Tmsb4x/NTS glomeruli. Arrow heads indicate positive F4/80 staining. (d) Negative 
control omitting the primary antibody. Scale bar = 20 µm. F4/80 positive cells were counted 
(e) in the glomerular tuft and (f) outside the glomerular tuft. Each data point represents the 
average of 50 glomeruli. Data are shown as the mean ±SEM of at least 4 mice. N=6 for 
PBS/NTS, N=4 for LacZ/NTS group and N=10 for Tmsb4x/NTS group. Quantification of the 
number of F4/80 positive cells (g) inside and (h) outside the glomerular tuft. Each data point 
represents 1 glomerulus. Data are shown as the mean ±SEM from at least 200 glomeruli 
from at least 4 mice. N=300 for PBS/NTS, N=200 for LacZ/NTS group and N=500 for 












































































































































































Macrophage count in glomerular tuft
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F4/80 positive cells was then analysed outside the glomerular tuft. AAV.LacZ treated 
mice significantly less F4/80 positive cells outside the tuft compared with PBS 
treated mice (P<0.001). Treatment with exogenous TB4 caused significantly more 
F4/80 positive cells outside the glomerular than AAV.LacZ treated mice (P<0.001), 
but significantly less than PBS treated mice (P<0.001) (Figure 4.10h).  
 
 Discussion 
This thesis chapter has provided evidence that exogenous TB4 suppresses the 
onset of NTS nephritis a form of severe, autoimmune glomerular injury (Pippin et al. 
2009). AAV gene therapy successfully upregulated the circulating TB4 concentration 
in C57BL/6 mice. Exogenous TB4 suppressed albuminuria after 7 days of NTS 
nephritis compared with PBS and AAV.LacZ treated mice, but not at 21 days after 
NTS injection. Interrogation of the glomeruli through IHC and immunofluorescence at 
21 days of NTS nephritis revealed that exogenous TB4 prevented podocyte loss.  
This was likely to be independent of TB4s anti-inflammatory properties, as TB4 had 
no effect on glomerular macrophage accumulation in this model. Collectively, the 
results presented in this thesis chapter provide some evidence that exogenous TB4 
has a beneficial role in the progression of NTS nephritis. 
 
This chapter of the thesis demonstrated that AAV.2/7 successfully transduced the 
liver, as shown by the increase in Tmsb4x transcript levels in the liver by qPCR. 
ELISAs showed that AAV.Tmsb4x treated mice had a higher plasma concentration 
of TB4 than PBS or AAV.LacZ injected mice, providing strong evidence that 
AAV.Tmsb4x caused systemic upregulation of TB4. AAV.2/7 did not transduce 
kidney cells, as there was no increase in kidney Tmsb4x mRNA levels. Therefore, a 
single injection of AAV induced a long-term increase in plasma TB4 concentration, 
as the ELISA to measure plasma TB4 concentration was undertaken on plasma 
taken from the mice 7 weeks after injection. Different doses of intravenous 
AAV.Tmsb4x injection than this thesis have previously been used. The previous 
chapter of this thesis used 5x1012 viral particles in comparison to 2x1012 viral 
particles in this chapter. Intravenous injection of 5x1012 viral particles of 
AAV.Tmsb4x has also been used to treat mice with LPS induced sepsis 
(Bongiovanni et al., 2015). These two higher doses may have induced a higher 
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upregulation of TB4 than in this thesis chapter, providing a higher degree of 
protection. Indeed, the previous chapter of this thesis reported a 10-fold upregulation 
of liver Tmsb4x levels compared with AAV.LacZ treated mice. However, the plasma 
circulating concentration was not as high as this thesis chapter, perhaps due to the 
way the TB4 ELISAs were performed. Collectively, this thesis chapter has provided 
further evidence that AAV.Tmsb4x is an effective method of treating mice with kidney 
injury.  
 
This thesis chapter showed that exogenous TB4 delays the onset of severe 
albuminuria in NTS nephritis, an experimental form of severe autoimmune 
glomerulonephritis (Pippin et al. 2009). An increase in albuminuria is a hallmark of 
glomerular injury (Gorriz and Martinez-Castelao 2012). Therefore, the prevention of 
albuminuria by exogenous TB4 provides evidence that exogenous TB4 is protective 
of the glomerular filtration barrier in NTS nephritis. The levels of albuminuria 
reflected the severity of glomerular injury. The urinary albumin concentration rose 
1000-fold after 7 days compared to the day of NTS injection, and then a further 3.3-
fold 21 days after NTS injection in AAV.LacZ and PBS treated mice. It is feasible that 
exogenous TB4 could not prevent the NTS-induced increase in albuminuria 21 days 
after NTS injection due to the severity of the injury making it possible that exogenous 
TB4 can prevent albuminuria up to a certain threshold of damage. The role of TB4 in 
NTS-induced albuminuria has been investigated before. Global knockout of Tmsb4x 
in C57BL/6 mice with NTS nephritis led to a ~5-fold increase in albuminuria after 21 
days of NTS nephritis compared with wild type littermates injected with NTS 
(Vasilopoulou et al. 2016). This study provided evidence that endogenous TB4 acts 
as a brake to slow the progression of glomerular injury in NTS nephritis. This thesis 
chapter provides evidence that boosting TB4 levels, at least transiently, therefore, 
slowing the progression of glomerular injury. The viral titre administered to mice in 
this thesis chapter was lower than administered to animals in other experimental 
pathological models (Bongiovanni et al., 2015; Ziegler et al., 2018), therefore future 
studies could investigate whether a higher dose of AAV may provide increased 
prevention of albuminuria in NTS nephritis.  
 
In the model of NTS nephritis employed in this thesis chapter, there was a higher 
number of WT-1 positive nuclei in the TB4 gene therapy treated group compared 
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with both PBS and AAV.LacZ treated mice, and it was shown that this was not due to 
podocyte proliferation. Therefore, the conclusion can be drawn that exogenous TB4 
prevents podocyte loss, which is likely to be a mechanism by which exogenous TB4 
prevented albuminuria. Podocyte loss causes areas of the GBM denuded of 
podocytes, the final component of the glomerular filtration barrier, allowing albumin 
to enter the urine (Shirato et al., 1996). Podocyte loss has previously been 
associated with an increase in albuminuria in glomerulonephritis. Mice injected 
intraperitoneally with 5 mg/kg NTS had podocyte loss after 14 days of NTS nephritis 
(Puelles et al. 2019). Interestingly, this study used 3D optical clearing techniques to 
visualise the whole glomerulus, instead of a cross section. Therefore, the number of 
podocytes reported in healthy glomeruli was ~80 on average, which was reduced to 
~30 in NTS nephritis (Puelles et al. 2019). Another study reported progressive loss 
of podocytes and podocyte density in rats after 7, 14 and 28 days of NTS nephritis, 
and viable podocytes were detected in the urine at each time point, suggesting that 
these podocytes had not undergone apoptosis or necrosis (Fukuda et al. 2017). The 
only previous study that examined TB4 in podocyte loss found that global loss of 
endogenous TB4 resulted in a lower number of WT-1 positive cells in the glomerular 
tuft 21 days after injection of NTS, suggesting that endogenous TB4 also prevents 
podocyte loss in NTS nephritis (Vasilopoulou et al. 2016). Overall, there is significant 
evidence that TB4 prevents podocyte loss in NTS nephritis, a form of severe 
glomerular injury, which is likely to be a contributing mechanism by which TB4 
protects glomerular function.  
 
This thesis chapter has shown that the protective effects of TB4 in NTS nephritis are 
likely independent of inflammation. One of the key mechanisms of glomerular 
damage in NTS nephritis is the inflammatory response (Khan et al. 2005; 
Moschovaki Filippidou et al. 2020). Macrophages are antigen presenting cells 
(Martinez-Pomares and Gordon 2007), and can be stimulated by either IFN-g, LPS 
or interleukin secretion in inflamed tissues (Fairweather and Cihakova 2009). 
Macrophages and neutrophils are the major infiltrating cells in autoimmune diseases, 
and cause damage to inflamed tissues by phagocytosis of healthy cells, release of 
proteases and oxidants to cause further damage to the tissue (Fairweather and 
Cihakova 2009). Macrophage depletion in NTS nephritis has been shown to prevent 
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increased proteinuria, BUN and decreased creatinine clearance (Chalmers et al. 
2015; Duffield et al. 2005). This provides strong evidence that macrophages play a 
key role in the pathogenesis of NTS nephritis and significantly contribute to 
albuminuria. Therefore, it is a surprise that TB4 was not likely to be modulating 
inflammation in this model of glomerular injury. The anti-inflammatory properties of 
TB4 in other tissues, such as the eye (Sosne 2018; Sosne et al. 2002; Sosne, Qiu, 
Christopherson, et al. 2007), are well established, but TB4 has also previously been 
shown to prevent inflammation in experimental models of kidney injury. Firstly, 
endogenous TB4 has been shown to suppress glomerular T cell infiltration and 
macrophage accumulation after 21 days in NTS nephritis (Vasilopoulou et al. 2016). 
Endogenous TB4 has also been shown to prevent kidney macrophage infiltration 
and expression of ICAM-1 in the angiotensin-II model of systemic and kidney 
hypertension (Kumar et al., 2018). In the IRI model of kidney injury, exogenous TB4 
suppressed levels of the pro-inflammatory cytokines NFkB, TNF-a, IL-1b and IL-6 
(Aksu et al. 2019). There are similarities and differences between this thesis chapter 
and the previous studies examining TB4 in the kidney. Firstly, the studies by 
Vasilopoulou et al., and Kumar et al., both investigated the role of endogenous TB4 
in kidney injury, in contrast to the analysis of exogenous TB4 in this thesis chapter. 
Also, the studies undertaken by Aksu et al., and Kumar et al., were in different forms 
of kidney injury (IRI and angiotensin-II induced hypertension) that do not specifically 
target the glomeruli. Like the study by Aksu et al., this thesis chapter did assess the 
levels of some inflammatory cytokines, such as TNF-a, but in this thesis chapter, the 
levels were unchanged in mice treated with TB4 gene therapy compared with PBS 
and AAV.LacZ treated mice. The differences between the data are likely because 
two different injury models were employed, that may induce the inflammatory 
response in different ways. Also, the study by Aksu et al., examined the protein 
concentration of these cytokines by Western Blot, whereas this thesis chapter 
assessed mRNA levels by qPCR, which could account for differences in the data. 
Taken together, there is significant data available that TB4 is effective in suppressing 
inflammation in different kidney pathologies, but potentially not NTS nephritis.  
 
One of the limitations of this thesis chapter was that there were some discrepancies 
between the control groups (PBS and AAV.LacZ) in the examination of macrophage 
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accumulation and in the number of proliferating podocytes and glomerular cells. To 
date, there has not been any data published examining anti-inflammatory properties 
of LacZ or its translated protein b-galactosidase, only that LacZ is expressed in 
macrophages (Hall et al. 2016). Furthermore, there have been no studies reporting 
the effects of b-galactosidase in cellular proliferation. The PBS and AAV.LacZ 
treated mouse groups had a lower sample size compared with the TB4 gene therapy 
treated mouse group. It is likely that the lower sample size in each group contributed 
to the discrepancies seen. To circumvent this issue, the experiment could be 
repeated with a higher number of mice in each group. The nephrotoxic phenotypes 
of NTS are well documented, such as severe albuminuria, podocyte loss and 
inflammation (Chen et al. 2002; Hoppe and Vielhauer 2014; Vasilopoulou et al. 
2016). Therefore, the main aim of this thesis chapter was to determine if TB4 gene 
therapy can alleviate some of the phenotypes of NTS nephritis. To make the data 
easier to interpret, an additional mouse group injected with only vehicle, and no NTS, 
could be included in future studies. One important aspect of this study is that the 
effect of TB4 on podocyte loss and inflammation was confirmed 21 days after NTS 
injection. TB4 gene therapy prevented albuminuria at 7 days, but not day 21. It is 
possible that at 21 days, the damage to the glomeruli that contributed to albuminuria 
was independent of both podocyte loss and inflammation. One important factor that 
has not been assessed in this thesis chapter was foot process effacement. This 
could be examined by electron microscopy, to determine if the interdigitating pattern 
of podocyte foot processes is still present at 21 days in AAV.Tmsb4x compared with 
PBS and AAV.LacZ treated mice. Alternatively, another experiment could be 
undertaken which culls mice at 7 days of NTS nephritis to examine histology, 
podocyte number and inflammation to see if the effects of TB4 are seen at this time 
point.  
 
The main function of TB4 is to regulate the F-actin cytoskeleton (Sanders et al. 
1992), therefore the therapeutic effect at 7 days, as seen by decreased albuminuria, 
could be due to preservation of the cytoskeleton. So far, there has been a limited 
amount of research into modulating actin-regulating molecules in NTS nephritis. 
Endogenous sirtuin 1, a NAD+-dependent deacetylase, is crucial for slowing the 
progression of NTS nephritis, as Sirt1 mRNA knockout mice experienced increases 
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albuminuria, BUN, glomerulosclerosis and tubular cast formation after 7 days 
(Motonishi et al. 2015). The authors then examined the effect of inhibiting sirtuin 1 in 
podocytes in vitro, and found that the podocytes experienced actin reorganisation, 
which was induced by sirtuin 1 being unable to deacetylate cortactin, an actin-
binding protein that stabilises F-actin (Motonishi et al. 2015; Weaver et al. 2001). 
This study suggests that protection of the podocyte cytoskeleton by overexpressing 
sirtuin 1 could prevent NTS nephritis in rodents. Another study examined the effect 
of knocking out roundabout guidance receptor 2 (Robo2), a cell surface receptor that 
inhibits myosin IIa activity and podocyte actin polymerisation induced by nephrin 
(Fan et al. 2012, 2016). Podocyte specific Robo2 inhibition by Cre recombinase 
alleviated NTS induced albuminuria, foot process effacement and preserved SDs in 
mice of a C57BL/6 background (Pisarek-Horowitz et al. 2020). Furthermore, Robo2 
overexpression in mouse podocytes in vitro significantly reduced podocyte F-actin 
fluorescence intensity, as determined by phalloidin staining, accompanied by 
podocyte detachment (Pisarek-Horowitz et al. 2020), suggesting that the podocyte 
protective effects of Robo2 knockout in podocytes could be mediated by the 
podocyte actin cytoskeleton. There has also been little research into how NTS 
affects the glomerular cytoskeleton in vivo, however, it has been shown that 
glomerular F-actin alterations occur 6 and 7 days after induction of NTS injury. This 
is presented as a decrease in mean glomerular F-actin fluorescence and a shift from 
regular F-actin expression along the capillary loops to irregular expression along the 
GBM, with some areas showing high accumulation of F-actin, and a build-up in the 
podocyte cell body in C57BL/6 mice (Besse-Eschmann et al. 2004; Kvirkvelia et al. 
2013). Future studies could investigate the effect of exogenous TB4 on the 
glomerular cytoskeleton at 7 and 21 days by phalloidin staining, to determine if the 
effect seen on albuminuria is associated with protection of the F-actin cytoskeleton.  
 
 Conclusions 
The results in this thesis chapter have provided evidence that exogenous TB4 
decelerates the onset of NTS nephritis. Systemic gene therapy for TB4 suppressed 
albuminuria 7 days after NTS injection, which was likely mediated by protection of 
podocyte loss. Collectively, it is proposed that TB4 is an important component in the 
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progression of NTS nephritis, and that modulation of TB4 alleviates the phenotypes 




Chapter 5: General discussion 
 The beneficial effect of exogenous TB4 in glomerular and podocyte 
pathology 
This thesis utilised a combination of in vitro and in vivo experiments to investigate 
the beneficial potential of exogenous TB4 in podocyte and glomerular injury. Using a 
novel strategy of gene therapy to systemically upregulate TB4 in vivo, it was 
demonstrated that exogenous TB4 prevented ADR-induced albuminuria by 
preventing podocyte loss. In vitro assessment of the podocyte F-actin cytoskeleton 
revealed that exogenous TB4 prevented ADR-induced F-actin disorganisation. 
Furthermore, exogenous TB4 decelerated the early stages of NTS nephritis by 
preventing podocyte loss, which was likely independent of TB4s anti-inflammatory 
properties.  
 
Glomerular injury is seen in a large proportion of patients with renal pathologies and 
is a leading cause of ESKD worldwide (Bikbov et al. 2020). Podocytes are a key 
component of the glomerular filtration barrier, the component responsible for the 
ultrafiltration of the blood (Brinkkoetter, Ising, and Benzing 2013). Podocyte foot 
process effacement and podocyte loss are hallmarks of glomerular injury (Menzel 
and Moeller 2011). Podocyte actin disorganisation is a significant contributing factor 
to podocyte foot process effacement and glomerular injury (Shirato et al., 1996; 
Welsh and Saleem, 2012; Tian and Ishibe, 2016). There are currently therapies 
available to patients that alleviate proteinuria, that have been proven to protect the 
podocyte cytoskeleton in experimental models of rodent glomerular injury and 
podocyte damage in culture. Cyclosporine A is used as a therapy for CKD patients 
and has been shown to prevent LPS induced proteinuria in severe combined 
immunodeficient (SCID) mice. This was attributed to blocking the calcineurin-
mediated dephosphorylation of the actin regulating protein synaptopodin as 
demonstrated in cultured podocytes in vitro (Faul et al. 2008). The chemotherapeutic 
drug Vincristine has been used to rescue albuminuria, foot process effacement and 
glomerulosclerosis in Sprague Dawley rats injured with ADR (Yin et al. 2017). This 
was associated with the F-actin cytoskeleton, as cultured podocytes exposed to ADR 
and Vincristine showed stabilised podocyte cell area and loss of actin stress fibres 
after phalloidin staining, in a similar method to this thesis (Yin et al. 2017). 
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Fluvastatin is another molecule that modulates the podocyte F-actin cytoskeleton. 
PAN injured Sprague-Dawley rats treated with Fluvastatin showed reduced 
proteinuria, improved creatinine clearance, and preserved glomerular expression of 
the SD proteins nephrin and podocin compared to PAN rats. Podocyte culture in vitro 
showed that Fluvastatin prevented PAN-induced actin reorganisation by suppression 
of RhoA upregulation (Shibata, Nagase, and Fujita 2006). These studies examining 
existing therapies demonstrate that targeting the podocyte cytoskeleton is an 
effective strategy to supress nephrotic syndrome. However, many glomerular 
pathologies remain resistant to pharmacological intervention (Hejazian et al. 2020). 
Identification of molecules, such as TB4, that decelerate and prevent the onset of 
glomerular injury in rodents will facilitate the development of novel therapies that can 
translate to therapeutic options for CKD patients. 
 
It was shown in this thesis by the novel analysis of single cell RNA sequencing data 
that podocyte Tmsb4x transcripts are reduced in ADR nephropathy in vivo. This was 
in vitro, where Tmsb4x levels were reduced by ADR in podocytes. By restoring levels 
of TB4 in ADR nephropathy in vivo, increased albuminuria was prevented, and 
podocyte loss was attenuated. Furthermore, restoring podocyte TB4 levels in vitro 
resulted in prevention of F-actin disorganisation from cortical F-actin fibres to 
unorganised F-actin. Podocyte specific loss of Tmsb4x mRNA in NTS nephritis could 
be confirmed by undertaking single cell analysis of the published data by (Chung et 
al. 2020). Loss of endogenous Tmsb4x has been previously shown to exacerbate 
the effects of NTS nephritis in vivo, and induce F-actin reorganisation and migration 
in healthy podocytes in vitro (Vasilopoulou et al. 2016). The reduced Tmsb4x mRNA 
levels caused by ADR exposure in this thesis could have contributed to albuminuria 
and podocyte loss in vivo and F-actin disorganisation in vitro. Collectively, stabilising 
the levels of TB4 in injured podocytes and glomeruli is critical for maintaining 
glomerular function, preventing podocyte loss in vivo and preventing podocyte F-
actin disorganisation in vitro.  
 
Altered levels of endogenous TB4 have recently been implicated in the progression 
of CKD in human patients. The amniotic fluid concentration of TB4 was 2-fold higher 
in compromised renal outcome foetal patients compared to healthy patients (Klein et 
al. 2020). This study also performed IHC of foetal kidneys with congenital 
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abnormalities, where it was shown that although the expression of TB4 was localised 
to the tubules in both healthy and compromised renal outcome patients, the renal 
parenchyma was disorganised in compromised renal outcome patients compared to 
healthy patients. The study did not quantify the amount of TB4 peptide in diseased 
kidneys compared to healthy kidneys, which would have provided stronger evidence 
that the increased levels of amniotic fluid TB4 are linked to the compromised renal 
outcome. Positive TB4 immunostaining was also absent from both the glomeruli in 
healthy and compromised renal outcome patients, suggesting that the increased TB4 
presence in the amniotic fluid was not derived from podocytes or the glomeruli (Klein 
et al. 2020). This is a difference to the results presented in this thesis, where it was 
shown that in adult healthy and ADR-injured mice, TB4 was expressed in the 
glomeruli and podocytes, which is likely due to the stage of kidney development. In 
another study examining adult human CKD patients, mass spectrometry identified 
that patients with ESKD had a 44-fold increased urinary secretion of TB4 compared 
with healthy patients (Kim et al. 2021). However, patients with primarily glomerular 
damage, primarily tubular damage and unknown causes of CKD were grouped in the 
analysis of urinary TB4 quantification, making it impossible to determine if glomerular 
injury specifically caused increased urinary TB4 concentration. Lysis of cells from 
different components of the kidney, such as tubular cells, podocytes, or immune 
cells, such as macrophages that express high levels of TB4 (Vasilopoulou et al. 
2016) could have contributed to the increased urinary TB4 concentration, depending 
on the specific pathology. Taken together, these two studies suggest that kidney 
disease is associated with increased urinary secretion of TB4. This could a result of 
TB4 upregulation as a compensatory mechanism to attempt to protect the kidney 
from further damage. It could also be because there may be a loss of TB4 protein by 
cellular lysis in the kidney in CKD, causing increased TB4 secretion to the urine. To 
explore these hypotheses, Western blot protein analysis of homogenised kidney 
biopsies from CKD patients could confirm if there was an upregulation or 
downregulation in the amount of TB4 peptide. However, it is a challenge to perform 
quantification analyses in human tissues, due to difficulty obtaining sufficient 
amounts of tissue. Therefore, studies in experimental models of rodent glomerular 




This thesis employed cytotoxic (ADR) and immune mediated (NTS) forms of 
glomerular injury models in rodents to investigate the potential of TB4 to improve 
glomerular disease. Until now, the effect of exogenous TB4 in glomerular injury 
models was unknown, and this thesis has provided the first evidence that exogenous 
TB4 is effective in slowing the progression of glomerular injury and development of 
albuminuria in ADR nephropathy and NTS nephritis. Since the glomerular filtration 
barrier becomes permeable to albumin in pathology (Savin et al. 1996), it is likely 
that TB4 prevented glomerular filtration barrier damage in the ADR and NTS 
nephritis models used in this thesis. This could be proven by electron microscopy 
studies to examine the podocyte foot processes in high resolution. The preventative 
effects of TB4 to slow an increase in albuminuria are in agreement with previously 
published data. Loss of endogenous TB4 exacerbated an increase in albuminuria in 
NTS nephritis (Vasilopoulou et al. 2016). Tmsb4x knockout has also been shown to 
exacerbate albuminuria compared to wild-type littermates in the non-glomerular 
specific injury model of angiotensin-II induced hypertension (Kumar et al., 2018). 
Taken together, TB4 prevents an increase in albuminuria in a diverse range of 
pathological conditions, providing strong evidence that TB4 is protective of the 
glomerular filtration barrier.  
 
This thesis is the first study to examine the effect of exogenous TB4 specifically on 
injured podocytes in vitro and in vivo and it was shown that exogenous TB4 prevents 
podocyte loss in ADR nephropathy and NTS nephritis in vivo. However, exogenous 
TB4 was not able to prevent ADR-induced loss of podocyte viability in vitro. 
Differences in the culture conditions in vitro and the glomerular microenvironment in 
vivo could account for the variations in the data between the in vitro and in vivo 
studies. One major difference between the in vivo and in vitro conditions is the 
presence of blood flow in vivo, which circulating factors, such as nitric oxide that TB4 
has been induce production of (Ryu, Lee, and Moon 2015), that could have 
contributed synergistically with TB4 to the prevention of podocyte loss in vivo. 
Furthermore, the GBM in vivo is perfectly tailored for podocyte adhesion. Differences 
in the substrate stiffness between the GBM and Matrigel, the basement matrix that 
was used to culture the podocytes in vitro could have also contributed to 
discrepancies between the data in vivo and in vitro. The only previous study 
examining TB4 in podocytes in vivo focused on endogenous TB4 and quantified the 
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number of WT-1 positive cells in the glomerular tuft in NTS nephritis in Tmsb4x 
knockout and wild-type mice. Loss of endogenous TB4 exacerbated podocyte loss in 
NTS nephritis compared to wild-type mice with NTS nephritis (Vasilopoulou et al. 
2016). One potential mechanism for the TB4 induced protection of podocyte loss in 
vivo is by prevention of podocyte detachment. The F-actin cytoskeleton is linked to 
the podocyte adhesion molecules integrin and dystroglycan (Lennon, Randles, and 
Humphries 2014). Exogenous TB4 prevented ADR-induced podocyte F-actin 
disorganisation in vitro, it is therefore possible that exogenous TB4 may also protect 
the podocyte F-actin cytoskeleton in vivo, thus preventing disruption to podocyte 
adhesion molecules and podocyte detachment from the GBM. Detachment from the 
GBM could be proved by culturing the urine collected from the mice. If there were 
viable cells in the urine, that expressed podocyte markers such as nephrin or 
podocin, it could be concluded that the mechanism of podocyte loss in ADR 
nephropathy was by podocyte detachment. Another possible mechanism for the 
prevention of podocyte loss by exogenous TB4 in ADR and NTS glomerular injury in 
vivo is by prevention of apoptosis, as ADR been shown to induce podocyte 
apoptosis (Zou et al., 2010). Yuan et al. demonstrated that exogenous TB4 reduced 
the number of TUNEL positive tubular cells in response to TGF-b exposure in vitro, 
showing that TB4 can prevent apoptosis in kidney derived cells (Yuan et al. 2017). 
Exogenous TB4 has also been shown to prevent apoptosis by suppression of 
increase in the pro-apoptotic transcripts caspase-3 and Bax in cardiomyocytes (Wei 
et al. 2012). TUNEL staining could be undertaken on kidney sections to prove if this 
was the mechanism of podocyte loss in this thesis.  
 
This is the first study to quantify the amount of F-actin in injuryed podocytes in vivo. 
One of the major mechanisms proposed in this study is that exogenous TB4 does 
not alter the amount of podocyte F-actin but prevents disorganisation of the podocyte 
F-actin cytoskeleton, therefore preventing damage to the glomerular filtration barrier. 
Previously, loss of endogenous Tmsb4x was shown to cause increased RhoA 
activity, which was linked with increased podocyte cytoplasmic stress fibres in vitro 
(Vasilopoulou et al. 2016). There are differences in the actin arrangements observed 
following loss of TB4 or ADR injury, however, collectively these results demonstrate 
that TB4 can maintain F-actin organisation in podocytes. Overall, the results 
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presented in this thesis, along with previous literature, re-enforce the evidence that 
exogenous TB4 is protective of F-actin in pathological conditions. Future studies 
could examine Rho GTPase activation levels or the F-actin to G-actin ratio to 
elucidate the mechanisms that underlie the protective effects of TB4 on the podocyte 
cytoskeleton.  
 
An alternative mechanism that contributes to albuminuria is the vesicular 
transcytosis of albumin in podocytes from the bloodstream to the urinary space. This 
has been demonstrated in rodents as assessed by electron, confocal and intravital 
microscopy in experimental models of glomerular injury (Burford et al. 2017; 
Ichimura et al. 2019; Schießl et al. 2016). Increased prevalence of vesicles was 
observed in ADR nephropathy, which TB4 prevented. F-actin encapsulated vesicles 
were not observed in ADR-injury in vitro, likely due to the absence of a blood supple, 
therefore, an absence of albumin to trigger vesicle formation. Polymerisation of F-
actin is critical for the formation of endocytic vesicles (Hinze and Boucrot 2018), and 
since the major property of TB4 is to sequester G-actin, it is possible that G-actin 
sequestering prevented vesicle formation in ADR nephropathy. TB4 has been shown 
to reduce endocytic vesicle formation in vitro (Lamaze et al. 1997). TB4 has also 
been recently shown to bind to the endocytic receptor low density lipoprotein 
receptor related protein 1 (LRP1) (Munshaw et al. 2021). It has not yet been 
investigated whether TB4 interacts with receptors that facilitate albumin endocytosis 
and downstream processing in the kidney. Modulation of vesicle formation and 
transcytosis of albumin by exogenous TB4 may provide a novel strategy to prevent 
albuminuria in glomerular disease. Future studies could also perform 
immunofluorescent staining on kidneys with NTS nephritis, to investigate if vesicle 
formation was occurring in this immune mediated glomerular injury model.  
 
This thesis used two different glomerular injury models, ADR, which did not involve 
an inflammatory response, and NTS, which has a significant inflammatory 
component. Suppression of inflammation is a key characteristic of TB4 (Sosne, Qiu, 
and Kurpakus-Wheater 2007), and its anti-inflammatory properties have previously 
been showcased in kidney injury. Tmsb4x knockout in C57BL/6 mice exacerbated 
glomerular inflammation in both the NTS nephritis and angiotensin II hypertensive 
kidney injury models (Vasilopoulou et al., 2016; Kumar et al., 2018). Exogenous TB4 
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was also shown to suppress inflammatory cytokine levels such as NFkB, TNFa, IL-
1b and IL-6, in the IRI model of kidney injury compared to vehicle treated rats as 
shown by Western blot of whole kidney lysates (Aksu et al. 2019). Interestingly, TB4 
did not affect inflammation in the UUO model in C57BL/6 mice, as determined by 
F4/80 immunostaining, however, its metabolite AcSDKP significantly reduced 
glomerular macrophage accumulation compared to vehicle treated mice (Zuo et al. 
2013). It is possible that any anti-inflammatory effects that occurred in the NTS 
nephritis model, but not observed in this thesis such as T or B cell suppression, were 
due to AcSDKP, as TB4 is metabolised within 6 hours of generation (Mora et al. 
1997). To confirm if this is the case, the study could be repeated with the addition of 
a POP inhibitor, to prevent AcSDKP formation from TB4.  
 
Fibrosis is caused by prolonged injury, and the inflammatory response has been 
associated with increased fibrosis in the kidney (Lee and Kalluri 2010). Prevention of 
fibrosis is a major mechanism in which TB4 has been implicated as a beneficial 
agent in kidney injury. In the UUO model of kidney injury, daily injection of 150 µg of 
TB4 intraperitoneally prevented interstitial fibrosis as quantified by Sirius red staining 
(Zuo et al. 2013). This was mediated by suppressing PAI-1 and TGF-b signalling, as 
determined by Western blot experiments of whole kidney lysates (Zuo et al. 2013). 
Intragastric lavage administration of 1 mg/kg/day and 5 mg/kg/day of exogenous TB4 
reduced the protein levels of TGF-b, a-SMA and increased P-cadherin in the UUO 
model in Sprague-Dawley rats, as determined by Western blot (Yuan et al. 2017). In 
this thesis, it was shown that exogenous TB4 did not alter mRNA transcript levels of 
a-SMA and collagen IV in NTS nephritis. Future studies could determine if TB4 is 
alleviating fibrosis in the NTS and ADR models of glomerular injury by periodic acid 
Schiff or Sirius red staining, or quantifying the protein levels of fibrotic markers, such 
as TGF-b and a-SMA by Western blot. 
 
 Limitations and future perspectives 
The data presented in this thesis has demonstrated that exogenous TB4 is a 
beneficial molecule in the context of early glomerular injury by modulation of the 
podocyte cytoskeleton and inflammation. This thesis has provided groundwork for 
follow up studies examining TB4 in kidney disease. Pharmacological interventions to 
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treat CKD are often prescribed when the progression of CKD is too advanced, as a 
large proportion of patients are asymptomatic until kidney function is depleted (Hirst 
et al. 2020). The experimental models used in this thesis pre-treated mice with AAV 
encoding Tmsb4x prior to the induction of glomerular injury as a preventative 
strategy. This is a limitation, because if the use of AAV.Tmsb4x was to be translated 
to human glomerular injury, it would be a challenge to treat the population with 
AAV.Tmsb4x in the chance that they may develop ESKD. The preventative therapy 
strategy was used because the transcriptional activation window is variable when 
using AAV gene therapy (Lackner and Muzyczka 2002), making it difficult to induce 
systemic TB4 upregulation that coincides with the onset of glomerular injury. To 
circumvent this issue, future studies could perform a time course experiment to 
identify when circulating TB4 concentration peaks. Mice would be injected with 
5x1012 viral particles, the highest dose used in this thesis, and plasma extracted at 
day 0, 4, 7, 10, 14 and 21 after injection of AAV to determine when TB4 
concentration peaks. Using this data, the ADR and NTS experiments could be 
repeated to induce systemic upregulation of TB4 after the onset of glomerular injury, 
to examine whether TB4 can reverse glomerular pathologies, as well as preventing 
them in these experimental models.  
 
There were some differences in the efficacy of TB4 gene therapy suppressing 
increased albuminuria in ADR nephropathy and NTS nephritis in this thesis. 
Exogenous TB4 completely prevented the ADR-induced increase in albuminuria at 
14 days, but only suppressed the increase transiently at 7 days in NTS nephritis. 
There were variable factors between the experiments which could explain these 
differences, such as the severity of injury. The maximum average albuminuria value 
induced by ADR was 1,448 µg/24 hours at 14 days, whereas the NTS-induced 
albuminuria values reached ~10,000 µg/24 hours at 7 days and ~33,000 µg/24 hours 
at 21 days. It is possible that NTS induced too severe glomerular injury at 21 days 
and the systemic upregulation of TB4 was not enough to alleviate this. Another 
difference was the mechanism of damage. ADR induces a cytotoxic effect to 
podocytes (Papeta et al. 2010), whereas NTS nephritis induces an autoimmune 
response against the whole glomerulus (Khan et al. 2005). To determine if the cause 
of the variance in albuminuria was the experimental model used, the ADR 
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nephropathy experiment could be repeated, but instead of a 14-day end point, a 
longer exposure to ADR could be utilised. Prolonged ADR exposure would result in 
more severe damage to the podocytes, causing higher albuminuria values. If TB4 
was still able to fully prevent albuminuria, it could be postulated that exogenous TB4 
has a higher efficacy to prevent albuminuria in an injury model that specifically 
targets the podocytes. Taking this further, the experiment could also be repeated in 
other kidney injury models such as diabetic nephropathy. Diabetes is a disease that 
affects many other organs in the body, and glomerular filtration barrier damage is a 
co-morbidity of hyperglycaemia (Dronavalli et al. 2008). Exogenous TB4 has been 
shown to suppress microalbuminuria in a model of type 2 diabetic nephropathy, 
however, TB4 was administered by daily intraperitoneal injection, and the effects of 
exogenous TB4 on the glomeruli were not examined in great detail (Zhu et al. 2015). 
TB4 gene therapy could therefore be explored in other forms of glomerular and 
kidney injury to determine if the effect seen in ADR nephropathy and NTS nephritis is 
translatable.  
 
Another limitation of this thesis is the differences in the dosing of AAV between the 
two injury models, which could have contributed to differences in the ability of TB4 to 
prevent albuminuria. ADR treated mice were pre-treated with 5x1012 viral particles 
(Chapter 3) versus a lower dose of 2x1012 viral particles in the NTS experiment 
(Chapter 4). The liver mRNA levels of Tmsb4x were telling of this, as 5x1012 viral 
particles caused a 10-fold increase in Tmsb4x and 2x1012 viral particles only caused 
a 2.5-fold increase. Conversely, the TB4 ELISA of mouse plasmas indicated that 
5x1012 viral particles caused a 3.5-fold increase in plasma TB4 concentration, 
whereas 2x1012 viral particles increased plasma TB4 concentration by 10-fold. This 
difference could be due to a number of factors, such as the mouse strain (BALB/c vs 
C57BL/6), the quality of plasma extraction and handling of plasma, or the laboratory 
conditions in which the ELISA was undertaken. Future studies utilising AAV therapy 
should undertake dose response experiments, in order to identify the AAV titre that is 
most effective at combating glomerular injury. For example, mice could be injected 
with 2 x1012, 5 x1012, 8 x1012 and 1 x1013 viral particles alongside NTS to examine if 
a higher viral load could further prevent increased albuminuria.  
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Delivery of TB4 to the podocytes via AAV injection has not been proven. It was 
shown that there was no upregulation of Tmsb4x mRNA in the kidneys, suggested 
that viral transduction did not occur in the kidneys. The glomeruli and podocytes both 
expressed TB4 at high levels in this thesis. There is an abundance of TB4 in healthy 
and diseased kidneys, making it difficult to distinguish between endogenous and 
exogenous TB4. In addition, due to its small molecular weight (~4kDa) (Safer et al. 
1991), quantification of TB4 by Western blot is challenging. Future studies could use 
Tmsb4x knockout mice (Vasilopoulou et al. 2016), administer AAV.Tmsb4x and then 
perform IHC experiments on kidney sections to identify and localise viral TB4 
peptide. An additional control group injecting mice with only PBS (the vehicle that the 
viral particles were diluted in) could have been included in order to rule out any 
effects caused by hepatic viral transduction. 
 
The reduction in albuminuria in ADR nephropathy and NTS nephritis provides strong 
evidence that TB4 gene therapy is protective of the final component of the 
glomerular filtration barrier. The definitive way to prove that the glomerular filtration 
barrier is protected by TB4 would be electron microscopy. Electron microscopy offers 
high resolving power compared with fluorescence and light microscopy, meaning 
that individual podocyte foot processes can be clearly imaged. Foot process 
effacement is a defining characteristic of glomerular filtration barrier break down 
(Deegens et al. 2008). Use of electron microscopy to image the podocyte foot 
processes in ADR nephropathy and NTS nephritis with and without TB4 gene 
therapy would conclusively prove if TB4 was protective of the final component 
glomerular filtration barrier; the podocyte foot processes, as they could be clearly 
visualised. Furthermore, the use of gold-conjugated antibodies with electron 
microscopy allows protein expression to be identified and localised to subcellular 
compartments (Peters, Bos, and Griekspoor 2006). Immunogold labelling has 
previously been used to identify foot process F-actin reorganisation in NTS nephritis 
(Shirato et al., 1996), therefore, future studies could quantify podocyte F-actin 
disorganisation in ADR and NTS nephropathy in vivo using this method of imaging. 
 
The glomerular filtration barrier is composed of three components; the podocytes, 
GBM and capillary endothelial cells (Patrakka and Tryggvason 2010). Mesangial 
cells also constitute a significant proportion of the glomerular tuft (Shoskes and 
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McMahon 2012). TB4 was identified to be a therapeutic molecule in the context of 
podocyte injury in this thesis, however, as the in vivo experiments induced a 
systemic upregulation of TB4, the GBM, mesangium and endothelium would have 
also been exposed to exogenous TB4. Damage to the endothelium has been 
associated with increased albuminuria in diabetic nephropathy (Weil et al. 2012), 
ADR nephropathy (Sun et al. 2013) and NTS nephritis (Kirsch et al. 2012). 
Alterations to the glomerular mesangial matrix have also been implicated in the 
progression of diabetic nephropathy (Tung et al. 2018) and nephrotoxic serum 
nephritis (Toda et al. 2017). The data from the ADR in vivo chapter (0) showed that 
ADR injury reduced the amount of total glomerular F-actin compared to saline 
treated mice. TB4 gene therapy prevented this change and preserved the amount of 
glomerular F-actin following ADR injury. Further investigation showed that the 
amount of F-actin in podocytes was unchanged in response to ADR injury with and 
without TB4 gene therapy. It is therefore possible that alterations to the amount of 
glomerular F-actin were localised to either the mesangium or capillary endothelium, 
as both cell types contain F-actin (Cortes et al. 2000). Therefore, follow up studies 
could quantify F-actin in those cells in vivo and culture glomerular mesangial cells or 
endothelial cells in vitro, to determine if ADR or NTS induces cytoskeletal changes in 
each respective cell type, and examine if TB4 prevents these potential changes.  
 
To fully elucidate the role of endogenous TB4 in podocyte health and disease, a 
mouse line with podocyte-specific knockout of TB4 could be generated. This would 
involve generating a mouse line with the Cre-recombinase gene tagged to Nphs2 so 
that Cre-recombinase is specifically expressed in the podocytes (Papakrivopoulou et 
al., 2018). These mice would then be crossed with mice expressing TB4-LoxP 
(although this mouse line has not been generated yet), which would insert two LoxP 
sites into intron regions that flank one exon of the Tmsb4x gene. Cre-mediated 
excision of the LoxP flanked regions would result in in vivo deletion of Tmsb4x gene, 
and therefore deletion of TB4 peptide in podocytes (Friedel et al. 2011). These mice 
without podocyte expression of TB4 would then be treated with ADR and NTS to 
determine if the effects of each experimental model are exacerbated. To take this 
further, these mice could be exposed to ADR or NTS after pre-treatment with 
AAV.Tmsb4x, which could determine if exogenous TB4 in the absence of 
endogenous TB4 is sufficient to prevent glomerular damage.  
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The sample sizes in the NTS nephritis chapter were another limitation of this thesis. 
Although the Tmsb4x/NTS group had an adequate sample size of 10, the PBS and 
LacZ treated mice only had 5 and 4 mice in them respectively. This could account for 
discrepancies seen within the chapter, such as the glomerular macrophage 
accumulation, where PBS/NTS mice displayed more macrophages than 
Tmsb4x/NTS, but LacZ/NTS treated mice showed less than Tmsb4x/NTS mice. 
There were also differences between the number of proliferating glomerular cells and 
podocytes between the PBS/NTS and LacZ/NTS groups, which could have been due 
to low samples sizes. In order to eliminate this limitation, the experiment could be 
repeated with more mice in each group, which would give each statistical calculation 
more power, increasing the reliability of the results.  
 
Long term, the data presented in this thesis and previously published research 
suggest that exogenous TB4 may be a therapeutic option that could translate to 
human glomerular injury. Exogenous TB4 is already used clinically to treat eye 
disorders and is in clinical trials for a range of other pathologies, with little 
unexpected adverse events (Sosne, 2018, 1.6.6). Further pre-clinical trials for use in 
kidney disease are necessary. Models of glomerular injury with TB4 gene therapy 
could be induced in greater mammals, such as non-human primates to determine if 




 General conclusion 
In conclusion, the data presented in this thesis provides strong experimental 
evidence that sustained upregulation of exogenous TB4 prevents early glomerular 
filtration barrier damage in two models of glomerular disease, ADR nephropathy and 
NTS nephritis. The proposed mechanism of action is that TB4 protects podocyte F-
actin distribution and prevents podocyte loss, independent of inflammation 
suppression, therefore preserving the final component of the glomerular filtration 
barrier. Taken together, these results provide strong evidence that exogenous TB4 
alleviates the phenotypes of glomerular injury in rodents and future studies further 
investigating the underlying mechanisms of its protective effects are justified. 
Identification of novel therapeutic molecules to alleviate glomerular injury are crucial 
to develop therapeutic strategies to combat CKD in humans. 
  
 225 
Chapter 6: Bibliography 
Aksu, Ugur, Onur M. Yaman, Ibrahim Guner, Gulcan Guntas, Fuat Sonmez, Gamze 
Tanriverdi, Mediha Eser, Aris Cakiris, Sibel Akyol, İsmail Seçkin, Hafize Uzun, 
Nermin Yelmen, and Gulderen Sahin. 2019. “The Protective Effects of 
Thymosin-β-4 in a Rat Model of Ischemic Acute Kidney Injury.” Journal of 
Investigative Surgery 8:1–9. 
Almaani, Salem, Alexa Meara, and Brad H. Rovin. 2017. “Update on Lupus 
Nephritis.” Clinical Journal of the American Society of Nephrology 12(5):825–35. 
Amr, Khalda, Hala T. El-Bassyouni, Eman Rabie, Abeer Selim, Moushira E. Zaki, 
Eman Abobakr Abd Alazem, Shereen El-Shaer, Sahar Rady, and Doaa M. 
Salah. 2020. “A Descriptive Study of NPHS1 and NPHS2 Mutations in Children 
with Congenital Nephrotic Syndrome.” Gene Reports 20:100722. 
Amura, Claudia R., R. Silverstein, and D. C. Morrison. 1998. “Mechanisms Involved 
in the Pathogenesis of Sepsis Are Not Necessarily Reflected by in Vitro Cell 
Activation Studies.” Infection and Immunity 66(11):5372–78. 
Andrews, Peter M. 1977. “The Effect of Vinblastine-Induced Microtubule Loss on 
Kidney Podocyte Morphology.” American Journal of Anatomy 150(1):53–61. 
Andrianantoandro, Ernesto and Thomas D. Pollard. 2006. “Mechanism of Actin 
Filament Turnover by Severing and Nucleation at Different Concentrations of 
ADF/Cofilin.” Molecular Cell 24(1):13–23. 
Anon. 2021. “RegeneRx Biopharmaceuticals, Inc.” Retrieved January 20, 2021 
(http://www.regenerx.com/home). 
Applewhite, Derek A., Melanie Barzik, Shin Ichiro Kojima, Tatyana M. Svitkina, Frank 
B. Gertler, and Gary G. Borisy. 2007. “Ena/VASP Proteins Have an Anti-
Capping Independent Function in Filopodia Formation.” Molecular Biology of the 
Cell 18(7):2579–91. 
Arends, Jon, Jean Wu, Jason Borillo, Luan Troung, Cindy Zhou, Nadarajah 
Vigneswaran, and Ya-Huan Lou. 2006. “T Cell Epitope Mimicry in 
Antiglomerular Basement Membrane Disease.” The Journal of Immunology 
176(2):1252–58. 
Arkill, Kenton P., Klaus Qvortrup, Tobias Starborg, Judith M. Mantell, Carlo Knupp, 
C. Charles Michel, Steve J. Harper, Andy H. Salmon, John M. Squire, Dave O. 
Bates, and Chris R. Neal. 2014. “Resolution of the Three Dimensional Structure 
 226 
of Components of the Glomerular Filtration Barrier.” BMC Nephrology 15(1):1–
13. 
Aronson, Doron, Murray A. Mittleman, and Andrew J. Burger. 2004. “Elevated Blood 
Urea Nitrogen Level as a Predictor of Mortality in Patients Admitted for 
Decompensated Heart Failure.” The American Journal of Medicine 116(7):466–
73. 
Asanuma, Katsuhiko, Kwanghee Kim, Jun Oh, Laura Giardino, Sophie Chabanis, 
Christian Faul, Jochen Reiser, and Peter Mundel. 2005. “Synaptopodin 
Regulates the Actin-Bundling Activity of α-Actinin in an Isoform-Specific 
Manner.” Journal of Clinical Investigation 115(5):1188–98. 
Asanuma, Katsuhiko, Etsuko Yanagida-Asanuma, Christian Faul, Yasuhiko Tomino, 
Kwanghee Kim, and Peter Mundel. 2006. “Synaptopodin Orchestrates Actin 
Organization and Cell Motility via Regulation of RhoA Signalling.” Nature Cell 
Biology 8(5):485–91. 
Assmann, Karel J. M., Martina M. Tangelder, Will P. J. Lange, Gideon Schrijver, and 
Robert AP Koene. 1985. “Anti-GBM Nephritis in the Mouse: Severe Proteinuria 
in the Heterologous Phase.” Virchows Archiv A Pathological Anatomy and 
Histopathology 406(3):285–99. 
Atkinson, Simon J., Melanie A. Hosford, and Bruce A. Molitoris. 2004. “Mechanism of 
Actin Polymerization in Cellular ATP Depletion.” Journal of Biological Chemistry 
279(7):5194–99. 
Austyn, Jonathan M. and Siamon Gordon. 1981. “F4/80, a Monoclonal Antibody 
Directed Specifically against the Mouse Macrophage.” European Journal of 
Immunology 11(10):805–15. 
Azizi, Michel, Eric Ezan, Jean Luc Reny, Joanna Wdzieczak-Bakala, Vincent 
Gerineau, and Joël Ménard. 1999. “Renal and Metabolic Clearance of N-Acetyl-
Seryl-Aspartyl-Lysyl-Proline (AcSDKP) during Angiotensin-Converting Enzyme 
Inhibition in Humans.” Hypertension 33(3):879–86. 
Bachmann, Christiane, Lieselore Fischer, Ulrich Walter, and Matthias Reinhard. 
1999. “The EVH2 Domain of the Vasodilator-Stimulated Phosphoprotein 
Mediates Tetramerization, F-Actin Binding, and Actin Bundle Formation.” 
Journal of Biological Chemistry 274(33):23549–57. 
Badamchian, Mahnaz, Mirela O. Fagarasan, Robert L. Danner, Anthony F. 
Suffredini, Hadi Damavandy, and Allan L. Goldstein. 2003. “Thymosin Β4 
 227 
Reduces Lethality and Down-Regulates Inflammatory Mediators in Endotoxin-
Induced Septic Shock.” International Immunopharmacology 3(8):1225–33. 
Bakris, George L., Rajiv Agarwal, Juliana C. Chan, Mark E. Cooper, Ron T. 
Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E. 
Schmieder, Christina Nowack, Peter Kolkhof, Amer Joseph, Alexander Pieper, 
Nina Kimmeskamp-Kirschbaum, and Luis M. Ruilope. 2015. “Effect of 
Finerenone on Albuminuria in Patients with Diabetic Nephropathy a 
Randomized Clinical Trial.” Journal of the American Medical Association 
314(9):884–94. 
Ball, Linda J., Thomas Jarchau, Hartmut Oschkinat, and Ulrich Walter. 2002. “EVH1 
Domains: Structure, Function and Interactions.” FEBS Letters 513(1):45–52. 
Bao, Weike, Victoria L. Ballard, Saul Needle, Bao Hoang, Stephen C. Lenhard, 
James R. Tunstead, Beat M. Jucker, Robert N. Willette, and G. Teg Pipes. 
2013. “Cardioprotection by Systemic Dosing of Thymosin Beta Four Following 
Ischemic Myocardial Injury.” Frontiers in Pharmacology 4:149. 
Barletta, Gina-Marie, Iulia A. Kovari, Rakesh K. Verma, Dontscho Kerjaschki, and 
Lawrence B. Holzman. 2003. “Nephrin and Neph1 Co-Localize at the Podocyte 
Foot Process Intercellular Junction and Form Cis Hetero-Oligomers.” Journal of 
Biological Chemistry 278(21):19266–71. 
Beijing Northland Biotech. Co. Ltd. 2021. “NL005.” Retrieved (http://www.northland-
bio.com/onepage9.html). 
Beijing Northland Biotech. Co. Ltd. - NCT04555850. 2020. “A Phase 1b Study of 
Thymosin Beta 4 in Healthy Volunteers - Full Text View - ClinicalTrials.Gov.” 
ClinicalTrials.Gov. Retrieved January 21, 2021 
(https://clinicaltrials.gov/ct2/show/NCT04555850?term=thymosin+beta+4&draw=
2&rank=9). 
Beijing Northland Biotech. Co. Ltd - NCT04555824. 2020. “A Phase 1a Study of 
Thymosin Beta 4 in Healthy Volunteers - Full Text View - ClinicalTrials.Gov.” 
ClinicalTrials.Gov. Retrieved January 21, 2021 
(https://clinicaltrials.gov/ct2/show/NCT04555824?term=thymosin+beta+4&draw=
2&rank=10). 
Berasain, Carmen and Matías A. Avila. 2015. “Regulation of Hepatocyte Identity and 
Quiescence.” Cellular and Molecular Life Sciences 72(20):3831–51. 
Berg, Anna-Lena and Peter Nilsson-Ehle. 1996. “ACTH Lowers Serum Lipids in 
 228 
Steroid-Treated Hyperlipemic Patients with Kidney Disease.” Kidney 
International 50:538–42. 
Berger, James M., Steven J. Gamblin, Stephen C. Harrison, and James C. Wang. 
1996. “Structure and Mechanism of DNA Topoisomerase II.” Nature 
379(6562):225–32. 
Bernstein, Barbara W. and James R. Bamburg. 2010. “ADF/Cofilin: A Functional 
Node in Cell Biology.” Trends in Cell Biology 20(4):187–95. 
Bertani, T., A. Poggi, R. Pozzoni, F. Delaini, G. Sacchi, Y. Thoua, G. Mecca, G. 
Remuzzi, and M. B. Donati. 1982. “Adriamycin-Induced Nephrotic Syndrome in 
Rats. Sequence of Pathologic Events.” Laboratory Investigation 46(1):16–23. 
Bertani, Tullio, Giovanna Rocchi, Giuseppe Sacchi, Giuliano Mecca, and Giuseppe 
Remuzzi. 1986. “Adriamycin-Induced Glomerulosclerosis in the Rat.” American 
Journal of Kidney Diseases 7(1):12–19. 
Bertram, John F., Rebecca N. Douglas-Denton, Boucar Diouf, Michael D. Hughson, 
and Wendy E. Hoy. 2011. “Human Nephron Number: Implications for Health and 
Disease.” Pp. 1529–33 in Pediatric Nephrology. Vol. 26. Springer. 
Besse-Eschmann, Valérie, Michel Le Hir, Nicole Endlich, and Karlhans Endlich. 
2004. “Alterations of Podocytes in a Murine Model of Crescentic 
Glomerulonephritis.” Histochemistry and Cell Biology 122(2):139–49. 
Bharakhada, Nilesh, Thomas Yates, Melanie J. Davies, Emma G. Wilmot, Charlotte 
Edwardson, Joe Henson, David Webb, and Kamlesh Khunti. 2012. “Association 
of Sitting Time and Physical Activity with CKD: A Cross-Sectional Study in 
Family Practices.” American Journal of Kidney Diseases 60(4):583–90. 
Bierzynska, Agnieszka, Katrina Soderquest, and Ania Koziell. 2014. “Genes and 
Podocytes - New Insights into Mechanisms of Podocytopathy.” Frontiers in 
Endocrinology 5:23. 
Bikbov, Boris, Caroline A. Purcell, Andrew S. Levey, Mari Smith, Amir Abdoli, Molla 
Abebe, Oladimeji M. Adebayo, Mohsen Afarideh, Sanjay Kumar Agarwal, 
Marcela Agudelo-Botero, Elham Ahmadian, Ziyad Al-Aly, Vahid Alipour, Amir 
Almasi-Hashiani, Rajaa M. Al-Raddadi, Nelson Alvis-Guzman, Saeed Amini, 
Tudorel Andrei, Catalina Liliana Andrei, Zewudu Andualem, Mina Anjomshoa, 
Jalal Arabloo, Alebachew Fasil Ashagre, Daniel Asmelash, Zerihun Ataro, Maha 
Moh d. Wahb. Atout, Martin Amogre Ayanore, Alaa Badawi, Ahad Bakhtiari, 
Shoshana H. Ballew, Abbas Balouchi, Maciej Banach, Simon Barquera, Sanjay 
 229 
Basu, Mulat Tirfie Bayih, Neeraj Bedi, Aminu K. Bello, Isabela M. Bensenor, Ali 
Bijani, Archith Boloor, Antonio M. Borzì, Luis Alberto Cámera, Juan J. Carrero, 
Félix Carvalho, Franz Castro, Ferrán Catalá-López, Alex R. Chang, Ken Lee 
Chin, Sheng Chia Chung, Massimo Cirillo, Ewerton Cousin, Lalit Dandona, 
Rakhi Dandona, Ahmad Daryani, Rajat Das Gupta, Feleke Mekonnen Demeke, 
Gebre Teklemariam Demoz, Desilu Mahari Desta, Huyen Phuc Do, Bruce B. 
Duncan, Aziz Eftekhari, Alireza Esteghamati, Syeda Sadia Fatima, João C. 
Fernandes, Eduarda Fernandes, Florian Fischer, Marisa Freitas, Mohamed M. 
Gad, Gebreamlak Gebremedhn Gebremeskel, Begashaw Melaku 
Gebresillassie, Birhanu Geta, Mansour Ghafourifard, Alireza Ghajar, Nermin 
Ghith, Paramjit Singh Gill, Ibrahim Abdelmageed Ginawi, Rajeev Gupta, Nima 
Hafezi-Nejad, Arvin Haj-Mirzaian, Arya Haj-Mirzaian, Ninuk Hariyani, Mehedi 
Hasan, Milad Hasankhani, Amir Hasanzadeh, Hamid Yimam Hassen, Simon I. 
Hay, Behnam Heidari, Claudiu Herteliu, Chi Linh Hoang, Mostafa Hosseini, 
Mihaela Hostiuc, Seyed Sina Naghibi Irvani, Sheikh Mohammed Shariful Islam, 
Nader Jafari Balalami, Spencer L. James, Simerjot K. Jassal, Vivekanand Jha, 
Jost B. Jonas, Farahnaz Joukar, Jacek Jerzy Jozwiak, Ali Kabir, Amaha 
Kahsay, Amir Kasaeian, Tesfaye Dessale Kassa, Hagazi Gebremedhin 
Kassaye, Yousef Saleh Khader, Rovshan Khalilov, Ejaz Ahmad Khan, 
Mohammad Saud Khan, Young Ho Khang, Adnan Kisa, Csaba P. Kovesdy, 
Barthelemy Kuate Defo, G. Anil Kumar, Anders O. Larsson, Lee Ling Lim, Alan 
D. Lopez, Paulo A. Lotufo, Azeem Majeed, Reza Malekzadeh, Winfried März, 
Anthony Masaka, Hailemariam Abiy Alemu Meheretu, Tomasz Miazgowski, 
Andreea Mirica, Erkin M. Mirrakhimov, Prasanna Mithra, Babak Moazen, Dara 
K. Mohammad, Reza Mohammadpourhodki, Shafiu Mohammed, Ali H. Mokdad, 
Linda Morales, Ilais Moreno Velasquez, Seyyed Meysam Mousavi, Satinath 
Mukhopadhyay, Jean B. Nachega, Girish N. Nadkarni, Jobert Richie Nansseu, 
Gopalakrishnan Natarajan, Javad Nazari, Bruce Neal, Ruxandra Irina Negoi, 
Cuong Tat Nguyen, Rajan Nikbakhsh, Jean Jacques Noubiap, Christoph 
Nowak, Andrew T. Olagunju, Alberto Ortiz, Mayowa Ojo Owolabi, Raffaele 
Palladino, Mona Pathak, Hossein Poustchi, Swayam Prakash, Narayan Prasad, 
Alireza Rafiei, Sree Bhushan Raju, Kiana Ramezanzadeh, Salman Rawaf, 
David Laith Rawaf, Lal Rawal, Robert C. Reiner, Aziz Rezapour, Daniel Cury 
Ribeiro, Leonardo Roever, Dietrich Rothenbacher, Godfrey M. Rwegerera, 
 230 
Seyedmohammad Saadatagah, Saeed Safari, Berhe Weldearegawi Sahle, 
Hosni Salem, Juan Sanabria, Itamar S. Santos, Arash Sarveazad, Monika 
Sawhney, Elke Schaeffner, Maria Inês Schmidt, Aletta Elisabeth Schutte, Sadaf 
G. Sepanlou, Masood Ali Shaikh, Zeinab Sharafi, Mehdi Sharif, Amrollah Sharifi, 
Diego Augusto Santos Silva, Jasvinder A. Singh, Narinder Pal Singh, Malede 
Mequanent M. Sisay, Amin Soheili, Ipsita Sutradhar, Berhane Fseha 
Teklehaimanot, Berhe etsay Tesfay, Getnet Fetene Teshome, Jarnail Singh 
Thakur, Marcello Tonelli, Khanh Bao Tran, Bach Xuan Tran, Candide Tran 
Ngoc, Irfan Ullah, Pascual R. Valdez, Santosh Varughese, Theo Vos, Linh Gia 
Vu, Yasir Waheed, Andrea Werdecker, Haileab Fekadu Wolde, Adam Belay 
Wondmieneh, Sarah Wulf Hanson, Tomohide Yamada, Yigizie Yeshaw, Naohiro 
Yonemoto, Hasan Yusefzadeh, Zoubida Zaidi, Leila Zaki, Sojib Bin Zaman, 
Nelson Zamora, Afshin Zarghi, Kaleab Alemayehu Zewdie, Johan Ärnlöv, Josef 
Coresh, Norberto Perico, Giuseppe Remuzzi, and Chris J. L. Murray. 2020. 
“Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: 
A Systematic Analysis for the Global Burden of Disease Study 2017.” The 
Lancet 395(10225):709–33. 
Bilancia, Colleen G., Jonathan D. Winkelman, Denis Tsygankov, Stephanie H. 
Nowotarski, Jennifer A. Sees, Kate Comber, Iwan Evans, Vinal Lakhani, Will 
Wood, Timothy C. Elston, David R. Kovar, and Mark Peifer. 2014. “Enabled 
Negatively Regulates Diaphanous-Driven Actin Dynamics in Vitro and in Vivo.” 
Developmental Cell 28(4):394–408. 
Birmingham, Daniel J. and Lee A. Hebert. 2015. “The Complement System in Lupus 
Nephritis.” Seminars in Nephrology 35(5):444–54. 
Blaine, Judith and James Dylewski. 2020. “Regulation of the Actin Cytoskeleton in 
Podocytes.” Cells 9(7):1700. 
Bock-Marquette, I., A. Saxena, M. White, J. DiMaio, and D. Srivastava. 2004. 
“Thymosin Beta4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell 
Migration, Survival and Cardiac Repair.” Nature 432:466–72. 
Bongiovanni, D, T. Ziegler, S. D’Almeida, T. Zhang, J. K. Ng, S. Dietzel, R. Hinkel, 
and C. Kupatt. 2015. “Thymosin Beta4 Attenuates Microcirculatory and 
Hemodynamic Destabilization in Sepsis.” Expert Opin Biol Ther 15 Suppl 
1:S203-10. 
Bongiovanni, Dario, Tilman Ziegler, Sascha D’almeida, Tianqiong Zhang, Judy Km 
 231 
Ng, Steffen Dietzel, Rabea Hinkel, and Christian Kupatt. 2015. “Thymosin Β4 
Attenuates Microcirculatory and Hemodynamic Destabilization in Sepsis.” Expert 
Opinion on Biological Therapy  15(Sup1):203–10. 
Boucrot, Emmanuel, Saveez Saffarian, Ramiro Massol, Tomas Kirchhausen, and 
Marcelo Ehrlich. 2006. “Role of Lipids and Actin in the Formation of Clathrin-
Coated Pits.” Experimental Cell Research 312(20):4036–48. 
Boukhalfa, G., A. Desmoulière, E. Rondeau, G. Gabbiani, and J. .. Sraer. 1996. 
“Relationship between Alpha-Smooth Muscle Actin Expression and Fibrotic 
Changes in Human Kidney - PubMed.” Experimental Nephrology 4(4):241–47. 
Boute, Nicolas, Olivier Gribouval, Séverine Roselli, France Benessy, Hyunjoo Lee, 
Arno Fuchshuber, Karin Dahan, Marie Claire Gubler, Patrick Niaudet, and 
Corinne Antignac. 2000. “NPHS2, Encoding the Glomerular Protein Podocin, Is 
Mutated in Autosomal Recessive Steroid-Resistant Nephrotic Syndrome.” 
Nature Genetics 24(4):349–54. 
Braam, Branko, Kenneth D. Mitchell, John Fox, L. Gabriel Navar, and L. Gabriel 
Navar Proximal. 1993. “Proximal Tubular Secretion of Angiotensin II in Rats.” 
American Phsiological Society 264(33):F891–98. 
Brähler, Sebastian, Haiyang Yu, Hani Suleiman, Gokul M. Krishnan, Brian T. 
Saunders, Jeffrey B. Kopp, Jeffrey H. Miner, Bernd H. Zinselmeyer, and Andrey 
S. Shaw. 2016. “Intravital and Kidney Slice Imaging of Podocyte Membrane 
Dynamics.” Journal of the American Society of Nephrology 27:3285–90. 
Breitsprecher, Dennis, Antje K. Kiesewetter, Joern Linkner, Marlene Vinzenz, 
Theresia E. B. Stradal, John Victor Small, Ute Curth, Richard B. Dickinson, and 
Jan Faix. 2011. “Molecular Mechanism of Ena/VASP-Mediated Actin-Filament 
Elongation.” The EMBO Journal 30(3):456–67. 
Brieher, William. 2013. “Mechanisms of Actin Disassembly.” Molecular Biology of the 
Cell 24(15):2299–2302. 
Brinkkoetter, Paul Thomas, Christina Ising, and Thomas Benzing. 2013. “The Role of 
the Podocyte in Albumin Filtration.” Nature Reviews Nephrology 9(6):328–36. 
Brown, Matthew D. and David B. Sacks. 2006. “IQGAP1 in Cellular Signaling: 
Bridging the GAP.” Trends in Cell Biology 16(5):242–49. 
Bruggeman, Leslie A., Paul E. Drawz, Nicole Kahoud, Ke Lin, Laura Barisoni, and 
Peter J. Nelson. 2011. “TNFR2 Interposes the Proliferative and NF-B-Mediated 
Inflammatory Response by Podocytes to TNF-α.” Laboratory Investigation 
 232 
91(3):413–25. 
Brunskill, Eric W., Joo-Seop Park, Eunah Chung, Feng Chen, Bliss Magella, and 
Steven S. Potter. 2014. “Single Cell Dissection of Early Kidney Development: 
Multilineage Priming.” Development 141:3093–3101. 
Bubb, Michael R., Elena G. Yarmola, Bruce G. Gibson, and Frederick S. Southwick. 
2003. “Depolymerization of Actin Filaments by Profilin: Effects of Profilin on 
Capping Protein Function.” Journal of Biological Chemistry 278(27):24629–35. 
Bundy, Joshua D., Lydia A. Bazzano, Dawei Xie, Janet Cohan, Jacqueline Dolata, 
Jeffrey C. Fink, Chi Yuan Hsu, Kenneth Jamerson, James Lash, Gail Makos, 
Susan Steigerwalt, Xue Wang, Katherine T. Mills, Jing Chen, Jiang He, 
Lawrence J. Appel, Harold I. Feldman, Alan S. Go, John W. Kusek, Akinlolu Ojo, 
Mahboob Rahman, and Raymond R. Townsend. 2018. “Self-Reported Tobacco, 
Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease.” 
Clinical Journal of the American Society of Nephrology 13(7):993–1001. 
Burford, James L., Georgina Gyarmati, Isao Shirato, Wilhelm Kriz, Kevin V. Lemley, 
and János Peti-Peterdi. 2017. “Combined Use of Electron Microscopy and 
Intravital Imaging Captures Morphological and Functional Features of Podocyte 
Detachment.” Pflugers Archiv - European Journal of Physiology 469:965–74. 
Burford, James L., Karie Villanueva, Lisa Lam, Anne Riquier-Brison, Matthias J. 
Hackl, Jeffrey Pippin, Stuart J. Shankland, and János Peti-Peterdi. 2014. 
“Intravital Imaging of Podocyte Calcium in Glomerular Injury and Disease.” 
Journal of Clinical Investigation 124(5):2050–58. 
Burke, James F., J. Frederick Laucius, Harvey S. Brodovsky, and Raymond Z. 
Soriano. 1977. “Doxorubicin Hydrochloride-Associated Renal Failure.” Archives 
of Internal Medicine 137(3):385–88. 
Butler, Andrew, Paul Hoffman, Peter Smibert, Efthymia Papalexi, and Rahul Satija. 
2018. “Integrating Single-Cell Transcriptomic Data across Different Conditions, 
Technologies, and Species.” Nature Biotechnology 36(5):411–20. 
Butt, Linus, David Unnersjö-Jess, Martin Höhne, Aurelie Edwards, Julia Binz-Lotter, 
Dervla Reilly, Robert Hahnfeldt, Vera Ziegler, Katharina Fremter, Markus M. 
Rinschen, Martin Helmstädter, Lena K. Ebert, Hayo Castrop, Matthias J. Hackl, 
Gerd Walz, Paul T. Brinkkoetter, Max C. Liebau, Kálmán Tory, Peter F. Hoyer, 
Bodo B. Beck, Hjalmar Brismar, Hans Blom, Bernhard Schermer, and Thomas 
Benzing. 2020. “A Molecular Mechanism Explaining Albuminuria in Kidney 
 233 
Disease.” Nature Metabolism 1–14. 
Buvall, Lisa, Priyanka Rashmi, Esther Lopez-Rivera, Svetlana Andreeva, Astrid 
Weins, Hanna Wallentin, Anna Greka, and Peter Mundel. 2013. “Proteasomal 
Degradation of Nck1 but Not Nck2 Regulates RhoA Activation and Actin 
Dynamics.” Nature Communications 4:2863. 
Buvall, Lisa, Hanna Wallentin, Jonas Sieber, Svetlana Andreeva, Hoon Young Choi, 
Peter Mundel, and Anna Greka. 2017. “Synaptopodin Is a Coincidence Detector 
of Tyrosine versus Serine/Threonine Phosphorylation for the Modulation of Rho 
Protein Crosstalk in Podocytes.” Journal of the American Society of Nephrology 
28(3):837–51. 
Call, Matthew E., Jason Pyrdol, Martin Wiedmann, and Kai W. Wucherpfennig. 2002. 
“The Organizing Principle in the Formation of the T Cell Receptor-CD3 
Complex.” Cell 111(7):967–79. 
Carlier, Marie-France, Catherine Jean, Klaus J. Riegert, Maryse Lenfantt, and 
Dominique Pantaloni. 1993. “Modulation of the Interaction between G-Actin and 
Thymosin I4 by the ATP/ADP Ratio: Possible Implication in the Regulation of 
Actin Dynamics.” Biochemistry 90:5034–38. 
Carliers, Marie-France, Dominique Pantalonis, and Edward D. Korns. 1987. “The 
Mechanisms of ATP Hydrolysis Accompanying the Polymerization of Mg-Actin 
and Ca-Actin.” The Journal of Biological Chemistry 262(7):3052–59. 
Carroll, Thomas J., Joo Seop Park, Shigemi Hayashi, Arindam Majumdar, and 
Andrew P. McMahon. 2005. “Wnt9b Plays a Central Role in the Regulation of 
Mesenchymal to Epithelial Transitions Underlying Organogenesis of the 
Mammalian Urogenital System.” Developmental Cell 9(2):283–92. 
Cassimeris, Lynne, Daniel Safer, Vivianne T. Nachmias, and S. H. Zigmond. 1992. 
“Thymosin Β4 Sequesters the Majority of G-Actin in Resting Human 
Polymorphonuclear Leukocytes.” Journal of Cell Biology 119(5):1261–70. 
Castoldi, G., C. R. T. Di Gioia, C. Bombardi, C. Preziuso, M. Leopizzi, S. Maestroni, 
B. Corradi, G. Zerbini, and A. Stella. 2013. “Renal Antifibrotic Effect of N-Acetyl-
Seryl-Aspartyl-Lysyl-Proline in Diabetic Rats.” American Journal of Nephrology 
37(1):65–73. 
Castrop, Hayo, Klaus Höcherl, Armin Kurtz, Frank Schweda, Vladimir Todorov, and 
Charlotte Wagner. 2010. “Physiology of Kidney Renin.” Physiological Reviews 
90(2):607–73. 
 234 
Cattran, Daniel C., Rosanna Coppo, H. Terence Cook, John Feehally, Ian S. D. 
Roberts, Stéphan Troyanov, Charles E. Alpers, Alessandro Amore, Jonathan 
Barratt, Francois Berthoux, Stephen Bonsib, Jan A. Bruijn, Vivette D’Agati, 
Giuseppe D’Amico, Steven Emancipator, Francesco Emma, Franco Ferrario, 
Fernando C. Fervenza, Sandrine Florquin, Agnes Fogo, Colin C. Geddes, 
Hermann Josef Groene, Mark Haas, Andrew M. Herzenberg, Prue A. Hill, 
Ronald J. Hogg, Stephen I. Hsu, J. Charles Jennette, Kensuke Joh, Bruce A. 
Julian, Tetsuya Kawamura, Fernand M. Lai, Chi Bon Leung, Lei Shi Li, Philip K. 
T. Li, Zhi Hong Liu, Bruce MacKinnon, Sergio Mezzano, F. Paolo Schena, 
Yasuhiko Tomino, Patrick D. Walker, Haiyan Wang, Jan J. Weening, Nori 
Yoshikawa, and Hong Zhang. 2009. “The Oxford Classification of IgA 
Nephropathy: Rationale, Clinicopathological Correlations, and Classification.” 
Kidney International 76(5):534–45. 
Cavasin, Maria A., Tang Dong Liao, Xiao Ping Yang, James J. Yang, and Oscar A. 
Carretero. 2007. “Decreased Endogenous Levels of Ac-SDKP Promote Organ 
Fibrosis.” Hypertension 50(1):130–36. 
Cechova, Sylvia, Fan Dong, Fang Chan, Michael J. Kelley, Phillip Ruiz, and Thu H. 
Le. 2018. “MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury 
and Migration.” Journal of the  American Society of  Nephrology 29:155–67. 
Chalmers, Samantha A., Violeta Chitu, Leal C. Herlitz, Ranjit Sahu, E. Richard 
Stanley, and Chaim Putterman. 2015. “Macrophage Depletion Ameliorates 
Nephritis Induced by Pathogenic Antibodies.” Journal of Autoimmunity 57:42–
52. 
Chan, Gary C. W., Wai Han Yiu, Hao Jia Wu, Dickson W. L. Wong, Miao Lin, Xiao 
Ru Huang, Hui Yao Lan, and Sydney C. W. Tang. 2015. “N-Acetyl-Seryl-
Aspartyl-Lysyl-Proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric 
Obstruction in BALB/C Mice.” Mediators of Inflammation 2015. 
Chang, Jei Wen, Victoriano Pardo, Junichiro Sageshima, Linda Chen, Hsin Lin Tsai, 
Jochen Reiser, Changli Wei, Gaetano Ciancio, George W. Burke, and Alessia 
Fornoni. 2012. “Podocyte Foot Process Effacement in Postreperfusion Allograft 
Biopsies Correlates with Early Recurrence of Proteinuria in Focal Segmental 
Glomerulosclerosis.” Transplantation 93(12):1238–44. 
Chen, A., L. F. Sheu, Y. S. Ho, Y. F. Lin, W. Y. Chou, T. C. Chou, and W. H. Lee. 
1998. “Experimental Focal Segmental Glomerulosclerosis in Mice.” Nephron 
 235 
78(4):440–52. 
Chen, Heng. 2007. “Comparative Observation of the Recombinant Adeno-
Associated Virus 2 Using Transmission Electron Microscopy and Atomic Force 
Microscopy.” Microscopy and Microanalysis 13:384–89. 
Chen, Qi, Zhida Shen, Yanjun Mao, Qinfeng Li, Yu Liu, Menghan Mei, Fuyu Qiu, and 
Meihui Wang. 2019. “Inhibition of MicroRNA-34a Mediates Protection of 
Thymosin Beta 4 in Endothelial Progenitor Cells against Advanced Glycation 
Endproducts by Targeting B-Cell Lymphoma 2.” Canadian Journal of Physiology 
and Pharmacology 97(10):945–51. 
Chen, Shih-Ming, Takuya Mukoyama, Noriko Sato, Shin-Ichi Yamagata, Yuichiro 
Arai, Nobunori Satoh, and Shiro Ueda. 2002. “Induction of Nephrotoxic Serum 
Nephritis in Inbred Mice and Suppressive Effect of Colchicine on the 
Development of This Nephritis.” Pharmacological Research 45(4):319–24. 
Chen, Teresa K., Daphne H. Knicely, and Morgan E. Grams. 2019. “Chronic Kidney 
Disease Diagnosis and Management: A Review.” JAMA - Journal of the 
American Medical Association 322(13):1294–1304. 
Chen, Zhuyun, Xiaofei An, Xi Liu, Jia Qi, Dafa Ding, Min Zhao, Suyan Duan, Zhimin 
Huang, Chengning Zhang, Lin Wu, Bo Zhang, Aihua Zhang, Yanggang Yuan, 
and Changying Xing. 2017. “Hyperoside Alleviates Adriamycin-Induced 
Podocyte Injury via Inhibiting Mitochondrial Fission.” Oncotarget 8(51):88792–
803. 
Chesarone, Melissa A. and Bruce L. Goode. 2009. “Actin Nucleation and Elongation 
Factors: Mechanisms and Interplay.” Current Opinion in Cell Biology 21(1):28–
37. 
Chiorini, J. A., L. Yang, Y. Liu, B. Safer, and R. M. Kotin. 1997. “Cloning of Adeno-
Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 
Particles.” Journal of Virology 71(9):6823–33. 
Chiorini, John A., Frank Kim, Linda Yang, and Robert M. Kotin. 1999. “Cloning and 
Characterization of Adeno-Associated Virus Type 5.” Journal of Virology 
73(2):1309–19. 
Chittiprol, Seetharamaiah, Phylip Chen, Danica Petrovic-Djergovic, Tad Eichler, and 
Richard F. Ransom. 2011. “Marker Expression, Behaviors, and Responses Vary 
in Different Lines of Conditionally Immortalized Cultured Podocytes.” American 
Journal of Physiology-Renal Physiology 301(3):F660–71. 
 236 
Chiu, Loraine LY, Lewis A. Reis, Abdul Momen, and Milica Radisic. 2012. 
“Controlled Release of Thymosin Β4 from Injected Collagen–Chitosan 
Hydrogels Promotes Angiogenesis and Prevents Tissue Loss after Myocardial 
Infarction.” Regenerative Medicine 7(4):523–33. 
Chiurchiu, Carlos, Giuseppe Remuzzi, and Piero Ruggenenti. 2005. “Angiotensin-
Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The 
Data of the Meta-Analyses.” Journal of the American Society of Nephrology 
16(SUPPL. 1):S58–63. 
Choi, Jae Won, Bala Murali Krishna Vasamsetti, Jaebum Choo, and Hak Yong Kim. 
2020. “Analysis of Deoxyribonuclease Activity by Conjugation-Free 
Fluorescence Polarisation in Sub-Nanolitre Droplets.” Analyst 145(9):3222–28. 
Chrysohoou, C., D. B. Panagiotakos, C. Pitsavos, J. Skoumas, M. Toutouza, I. 
Papaioannou, and C. Stefanadis. 2010. “Renal Function, Cardiovascular 
Disease Risk Factors’ Prevalence and 5-Year Disease Incidence; the Role of 
Diet, Exercise, Lipids and Inflammation Markers: The ATTICA Study.” QJM 
103(6):413–22. 
Chung, Jun Jae, Leonard Goldstein, Ying Jiun J. Chen, Jiyeon Lee, Joshua D. 
Webster, Merone Roose-Girma, Sharad C. Paudyal, Zora Modrusan, Anwesha 
Dey, and Andrey S. Shaw. 2020. “Single-Cell Transcriptome Profiling of the 
Kidney Glomerulus Identifies Key Cell Types and Reactions to Injury.” Journal of 
the American Society of Nephrology 31(10):2341–54. 
Ciani, Lorenza, Anjla Patel, Nicholas D. Allen, and Charles ffrench-Constant. 2003. 
“Mice Lacking the Giant Protocadherin MFAT1 Exhibit Renal Slit Junction 
Abnormalities and a Partially Penetrant Cyclopia and Anophthalmia Phenotype.” 
Molecular and Cellular Biology 23(10):3575–82. 
Clarke, Margaret and James A. Spudich. 1977. “NONMUSCLE CONTRACTILE 
PROTEINS: The Role of Actin and Myosin in Cell Motility and Shape 
Determination.” Annual Review of Biochemistry 46:797–822. 
Cole, Banumathi K., Marcello Curto, Annie W. Chan, and Andrea I. Mcclatchey. 
2008. “Localization to the Cortical Cytoskeleton Is Necessary for Nf2/Merlin-
Dependent Epidermal Growth Factor Receptor Silencing †.” MOLECULAR AND 
CELLULAR BIOLOGY 28(4):1274–84. 
Conte, Enrico, Tiziana Genovese, Elisa Gili, Emanuela Esposito, Maria Iemmolo, 
Mary Fruciano, Evelina Fagone, Maria P. Pistorio, Nunzio Crimi, Salvatore 
 237 
Cuzzocrea, and Carlo Vancheri. 2013. “Thymosin Β4 Protects C57BL/6 Mice 
from Bleomycin-Induced Damage in the Lung.” European Journal of Clinical 
Investigation 43(3):309–15. 
Cormack-Aboud, F. C., P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. 
Durvasula. 2008. “Rosuvastatin Protects against Podocyte Apoptosis in Vitro.” 
Nephrology Dialysis Transplantation 24(2):404–12. 
Cortes, P., M. Mendez, B. L. Riser, C. J. Guerin, A. Rodriguez-Barbero, C. Hassett, 
and J. Yee. 2000. “F-Actin Fiber Distribution in Glomerular Cells: Structural and 
Functional Implications.” Kidney International 58(6):2452–61. 
Costantini, Frank and Raphael Kopan. 2010. “Patterning a Complex Organ: 
Branching Morphogenesis and Nephron Segmentation in Kidney Development.” 
Developmental Cell 18(5):698–712. 
Courtemanche, Naomi and Thomas D. Pollard. 2013. “Interaction of Profilin with the 
Barbed End of Actin Filaments.” Biochemistry 52(37):6456–66. 
Couser, William G. 2012. “Basic and Translational Concepts of Immune-Mediated 
Glomerular Diseases.” Journal of the American Society of Nephrology 
23(3):381–99. 
Couser, William G. 2016. “Pathogenesis and Treatment of Glomerulonephritis-an 
Update.” Brazilian Journal of Nephrology 38(1):107–22. 
Cranford, T. L., R. T. Enos, K. T. Velázquez, J. L. McClellan, J. M. Davis, U. P. 
Singh, M. Nagarkatti, P. S. Nagarkatti, C. M. Robinson, and E. A. Murphy. 2016. 
“Role of MCP-1 on Inflammatory Processes and Metabolic Dysfunction 
Following High-Fat Feedings in the FVB/N Strain.” International Journal of 
Obesity 40(5):844–51. 
Crews, Deidra C., Marie Fanelli Kuczmarski, Vanessa Grubbs, Elizabeth Hedgeman, 
Vahakn B. Shahinian, Michele K. Evans, Alan B. Zonderman, Nilka Rios 
Burrows, Desmond E. Williams, Rajiv Saran, and Neil R. Powe. 2014. “Effect of 
Food Insecurity on Chronic Kidney Disease in Lower-Income Americans.” 
American Journal of Nephrology 39(1):27–35. 
Crowther, S. M., L. A. Reynolds, and E. M. Tansey. 2010. History of Dialysis in the 
UK: C.1950-1980. Vol. 37. 1st ed. edited by S. M. Crowther, L. A. Reynolds, and 
E. M. Tansey. London: Wellcome Trust Centre for the History of Medicine at 
UCL. 
Cunningham, Sharon C., Allison P. Dane, Afroditi Spinoulas, and Ian E. Alexander. 
 238 
2008. “Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors.” 
Molecular Therapy 16(6):1081–88. 
Curthoys, Norman P. and Orson W. Moe. 2014. “Proximal Tubule Function and 
Response to Acidosis.” Clinical Journal of the American Society of Nephrology 
9:1627–38. 
Curtin, John A., Elizabeth Quint, Vicky Tsipouri, Ruth M. Arkell, Bruce Cattanach, 
Andrew J. Copp, Deborah J. Henderson, Nigel Spurr, Philip Stanier, Elizabeth 
M. Fisher, Patrick M. Nolan, Karen P. Steel, Steve D. M. Brown, Ian C. Gray, 
and Jennifer N. Murdoch. 2003. “Mutation of Celsr1 Disrupts Planar Polarity of 
Inner Ear Hair Cells and Causes Severe Neural Tube Defects in the Mouse.” 
Current Biology 13(13):1129–33. 
Cutts, Suzanne M., Peter G. Parsons, Richard A. Sturm, and Don R. Phillips. 1996. 
“Adriamycin-Induced DNA Adducts Inhibit the DNA Interactions of Transcription 
Factors and RNA Polymerase.” Journal of Biological Chemistry 271(10):5422–
29. 
Daha, Mohamed R. and Cees van Kooten. 2016. “Role of Complement in IgA 
Nephropathy.” Journal of Nephrology 29(1):1–4. 
Dai, Chunsun, Moin A. Saleem, Lawrence B. Holzman, Peter Mathieson, and 
Youhua Liu. 2010. “Hepatocyte Growth Factor Signaling Ameliorates Podocyte 
Injury and Proteinuria.” Kidney International 77(11):962–73. 
Dai, Rufeng, Haimei Liu, Xinli Han, Junchao Liu, Yihui Zhai, Jia Rao, Qian Shen, and 
Hong Xu. 2019. “Angiopoietin-like-3 Knockout Protects against 
Glomerulosclerosis in Murine Adriamycin-Induced Nephropathy by Attenuating 
Podocyte Loss.” BMC Nephrology 20(1):185. 
Dai, Yan, Anqun Chen, Ruijie Liu, Leyi Gu, Shuchita Sharma, Weijing Cai, Fadi 
Salem, David J. Salant, Jeffrey W. Pippin, Stuart J. Shankland, Marcus J. 
Moeller, Norbert B. Ghyselinck, Xiaoqiang Ding, Peter Y. Chuang, Kyung Lee, 
and John Cijiang He. 2017. “Retinoic Acid Improves Nephrotoxic Serum–
Induced Glomerulonephritis through Activation of Podocyte Retinoic Acid 
Receptor α.” Kidney International 92(6):1444–57. 
Daugirdas, John T., Peter Gerard Blake, and Todd S. Ing. 2007. Handbook of 
Dialysis. Lippincott Williams & Wilkins. 
Davidoff, Andrew M., John T. Gray, Catherine Y. C. Ng, Youbin Zhang, Junfang 
Zhou, Yunyu Spence, Yusura Bakar, and Amit C. Nathwani. 2005. “Comparison 
 239 
of the Ability of Adeno-Associated Viral Vectors Pseudotyped with Serotype 2, 5, 
and 8 Capsid Proteins to Mediate Efficient Transduction of the Liver in Murine 
and Nonhuman Primate Models.” Molecular Therapy 11(6):875–88. 
Deegens, Jeroen K. J., Henry B. P. M. Dijkman, George F. Borm, Eric J. 
Steenbergen, José G. van den Berg, Jan J. Weening, and Jack F. M. Wetzels. 
2008. “Podocyte Foot Process Effacement as a Diagnostic Tool in Focal 
Segmental Glomerulosclerosis.” Kidney International 74(12):1568–76. 
Deen, Peter M. T., Bas W. M. Van Balkom, and Erik Jan Kamsteeg. 2000. “Routing 
of the Aquaporin-2 Water Channel in Health and Disease.” European Journal of 
Cell Biology 79(8):523–30. 
Deen, W. M., C. R. Robertson, B. M. Brenner, and B. M. A. Brenner. 1972. “A Model 
of Glomerular Ultrafiltration in the Rat.” American Journal of Physiology 
223(5):1178–83. 
Deffie, Abdul M., Janendra K. Batra, and Gerald J. Goldenberg. 1989. “Direct 
Correlation between DNA Topoisomerase II Activity and Cytotoxicity in 
Adriamycin-Sensitive and -Resistant P388 Leukemia Cell Lines.” Cancer 
Research 49(1):58–62. 
Defilippi, Paola, Cristina Olivo, Mascia Venturino, Laura Dolce, Lorenzo Silengo, and 
Guido Tarone. 1999. “Actin Cytoskeleton Organization in Response to Integrin-
Mediated Adhesion.” Microscopy Research and Technique 47(1):67–78. 
Deshmane, Satish L., Sergey Kremlev, Shohreh Amini, and Bassel E. Sawaya. 
2009. “Monocyte Chemoattractant Protein-1 (MCP-1): An Overview.” Journal of 
Interferon and Cytokine Research 29(6):313–25. 
Ding, G., Z. Zhang, M. Chopp, L. Li, L. Zhang, Q. Li, M. Wei, and Q. Jiang. 2014. 
“MRI Evaluation of BBB Disruption after Adjuvant AcSDKP Treatment of Stroke 
with TPA in Rat.” Neuroscience 271:1–8. 
Ding, Zhijie and Partha Roy. 2013. “Profilin-1 versus Profilin-2: Two Faces of the 
Same Coin?” Breast Cancer Research 15(3):1–2. 
Ditrich, Hans. 2007. “The Origin of Vertebrates: A Hypothesis Based on Kidney 
Development.” Zoological Journal of the Linnean Society 150(2):435–41. 
Donoviel, Dorit B., Deon D. Freed, Hannes Vogel, David G. Potter, Edith Hawkins, 
James P. Barrish, Brian N. Mathur, C. Alexander Turner, Robert Geske, Charles 
A. Montgomery, Michael Starbuck, Mary Brandt, Anupma Gupta, Ramiro 
Ramirez-Solis, Brian P. Zambrowicz, and David R. Powell. 2001. “Proteinuria 
 240 
and Perinatal Lethality in Mice Lacking NEPH1, a Novel Protein with Homology 
to NEPHRIN.” Molecular and Cellular Biology 21(14):4829–36. 
Drenckhahn, D. and R. P. Franke. 1988. “Ultrastructural Organization of Contractile 
and Cytoskeletal Proteins in Glomerular Podocytes of Chicken, Rat, and Man.” 
Laboratory Investigation 59(5):673–82. 
Dronavalli, Suma, Irena Duka, and George L. Bakris. 2008. “The Pathogenesis of 
Diabetic Nephropathy.” Nature Clinical Practice Endocrinology and Metabolism 
4(8):444–52. 
Drude, Solveig, Annett Geißler, Jakob Olfe, Astrid Starke, Grazyna Domanska, 
Christine Schuett, and Cornelia Kiank-Nussbaum. 2011. “Side Effects of Control 
Treatment Can Conceal Experimental Data When Studying Stress Responses 
to Injection and Psychological Stress in Mice.” Lab Animal 40(4):119–28. 
Duan, Dongsheng, Prerna Sharma, Jusan Yang, Yongping Yue, Lorita Dudus, 
Yulong Zhang, Krishna J. Fisher, and John F. Engelhardt. 1998. “Circular 
Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural 
Characteristics Responsible for Long-Term Episomal Persistence in Muscle 
Tissue.” Journal of Virology 72(11):8568–77. 
Dudek, Amanda M., Sirika Pillay, Andreas S. Puschnik, Claude M. Nagamine, Fang 
Cheng, Jianming Qiu, Jan E. Carette, and Luk H. Vandenberghe. 2018. “An 
Alternate Route for Adeno-Associated Virus (AAV) Entry Independent of AAV 
Receptor.” Journal of Virology 92(7):2213–30. 
Duffield, Jeremy S., Peter G. Tipping, Tiina Kipari, Jean François Cailhier, Spike 
Clay, Richard Lang, Joseph V. Bonventre, and Jeremy Hughes. 2005. 
“Conditional Ablation of Macrophages Halts Progression of Crescentic 
Glomerulonephritis.” American Journal of Pathology 167(5):1207–19. 
Dunn, Steven P., David G. Heidemann, Christopher Y. C. Chow, David Crockford, 
Nabila Turjman, Janet Angel, Christian B. Allan, and Gabriel Sosne. 2010. 
“Treatment of Chronic Nonhealing Neurotrophic Corneal Epithelial Defects with 
Thymosin Β4.” Annals of the New York Academy of Sciences 1194(1):199–206. 
Eadie, James S., Sonia W. Kim, Philip G. Allen, Lloyd M. Hutchinson, Jason D. 
Kantor, and Bruce R. Zetter. 2000. “C-Terminal Variations in β-Thymosin Family 
Members Specify Functional Differences in Actin-Binding Properties.” Journal of 
Cellular Biochemistry 77(2):277–87. 
Eckardt, Kai Uwe, Josef Coresh, Olivier Devuyst, Richard J. Johnson, Anna Köttgen, 
 241 
Andrew S. Levey, and Adeera Levin. 2013. “Evolving Importance of Kidney 
Disease: From Subspecialty to Global Health Burden.” The Lancet 
382(9887):158–69. 
Edwards, Marc, Adam Zwolak, Dorothy A. Schafer, David Sept, Roberto Dominguez, 
and John A. Cooper. 2014. “Capping Protein Regulators Fine-Tune Actin 
Assembly Dynamics.” Nature Reviews Molecular Cell Biology 15(10):677–89. 
Eknoyan, Garabed. 2009. “The Wonderful Apparatus of John Jacob Abel Called the 
‘Artificial Kidney.’” Seminars in Dialysis 22(3):287–96. 
Elalouf, J. M., N. Roinel, and C. de Rouffignac. 1984. “Effects of Antidiuretic 
Hormone on Electrolyte Reabsorption and Secretion in Distal Tubules of Rat 
Kidney.” Pflügers Archiv European Journal of Physiology 401(2):167–73. 
Endlich, Karlhans, Felix Kliewe, and Nicole Endlich. 2017. “Stressed Podocytes-
Mechanical Forces, Sensors, Signaling and Response.” European Journal of 
Physiology 469:937–49. 
Endlich, Nicole, Florian Siegerist, and Karlhans Endlich. 2017. “Are Podocytes 
Motile?” Pflugers Archiv European Journal of Physiology 469(7–8):951–57. 
Endlich, Nicole, Ole Simon, Achim Göpferich, Henny Wegner, Marcus J. Moeller, 
Elisabeth Rumpel, Ahmed M. Kotb, and Karlhans Endlich. 2014. “Two-Photon 
Microscopy Reveals Stationary Podocytes in Living Zebrafish Larvae.” J Am Soc 
Nephrol 25:681–86. 
Etienne-Manneville, Sandrine. 2018. “Cytoplasmic Intermediate Filaments in Cell 
Biology.” Annual Review of Cell and Developmental Biology 34:1–28. 
Etienne-Manneville, Sandrine and Alan Hall. 2002. “Rho GTPases in Cell Biology.” 
Nature 420(6916):629–35. 
Eulitz, Dirk and Hans Georg Mannherz. 2007. “Inhibition of Deoxyribonuclease I by 
Actin Is to Protect Cells from Premature Cell Death.” Apoptosis 12(8):1511–21. 
Evans, Mark A., Nicola Smart, Karina N. Dubé, Sveva Bollini, James E. Clark, 
Hayley G. Evans, Leonie S. Taams, Rebecca Richardson, Mathieu Lévesque, 
Paul Martin, Kevin Mills, Johannes Riegler, Anthony N. Price, Mark F. Lythgoe, 
and Paul R. Riley. 2013. “Thymosin Β4-Sulfoxide Attenuates Inflammatory Cell 
Infiltration and Promotes Cardiac Wound Healing.” Nature Communications 
4:2081. 
Fairweather, De Lisa and Daniela Cihakova. 2009. “Alternatively Activated 
Macrophages in Infection and Autoimmunity.” Journal of Autoimmunity 33(3–
 242 
4):222–30. 
Fan, Jun, Marissa G. Saunders, Esmael J. Haddadian, Karl F. Freed, Enrique M. De 
La Cruz, and Gregory A. Voth. 2013. “Molecular Origins of Cofilin-Linked 
Changes in Actin Filament Mechanics.” Journal of Molecular Biology 
425(7):1225–40. 
Fan, Xueping, Qinggang Li, Anna Pisarek-Horowitz, Hila Milo Rasouly, Xiangling 
Wang, Ramon G. Bonegio, Hang Wang, Margaret McLaughlin, Steve Mangos, 
Raghu Kalluri, Lawrence B. Holzman, Iain A. Drummond, Dennis Brown, David 
J. Salant, and Weining Lu. 2012. “Inhibitory Effects of Robo2 on Nephrin: A 
Crosstalk between Positive and Negative Signals Regulating Podocyte 
Structure.” Cell Reports 2(1):52–61. 
Fan, Xueping, Hongying Yang, Sudhir Kumar, Kathleen E. Tumelty, Anna Pisarek-
Horowitz, Hila Milo Rasouly, Richa Sharma, Stefanie Chan, Edyta Tyminski, 
Michael Shamashkin, Mostafa Belghasem, Joel M. Henderson, Anthony J. 
Coyle, David J. Salant, Stephen P. Berasi, and Weining Lu. 2016. 
“SLIT2/ROBO2 Signaling Pathway Inhibits Nonmuscle Myosin IIA Activity and 
Destabilizes Kidney Podocyte Adhesion.” JCI Insight 1(19):e86934. 
Fan, Yi, Yanqing Gong, Prabar K. Ghosh, Linda M. Graham, and Paul L. Fox. 2009. 
“Spatial Coordination of Actin Polymerization and ILK–Akt2 Activity during 
Endothelial Cell Migration.” Developmental Cell 16(5):661–74. 
Farber, Gregory, Romulo Hurtado, Sarah Loh, Sébastien Monette, James Mtui, 
Raphael Kopan, Susan Quaggin, Catherine Meyer-Schwesinger, Doris 
Herzlinger, Rizaldy P. Scott, and Carl P. Blobel. 2018. “Glomerular Endothelial 
Cell Maturation Depends on ADAM10, a Key Regulator of Notch Signaling.” 
Angiogenesis 21(2):335–47. 
Faul, Christian, Katsuhiko Asanuma, Etsuko Yanagida-Asanuma, Kwanghee Kim, 
and Peter Mundel. 2007. “Actin up: Regulation of Podocyte Structure and 
Function by Components of the Actin Cytoskeleton.” Trends in Cell Biology 
17(9):428–37. 
Faul, Christian, Mary Donnelly, Sandra Merscher-Gomez, Yoon Hee Chang, Stefan 
Franz, Jacqueline Delfgaauw, Jer-Ming Chang, Hoon Young Choi, Kirk N. 
Campbell, Kwanghee Kim, Jochen Reiser, and Peter Mundel. 2008. “The Actin 
Cytoskeleton of Kidney Podocytes Is a Direct Target of the Antiproteinuric Effect 
of Cyclosporine A.” Nature Medicine 14(9):931–38. 
 243 
Fehon, Richard G., Andrea I. McClatchey, and Anthony Bretscher. 2010. “Organizing 
the Cell Cortex: The Role of ERM Proteins.” Nature Reviews Molecular Cell 
Biology 11(4):276–87. 
Feldt, Jessica, Martin Schicht, Fabian Garreis, Jessica Welss, Ulrich W. Schneider, 
and Friedrich Paulsen. 2019. “Structure, Regulation and Related Diseases of 
the Actin-Binding Protein Gelsolin.” Expert Reviews in Molecular Medicine  
20(e7):1–10. 
Feng, Di, Jacob Notbohm, Ava Benjamin, Shijie He, Minxian Wang, Lay Hong Ang, 
Minaspi Bantawa, Mehdi Bouzid, Emanuela Del Gado, Ramaswamy Krishnan, 
and Martin R. Pollak. 2018. “Disease-Causing Mutation in α-Actinin-4 Promotes 
Podocyte Detachment through Maladaptation to Periodic Stretch.” Proceedings 
of the National Academy of Sciences of the United States of America 
115(7):1517–22. 
Feng, Lei, Meijin Guo, Shuxiang Zhang, Ju Chu, Yingping Zhuang, and Siliang 
Zhang. 2007. “Optimization of Transfection Mediated by Calcium Phosphate for 
Plasmid RAAV-LacZ (Recombinant Adeno-Associated Virus–β-Galactosidase 
Reporter Gene) Production in Suspension-Cultured HEK-293 (Human 
Embryonic Kidney 293) Cells.” Biotechnology and Applied Biochemistry 
46(2):135. 
Feng, Lili, Gabriela E. Garcia, Young Yang, Yiyang Xia, Francis B. Gabbai, Orjan W. 
Peterson, Judith A. Abraham, Roland C. Blantz, and Curtis B. Wilson. 2000. 
“Heparin-Binding EGF-like Growth Factor Contributes to Reduced Glomerular 
Filtration Rate during Glomerulonephritis in Rats.” Journal of Clinical 
Investigation 105(3):341–50. 
Ferrari, F. K., T. Samulski, T. Shenk, and R. J. Samulski. 1996. “Second-Strand 
Synthesis Is a Rate-Limiting Step for Efficient Transduction by Recombinant 
Adeno-Associated Virus Vectors.” Journal of Virology 70(5):3227–34. 
Ferron, François, Grzegorz Rebowski, Sung Haeng Lee, and Roberto Dominguez. 
2007. “Structural Basis for the Recruitment of Profilin–Actin Complexes during 
Filament Elongation by Ena/VASP.” The EMBO Journal 26(21):4597–4606. 
Filipowicz, A. W. and B. L. Horecker. 1983. “In Vitro Synthesis of Thymosin Β4 
Encoded by Rat Spleen MRNA.” Proceedings of the National Academy of 
Sciences of the United States of America 80(7 I):1811–15. 
Filippatos, Gerasimos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars 
 244 
Køber, Henry Krum, Aldo P. Maggioni, Piotr Ponikowski, Adriaan A. Voors, 
Faiez Zannad, So-Young Kim, Christina Nowack, Giovanni Palombo, Peter 
Kolkhof, Nina Kimmeskamp-Kirschbaum, Alexander Pieper, and Bertram Pitt. 
2016. “A Randomized Controlled Study of Finerenone vs. Eplerenone in 
Patients with Worsening Chronic Heart Failure and Diabetes Mellitus and/or 
Chronic Kidney Disease.” European Heart Journal 37(27):2105–14. 
Fisher, K. J., G. P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. M. 
Wilson. 1996. “Transduction with Recombinant Adeno-Associated Virus for 
Gene Therapy Is Limited by Leading-Strand Synthesis.” Journal of Virology 
70(1):520–32. 
Foreman, Kyle J., Neal Marquez, Andrew Dolgert, Kai Fukutaki, Nancy Fullman, 
Madeline McGaughey, Martin A. Pletcher, Amanda E. Smith, Kendrick Tang, 
Chun Wei Yuan, Jonathan C. Brown, Joseph Friedman, Jiawei He, Kyle R. 
Heuton, Mollie Holmberg, Disha J. Patel, Patrick Reidy, Austin Carter, Kelly 
Cercy, Abigail Chapin, Dirk Douwes-Schultz, Tahvi Frank, Falko Goettsch, 
Patrick Y. Liu, Vishnu Nandakumar, Marissa B. Reitsma, Vince Reuter, Nafis 
Sadat, Reed J. D. Sorensen, Vinay Srinivasan, Rachel L. Updike, Hunter York, 
Alan D. Lopez, Rafael Lozano, Stephen S. Lim, Ali H. Mokdad, Stein Emil 
Vollset, and Christopher J. L. Murray. 2018. “Forecasting Life Expectancy, 
Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes 
of Death: Reference and Alternative Scenarios for 2016–40 for 195 Countries 
and Territories.” The Lancet 392(10159):2052–90. 
Forst, Anna Lena, Vlad Sorin Olteanu, Géraldine Mollet, Tanja Wlodkowski, Franz 
Schaefer, Alexander DIetrich, Jochen Reiser, Thomas Gudermann, Michael 
Mederos Schnitzler, and Ursula Storch. 2016. “Podocyte Purinergic P2X4 
Channels Are Mechanotransducers That Mediate Cytoskeletal Disorganization.” 
Journal of the American Society of Nephrology 27(3):848–62. 
Franke, W. W., C. Grund, and A. Fink. 1978. “Location of Actin in the Microfilament 
Bundles Associated with the Junctional Specialisations between Sertoli Cells 
and Spermatids.” Biologie Cellulaire 31(1):7–13. 
Freeman, Kevin W., Brian R. Bowman, and Bruce R. Zetter. 2011. “Regenerative 
Protein Thymosin Beta-4 Is a Novel Regulator of Purinergic Signaling.” The 
FASEB Journal 25:907–15. 
Friedel, Roland H., Wolfgang Wurst, Benedikt Wefers, and Ralf Kühn. 2011. 
 245 
“Generating Conditional Knockout Mice.” Methods in Molecular Biology (Clifton, 
N.J.) 693:205–31. 
Friedland, Julie C., Mark H. Lee, and David Boettiger. 2009. “Mechanically Activated 
Integrin Switch Controls Α5β1 Function.” Science 323(5914):642–44. 
Fu, Jia, Kemal M. Akat, Zeguo Sun, Weijia Zhang, Detlef Schlondorff, Zhihong Liu, 
Thomas Tuschl, Kyung Lee, and John Cijiang He. 2019. “Single-Cell RNA 
Profiling of Glomerular Cells Shows Dynamic Changes in Experimental Diabetic 
Kidney Disease.” Journal of the American Society of Nephrology 30(4):533–45. 
Fukuda, Akihiro, Akihiro Minakawa, Yuji Sato, Takashi Iwakiri, Shuji Iwatsubo, 
Hiroyuki Komatsu, Masao Kikuchi, Kazuo Kitamura, Roger C. Wiggins, and 
Shouichi Fujimoto. 2017. “Urinary Podocyte and TGF-Β1 MRNA as Markers for 
Disease Activity and Progression in Anti-Glomerular Basement Membrane 
Nephritis.” Nephrology Dialysis Transplantation 32(11):1818–30. 
Gallagher, J. C., Prema Rapuri, and Lynette Smith. 2007. “Falls Are Associated with 
Decreased Renal Function and Insufficient Calcitriol Production by the Kidney.” 
Journal of Steroid Biochemistry and Molecular Biology 103(3–5):610–13. 
Gao, Guang Ping, Mauricio R. Alvira, Lili Wang, Roberto Calcedo, Jule Johnston, 
and James M. Wilson. 2002. “Novel Adeno-Associated Viruses from Rhesus 
Monkeys as Vectors for Human Gene Therapy.” Proceedings of the National 
Academy of Sciences of the United States of America 99(18):11854–59. 
Gao, Guangping, Luk H. Vandenberghe, Mauricio R. Alvira, You Lu, Roberto 
Calcedo, Xiangyang Zhou, and James M. Wilson. 2004. “Clades of Adeno-
Associated Viruses Are Widely Disseminated in Human Tissues.” Journal of 
Virology 78(12):6381–88. 
Gao, Xia, Hong Xu, Haimei Liu, Jia Rao, Yunling Li, and Xiliang Zha. 2010. 
“Angiopoietin-like Protein 3 Regulates the Motility and Permeability of Podocytes 
by Altering Nephrin Expression in Vitro.” Biochemical and Biophysical Research 
Communications 399(1):31–36. 
Garg, Puneet. 2018. “A Review of Podocyte Biology.” American Journal of 
Nephrology 47(Suppl. 1):3–13. 
Garg, Puneet, Rakesh Verma, Leslie Cook, Abdul Soofi, Madhusudan 
Venkatareddy, Britta George, Kensaku Mizuno, Christine Gurniak, Walter Witke, 
and Lawrence B. Holzman. 2010. “Actin-Depolymerizing Factor Cofilin-1 Is 
Necessary in Maintaining Mature Podocyte Architecture.” The Journal of 
 246 
Biological Chemistry 285(29):22676–88. 
Gatto, Mariele, Margherita Zen, Anna Ghirardello, Silvano Bettio, Nicola Bassi, Luca 
Iaccarino, Leonardo Punzi, and Andrea Doria. 2013. “Emerging and Critical 
Issues in the Pathogenesis of Lupus.” Autoimmunity Reviews 12(4):523–36. 
Gavin, R. H. 1997. “Microtubule-Microfilament Synergy in the Cytoskeleton.” 
International Review of Cytology 173:207–42. 
George, Britta, Rakesh Verma, Abdulsalam A. Soofi, Puneet Garg, Jidong Zhang, 
Tae Ju Park, Laura Giardino, Larisa Ryzhova, Duncan B. Johnstone, Hetty 
Wong, Deepak Nihalani, David J. Salant, Steven K. Hanks, Tom Curran, Maria 
Pia Rastaldi, and Lawrence B. Holzman. 2012. “Crk1/2-Dependent Signaling Is 
Necessary for Podocyte Foot Process Spreading in Mouse Models of 
Glomerular Disease.” Journal of Clinical Investigation 122(2):674–92. 
George, Lindsey A., Spencer K. Sullivan, Adam Giermasz, John E. J. Rasko, 
Benjamin J. Samelson-Jones, Jonathan Ducore, Adam Cuker, Lisa M. Sullivan, 
Suvankar Majumdar, Jerome Teitel, Catherine E. McGuinn, Margaret V. Ragni, 
Alvin Y. Luk, Daniel Hui, J. Fraser Wright, Yifeng Chen, Yun Liu, Katie Wachtel, 
Angela Winters, Stefan Tiefenbacher, Valder R. Arruda, Johannes C. M. van der 
Loo, Olga Zelenaia, Daniel Takefman, Marcus E. Carr, Linda B. Couto, Xavier 
M. Anguela, and Katherine A. High. 2017. “Hemophilia B Gene Therapy with a 
High-Specific-Activity Factor IX Variant.” New England Journal of Medicine 
377(23):2215–27. 
Gerke, Peter, Tobias B. Huber, Lorenz Sellin, Thomas Benzing, and Gerd Walz. 
2003. “Homodimerization and Heterodimerization of the Glomerular Podocyte 
Proteins Nephrin and NEPH1.” Journal of the American Society of Nephrology : 
JASN 14(4):918–26. 
Gerke, Peter, Lorenz Sellin, Oliver Kretz, Daniel Petraschka, Hanswalter Zentgraf, 
Thomas Benzing, and Gerd Walz. 2005. “NEPH2 Is Located at the Glomerular 
Slit Diaphragm, Interacts with Nephrin and Is Cleaved from Podocytes by 
Metalloproteinases.” J Am Soc Nephrol 16:1693–1702. 
Gerosa, Clara, Daniela Fanni, Sonia Nemolato, Annalisa Locci, Viviana Marinelli, 
Tiziana Cabras, Irene Messana, Massimo Castagnola, and Guido Monga. 2010. 
“Thymosin Beta-10 Expression in Developing Human Kidney.” The Journal of 
Maternal-Fetal & Neonatal Medicine 23(S3):125–28. 
Gertler, Frank B., Kirsten Niebuhr, Matthias Reinhard, Jürgen Wehland, and Philippe 
 247 
Soriano. 1996. “Mena, a Relative of VASP and Drosophila Enabled, Is 
Implicated in the Control of Microfilament Dynamics.” Cell 87(2):227–39. 
Gigante, Maddalena, Paola Pontrelli, Eustacchio Montemurno, Leonarda Roca, 
Filippo Aucella, Rosa Penza, Gianluca Caridi, Elena Ranieri, Gian Marco 
Ghiggeri, and Loreto Gesualdo. 2009. “CD2AP Mutations Are Associated with 
Sporadic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis 
(FSGS).” Nephrology Dialysis Transplantation 24(6):1858–64. 
Godoy-Parejo, Carlos, Chunhao Deng, Weiwei Liu, and Guokai Chen. 2019. “Insulin 
Stimulates PI3K/AKT and Cell Adhesion to Promote the Survival of 
Individualized Human Embryonic Stem Cells.” Stem Cells 37(8):1030–41. 
Gokal, R. and N. P. Mallick. 1999. “Peritoneal Dialysis.” Lancet 353(9155):823–28. 
Goldman, Robert D., Satya Khuon, Ying Hao Chou, Puneet Opal, and Peter M. 
Steinert. 1996. “The Function of Intermediate Filaments in Cell Shape and 
Cytoskeletal Integrity.” The Journal of Cell Biology 134(4):971–83. 
Goldschmidt-Clermont, P. J., M. I. Furman, D. Wachsstock, D. Safer, V. T. 
Nachmias, and T. D. Pollard. 1992. “The Control of Actin Nucleotide Exchange 
by Thymosin Beta 4 and Profilin. A Potential Regulatory Mechanism for Actin 
Polymerization in Cells.” Molecular Biology of the Cell 3(9):1015–24. 
Gooch, Katherine, Bruce F. Culleton, Braden J. Manns, Jianguo Zhang, Helman 
Alfonso, Marcello Tonelli, Cy Frank, Scott Klarenbach, and Brenda R. 
Hemmelgarn. 2007. “NSAID Use and Progression of Chronic Kidney Disease.” 
American Journal of Medicine 120(3):280.e1-280.e7. 
Goodall, G. J., J. L. Hempstead, and J. I. Morgan. 1983. “Production and 
Characterization of Antibodies to Thymosin Beta 4.” The Journal of Immunology 
131(2):821–25. 
Goodson, Holly V and Erin M. Jonasson. 2018. “Microtubules and Microtubule-
Associated Proteins.” Cold Spring Harb Perspect Biol 10:a022608. 
Gorman, C. M., D. Gies, G. McCray, and M. Huang. 1989. “The Human 
Cytomegalovirus Major Immediate Early Promoter Can Be Trans-Activated by 
Adenovirus Early Proteins.” Virology 171(2):377–85. 
Gorriz, Jose Luis and Alberto Martinez-Castelao. 2012. “Proteinuria: Detection and 
Role in Native Renal Disease Progression.” Transplantation Reviews 26(1):3–
13. 
Goutebroze, Laurence, Estelle Brault, Christian Muchardt, Jacques Camonis, and 
 248 
Gilles Thomas. 2000. Cloning and Characterization of SCHIP-1, a Novel Protein 
Interacting Specifically with Spliced Isoforms and Naturally Occurring Mutant 
NF2 Proteins. Vol. 20. 
Grahammer, Florian, Christoph Schell, and Tobias B. Huber. 2013. “The Podocyte 
Slit Diaphragm—from a Thin Grey Line to a Complex Signalling Hub.” Nature 
Publishing Group 9:587–98. 
Grant, D. S., W. Rose, C. Yaen, A. Goldstein, J. Martinez, and H. Kleinman. 1999. 
“Thymosin Beta4 Enhances Endothelial Cell Differentiation and Angiogenesis.” 
Angiogenesis 3(2):125–35. 
Gross, Oliver, Bogdan Beirowski, Scott J. Harvey, Catherine Mcfadden, Dilys Chen, 
Stephanie Tam, Paul S. Thorner, Neil Smyth, Klaus Addicks, Wilhelm Bloch, 
Yoshifumi Ninomiya, Yoshikazu Sado, Manfred Weber, and Wolfgang F. Vogel. 
2004. “DDR1-Deficient Mice Show Localized Subepithelial GBM Thickening with 
Focal Loss of Slit Diaphragms and Proteinuria.” Kidney International 66(1):102–
11. 
Guarnera, G., A. DeRosa, and R. Camerini. 2010. “The Effect of Thymosin 
Treatment of Venous Ulcers.” Annals of the New York Academy of Sciences 
1194(1):207–12. 
Guilbaud, Mickaë L., Marie Devaux, Celia Couzinié, Johanne Le Duff, Alice 
Toromanoff, Cé Line Vandamme, Nicolas Jaulin, Gwladys Gernoux, Thibaut 
Larcher, Philippe Moullier, Caroline Le Guiner, and Oumeya Adjali. 2019. “Five 
Years of Successful Inducible Transgene Expression Following Locoregional 
Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable 
Immunity.” Human Gene Therapy 30(7):802–13. 
Guinobert, Isabelle, Melanie Viltard, David Piquemal, Jean-Marc Elalouf, Jacques 
Marti, and Martine Lelievre-Pegorier. 2005. “Identification of Differentially 
Expressed Genes between Fetal and Adult Mouse Kidney: Candidate Gene in 
Kidney Development.” Nephron Physiology 102:81–91. 
Gunning, P. W., U. Ghoshdastider, S. Whitaker, D. Popp, and R. C. Robinson. 2015. 
“The Evolution of Compositionally and Functionally Distinct Actin Filaments.” 
Journal of Cell Science 128(11):2009–19. 
Guo, Jian-Kan, Aswin L. Menke, Marie-Claire Gubler, Alan R. Clarke, David 
Harrison, Annette Hammes, Nicholas D. Hastie, and Andreas Schedl. 2002. 
“WT1 Is a Key Regulator of Podocyte Function: Reduced Expression Levels 
 249 
Cause Crescentic Glomerulonephritis and Mesangial Sclerosis.” Human 
Molecular Genetics 11(6):651–59. 
Guo, Jiancheng, Radha Ananthakrishnan, Wu Qu, Yan Lu, Nina Reiniger, Shan 
Zeng, Wanchao Ma, Rosa Rosario, Shi Fang Yan, Ravichandran Ramasamy, 
Vivette D’agati, and Ann Marie Schmidt. 2008. “RAGE Mediates Podocyte Injury 
in Adriamycin-Induced Glomerulosclerosis The Interaction of Receptor for 
Advanced Glyca-Tion End Products (RAGE) with Its Ligands.” J Am Soc 
Nephrol 19:961–72. 
Guo, Na, Jin Guo, and Dongfang Su. 2016. “MicroRNA-206 and Its down-Regulation 
of Wilms’Tumor-1 Dictate Podocyte Health in Adriamycin-Induced 
Nephropathy.” Renal Failure 38(6):989–95. 
Gutiérrez, Orlando M. 2015. “Contextual Poverty, Nutrition, and Chronic Kidney 
Disease.” Advances in Chronic Kidney Disease 22(1):31–38. 
Hackl, Matthias J., James L. Burford, Karie Villanueva, Lisa Lam, Katalin Suszták, 
Bernhard Schermer, Thomas Benzing, and János Peti-Peterdi. 2013. “Tracking 
the Fate of Glomerular Epithelial Cells in Vivo Using Serial Multiphoton Imaging 
in New Mouse Models with Fluorescent Lineage Tags.” Nature Medicine 
19(12):1661–66. 
Hadjiyanni, I., K. A. Siminovitch, J. S. Danska, and D. J. Drucker. 2010. “Glucagon-
like Peptide-1 Receptor Signalling Selectively Regulates Murine Lymphocyte 
Proliferation and Maintenance of Peripheral Regulatory T Cells.” Diabetologia 
53(4):730–40. 
Haemmerli, Gisela, Beatrice Arnold, and Peter Sträuli. 1983. “Cellular Motility on 
Glass and in Tissues: Similarities and Dissimilarities.” Cell Biology International 
Reports 7(9):709–25. 
Al Haj, Abdulatif, Antonina Joanna Mazur, Sabine Buchmeier, Christine App, Carsten 
Theiss, Unai Silvan, Cora-Ann Schoenenberger, Brigitte M. Jockusch, Ewald 
Hannappel, Alan G. Weeds, and Hans Georg Mannherz. 2014. “Thymosin 
Beta4 Inhibits ADF/Cofilin Stimulated F-Actin Cycling and Hela Cell Migration: 
Reversal by Active Arp2/3 Complex.” Cytoskeleton 71(2):95–107. 
Halbert, C. L., T. A. Standaert, M. L. Aitken, I. E. Alexander, D. W. Russell, and A. D. 
Miller. 1997. “Transduction by Adeno-Associated Virus Vectors in the Rabbit 
Airway: Efficiency, Persistence, and Readministration.” Journal of Virology 
71(8):5932–41. 
 250 
Hall, Alan. 1998. “Rho GTPases and the Actin Cytoskeleton.” Science 
279(509):509–14. 
Hall, Alan K. 1994. “Amplification-Independent Overexpression of Thymosin Beta-10 
MRNA in Human Renal Cell Carcinoma.” Renal Failure 16(2):243–54. 
Hall, Brandon M., Vitaly Balan, Anatoli S. Gleiberman, Evguenia Strom, Peter 
Krasnov, Lauren P. Virtuoso, Elena Rydkina, Slavoljub Vujcic, Karina Balan, Ilya 
Gitlin, Katerina Leonova, Alexander Polinsky, Olga B. Chernova, and Andrei V. 
Gudkov. 2016. “Aging of Mice Is Associated with P16(Ink4a)- and β-
Galactosidasepositive Macrophage Accumulation That Can Be Induced in 
Young Mice by Senescent Cells.” Aging 8(7):1294–1315. 
Hanamura, Kikuno, Akihiro Tojo, Satoshi Kinugasa, Kensuke Asaba, and Toshiro 
Fujita. 2012. “The Resistive Index Is a Marker of Renal Function, Pathology, 
Prognosis, and Responsiveness to Steroid Therapy in Chronic Kidney Disease 
Patients.” International Journal of Nephrology 2012(Article ID 139565):1–9. 
Hanna, Mary, Haibo Liu, Jawaria Amir, Yi Sun, Stephan W. Morris, M. A. Q. Siddiqui, 
Lester F. Lau, and Brahim Chaqour. 2009. “Mechanical Regulation of the 
Proangiogenic Factor CCN1/CYR61 Gene Requires the Combined Activities of 
MRTF-A and CREB-Binding Protein Histone Acetyltransferase.” Journal of 
Biological Chemistry 284(34):23125–36. 
Hanna, Samer and Mirvat El-Sibai. 2013. “Signaling Networks of Rho GTPases in 
Cell Motility.” Cellular Signalling 25(10):1955–61. 
Hannappel, E., G. J. Xu, J. Morgan, J. Hempstead, and B. L. Horecker. 1982. 
“Thymosin Β4: A Ubiquitous Peptide in Rat and Mouse Tissues.” Proceedings of 
the National Academy of Sciences of the United States of America 79(7 I):2172–
75. 
Hansen, Scott D. and R. Dyche Mullins. 2010. “VASP Is a Processive Actin 
Polymerase That Requires Monomeric Actin for Barbed End Association.” 
Journal of Cell Biology 191(3):571–84. 
Harker, Alyssa J., Harshwardhan H. Katkar, Tamara C. Bidone, Fikret Aydin, 
Gregory A. Voth, Derek A. Applewhite, and David R. Kovar. 2019. “Ena/VASP 
Processive Elongation Is Modulated by Avidity on Actin Filaments Bundled by 
the Filopodia Cross-Linker Fascin” edited by M. Théry. Molecular Biology of the 
Cell 30(7):851–62. 
Harris, Jessica J., Hugh J. McCarthy, Lan Ni, Matthew Wherlock, Heegyung Kang, 
 251 
Jack F. Wetzels, Gavin I. Welsh, and Moin A. Saleem. 2013. “Active Proteases 
in Nephrotic Plasma Lead to a Podocin-Dependent Phosphorylation of VASP in 
Podocytes via Protease Activated Receptor-1.” Journal of Pathology 
229(5):660–71. 
Haupt, Ygal, Ruth Maya, Anat Kazaz, and Moshe Oren. 1997. “Mdm2 Promotes the 
Rapid Degradation of P53.” Nature 387(6630):296–99. 
He, Mingjuan, Yixiang Li, Li Wang, Bei Guo, Wen Mei, Biao Zhu, Jiajia Zhang, Yan 
Ding, Biying Meng, Liming Zhang, Lin Xiang, Jing Dong, Min Liu, Lingwei Xiang, 
and Guangda Xiang. 2020. “MYDGF Attenuates Podocyte Injury and Proteinuria 
by Activating Akt/BAD Signal Pathway in Mice with Diabetic Kidney Disease.” 
Diabetologia 63(9):1916–31. 
Hébert, Marie Josée, Tomoko Takano, Aikaterina Papayianni, Helmut G. Rennke, 
Andrew Minto, David J. Salant, Michael C. Carroll, and Hugh R. Brady. 1998. 
“Acute Nephrotoxic Serum Nephritis in Complement Knockout Mice: Relative 
Roles of the Classical and Alternate Pathways in Neutrophil Recruitment and 
Proteinuria.” Nephrology Dialysis Transplantation 13(11):2799–2803. 
Heerspink, Hiddo J. L., Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, 
Gabriel Chodick, Kamlesh Khunti, John P. H. Wilding, Luis Alberto Garcia 
Rodriguez, Lucia Cea-Soriano, Shun Kohsaka, Antonio Nicolucci, Giuseppe 
Lucisano, Fang Ju Lin, Chih Yuan Wang, Eric Wittbrodt, Peter Fenici, and 
Mikhail Kosiborod. 2020. “Kidney Outcomes Associated with Use of SGLT2 
Inhibitors in Real-World Clinical Practice (CVD-REAL 3): A Multinational 
Observational Cohort Study.” The Lancet Diabetes and Endocrinology 8(1):27–
35. 
Heikkilä, Eija, Juuso Juhila, Markus Lassila, Marcel Messing, Nina Perälä, Eero 
Lehtonen, Sanna Lehtonen, Joseph Sjef Verbeek, and Harry Holthofer. 2010. 
“β-Catenin Mediates Adriamycin-Induced Albuminuria and Podocyte Injury in 
Adult Mouse Kidneys.” Nephrology Dialysis Transplantation 25(8):2437–46. 
Hejazian, Seyede Mina, Sepideh Zununi Vahed, Hakimeh Moghaddas Sani, Ziba 
Nariman-Saleh-Fam, Milad Bastami, Seyed Mahdi Hosseiniyan Khatibi, 
Mohammadreza Ardalan, and Nasser Samadi. 2020. “Steroid-Resistant 
Nephrotic Syndrome: Pharmacogenetics and Epigenetic Points and Views.” 
Expert Review of Clinical Pharmacology 13(2):147–56. 
Heng, Yi Wen and Cheng Gee Koh. 2010. “Actin Cytoskeleton Dynamics and the 
 252 
Cell Division Cycle.” International Journal of Biochemistry and Cell Biology 
42(10):1622–33. 
Henique, Carole, Guillaume Bollée, Xavier Loyer, Florian Grahammer, Neeraj 
Dhaun, Marine Camus, Julien Vernerey, Léa Guyonnet, François Gaillard, 
Hélène Lazareth, Charlotte Meyer, Imane Bensaada, Luc Legrès, Takashi 
Satoh, Shizuo Akira, Patrick Bruneval, Stefanie Dimmeler, Alain Tedgui, 
Alexandre Karras, Eric Thervet, Dominique Nochy, Tobias B. Huber, Laurent 
Mesnard, Olivia Lenoir, and Pierre Louis Tharaux. 2017. “Genetic and 
Pharmacological Inhibition of MicroRNA-92a Maintains Podocyte Cell Cycle 
Quiescence and Limits Crescentic Glomerulonephritis.” Nature Communications 
8(1). 
Hermonat, P. L. and N. Muzyczka. 1984. “Use of Adeno-Associated Virus as a 
Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance into 
Mammalian Tissue Culture Cells.” Proceedings of the National Academy of 
Sciences of the United States of America 81(20 I):6466–70. 
Hildinger, Markus, Alberto Auricchio, Guangping Gao, Lili Wang, Narendra Chirmule, 
and James M. Wilson. 2001. “Hybrid Vectors Based on Adeno-Associated Virus 
Serotypes 2 and 5 for Muscle-Directed Gene Transfer.” Journal of Virology 
75(13):6199–6203. 
Hinkel, Rabea, Teresa Trenkwalder, Björn Petersen, Wira Husada, Florian 
Gesenhues, Seungmin Lee, Ewald Hannappel, Ildiko Bock-Marquette, Daniel 
Theisen, Laura Leitner, Peter Boekstegers, Czeslaw Cierniewski, Oliver J. 
Müller, Ferdinand le Noble, Ralf H. Adams, Christine Weinl, Alfred Nordheim, 
Bruno Reichart, Christian Weber, Eric Olson, Guido Posern, Elisabeth Deindl, 
Heiner Niemann, and Christian Kupatt. 2014. “MRTF-A Controls Vessel Growth 
and Maturation by Increasing the Expression of CCN1 and CCN2.” Nature 
Communications 5:3970. 
Hinze, Claudia and Emmanuel Boucrot. 2018. “Local Actin Polymerization during 
Endocytic Carrier Formation.” Biochemical Society Transactions 46(3):565–76. 
Le Hir, Michel, Cornelia Keller, Valérie Eschmann, Brunhilde Hähnel, Hiltraude 
Hosser, and Wilhelm Kriz. 2001. “Podocyte Bridges between the Tuft and 
Bowman’s Capsule: An Early Event in Experimental Crescentic 
Glomerulonephritis | American Society of Nephrology.” Journal of the American 
Society of Nephrology 12(10):2060–71. 
 253 
Hirst, Jennifer A., José M. Ordóñez Mena, Clare J. Taylor, Yaling Yang, F. D. 
Richard Hobbs, Chris A. O’Callaghan, Richard J. McManus, Emma Ogburn, 
Maria D. L. A. Vazquez-Montes, Nathan Hill, Daniel Lasserson, and Brian Shine. 
2020. “Prevalence of Chronic Kidney Disease in the Community Using Data 
from OxRen: A UK Population-Based Cohort Study.” British Journal of General 
Practice 70(693):E285–93. 
Ho, J. H. C., K. C. Tseng, W. H. Ma, K. H. Chen, O. K. S. Lee, and Y. Su. 2008. 
“Thymosin Beta-4 Upregulates Anti-Oxidative Enzymes and Protects Human 
Cornea Epithelial Cells against Oxidative Damage.” British Journal of 
Ophthalmology 92(7):992–97. 
Ho, Jennifer Hui Chun, Chiao Hui Chuang, Chih Yuan Ho, Yu Ru Vernon Shih, 
Oscar Kuang Sheng Lee, and Yeu Su. 2007. “Internalization Is Essential for the 
Antiapoptotic Effects of Exogenous Thymosin β-4 on Human Corneal Epithelial 
Cells.” Investigative Ophthalmology and Visual Science 48(1):27–33. 
Hogg, Ronald, John Middleton, and V. Matti Vehaskari. 2007. “Focal Segmental 
Glomerulosclerosis - Epidemiology Aspects in Children and Adults.” Pediatric 
Nephrology 22(2):183–86. 
Holland, Steven M. 2010. “Chronic Granulomatous Disease.” Clinical Reviews in 
Allergy and Immunology 38(1):3–10. 
Hollenbeck, Peter. 2001. “Cytoskeleton: Microtubules Get the Signal.” Current 
Biology 11(20):R820–23. 
Holness, C. .. and D. .. Simmons. 1993. “Molecular Cloning of CD68, a Human 
Macrophage Marker Related to Lysosomal Glycoproteins - PubMed.” Blood 
81(6):1607–13. 
Honda, Kazufumi, Tesshi Yamada, Ritsuko Endo, Yoshinori Ino, Masahiro Gotoh, 
Hitoshi Tsuda, Yozo Yamada, Hiroshige Chiba, and Setsuo Hirohashi. 1998. 
“Actinin-4, a Novel Actin-Bundling Protein Associated with Cell Motility and 
Cancer Invasion.” Journal of Cell Biology 140(6):1383–93. 
Hoppe, John M. and Volker Vielhauer. 2014. “Induction and Analysis of Nephrotoxic 
Serum Nephritis in Mice.” Pp. 159–74 in Methods in Molecular Biology. Vol. 
1169, edited by H. Anders and A. Migliorini. New York, NY: Humana Press Inc. 
Hosoe-Nagai, Yoshiko, Teruo Hidaka, Ayano Sonoda, Yu Sasaki, Kanae Yamamoto-
Nonaka, Takuto Seki, Rin Asao, Eriko Tanaka, Juan Alejandro Oliva Trejo, 
Fumiko Kodama, Miyuki Takagi, Nobuhiro Tada, Takashi Ueno, Ryuichi 
 254 
Nishinakamura, Yasuhiko Tomino, and Katsuhiko Asanuma. 2017. “Re-
Expression of Sall1 in Podocytes Protects against Adriamycin-Induced 
Nephrosis.” Laboratory Investigation 97(11):1306–20. 
Hotulainen, Pirta, Eija Paunola, Maria K. Vartiainen, and Pekka Lappalainen. 2005. 
“Actin-Depolymerizing Factor and Cofilin-1 Play Overlapping Roles in Promoting 
Rapid F-Actin Depolymerization in Mammalian Nonmuscle Cells □ D □ V.” 
Molecular Biology of the Cell 16:649–64. 
Hu, Jianwen, Jizhong Han, Haoran Li, Xian Zhang, Lan lan Liu, Fei Chen, and Bin 
Zeng. 2018. “Human Embryonic Kidney 293 Cells: A Vehicle for 
Biopharmaceutical Manufacturing, Structural Biology, and Electrophysiology.” 
Cells Tissues Organs 205(1):1–8. 
Huang, Z., L. Zhang, Y. Chen, H. Zhang, Q. Zhang, R. Li, J. Ma, Z. Li, C. Yu, Y. Lai, 
T. Lin, X. Zhao, B. Zhang, Z. Ye, S. Liu, W. Wang, X. Liang, R. Liao, and W. Shi. 
2016. “Cdc42 Deficiency Induces Podocyte Apoptosis by Inhibiting the 
Nwasp/Stress Fibers/YAP Pathway.” Cell Death and Disease 7(3):e2142–
e2142. 
Huber, Tobias B., Miriam Schmidts, Peter Gerke, Bernhard Schermer, Anne Zahn, 
Björn Hartleben, Lorenz Sellin, Gerd Walz, and Thomas Benzing. 2003. “The 
Carboxyl Terminus of Neph Family Members Binds to the PDZ Domain Protein 
Zonula Occludens-1.” Journal of Biological Chemistry 278(15):13417–21. 
Huehn, Andrew, Wenxiang Cao, W. Austin Elam, Xueqi Liu, Enrique M. De La Cruz, 
and Charles V. Sindelar. 2018. “The Actin Filament Twist Changes Abruptly at 
Boundaries between Bare and Cofilin-Decorated Segments.” Journal of 
Biological Chemistry 293(15):5377–83. 
Hueschen, Christina L., Samuel J. Kenny, Ke Xu, and Sophie Dumont. 2017. “NuMA 
Recruits Dynein Activity to Microtubule Minus-Ends at Mitosis.” ELife 6:e29328. 
Husson, Clotilde, François-Xavier Cantrelle, Pierre Roblin, Dominique Didry, Kim Ho, 
Diep Le, Javier Perez, Eric Guittet, Carine Van Heijenoort, Louis Renault, and 
Marie-France Carlier. 2010. “Multifunctionality of the β-Thymosin/WH2 Module: 
G-Actin Sequestration, Actin Filament Growth, Nucleation, and Severing.” 
Annals of the New York Academy of Sciences 1194:44–52. 
Ichimura, Koichiro, Hidetake Kurihara, and Tatsuo Sakai. 2003. “Actin Filament 
Organization of Foot Processes in Rat Podocytes.” Journal of Histochemistry & 
Cytochemistry 51(12):1589–1600. 
 255 
Ichimura, Koichiro, Hidetake Kurihara, and Tatsuo Sakai. 2007. “Actin Filament 
Organization of Foot Processes in Vertebrate Glomerular Podocytes.” Cell and 
Tissue Research 329(3):541–57. 
Ichimura, Koichiro, Takayuki Miyaki, Yuto Kawasaki, Mui Kinoshita, Soichiro Kakuta, 
and Tatsuo Sakai. 2019. “Morphological Processes of Foot Process Effacement 
in Puromycin Aminonucleoside Nephrosis Revealed by FIB/SEM Tomography.” 
Journal of the American Society of Nephrology 30(1):96–108. 
Idriss, Haitham T. and James H. Naismith. 2000. “TNFα and the TNF Receptor 
Superfamily: Structure-Function Relationship(S).” Microscopy Research and 
Technique 50(3):184–95. 
Ikeda, Yoichiro, Zhao Sun, Xiao Ru, Luk H. Vandenberghe, and Benjamin D. 
Humphreys. 2018. “Efficient Gene Transfer to Kidney Mesenchymal Cells Using 
a Synthetic Adeno-Associated Viral Vector.” Journal of the American Society of 
Nephrology 29(9):2287–97. 
Ikezumi, Yohei, Toshiaki Suzuki, Tamaki Karasawa, Hiroshi Kawachi, David J. 
Nikolic-Paterson, and Makoto Uchiyama. 2008. “Activated Macrophages Down-
Regulate Podocyte Nephrin and Podocin Expression via Stress-Activated 
Protein Kinases.” Biochemical and Biophysical Research Communications 
376(4):706–11. 
Isambert, H., P. Venier, A. C. Maggs, A. Fattoum, R. Kassab, D. Pantaloni, and M. F. 
Carlier. 1995. “Flexibility of Actin Filaments Derived from Thermal Fluctuations. 
Effect of Bound Nucleotide, Phalloidin, and Muscle Regulatory Proteins.” 
Journal of Biological Chemistry 270(19):11437–44. 
Jacobson, Samuel G., Artur V. Cideciyan, Alejandro J. Roman, Alexander 
Sumaroka, Sharon B. Schwartz, Elise Heon, and William W. Hauswirth. 2015. 
“Improvement and Decline in Vision with Gene Therapy in Childhood Blindness.” 
New England Journal of Medicine 372(20):1920–26. 
Jarad, George and Jeffrey H. Miner. 2009. “Update on the Glomerular Filtration 
Barrier.” Current Opinion in Nephrology and Hypertension 18(3):226–32. 
Jat, Parmjit S., Mark D. Noble, Paris Ataliotis, Yujiro Tanaka, Nikos Yannoutsos, 
Lena Larsen, and Dimitris Kioussis. 1991. “Direct Derivation of Conditionally 
Immortal Cell Lines from an H-2Kb-TsA58 Transgenic Mouse.” Proceedings of 
the National Academy of Sciences of the United States of America 88(12):5096–
5100. 
 256 
Jefferson, J. Ashley and Stuart J. Shankland. 2014. “The Pathogenesis of Focal 
Segmental Glomerulosclerosis.” Advances in Chronic Kidney Disease 
21(5):408–16. 
Jennette, J. Charles and Ronald J. Falk. 1997. “Small-Vessel Vasculitis.” New 
England Journal of Medicine 337(21):1512–23. 
Jeon, Byung Joon, Yoolhee Yang, Su Kyung Shim, Heung Mo Yang, Daeho Cho, 
and Sa Ik Bang. 2013. “Thymosin Beta-4 Promotes Mesenchymal Stem Cell 
Proliferation via an Interleukin-8-Dependent Mechanism.” Experimental Cell 
Research 319(17):2526–34. 
Johnson, R. J., C. E. Alpers, A. Yoshimura, D. Lombardi, P. Pritzl, J. Floege, and S. 
M. Schwartz. 1992. “Renal Injury from Angiotensin II-Mediated Hypertension.” 
Hypertension 19(5):464–74. 
Johnson, Richard J., Hiroyuki Lida, Charles E. Alpers, Mark W. Majesky, Stephen M. 
Schwartz, Pam Pritzl, Kathy Gordon, and Allen M. Gownt. 1991. “Expression of 
Smooth Muscle Cell Phenotype by Rat Mesangial Cells in Immune Complex 
Nephritis.” Journal of Clinical Investigation 87:847–58. 
Jones, Nina, Ivan M. Blasutig, Vera Eremina, Julie M. Ruston, Friedhelm Bladt, 
Hongping Li, Maiming Huang, Louise Larose, Shawn S. C. Li, Tomoko Takano, 
Susan E. Quaggin, and Tony Pawson. 2006. “Nck Adaptor Proteins Link 
Nephrin to the Actin Cytoskeleton of Kidney Podocytes.” Nature 440(7085):818–
23. 
Junot, Christophe, Laurence Nicolet, Eric Ezan, Marie-Francoise Gonzales, Joel 
Menard, and Michel Azizi. 1999. “Effect of Angiotensin-Converting Enzyme 
Inhibition on Plasma, Urine, and Tissue Concentrations of Hemoregulatory 
Peptide Acetyl-Ser-Asp-Lys-Pro in Rats.” The Journal of Pharmacology and 
Experimental Therapeutics 291(3):982–87. 
Kandel, Mikhail E., Kai Wen Teng, Paul R. Selvin, and Gabriel Popescu. 2017. 
“Label-Free Imaging of Single Microtubule Dynamics Using Spatial Light 
Interference Microscopy.” ACS Nano 11(1):647–55. 
Kaneko, Yoshikatsu, Takamasa Cho, Yuya Sato, Kei Goto, Suguru Yamamoto, Shin 
Goto, Michael P. Madaio, and Ichiei Narita. 2018. “Attenuated Macrophage 
Infiltration in Glomeruli of Aged Mice Resulting in Ameliorated Kidney Injury in 
Nephrotoxic Serum Nephritis.” The Journals of Gerontology: Series A 
73(9):1178–86. 
 257 
Kaplan, Joshua M., Sung Han Kim, Kathryn N. North, Helmut Rennke, Lori Ann 
Correia, Hui Qi Tong, Beverly J. Mathis, José Carlos Rodríguez-Pérez, Philip G. 
Allen, Alan H. Beggs, and Martin R. Pollak. 2000. “Mutations in ACTN4, 
Encoding α-Actinin-4, Cause Familial Focal Segmental Glomerulosclerosis.” 
Nature Genetics 24(3):251–56. 
Karaiskos, Nikos, Mahdieh Rahmatollahi, Anastasiya Boltengagen, Haiyue Liu, 
Martin Hoehne, Markus Rinschen, Bernhard Schermer, Thomas Benzing, 
Nikolaus Rajewsky, Christine Kocks, Martin Kann, and Roman Ulrich Müller. 
2018. “A Single-Cell Transcriptome Atlas of the Mouse Glomerulus.” Journal of 
the American Society of Nephrology 29(8):2060–68. 
Kardos, Roland, Andrea Vig, József Orbán, Gábor Hild, Miklós Nyitrai, and Dénes 
Lorinczy. 2007. “The Effect of Jasplakinolide on the Thermodynamic Properties 
of ADP.BeFx Bound Actin Filaments.” Thermochimica Acta 463(1–2):77–80. 
Karger, S., Li-Hong Ren, Hai-Tao Zhang, Wei-Wei Wang, Xia-Xia Zhao, Zhi-Hui 
Wang, De-Li Zhuang, and Yun-Nuo Bai. 2016. “The MTORC2/Akt/NFκB 
Pathway-Mediated Activation of TRPC6 Participates in Adriamycin-Induced 
Podocyte Apoptosis.” Cell Physiol Biochem 40:1079–93. 
Karnovsky, M. J. and S. K. Ainsworth. 1972. “The Structural Basis of Glomerular 
Filtration.” Advances in Nephrology from the Necker Hospital 2:35–60. 
Kaverina, Natalya V., Diana G. Eng, Andrea D. Largent, Ilse Daehn, Anthony Chang, 
Kenneth W. Gross, Jeffrey W. Pippin, Peter Hohenstein, and Stuart J. 
Shankland. 2017. “WT1 Is Necessary for the Proliferation and Migration of Cells 
of Renin Lineage Following Kidney Podocyte Depletion.” Stem Cell Reports 
9(4):1152–66. 
Keith, Allison R., Kirk Twaroski, Christen L. Ebens, and Jakub Tolar. 2020. “Leading 
Edge: Emerging Drug, Cell, and Gene Therapies for Junctional Epidermolysis 
Bullosa.” Expert Opinion on Biological Therapy 20(8):911–23. 
Kelich, Joseph M., Jiong Ma, Biao Dong, Qizhao Wang, Mario Chin, Connor M. 
Magura, Weidong Xiao, and Weidong Yang. 2015. “Super-Resolution Imaging of 
Nuclear Import of Adeno-Associated Virus in Live Cells.” Molecular Therapy - 
Methods and Clinical Development 2:15047. 
Kerjaschki, Dontscho, David J. Sharkey, and Marilyn Gist Farquhar. 1984. 
“Identification and Characterization of Podocalyxin-the Major Sialoprotein of the 
Renal Glomerular Epithelial Cell.” The Journal of Cell Biology 98:1591–96. 
 258 
Kerr, Marion, Benjamin Bray, James Medcalf, Donal J. O’Donoghue, and Beverley 
Matthews. 2012. “Estimating the Financial Cost of Chronic Kidney Disease to 
the NHS in England.” Nephrology Dialysis Transplantation 27(SUPPL. 3):iii73-
80. 
Kestilä, Marjo, Ulla Lenkkeri, Minna Männikkö, Jane Lamerdin, Paula McCready, 
Heli Putaala, Vesa Ruotsalainen, Takako Morita, Marja Nissinen, Riitta Herva, 
Clifford E. Kashtan, Leena Peltonen, Christer Holmberg, Anne Olsen, and Karl 
Tryggvason. 1998. “Positionally Cloned Gene for a Novel Glomerular Protein—
Nephrin—Is Mutated in Congenital Nephrotic Syndrome.” Molecular Cell 
1(4):575–82. 
Kevany, Brian M., Scott Kerns, Linas Padegimas, and Timothy J. Miller. 2019. “AAV 
Gene Therapy for the Treatment of Fabry Disease: A Novel Capsid with 
Improved Tropism to Heart, Kidney and CNS and Improved GLA Expression.” 
Molecular Genetics and Metabolism 126(2):S83. 
Khan, Sarah B., H. Terence Cook, Gurjeet Bhangal, Jennifer Smith, Frederick W. K. 
Tam, and Charles D. Pusey. 2005. “Antibody Blockade of TNF-α Reduces 
Inflammation and Scarring in Experimental Crescentic Glomerulonephritis.” 
Kidney International 67(5):1812–20. 
Khoshnoodi, Jamshid, Kristmundur Sigmundsson, Lars Göran Öfverstedt, Ulf 
Skoglund, Björn Obrink, Jorma Wartiovaara, and Karl Tryggvason. 2003. 
“Nephrin Promotes Cell-Cell Adhesion through Homophilic Interactions.” 
American Journal of Pathology 163(6):2337–46. 
Kim, Jae-Gyu, Rokibul Islam, Jung Y. Cho, Hwalrim Jeong, Kim-Cuong Cap, Yohan 
Park, Abu J. Hossain, and Jae-Bong Park. 2018. “Regulation of RhoA GTPase 
and Various Transcription Factors in the RhoA Pathway.” Journal of Cellular 
Physiology 233(9):6381–92. 
Kim, Jane H., Martha Konieczkowski, Amitava Mukherjee, Sam Schechtman, 
Shenaz Khan, Jeffrey R. Schelling, Michael D. Ross, Leslie A. Bruggeman, and 
John R. Sedor. 2010. “Podocyte Injury Induces Nuclear Translocation of WTIP 
via Microtubule-Dependent Transport.” The Journal of Biological Chemistry 
285(13):9995–10004. 
Kim, Ji Eun, Dohyun Han, Jin Seon Jeong, Jong Joo Moon, Hyun Kyung Moon, 
Sunhwa Lee, Yong Chul Kim, Kyung Don Yoo, Jae Wook Lee, Dong Ki Kim, 
Young Joo Kwon, Yon Su Kim, and Seung Hee Yang. 2021. “Multi-Sample 
 259 
Mass Spectrometry-Based Approach for Discovering Injury Markers in Chronic 
Kidney Disease.” Molecular & Cellular Proteomics. 
Kim, S. H. and J. H. Kim. 1972. Lethal Effect of Adriamycin on the Division Cycle of 
HeLa Cells1. Vol. 32. 
Kim, Seyun and Pierre A. Coulombe. 2007. “Intermediate Filament Scaffolds Fulfill 
Mechanical, Organizational, and Signaling Functions in the Cytoplasm.” Genes 
and Development 21:1581–97. 
Kim, Sokho and Jungkee Kwon. 2015. “Actin Cytoskeletal Rearrangement and 
Dysfunction Due to Activation of the Receptor for Advanced Glycation End 
Products Is Inhibited by Thymosin Beta 4.” The Journal of Physiology 
593(8):1873–86. 
Kim, Sokho and Jungkee Kwon. 2017. “Thymosin β 4 Has a Major Role in Dermal 
Burn Wound Healing That Involves Actin Cytoskeletal Remodelling via Heat-
Shock Protein 70.” Journal of Tissue Engineering and Regenerative Medicine 
11(4):1262–73. 
Kirsch, A. H., V. Riegelbauer, A. Tagwerker, M. Rudnicki, A. R. Rosenkranz, and K. 
Eller. 2012. “The MTOR-Inhibitor Rapamycin Mediates Proteinuria in 
Nephrotoxic Serum Nephritis by Activating the Innate Immune Response.” 
American Journal of Physiology-Renal Physiology 303(4):F569–75. 
Kitada, Munehiro, Yoshio Ogura, and Daisuke Koya. 2016. “Rodent Models of 
Diabetic Nephropathy: Their Utility and Limitations.” International Journal of 
Nephrology and Renovascular Disease 9:279–90. 
Klastersky, J., J. P. Sculier, J. P. Dumont, D. Becquart, G. Vandermoten, P. 
Rocmans, J. Michel, E. Longeval, and O. Dalesio. 1985. “Combination 
Chemotherapy with Adriamycin, Etoposide, and Cyclophosphamide for Small 
Cell Carcinoma of the Lung. A Study by the EORTC Lung Cancer Working Party 
(Belgium).” Cancer 56(1):71–75. 
Klein, Julie, Bénédicte Buffin-Meyer, Franck Boizard, Nabila Moussaoui, Ophélie 
Lescat, Benjamin Breuil, Camille Fedou, Guylène Feuillet, Audrey Casemayou, 
Eric Neau, An Hindryckx, Luc Decatte, Elena Levtchenko, Anke Raaijmakers, 
Christophe Vayssière, Valérie Goua, Charlotte Lucas, Franck Perrotin, Sylvie 
Cloarec, Alexandra Benachi, Marie-Christine Manca-Pellissier, Hélène 
Laurichesse Delmas, Lucie Bessenay, Claudine Le Vaillant, Emma Allain-
Launay, Jean Gondry, Bernard Boudailliez, Elisabeth Simon, Fabienne Prieur, 
 260 
Marie-Pierre Lavocat, Anne-Hélène Saliou, Loic De Parscau, Laurent Bidat, 
Catherine Noel, Corinne Floch, Guylène Bourdat-Michel, Romain Favre, Anne-
Sophie Weingertner, Jean-François Oury, Véronique Baudouin, Jean-Paul Bory, 
Christine Pietrement, Maryse Fiorenza, Jérôme Massardier, Sylvie Kessler, 
Nadia Lounis, Françoise Conte Auriol, Pascale Marcorelles, Sophie Collardeau-
Frachon, Petra Zürbig, Harald Mischak, Pedro Magalhães, Julie Batut, Patrick 
Blader, Jean-Sebastien Saulnier Blache, Jean-Loup Bascands, Franz Schaefer, 
Stéphane Decramer, Joost P. Schanstra, Karel Allegaert, Yves Aubard, Odile 
Basmaison, Jean-Baptiste Benevent, Florence Biquard, Gérard Champion, 
Jean-Marie Delbosc, Philippe Eckart, Marie-Françoise Froute, Pascal 
Gaucherand, Marion Groussolles, Vincent Guigonis, Blandine Hougas, 
Gwenaelle Le Bouar, Alain Martin, Sophie Martin, Mariannick Maupin-Hyvonnet, 
Marina Merveille, Eve Mousty, François Nobili, Amelie Ryckewaert, Agnes 
Sartor, Sophie Taque, and Norbert Winer. 2020. “Amniotic Fluid Peptides 
Predict Postnatal Kidney Survival in Developmental Kidney Disease.” Kidney 
International S0085-2538(20):30894–2. 
Kobayashi, Akio, M. Todd Valerius, Joshua W. Mugford, Thomas J. Carroll, Michelle 
Self, Guillermo Oliver, and Andrew P. McMahon. 2008. “Six2 Defines and 
Regulates a Multipotent Self-Renewing Nephron Progenitor Population 
throughout Mammalian Kidney Development.” Cell Stem Cell 3(2):169–81. 
Kobayashi, Naoto, Jochen Reiser, Wilhelm Kriz, Ryoko Kuriyama, and Peter Mundel. 
1998. “Nonuniform Microtubular Polarity Established by CHO1/MKLP1 Motor 
Protein Is Necessary for Process Formation of Podocytes.” Journal of Cell 
Biology 143(7):1961–70. 
Kobayashi, Naoto, Jochen Reiser, Karin Schwarz, Tatsuo Sakai, Wilhelm Kriz, and 
Peter Mundel. 2001. “Process Formation of Podocytes: Morphogenetic Activity 
of Microtubules and Regulation by Protein Serine/Threonine Phosphatase 
PP2A.” Histochemistry and Cell Biology 115(3):255–66. 
Kokko, Juha P. 1970. “Sodium Chloride and Water Transport in the Descending 
Limb of Henle.” The Journal of Clinical Investigation 49:1838–46. 
Kolkhof, Peter, Martina Delbeck, Axel Kretschmer, Wolfram Steinke, Elke Hartmann, 
Lars Bärfacker, Frank Eitner, Barbara Albrecht-Küpper, and Stefan Schäfer. 
2014. “Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor 
Antagonist Protects From Rat Cardiorenal Injury.” Journal of Cardiovascular 
 261 
Pharmacology 64(1):69–78. 
Koning, Sarah H., Ron T. Gansevoort, Kenneth J. Mukamal, Eric B. Rimm, Stephan 
J. L. Bakker, and Michel M. Joosten. 2015. “Alcohol Consumption Is Inversely 
Associated with the Risk of Developing Chronic Kidney Disease.” Kidney 
International 87(5):1009–16. 
Korhonen, M., J. Ylänne, L. Laitinen, and I. Virtanen. 1990. “Distribution of Beta 1 
and Beta 3 Integrins in Human Fetal and Adult Kidney - PubMed.” Lab Invest. 
62(5):616–25. 
Korsunsky, Ilya, Nghia Millard, Jean Fan, Kamil Slowikowski, Fan Zhang, Kevin Wei, 
Yuriy Baglaenko, Michael Brenner, Po ru Loh, and Soumya Raychaudhuri. 
2019. “Fast, Sensitive and Accurate Integration of Single-Cell Data with 
Harmony.” Nature Methods 16(12):1289–96. 
Kovar, David R., Elizabeth S. Harris, Rachel Mahaffy, Henry N. Higgs, and Thomas 
D. Pollard. 2006. “Control of the Assembly of ATP- and ADP-Actin by Formins 
and Profilin.” Cell 124(2):423–35. 
Kraus, Alison C., Ines Ferber, Sven Oliver Bachmann, Hannah Specht, Anja 
Wimmel, Markus W. Gross, Juergen Schlegel, Guntram Suske, and Marcus 
Schuermann. 2002. “In Vitro Chemo- and Radio-Resistance in Small Cell Lung 
Cancer Correlates with Cell Adhesion and Constitutive Activation of AKT and 
MAP Kinase Pathways.” Oncogene 21(57):8683–95. 
Kretzler, Matthias, Vicente P. C. Teixeira, Paul G. Unschuld, Clemens D. Cohen, 
Rüdiger Wanke, Ilka Edenhofer, Peter Mundel, Detlef Schlöndorff, and Harry 
Holthöfer. 2001. “Integrin Linked Kinase as a Candidate Downstream Effector in 
Proteinuria.” The FASEB Journal 15(10):1843–45. 
Kriz, W., N. Gretz, and K. V. Lemley. 1998. “Progression of Glomerular Diseases: Is 
the Podocyte the Culprit?” Kidney International 54(3):687–97. 
Kriz, Wilhelm, Eberhard Hackenthal, Rainer Nobiling, Tatsuo Sakai, and Marlies 
Elger. 1994. “A Role for Podocytes to Counteract Capillary Wall Distension.” 
Kidney International 45:369–76. 
Kriz, Wilhelm, Isao Shirato, Michio Nagata, Michel LeHir, and Kevin V. Lemley. 2013. 
“The Podocyte’s Response to Stress: The Enigma of Foot Process Effacement.” 
American Journal of Physiology - Renal Physiology 304(4). 
Kruger, Claudia, Susan J. Burke, J. Jason Collier, Trang Tiffany Nguyen, J. Michael 
Salbaum, and Krisztian Stadler. 2018. “Lipid Peroxidation Regulates Podocyte 
 262 
Migration and Cytoskeletal Structure through Redox Sensitive RhoA Signaling.” 
Redox Biology 16:248–54. 
Kubo, Ayano, Teruo Hidaka, Maiko Nakayama, Yu Sasaki, Miyuki Takagi, Hitoshi 
Suzuki, and Yusuke Suzuki. 2020. “Protective Effects of DPP-4 Inhibitor on 
Podocyte Injury in Glomerular Diseases.” BMC Nephrology 21(1):402. 
Kumar, Nitin, Tang-Dong Liao, Cesar A. Romero, Mani Maheshwari, Edward L. 
Peterson, and Oscar A. Carretero. 2018. “Thymosin Beta4 Deficiency 
Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension.” 
Hypertension (71):1133–42. 
Kumar, Nitin, Tang Dong Liao, Cesar A. Romero, Mani Maheshwari, Edward L. 
Peterson, and Oscar A. Carretero. 2018. “Thymosin Β4 Deficiency Exacerbates 
Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension.” Hypertension 
71(6):1133–42. 
Kumar, Nitin, Pablo Nakagawa, Branislava Janic, Cesar A. Romero, Morel E. Worou, 
Sumit R. Monu, Edward L. Peterson, Jiajiu Shaw, Frederick Valeriote, Elimelda 
M. Ongeri, Jean-Marie V. Niyitegeka, Nour-Eddine Rhaleb, and Oscar A. 
Carretero. 2016. “The Anti-Inflammatory Peptide Ac-SDKP Is Released from 
Thymosin-Β4 by Renal Meprin-α and Prolyl Oligopeptidase.” American Journal 
of Physiology-Renal Physiology 310(10):F1026–34. 
Kumar, Nitin and Congcong Yin. 2018. “The Anti-Inflammatory Peptide Ac-SDKP: 
Synthesis, Role in ACE Inhibition, and Its Therapeutic Potential in Hypertension 
and Cardiovascular Diseases.” Pharmacological Research 134:268–79. 
Kumar, S. and S. Gupta. 2011. “Thymosin Beta 4 Prevents Oxidative Stress by 
Targeting Antioxidant and Anti-Apoptotic Genes in Cardiac Fibroblasts.” PLoS 
ONE 6(10):26912. 
Kurimasa, Akihiro, Honghai Ouyang, Li Jin Dong, Sa Wang, Xiaoling Li, Carlos 
Cordon-Cardo, David J. Chen, and Gloria C. Li. 1999. “Catalytic Subunit of 
DNA-Dependent Protein Kinase: Impact on Lymphocyte Development and 
Tumorigenesis.” Proceedings of the National Academy of Sciences of the United 
States of America 96(4):1403–8. 
Kursula, Petri, Inari Kursula, Marzia Massimi, Young Hwa Song, Joshua Downer, 
Will A. Stanley, Walter Witke, and Matthias Wilmanns. 2008. “High-Resolution 
Structural Analysis of Mammalian Profilin 2a Complex Formation with Two 
Physiological Ligands: The Formin Homology 1 Domain of MDia1 and the 
 263 
Proline-Rich Domain of VASP.” Journal of Molecular Biology 375(1):270–90. 
Kvirkvelia, Nino, Malgorzata McMenamin, Kapil Chaudhary, Manuela Bartoli, and 
Michael P. Madaio. 2013. “Prostaglandin E 2 Promotes Cellular Recovery from 
Established Nephrotoxic Serum Nephritis in Mice, Prosurvival, and 
Regenerative Effects on Glomerular Cells.” American Journal of Physiology-
Renal Physiology 304(5):F463–70. 
Kwiatkowski, Adam V., Frank B. Gertler, and Joseph J. Loureiro. 2003. “Function 
and Regulation of Ena/VASP Proteins.” Trends in Cell Biology 13(7):386–92. 
De La Cruz, E M, E. Michael Ostap, Rodney A. Brundage, K. S. Reddy, H. Lee 
Sweeney, and Daniel Safer. 2000. “Thymosin-␤ 4 Changes the Conformation 
and Dynamics of Actin Monomers.” Biophysical Journal 78:2516–27. 
De La Cruz, Enrique M. 2009. “How Cofilin Severs an Actin Filament.” Biophysical 
Reviews 1(2):51–59. 
De La Cruz, Enrique M., E. Michael Ostap, Rodney A. Brundage, K. S. Reddy, H. 
Lee Sweeney, and Daniel Safer. 2000. “Thymosin-Β4 Changes the 
Conformation and Dynamics of Actin Monomers.” Biophysical Journal 
78(5):2516–27. 
Lackner, Daniel F. and Nicholas Muzyczka. 2002. “Studies of the Mechanism of 
Transactivation of the Adeno-Associated Virus P19 Promoter by Rep Protein.” 
Journal of Virology 76(16):8225–35. 
Lamaze, C., L. M. Fujimoto, H. L. Yin, and S. L. Schmid. 1997. “The Actin 
Cytoskeleton Is Required for Receptor-Mediated Endocytosis in Mammalian 
Cells.” The Journal of Biological Chemistry 272(33):20332–35. 
Lankelma, Jan, Henk Dekker, Rafael Fernández Luque, Sylvia Luykx, Klaas 
Hoekman, Paul Van Der Valk, Paul J. Van Diest, and Herbert M. Pinedo. 1999. 
“Doxorubicin Gradients in Human Breast Cancer.” Clinical Cancer Research 
5:1703–7. 
Larson, Adam M. 2011. “Multiphoton Microscopy.” Nature Photonics 5(1):1–1. 
Lazarides, E. and U. Lindberg. 1974. “Actin Is the Naturally Occurring Inhibitor of 
Deoxyribonuclease I.” Proceedings of the National Academy of Sciences of the 
United States of America 71(12):4742–46. 
Le, Shimin, Miao Yu, Alexander Bershadsky, and Jie Yan. 2020. “Mechanical 
Regulation of Formin-Dependent Actin Polymerization.” Seminars in Cell and 
 264 
Developmental Biology 102:73–80. 
Lee, Sang-Im, Duck-Su Kim, Hwa-Jeong Lee, Hee-Jae Cha, and Eun-Cheol Kim. 
2013. “The Role of Thymosin Beta 4 on Odontogenic Differentiation in Human 
Dental Pulp Cells” edited by I. Kerkis. PLoS ONE 8(4):e61960. 
Lee, Soo Bong and Raghu Kalluri. 2010. “Mechanistic Connection between 
Inflammation and Fibrosis.” Kidney International 78(SUPPL. 119):S22–26. 
Lee, Vincent WS and David CH Harris. 2011. “Adriamycin Nephropathy: A Model of 
Focal Segmental Glomerulosclerosis.” Nephrology 16(1):30–38. 
Lefebvre, Jonathan, Michael Clarkson, Filippo Massa, Stephen T. Bradford, Aurelie 
Charlet, Fabian Buske, Sandra Lacas-Gervais, Herbert Schulz, Charlotte 
Gimpel, Yutaka Hata, Franz Schaefer, and Andreas Schedl. 2015. “Alternatively 
Spliced Isoforms of WT1 Control Podocyte-Specific Gene Expression.” Kidney 
International 88(2):321–31. 
Lenkkeri, Ulla, Minna Männikkö, Paula McCready, Jane Lamerdin, Olivier Gribouval, 
Patrick Niaudet, Corinne Antignac, Clifford E. Kashtan, Christer Holmberg, Anne 
Olsen, Marjo Kestilä, and Karl Tryggvason. 1999. “Structure of the Gene for 
Congenital Nephrotic Syndrome of the Finnish Type (NPHS1) and 
Characterization of Mutations.” The American Journal of Human Genetics 
64(1):51–61. 
Lennon, Rachel, Michael J. Randles, and Martin J. Humphries. 2014. “The 
Importance of Podocyte Adhesion for a Healthy Glomerulus.” Frontiers in 
Endocrinology 5(OCT):160. 
Leube, Rudolf E., Marcin Moch, and Reinhard Windoffer. 2015. “Intermediate 
Filaments and the Regulation of Focal Adhesion.” Current Opinion in Cell 
Biology 32:13–20. 
Levey, Andrew S. and Josef Coresh. 2012. “Chronic Kidney Disease.” The Lancet 
379(9811):165–80. 
Li, Chao, Li Zhang, Chunyang Wang, Hua Teng, Baoyan Fan, Michael Chopp, and 
Zheng Gang Zhang. 2019. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments 
Thrombolysis of TPA (Tissue-Type Plasminogen Activator) in Aged Rats After 
Stroke.” Stroke 50(9):2547–54. 
Li, Chengwen and R. Jude Samulski. 2020. “Engineering Adeno-Associated Virus 
Vectors for Gene Therapy.” Nature Reviews Genetics 21(4):255–72. 
Li, Hongwei, Yonggang Wang, Xuchang Hu, Bing Ma, and Haihong Zhang. 2019. 
 265 
“Thymosin Beta 4 Attenuates Oxidative Stress-Induced Injury of Spinal Cord-
Derived Neural Stem/Progenitor Cells through the TLR4/MyD88 Pathway.” 
Gene 707:136–42. 
Li, Jinhua, Xinli Qu, and John F. Bertram. 2009. “Endothelial-Myofibroblast Transition 
Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in 
Streptozotocin-Induced Diabetic Mice.” American Journal of Pathology 
175(4):1380–88. 
Li, Xiaozhong, Haitao Yuan, and Xueguang Zhang. 2003. “Adriamycin Increases 
Podocyte Permeability: Evidence and Molecular Mechanism.” Chinese Medical 
Journal 116(12):1831–35. 
Liao, Tang-Dong, Pablo Nakagawa, Branislava Janic, Martin D’Ambrosio, Morel E. 
Worou, Edward L. Peterson, Nour-Eddine Rhaleb, Xiao-Ping Yang, and Oscar 
A. Carretero. 2015. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: Mechanisms of 
Renal Protection in Mouse Model of Systemic Lupus Erythematosus.” American 
Journal of Physiology - Renal Physiology 308(10):F1146–54. 
Liapis, Helen, Paola Romagnani, and Hans Joachim Anders. 2013. “New Insights 
into the Pathology of Podocyte Loss: Mitotic Catastrophe.” American Journal of 
Pathology 183(5):1364–74. 
Licette, C. Y., Elise Liu, and Ron Schutte. 2015. “Finerenone: Third-Generation 
Mineralocorticoid Receptor Antagonist for the Treatment of Heart Failure and 
Diabetic Kidney Disease.” Expert Opinion on Investigational Drugs  24(8):1123–
35. 
Lim, Beom Jin, Jae Won Yang, Woo Sung Do, and Agnes B. Fogo. 2016. 
“Pathogenesis of Focal Segmental Glomerulosclerosis.” Journal of Pathology 
and Translational Medicine 50(6):405–10. 
Lin, Fu Jun, Lei Yao, Xue Qing Hu, Fan Bian, Gang Ji, Geng Ru Jiang, Daniel P. 
Gale, and Hong Qi Ren. 2019. “First Identification of PODXL Nonsense 
Mutations in Autosomal Dominant Focal Segmental Glomerulosclerosis.” 
Clinical Science 133(1):9–21. 
Lindström, Nils O., Melanie L. Lawrence, Sally F. Burn, Jeanette A. Johansson, 
Elvira R. M. Bakker, Rachel A. Ridgway, C. Hong Chang, Michele J. Karolak, 
Leif Oxburgh, Denis J. Headon, Owen J. Sansom, Ron Smits, Jamie A. Davies, 
and Peter Hohenstein. 2014. “Integrated β-Catenin, BMP, PTEN, and Notch 
Signalling Patterns the Nephron.” ELife 3:e04000. 
 266 
Ling, Li, Libo Chen, Changning Zhang, Shuyan Gui, Haiyan Zhao, and Zhengzhang 
Li. 2018. “High Glucose Induces Podocyte Epithelial-to-Mesenchymal Transition 
by Demethylation-Mediated Enhancement of MMP9 Expression.” Molecular 
Medicine Reports 17(4):5642–51. 
Lipshultz, Steven E., Rebecca E. Scully, Stuart R. Lipsitz, Stephen E. Sallan, Lewis 
B. Silverman, Tracie L. Miller, Elly V. Barry, Barbara L. Asselin, Uma Athale, 
Luis A. Clavell, Eric Larsen, Albert Moghrabi, Yvan Samson, Bruno Michon, 
Marshall A. Schorin, Harvey J. Cohen, Donna S. Neuberg, E. John Orav, and 
Steven D. Colan. 2010. “Assessment of Dexrazoxane as a Cardioprotectant in 
Doxorubicin-Treated Children with High-Risk Acute Lymphoblastic Leukaemia: 
Long-Term Follow-up of a Prospective, Randomised, Multicentre Trial.” The 
Lancet Oncology 11(10):950–61. 
Liu, Gary W., Alexander N. Prossnitz, Diana G. Eng, Yilong Cheng, Nithya 
Subrahmanyam, Jeffrey W. Pippin, Robert J. Lamm, Chayanon 
Ngambenjawong, Hamidreza Ghandehari, Stuart J. Shankland, and Suzie H. 
Pun. 2018. “Glomerular Disease Augments Kidney Accumulation of Synthetic 
Anionic Polymers.” Biomaterials 178:317–25. 
Liu, Haimei, Xia Gao, Hong Xu, Chun Feng, Xinyu Kuang, Zengxia Li, and Xiliang 
Zha. 2012. “A-Actinin-4 Is Involved in the Process by Which Dexamethasone 
Protects Actin Cytoskeleton Stabilization from Adriamycin-Induced Podocyte 
Injury.” Nephrology 17:669–75. 
Liu, Xi, Wei Cao, Jia Qi, Qing Li, Min Zhao, Zhuyun Chen, Jingfeng Zhu, Zhimin 
Huang, Lin Wu, Bo Zhang, Yanggang Yuan, and Changying Xing. 2018. 
“Leonurine Ameliorates Adriamycin-Induced Podocyte Injury via Suppression of 
Oxidative Stress.” Free Radical Research 52(9):952–60. 
Liu, Yujuan and Hans-Joachim Anders. 2014. “Lupus Nephritis: From Pathogenesis 
to Targets for Biologic Treatment.” Nephron Clinical Practice 128(3–4):224–31. 
Lo, Eng H., Turgay Dalkara, and Michael A. Moskowitz. 2003. “Neurological 
Diseases: Mechanisms, Challenges and Opportunities in Stroke.” Nature 
Reviews Neuroscience 4(5):399–414. 
Long, David A., Maria Kolatsi-Joannou, Karen L. Price, Cecile Dessapt-Baradez, 
Jennifer L. Huang, Eugenia Papakrivopoulou, Mike Hubank, Ron Korstanje, 
Luigi Gnudi, and Adrian S. Woolf. 2013. “Albuminuria Is Associated with Too 
Few Glomeruli and Too Much Testosterone.” Kidney International 83(6):1118–
 267 
29. 
Low, T. L. and A. L. Goldstein. 1982. “Chemical Characterization of Thymosin Beta 
4.” Journal of Biological Chemistry 257(2):1000–1006. 
Low, T. L., S. K. Hu, and A. L. Goldstein. 1981. “Complete Amino Acid Sequence of 
Bovine Thymosin Beta 4: A Thymic Hormone That Induces Terminal 
Deoxynucleotidyl Transferase Activity in Thymocyte Populations.” Proceedings 
of the National Academy of Sciences of the United States of America 
78(2):1162–66. 
Lu, Huan, Qun Zhao, Hao Jiang, Tongge Zhu, Peng Xia, William Seffens, Felix 
Aikhionbare, Dongmei Wang, Zhen Dou, and Xuebiao Yao. 2014. 
“Characterization of Ring-like F-Actin Structure as a Mechanical Partner for 
Spindle Positioning in Mitosis.” PLoS ONE 9(10):e102547. 
Lu, Yuqiu, Yuting Ye, Qianqian Yang, and Shaolin Shi. 2017. “Single-Cell RNA-
Sequence Analysis of Mouse Glomerular Mesangial Cells Uncovers Mesangial 
Cell Essential Genes.” Kidney International 92(2):504–13. 
Lv, Shumin, Hongwen Cai, Yifei Xu, Jin Dai, Xiqing Rong, and Lanzhi Zheng. 2020. 
“Thymosin-β 4 Induces Angiogenesis in Critical Limb Ischemia Mice via 
Regulating Notch/NF-ΚB Pathway.” International Journal of Molecular Medicine 
46(4):1347–58. 
Von Der Maase, Hans, Lisa Sengelov, James T. Roberts, Sergio Ricci, Luigi 
Dogliotti, T. Oliver, Malcolm J. Moore, Annamaria Zimmermann, and Michael 
Arning. 2005. “Long-Term Survival Results of a Randomized Trial Comparing 
Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus 
Cisplatin in Patients With Bladder Cancer.” Journal of Clinical Oncology 
23(21):4602–8. 
Macdonald, Richard A. 1961. “‘Lifespan’ of Liver Cells: Autoradiographic Study Using 
Tritiated Thymidine in Normal, Cirrhotic, and Partially Hepatectomized Rats.” 
Archives of Internal Medicine 107(3):335–43. 
Magistroni, Riccardo, Vivette D. D’Agati, Gerald B. Appel, and Krzysztof Kiryluk. 
2015. “New Developments in the Genetics, Pathogenesis, and Therapy of IgA 
Nephropathy.” Kidney International 88(5):974–89. 
Maheshwari, Mani, Cesar A. Romero, Sumit R. Monu, Nitin Kumar, Tang Dong Liao, 
Edward L. Peterson, and Oscar A. Carretero. 2018. “Renal Protective Effects of 
N -Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt 
 268 
Diet.” American Journal of Hypertension 31(8):902–9. 
Maimaitiyiming, Hasiyeti, Qi Zhou, and Shuxia Wang. 2016. “Thrombospondin 1 
Deficiency Ameliorates the Development of Adriamycin-Induced Proteinuric 
Kidney Disease” edited by Z. Jia. PLOS ONE 11(5):e0156144. 
Mallick, N. P. and R. Gokal. 1999. “Haemodialysis.” Lancet 353(9154):737–42. 
Marshall, Caroline B., Ron D. Krofft, Jeffrey W. Pippin, and Stuart J. Shankland. 
2010. “CDK Inhibitor P21 Is Prosurvival in Adriamycin-Induced Podocyte Injury, 
in Vitro and in Vivo.” American Journal of Physiology-Renal Physiology 
298(5):F1140–51. 
Martin, Claire E. and Nina Jones. 2018. “Nephrin Signaling in the Podocyte: An 
Updated View of Signal Regulation at the Slit Diaphragm and Beyond.” Frontiers 
in Endocrinology 9(302). 
Martinez-Pomares, Luisa and Siamon Gordon. 2007. “Antigen Presentation the 
Macrophage Way.” Cell 131(4):641–43. 
McCarty, D. M., H. Fu, P. E. Monahan, C. E. Toulson, P. Naik, and R. J. Samulski. 
2003. “Adeno-Associated Virus Terminal Repeat (TR) Mutant Generates Self-
Complementary Vectors to Overcome the Rate-Limiting Step to Transduction in 
Vivo.” Gene Therapy 10(26):2112–18. 
McClatchey, Andrea I. and Richard G. Fehon. 2009. “Merlin and the ERM Proteins - 
Regulators of Receptor Distribution and Signaling at the Cell Cortex.” Trends in 
Cell Biology 19(5):198–206. 
McCullagh, Martin, Marissa G. Saunders, and Gregory A. Voth. 2014. “Unraveling 
the Mystery of ATP Hydrolysis in Actin Filaments.” Journal of the American 
Chemical Society 136(37):13053–58. 
McMahon, Andrew P. 2016. “Development of the Mammalian Kidney.” Current 
Topics in Developmental Biology 117:31–64. 
Melak, Michael, Matthias Plessner, and Robert Grosse. 2017. “Actin Visualization at 
a Glance.” Journal of Cell Science 130(3):525–30. 
Menzel, Sylvia and Marcus J. Moeller. 2011. “Role of the Podocyte in Proteinuria.” 
Pediatric Nephrology 26(10):1775–80. 
Merino, Felipe, Sabrina Pospich, Johanna Funk, Thorsten Wagner, Florian Küllmer, 
Hans Dieter Arndt, Peter Bieling, and Stefan Raunser. 2018. “Structural 
Transitions of F-Actin upon ATP Hydrolysis at near-Atomic Resolution Revealed 
by Cryo-EM.” Nature Structural and Molecular Biology 25(6):528–37. 
 269 
Le Meur, Yannick, Valerie Lorgeot, Lydie Comte, Jean Christophe Szelag, Jean 
Claude Aldigier, Claude Leroux-Robert, and Vincent Praloran. 2001. “Plasma 
Levels and Metabolism of AcSDKP in Patients with Chronic Renal Failure: 
Relationship with Erythropoietin Requirements.” American Journal of Kidney 
Diseases 38(3):510–17. 
Miao, Yansong, Catherine C. L. Wong, Vito Mennella, Alphee Michelot, David A. 
Agard, Liam J. Holt, John R. Yates, and David G. Drubin. 2013. “Cell-Cycle 
Regulation of Formin-Mediated Actin Cable Assembly.” Proceedings of the 
National Academy of Sciences of the United States of America 110(47):E4446–
55. 
Miklavc, Pika, Elena Hecht, Nina Hobi, Oliver H. Wittekindt, Paul Dietl, Christine 
Kranz, and Manfred Frick. 2012. “Actin Coating and Compression of Fused 
Secretory Vesicles Are Essential for Surfactant Secretion - a Role for Rho, 
Formins and Myosin II.” Journal of Cell Science 125(11):2765–74. 
Miklavc, Pika, Oliver H. Wittekindt, Edward Felder, and Paul Dietl. 2009. “Ca 2+ -
Dependent Actin Coating of Lamellar Bodies after Exocytotic Fusion: A 
Prerequisite for Content Release or Kiss-and-Run.” Annals of the New York 
Academy of Sciences 1152(1):43–52. 
Miner, Jeffrey H. 2008. “Glomerular Filtration: The Charge Debate Charges Ahead.” 
Kidney International 74(3):259–61. 
Mirski, Shelagh E. L., James H. Gerlach, and Susan P. C. Cole2. 1987. Multidrug 
Resistance in a Human Small Cell Lung Cancer Cell Line Selected in 
Adriamycin. Vol. 47. 
Mitchison, T. J. and L. P. Cramer. 1996. “Actin-Based Cell Motility and Cell 
Locomotion.” Cell 84(3):371–79. 
Mitra, Vikramjit and Jane Metcalf. 2009. “Functional Anatomy and Blood Supply of 
the Liver.” Anaesthesia and Intensive Care Medicine 10(7):332–33. 
Miyamoto-Sato, Etsuko, Shigeo Fujimori, Masamichi Ishizaka, Naoya Hirai, Kazuyo 
Masuoka, Rintaro Saito, Yosuke Ozawa, Katsuya Hino, Takanori Washio, 
Masaru Tomita, Tatsuhiro Yamashita, Tomohiro Oshikubo, Hidetoshi Akasaka, 
Jun Sugiyama, Yasuo Matsumoto, and Hiroshi Yanagawa. 2010. “A 
Comprehensive Resource of Interacting Protein Regions for Refining Human 
Transcription Factor Networks.” PloS One 5(2):e9289. 
Miyata, Kohei, Fusanori Yotsumoto, Sung Ouk Nam, Masahide Kuroki, and Shingo 
 270 
Miyamoto. 2012. “Regulatory Mechanisms of the HB-EGF Autocrine Loop in 
Inflammation, Homeostasis, Development and Cancer.” Anticancer Research 
32(6):2347–52. 
Moëll, Hans. 1956. “Size of Normal Kidneys.” Acta Radiologica 46(5):640–45. 
Mogilner, Alexander and George Oster. 1996. “Cell Motility Driven by Actin 
Polymerization.” Biophysical Journal 71(6):3030–45. 
Molina, D. Kimberley and Vincent J. M. DiMaio. 2012. “Normal Organ Weights in 
Men.” The American Journal of Forensic Medicine and Pathology 33(4):368–72. 
Momparler, R. L., M. Karon, S. E. Siegel, and F. Avila. 1976. “Effect of Adriamycin 
on DNA, RNA, and Protein Synthesis in Cell-Free Systems and Intact Cells.” 
Cancer Research 36(8):2891–95. 
Mon La, The, Hiromi Tachibana, Shun-Ai Li, Tadashi Abe, Sayaka Seiriki, Hikaru 
Nagaoka, Eizo Takashima, Tetsuya Takeda, Daisuke Ogawa, Shin-ichi Makino, 
Katsuhiko Asanuma, Masami Watanabe, Xuefei Tian, Ayuko Sakane, Takuya 
Sasaki, Jun Wada, Kohji Takei, and Hiroshi Yamada. 2020. “Dynamin 1 Is 
Important for Microtubule Organization and Stabilization in Glomerular 
Podocytes.” The FASEB Journal 34:16449–63. 
Moon, Eun-Yi, Ji-Hee Song, and Kyu-Hwan Yang. 2007. “Actin-Sequestering 
Protein, Thymosin-Beta-4 (TB4), Inhibits Caspase-3 Activation in Paclitaxel-
Induced Tumor Cell Death.” Oncology Research Featuring Preclinical and 
Clinical Cancer Therapeutics 16(11):507–16. 
Moore, Nicholas A., Nuria Morral, Thomas A. Ciulla, and Peter Bracha. 2018. “Gene 
Therapy for Inherited Retinal and Optic Nerve Degenerations.” Expert Opinion 
on Biological Therapy 18(1):37–49. 
Mora, Carlos A., Christian A. Baumann, Javier E. Paino, Allan L. Goldstein, and 
Mahnaz Badamchian. 1997. “Biodistribution of Synthetic Thymosin Beta 4 in the 
Serum, Urine and Major Organs of Mice.” Int. J. Immunopharmac 19(1):1–8. 
Mori, Seiichiro, Lina Wang, Takamasa Takeuchi, and Tadahito Kanda. 2004. “Two 
Novel Adeno-Associated Viruses from Cynomolgus Monkey: Pseudotyping 
Characterization of Capsid Protein.” Virology 330(2):375–83. 
Moriguchi, Takashi, Michito Hamada, Naoki Morito, Tsumoru Terunuma, Kazuteru 
Hasegawa, Chuan Zhang, Tomomasa Yokomizo, Ritsuko Esaki, Etsushi 
Kuroda, Keigyou Yoh, Takashi Kudo, Michio Nagata, David R. Greaves, James 
Douglas Engel, Masayuki Yamamoto, and Satoru Takahashi. 2006. “MafB Is 
 271 
Essential for Renal Development and F4/80 Expression in Macrophages.” 
Molecular and Cellular Biology 26(15):5715–27. 
Morita, Tsuyoshi and Ken’ichiro Hayashi. 2013. “G-Actin Sequestering Protein 
Thymosin-Β4 Regulates the Activity of Myocardin-Related Transcription Factor.” 
Biochemical and Biophysical Research Communications 437(3):331–35. 
Morris, D. C., Y. Cui, W. L. Cheung, M. Lu, L. Zhang, Z. G. Zhang, and M. Chopp. 
2014. “A Dose–Response Study of Thymosin Β4 for the Treatment of Acute 
Stroke.” Journal of the Neurological Sciences 345(1–2):61–67. 
Morris, Daniel C., Wing Lee Cheung, Richard Loi, Talan Zhang, Mei Lu, Zheng G. 
Zhang, and Michael Chopp. 2017. “Thymosin Β4 for the Treatment of Acute 
Stroke in Aged Rats.” Neuroscience Letters 659:7–13. 
Morris, Daniel C., Zheng G. Zhang, and Michael Chopp. 2018. “Thymosin Β4 for the 
Treatment of Acute Stroke: Neurorestorative or Neuroprotective?” Expert 
Opinion on Biological Therapy 18(SUP1):149–58. 
Morrison, Avril A., Rebecca L. Viney, Moin A. Saleem, and Michael R. Ladomery. 
2008. “New Insights into the Function of the Wilms Tumor Suppressor Gene 
WT1 in Podocytes.” Am J Physiol Renal Physiol 295:12–17. 
Moschovaki Filippidou, Foteini, Alexander H. Kirsch, Matthias Thelen, Máté Kétszeri, 
Katharina Artinger, Ida Aringer, Corinna Schabhüttl, Agnes A. Mooslechner, 
Bianca Frauscher, Marion Pollheimer, Tobias Niedrist, Andreas Meinitzer, 
Daniel J. Drucker, Thomas R. Pieber, Philipp Eller, Alexander R. Rosenkranz, 
Akos Heinemann, and Kathrin Eller. 2020. “Glucagon-Like Peptide-1 Receptor 
Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell 
Proliferation.” American Journal of Pathology 190(2):400–411. 
Motonishi, Shuta, Masaomi Nangaku, Takehiko Wada, Yu Ishimoto, Takamoto 
Ohse, Taiji Matsusaka, Naoto Kubota, Akira Shimizu, Takashi Kadowaki, 
Kazuyuki Tobe, and Reiko Inagi. 2015. “Sirtuin1 Maintains Actin Cytoskeleton 
by Deacetylation of Cortactin in Injured Podocytes.” J Am Soc Nephrol 26:1939–
59. 
Mouneimne, Ghassan, Scott D. Hansen, Laura M. Selfors, Lara Petrak, Michele M. 
Hickey, Lisa L. Gallegos, Kaylene J. Simpson, James Lim, Frank B. Gertler, 
John H. Hartwig, R. Dyche Mullins, and Joan S. Brugge. 2012. “Differential 
Remodeling of Actin Cytoskeleton Architecture by Profilin Isoforms Leads to 
Distinct Effects on Cell Migration and Invasion.” Cancer Cell 22(5):615–30. 
 272 
Mount, David B. 2014. “Thick Ascending Limb of the Loop of Henle.” Clinical Journal 
of the American Society of Nephrology 9:1974–86. 
Mueller, C. Barber, A. D. Mason, and D. G. Stout. 1955. “Anatomy of the 
Glomerulus.” The American Journal of Medicine 18(2):267–76. 
Mulay, Shrikant R., Dana Thomasova, Mi Ryu, Onkar P. Kulkarni, Adriana Migliorini, 
Hauke Bruns, Regina Gröbmayr, Elena Lazzeri, Laura Lasagni, Helen Liapis, 
Paola Romagnani, and Hans-Joachim Anders. 2013. “Podocyte Loss Involves 
MDM2-Driven Mitotic Catastrophe.” The Journal of Pathology 230(3):322–35. 
Mundel, P., H. W. Heid, T. M. Mundel, M. Krüger, J. Reiser, and W. Kriz. 1997. 
“Synaptopodin: An Actin-Associated Protein in Telencephalic Dendrites and 
Renal Podocytes.” The Journal of Cell Biology 139(1):193–204. 
Mundel, P., J. Reiser, A. Zúñiga Mejía Borja, H. Pavenstädt, G. R. Davidson, W. 
Kriz, and R. Zeller. 1997. “Rearrangements of the Cytoskeleton and Cell 
Contacts Induce Process Formation during Differentiation of Conditionally 
Immortalized Mouse Podocyte Cell Lines.” Experimental Cell Research 
236(1):248–58. 
Mundlos, S., J. Pelletier, A. Darveau, M. Bachmann, A. Winterpacht, and B. Zabel. 
1993. “Nuclear Localization of the Protein Encoded by the Wilms’ Tumor Gene 
WT1 in Embryonic and Adult Tissues | Development.” Development 119:1329–
41. 
Munshaw, Sonali, Susann Bruche, Andia N. Redpath, Alisha Jones, Jyoti Patel, 
Karina N. Dubé, Regent Lee, Svenja S. Hester, Rachel Davies, Giles Neal, 
Ashok Handa, Michael Sattler, Roman Fischer, Keith M. Channon, and Nicola 
Smart. 2021. “Thymosin Β4 Protects against Aortic Aneurysm via Endocytic 
Regulation of Growth Factor Signaling.” The Journal of Clinical Investigation. 
Muramatsu, Shin Ichi, Hiroaki Mizukami, Neal S. Young, and Kevin E. Brown. 1996. 
“Nucleotide Sequencing and Generation of an Infectious Clone of Adeno- 
Associated Virus 3.” Virology 221(1):208–17. 
Mutchnick, Milton G., Horchang H. Lee, David I. Hollander, Gregory D. Haynes, and 
David C. Chua. 1988. “Defective in Vitro Gamma Interferon Production and 
Elevated Serum Immunoreactive Thymosin Β4 Levels in Patients with 
Inflammatory Bowel Disease.” Clinical Immunology and Immunopathology 
47(1):84–92. 
Muzyczka, N. 1992. “Use of Adeno-Associated Virus as a General Transduction 
 273 
Vector for Mammalian Cells.” Current Topics in Microbiology and Immunology 
158:97–129. 
Myrehaug, Sten, Melania Pintilie, Richard Tsang, Robert Mackenzie, Michael Crump, 
Zhongliang Chen, Alexander Sun, and David C. Hodgson. 2008. “Cardiac 
Morbidity Following Modern Treatment for Hodgkin Lymphoma: Supra-Additive 
Cardiotoxicity of Doxorubicin and Radiation Therapy.” Leukemia & Lymphoma 
49(8):1486–93. 
Nachmias, Vivianne T. 1993. “Small Actin-Binding Proteins: The β-Thymosin 
Family.” Current Opinion in Cell Biology 5(1):56–62. 
Nag, Shalini, Mårten Larsson, Robert C. Robinson, and Leslie D. Burtnick. 2013. 
“Gelsolin: The Tail of a Molecular Gymnast.” Cytoskeleton 70(7):360–84. 
Nagai, Takako, Megumi Kanasaki, Swayam Prakash Srivastava, Yuka Nakamura, 
Yasuhito Ishigaki, Munehiro Kitada, Sen Shi, Keizo Kanasaki, and Daisuke 
Koya. 2014. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits Diabetes-Associated 
Kidney Fibrosis and Endothelial-Mesenchymal Transition.” BioMed Research 
International 2014. 
Nagai, Takako, Kyoko Nitta, Megumi Kanasaki, Daisuke Koya, and Keizo Kanasaki. 
2015. “The Biological Significance of Angiotensin-Converting Enzyme Inhibition 
to Combat Kidney Fibrosis.” Clinical and Experimental Nephrology 19(1):65–74. 
Nagao, Tomokazu, Mimiko Matsumura, Ayako Mabuchi, Akiko Ishida-Okawara, 
Osamu Koshio, Toshinori Nakayama, Haruyuki Minamitani, and Kazuo Suzuki. 
2007. “Up-Regulation of Adhesion Molecule Expression in Glomerular 
Endothelial Cells by Anti-Myeloperoxidase Antibody.” Nephrology Dialysis 
Transplantation 22(1):77–87. 
Nakagawa, Takahiko, Yoneko Hayase, Masakiyo Sasahara, Masakazu Haneda, 
Ryuichi Kikkawa, Shigeki Higashiyama, Naoyuki Taniguchi, and Fumitada 
Hazama. 1997. “Distribution of Heparin-Binding EGF-like Growth Factor Protein 
and MRNA in the Normal Rat Kidneys.” Kidney International 51(6):1774–79. 
Nakai, Hiroyuki, Theresa A. Storm, and Mark A. Kay. 2000. “Recruitment of Single-
Stranded Recombinant Adeno-Associated Virus Vector Genomes and 
Intermolecular Recombination Are Responsible for Stable Transduction of Liver 
In Vivo.” Journal of Virology 74(20):9451–63. 
Nakazawa, Daigo, Sakiko Masuda, Utano Tomaru, and Akihiro Ishizu. 2019. 
“Pathogenesis and Therapeutic Interventions for ANCA-Associated Vasculitis.” 
 274 
Nature Reviews Rheumatology 15(2):91–101. 
Nasr, Samih H. and Vivette D. D’Agati. 2011. “IgA-Dominant Postinfectious 
Glomerulonephritis: A New Twist on an Old Disease.” Nephron Clinical Practice 
119(1):c18–26. 
Nasrallah, Rania, Susan J. Robertson, Jacob Karsh, and Richard L. Hébert. 2013. 
“Celecoxib Modifies Glomerular Basement Membrane, Mesangium and 
Podocytes in OVE26 Mice, but Ibuprofen Is More Detrimental.” Clinical Science 
124(11):685–94. 
Nass, Shelley A., Maryellen A. Mattingly, Denise A. Woodcock, Brenda L. Burnham, 
Jeffrey A. Ardinger, Shayla E. Osmond, Amy M. Frederick, Abraham Scaria, 
Seng H. Cheng, and Catherine R. O’Riordan. 2018. “Universal Method for the 
Purification of Recombinant AAV Vectors of Differing Serotypes.” Molecular 
Therapy - Methods and Clinical Development 9:33–46. 
Nathwani, Amit C., Ulreke M. Reiss, Edward G. D. Tuddenham, Cecilia Rosales, 
Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal 
Patel, Deepak Raj, Anne Riddell, Jun Pie, Savita Rangarajan, David Bevan, 
Michael Recht, Yu-Min Shen, Kathleen G. Halka, Etiena Basner-Tschakarjan, 
Federico Mingozzi, Katherine A. High, James Allay, Mark A. Kay, Catherine Y. 
C. Ng, Junfang Zhou, Maria Cancio, Christopher L. Morton, John T. Gray, 
Deokumar Srivastava, Arthur W. Nienhuis, and Andrew M. Davidoff. 2014. 
“Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B.” 
New England Journal of Medicine 371(21):1994–2004. 
Nathwani, Amit C., Edward G. D. Tuddenham, Savita Rangarajan, Cecilia Rosales, 
Jenny McIntosh, David C. Linch, Pratima Chowdary, Anne Riddell, Arnulfo 
Jaquilmac Pie, Chris Harrington, James O’Beirne, Keith Smith, John Pasi, Bertil 
Glader, Pradip Rustagi, Catherine Y. C. Ng, Mark A. Kay, Junfang Zhou, Yunyu 
Spence, Christopher L. Morton, James Allay, John Coleman, Susan Sleep, John 
M. Cunningham, Deokumar Srivastava, Etiena Basner-Tschakarjan, Federico 
Mingozzi, Katherine A. High, John T. Gray, Ulrike M. Reiss, Arthur W. Nienhuis, 
and Andrew M. Davidoff. 2011. “Adenovirus-Associated Virus Vector–Mediated 
Gene Transfer in Hemophilia B.” New England Journal of Medicine 
365(25):2357–65. 
Neal, Christopher R., Hayley Crook, Edward Bell, Steven J. Harper, and David O. 
Bates. 2005. “Three-Dimensional Reconstruction of Glomeruli by Electron 
 275 
Microscopy Reveals a Distinct Restrictive Urinary Subpodocyte Space.” Journal 
of the American Society of Nephrology 16(5):1223–35. 
Neidt, Erin M., Bonnie J. Scott, and David R. Kovar. 2009. “Formin Differentially 
Utilizes Profilin Isoforms to Rapidly Assemble Actin Filaments.” Journal of 
Biological Chemistry 284(1):673–84. 
Nemolato, S., T. Cabras, M. U. Fanari, F. Cau, D. Fanni, C. Gerosa, B. Manconi, I. 
Messana, M. Castagnola, and G. Faa. 2010. “Immunoreactivity of Thymosin 
Beta 4 in Human Foetal and Adult Genitourinary Tract.” European Journal of 
Histochemistry 54(4):193–96. 
Neuen, Brendon L., Tamara Young, Hiddo J. L. Heerspink, Bruce Neal, Vlado 
Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. 
Wheeler, Clare Arnott, Severine Bompoint, Adeera Levin, and Meg J. Jardine. 
2019. “SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with 
Type 2 Diabetes: A Systematic Review and Meta-Analysis.” The Lancet 
Diabetes and Endocrinology 7(11):845–54. 
Neuhaus, Jean-Marc, Michael Wanger, Thomas Keiser, and Albrecht Wegner. 1983. 
“Treadmilling of Actin.” Journal of Muscle Research and Cell Motility 4:507–27. 
Ngo, Kien Xuan, Noriyuki Kodera, Eisaku Katayama, Toshio Ando, and Taro Qp 
Uyeda. 2015. “Cofilin-Induced Unidirectional Cooperative Conformational 
Changes in Actin Filaments Revealed by High-Speed Atomic Force 
Microscopy.” ELife 4(e04806):1–22. 
Nguyen, Nga T. Q., Paul Cockwell, Alexander P. Maxwell, Matthew Griffin, Timothy 
O’Brien, and Ciaran O’Neill. 2018. “Chronic Kidney Disease, Health-Related 
Quality of Life and Their Associated Economic Burden among a Nationally 
Representative Sample of Community Dwelling Adults in England” edited by D. 
Bolignano. PLOS ONE 13(11):e0207960. 
Ni, Yongliang, Xin Wang, Xiaoxuan Yin, Yan Li, Xigao Liu, Haixin Wang, Xiangjv Liu, 
Jun Zhang, Haiqing Gao, Benkang Shi, and Shaohua Zhao. 2018. “Plectin 
Protects Podocytes from Adriamycin-Induced Apoptosis and F-Actin 
Cytoskeletal Disruption through the Integrin Α6β4/FAK/P38 MAPK Pathway.” 
Journal of Cellular and Molecular Medicine 22(11):5450–67. 
Nichols, Kelly K., David G. Evans, and Paul M. Karpecki. 2020. “A Comprehensive 
Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of 
the Vehicle Comparators in These Trials.” Current Eye Research 1–6. 
 276 
Nielsen, Julie S. and Kelly M. Mcnagny. 2009. “The Role of Podocalyxin in Health 
and Disease.” Journal of the American Society of Nephrology 20:1669–76. 
Nijenhuis, Tom, Alexis J. Sloan, Joost G. J. Hoenderop, Jan Flesche, Harry van 
Goor, Andreas D. Kistler, Marinka Bakker, Rene J. M. Bindels, Rudolf A. de 
Boer, Clemens C. Möller, Inge Hamming, Gerjan Navis, Jack F. M. Wetzels, Jo 
H. M. Berden, Jochen Reiser, Christian Faul, and Johan van der Vlag. 2011. 
“Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression 
via an NFAT-Mediated Positive Feedback Signaling Pathway.” The American 
Journal of Pathology 179(4):1719–32. 
Ning, Liang, Hani Y. Suleiman, and Jeffrey H. Miner. 2020. “Synaptopodin Is 
Dispensable for Normal Podocyte Homeostasis but Is Protective in the Context 
of Acute Podocyte Injury.” Journal of the American Society of Nephrology 
31:ASN.2020050572. 
Nitta, Kyoko, Takako Nagai, Yuiko Mizunuma, Munehiro Kitada, Atsushi Nakagawa, 
Masaru Sakurai, Masao Toyoda, Masakazu Haneda, Keizo Kanasaki, and 
Daisuke Koya. 2019. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Is a Potential 
Biomarker of Renal Function in Normoalbuminuric Diabetic Patients with EGFR 
≥ 30 Ml/Min/1.73 M2.” Clinical and Experimental Nephrology 23(8):1004–12. 
Novick, Tessa, Yang Liu, Anika Alvanzo, Alan B. Zonderman, Michele K. Evans, and 
Deidra C. Crews. 2016. “Lifetime Cocaine and Opiate Use and Chronic Kidney 
Disease.” American Journal of Nephrology 44:447–53. 
O’Brien, Stephen P., Mandy Smith, Hong Ling, Lucy Phillips, William Weber, John 
Lydon, Colleen Maloney, Steven Ledbetter, Cynthia Arbeeny, and Stefan 
Wawersik. 2013. “Glomerulopathy in the KK.Cg- Ay/J Mouse Reflects the 
Pathology of Diabetic Nephropathy.” Journal of Diabetes Research 2013:Article 
ID 498925. 
Oh, Jun, Jochen Reiser, and Peter Mundel. 2004. “Dynamic (Re)Organization of the 
Podocyte Actin Cytoskeleton in the Nephrotic Syndrome.” Pediatric Nephrology 
19(2):130–37. 
Okuda, Seiya, Yukinori Oh, Hiroshi Tsuruda, Kaoru Onoyama, Satoru Fujimi, and 
Masatoshi Fujishima. 1986. “Adriamycin-Induced Nephropathy as a Model of 
Chronic Progressive Glomerular Disease.” Kidney International 29:502–10. 
Olin, Jeffrey W., Kathleen M. Beusterien, Mary Beth Childs, Caroline Seavey, Linda 
McHugh, and Robert I. Griffiths. 1999. “Medical Costs of Treating Venous Stasis 
 277 
Ulcers: Evidence from a Retrospective Cohort Study.” Vascular Medicine 
4(1):1–7. 
Omata, Mitsugu, Hajime Taniguchi, Daisuke Koya, Keizo Kanasaki, Rumiko Sho, 
Yoshimi Kato, Ryoji Kojima, Masakazu Haneda, and Norio Inomata. 2006. “N-
Acetyl-Seryl-Asparlyl-Lysyl-Proline Ameliorates the Progression of Renal 
Dysfunction and Fibrosis in WKY Rats with Established Anti-Glomerular 
Basement Membrane Nephritis.” Journal of the American Society of Nephrology 
17(3):674–85. 
Oosawa, Fumio, Sho Asakura, Ken Hotta, Nobuhisa Imai, and Tatsuo Ooi. 1959. “G-
F Transformation of Actin as a Fibrous Condensation.” Journal of Polymer 
Science 37(132):323–36. 
Orlando, Robert A., Tetsuro Takeda, Beverly Zak, Sandra Schmieder, Vivian M. 
Benoit, Tammie Mcquistan, Heinz Furthmayr, and Marilyn G. Farquhar. 2001. 
“The Glomerular Epithelial Cell Anti-Adhesin Podocalyxin Associates with the 
Actin Cytoskeleton through Interactions with Ezrin.” Journal of the American 
Society of Nephrology 12:1589–98. 
Orlowski, Robert Z., Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hajek, 
Andrew Spencer, San Miguel, Tadeusz Robak, Anna Dmoszynska, Noemi 
Horvath, Ivan Spicka, Heather J. Sutherland, Alexander N. Suvorov, Sen H. 
Zhuang, Trilok Parekh, Liang Xiu, Zhilong Yuan, Wayne Rackoff, and Jean-Luc 
Harousseau. 2007. “Randomized Phase III Study of Pegylated Liposomal 
Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or 
Refractory Multiple Myeloma: Combination Therapy Improves Time to 
Progression.” Journal of Clinical Oncology 25(25):3892–3901. 
Otey, C. A., G. B. Vasquez, K. Burridge, and B. W. Erickson. 1993. “Mapping of the 
Alpha-Actinin Binding Site Within the Beta 1 Integrin Cytoplasmic Domain.” J 
Biol Chem. 268(28):21193–97. 
Ougaard, M. K. E., P. H. Kvist, H. E. Jensen, C. Hess, I. Rune, and H. Søndergaard. 
2018. “Murine Nephrotoxic Nephritis as a Model of Chronic Kidney Disease.” 
International Journal of Nephrology 2018(Article ID 8424502):1–12. 
Paavilainen, Ville O., Enni Bertling, Sandra Falck, and Pekka Lappalainen. 2004. 
“Regulation of Cytoskeletal Dynamics by Actin-Monomer-Binding Proteins.” 
Trends in Cell Biology 14(7):386–94. 
Padmanabhan, Krishnanand, Hanna Grobe, Jonathan Cohen, Arad Soffer, Adnan 
 278 
Mahly, Orit Adir, Ronen Zaidel-Bar, and Chen Luxenburg. 2020. “Thymosin Β4 
Is Essential for Adherens Junction Stability and Epidermal Planar Cell Polarity.” 
Development (Cambridge, England) 147(23):1–15. 
Pai, Shan and M. Peter Marinkovich. 2002. “Epidermolysis Bullosa: New and 
Emerging Trends.” American Journal of Clinical Dermatology 3(6):371–80. 
Pan, Chi-syuan, Teressa Reanne Ju, Chi Chan Lee, Yu-Pei Chen, Chung-Y. Hsu, 
Dong-Zong Hung, Wei-Kung Chen, and I. Kuan Wang. 2018. “Alcohol Use 
Disorder Tied to Development of Chronic Kidney Disease: A Nationwide 
Database Analysis” edited by W. Cheungpasitporn. PLOS ONE 
13(9):e0203410. 
Pantaloni, Dominique and Marie-France Carlier. 1993. “How Profilin Promotes Actin 
Filament Assembly in the Presence of Thymosin P4.” Cell 75:1007–14. 
Papakrivopoulou, E, E. Vasilopoulou, M. T. Lindenmeyer, S. Pacheco, H. Ł. Brzóska, 
K. L. Price, M. Kolatsi-Joannou, K. E. White, D. J. Henderson, C. H. Dean, C. D. 
Cohen, A. D. Salama, A. S. Woolf, and D. A. Long. 2018. “Vangl2, a Planar Cell 
Polarity Molecule, Is Implicated in Irreversible and Reversible Kidney Glomerular 
Injury.” Journal of Pathology 246(4). 
Papakrivopoulou, Eugenia, Daniyal J. Jafree, Charlotte H. Dean, and David A. Long. 
2021. “The Biological Significance and Implications of Planar Cell Polarity for 
Nephrology.” Frontiers in Physiology 12:599529. 
Papakrivopoulou, Eugenia, Elisavet Vasilopoulou, Maja T. Lindenmeyer, Sabrina 
Pacheco, Hortensja Ł. Brzóska, Karen L. Price, Maria Kolatsi-Joannou, Kathryn 
E. White, Deborah J. Henderson, Charlotte H. Dean, Clemens D. Cohen, Alan 
D. Salama, Adrian S. Woolf, and David A. Long. 2018. “Vangl2, a Planar Cell 
Polarity Molecule, Is Implicated in Irreversible and Reversible Kidney Glomerular 
Injury.” The Journal of Pathology 246(4):485–96. 
Papeta, Natalia, Zongyu Zheng, Eric A. Schon, Sonja Brosel, Mehmet M. Altintas, 
Samih H. Nasr, Jochen Reiser, Vivette D. D’Agati, and Ali G. Gharavi. 2010. 
“Prkdc Participates in Mitochondrial Genome Maintenance and Prevents 
Adriamycin-Induced Nephropathy in Mice.” The Journal of Clinical Investigation 
120(11):4055–64. 
Parsons, J. Thomas, Alan Rick Horwitz, and Martin A. Schwartz. 2010. “Cell 
Adhesion: Integrating Cytoskeletal Dynamics and Cellular Tension.” Nature 
Reviews Molecular Cell Biology 11(9):633–43. 
 279 
Patrakka, Jaakko and Karl Tryggvason. 2010. “Molecular Make-up of the Glomerular 
Filtration Barrier.” Biochemical and Biophysical Research Communications 
396(1):164–69. 
Paul, Aditya S. and Thomas D. Pollard. 2009. “Review of the Mechanism of 
Processive Actin Filament Elongation by Formins.” Cell Motility and the 
Cytoskeleton 66(8):606–17. 
De Paulo Castro Teixeira, Vicente, Simone Monika Blattner, Min Li, Hans Joachim 
Anders, Clemens David Cohen, Ilka Edenhofer, Novella Calvaresi, Monika 
Merkle, Maria Pia Rastaldi, and Matthias Kretzler. 2005. “Functional 
Consequences of Integrin-Linked Kinase Activation in Podocyte Damage.” 
Kidney International 67(2):514–23. 
Paulussen, Melissa, Bart Landuyt, Liliane Schoofs, Walter Luyten, and Lut Arckens. 
2009. “Thymosin Beta 4 MRNA and Peptide Expression in Phagocytic Cells of 
Different Mouse Tissues.” Peptides 30(10):1822–32. 
Pavenstädt, Hermann, Wilhelm Kriz, and Matthias Kretzler. 2003. “Cell Biology of the 
Glomerular Podocyte.” Physiological Reviews 83(1):253–307. 
Pedchenko, Vadim, Olga Bondar, Agnes B. Fogo, Roberto Vanacore, Paul Voziyan, 
A. Richard Kitching, Jörgen Wieslander, Clifford Kashtan, Dorin-Bogdan Borza, 
Eric G. Neilson, Curtis B. Wilson, and Billy G. Hudson. 2010. “Molecular 
Architecture of the Goodpasture Autoantigen in Anti-GBM Nephritis.” New 
England Journal of Medicine 363(4):343–54. 
Peng, Hongmei, Jiang Xu, Xiao Ping Yang, Xiangguo Dai, Edward L. Peterson, 
Oscar A. Carretero, and Nour Eddine Rhaleb. 2014. “Thymosin-Β4 Prevents 
Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial 
Infarction.” American Journal of Physiology - Heart and Circulatory Physiology 
307(5):H751. 
Pereira, Wagner de Fátima, Gustavo Eustáquio A. Brito-Melo, Cayo Antônio Soares 
de Almeida, Lázaro Lopes Moreira, Cleiton Willian Cordeiro, Thiago Guimarães 
Rosa Carvalho, Elvis Cueva Mateo, and Ana Cristina Simões e Silva. 2015. 
“The Experimental Model of Nephrotic Syndrome Induced by Doxorubicin in 
Rodents: An Update.” Inflammation Research 64(5):287–301. 
Perico, Luca, Sara Conti, Ariela Benigni, and Giuseppe Remuzzi. 2016. “Podocyte-
Actin Dynamics in Health and Disease.” Nature Reviews Nephrology 
12(11):692–710. 
 280 
Perisic, Ljubica, Patricia Q. Rodriguez, Kjell Hultenby, Ying Sun, Mark Lal, Christer 
Betsholtz, Mathias Uhlén, Annika Wernerson, Ulf Hedin, Timo Pikkarainen, Karl 
Tryggvason, and Jaakko Patrakka. 2015. “Schip1 Is a Novel Podocyte Foot 
Process Protein That Mediates Actin Cytoskeleton Rearrangements and Forms 
a Complex with Nherf2 and Ezrin” edited by M. P. Rastaldi. PLOS ONE 
10(3):e0122067. 
Van Der Perren, A., J. Toelen, M. Carlon, C. Van Den Haute, F. Coun, B. Heeman, 
V. Reumers, L. H. Vandenberghe, J. M. Wilson, Z. Debyser, and V. Baekelandt. 
2011. “Efficient and Stable Transduction of Dopaminergic Neurons in Rat 
Substantia Nigra by RAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9.” Gene Therapy 
18(5):517–27. 
Peters, Peter J., Erik Bos, and Alexander Griekspoor. 2006. “Cryo-Immunogold 
Electron Microscopy.” Current Protocols in Cell Biology 30(1):4.7.1-4.7.19. 
Peti-Peterdi, János and Arnold Sipos. 2010. “A High-Powered View of the Filtration 
Barrier.” Journal of the American Society of Nephrology 21(11):1835–41. 
Philp, D., T. Huff, Y. S. Gho, E. Hannappel, and H. K. Kleinman. 2003. “The Actin 
Binding Site on Thymosin β 4 Promotes Angiogenesis.” The FASEB Journal 
17(14):1–13. 
Pillay, S., N. L. Meyer, A. S. Puschnik, O. Davulcu, J. Diep, Y. Ishikawa, L. T. Jae, J. 
E. Wosen, C. M. Nagamine, M. S. Chapman, and J. E. Carette. 2016. “An 
Essential Receptor for Adeno-Associated Virus Infection.” Nature 
530(7588):108–12. 
Pinto, Nicole, Fei Chi Yang, Atsuko Negishi, Maikel C. Rheinstädter, Todd E. Gillis, 
and Douglas S. Fudge. 2014. “Self-Assembly Enhances the Strength of Fibers 
Made from Vimentin Intermediate Filament Proteins.” Biomacromolecules 
15(2):574–81. 
Pippin, Jeffrey W., Paul T. Brinkkoetter, Fionnualla C. Cormack-Aboud, Raghu V. 
Durvasula, Peter V. Hauser, Jolanta Kowalewska, Ronald D. Krofft, Christine M. 
Logar, Caroline B. Marshall, Takamoto Ohse, and Stuart J. Shankland. 2009. 
“Inducible Rodent Models of Acquired Podocyte Diseases.” American Journal of 
Physiology - Renal Physiology 296(2):213–29. 
Pisarek-Horowitz, Anna, Xueping Fan, Sudhir Kumar, Hila M. Rasouly, Richa 
Sharma, Hui Chen, Kathryn Coser, Crystal T. Bluette, Dinesh Hirenallur-
Shanthappa, Sarah R. Anderson, Hongying Yang, Laurence H. Beck, Ramon G. 
 281 
Bonegio, Joel M. Henderson, Stephen P. Berasi, David J. Salant, and Weining 
Lu. 2020. “Loss of Roundabout Guidance Receptor 2 (Robo2) in Podocytes 
Protects Adult Mice from Glomerular Injury by Maintaining Podocyte Foot 
Process Structure.” American Journal of Pathology 190(4):799–816. 
Piscitelli, Stephen C., Keith A. Rodvold, Daniel A. Rushing, and Duane A. 
Tewksbury. 1993. “Pharmacokinetics and Pharmacodynamics of Doxorubicin in 
Patients with Small Cell Lung Cancer.” Clinical Pharmacology and Therapeutics 
53(5):555–61. 
Pocock, Gillian and Christopher D. Richards. 2009. The Human Body - An 
Introduction for the Biomedical and Health Sciences. Oxford: Oxford University 
Press. 
Poh, Kian Keong, Poay Sian Sabrina Lee, Andie Hartanto Djohan, Mary Joyce 
Galupo, Geronica Gorospe Songco, Tiong Cheng Yeo, Huay Cheem Tan, 
Arthur Mark Richards, and Lei Ye. 2020. “Transplantation of Endothelial 
Progenitor Cells in Obese Diabetic Rats Following Myocardial Infarction: Role of 
Thymosin Beta-4.” Cells 9(4):949. 
Polley, Mei-Yin C., Samuel C. Y. Leung, Lisa M. McShane, Dongxia Gao, Judith C. 
Hugh, Mauro G. Mastropasqua, Giuseppe Viale, Lila A. Zabaglo, Frédérique 
Penault-Llorca, John M. S. Bartlett, Allen M. Gown, W. Fraser Symmans, 
Tammy Piper, Erika Mehl, Rebecca A. Enos, Daniel F. Hayes, Mitch Dowsett, 
and Torsten O. Nielsen. 2013. “An International Ki67 Reproducibility Study.” 
Journal of the National Cancer Institute 105(24):1897–1906. 
Pollitt, Alice Y. and Robert H. Insall. 2009. “WASP and SCAR/WAVE Proteins: The 
Drivers of Actin Assembly.” Journal of Cell Science 122(15):2575–78. 
Pozzi, Ambra, George Jarad, Gilbert W. Moeckel, Sergio Coffa, Xi Zhang, Leslie 
Gewin, Vera Eremina, Billy G. Hudson, Dorin Bogdan Borza, Raymond C. 
Harris, Lawrence B. Holzman, Carrie L. Phillips, Reinhard Fassler, Susan E. 
Quaggin, Jeffrey H. Miner, and Roy Zent. 2008. “Β1 Integrin Expression by 
Podocytes Is Required to Maintain Glomerular Structural Integrity.” 
Developmental Biology 316(2):288–301. 
Pradelles, Philippe, Yveline Frobert, Christophe Créminon, Hélène Ivonine, and 
Emilia Frindel. 1991. “Distribution of a Negative Regulator of Haematopoietic 
Stem Cell Proliferation (AcSDKP) and Thymosin, Β4 in Mouse Tissues.” FEBS 
Letters 289(2):171–75. 
 282 
Prochniewicz, Ewa, Neal Janson, David D. Thomas, and Enrique M. De La Cruz. 
2005. “Cofilin Increases the Torsional Flexibility and Dynamics of Actin 
Filaments.” Journal of Molecular Biology 353(5):990–1000. 
Puelles, Victor G., D. Fleck, Lena Ortz, Stella Papadouri, Thiago Strieder, Alexander 
M. C. Böhner, James W. van der Wolde, Michael Vogt, Turgay Saritas, 
Christoph Kuppe, Astrid Fuss, Sylvia Menzel, Barbara M. Klinkhammer, Gerhard 
Müller-Newen, F. Heymann, Leon Decker, Fabian Braun, Oliver Kretz, Tobias B. 
Huber, Etsuo A. Susaki, Hiroki R. Ueda, P. Boor, Jürgen Floege, Rafael 
Kramann, Christian Kurts, John F. Bertram, Marc Spehr, David J. Nikolic-
Paterson, and Marcus J. Moeller. 2019. “Novel 3D Analysis Using Optical 
Tissue Clearing Documents the Evolution of Murine Rapidly Progressive 
Glomerulonephritis.” Kidney International 96(2):505–16. 
Qiao, Xi, Rong-Shan Li, Hong Li, Guo-Zhen Zhu, Xiao-Guang Huang, Shan Shao, 
and Bo Bai. 2013. “Intermedin Protects against Renal Ischemia-Reperfusion 
Injury by Inhibition of Oxidative Stress.” American Journal of Physiology-Renal 
Physiology 304(1):F112–19. 
Qin, D. D., D. Song, J. Huang, Feng Yu, and M. H. Zhao. 2015. “Plasma-Soluble 
Urokinase-Type Plasminogen Activator Receptor Levels Are Associated with 
Clinical and Pathological Activities in Lupus Nephritis: A Large Cohort Study 
from China.” Lupus 24(6):546–57. 
Qiu, Ping, Michelle Kurpakus-Wheater, and Gabriel Sosne. 2007. “Matrix 
Metalloproteinase Activity Is Necessary for Thymosin Beta 4 Promotion of 
Epithelial Cell Migration.” Journal of Cellular Physiology 212(1):165–73. 
Raats, C. J. Ils., Jacob van den Born, Marinka A. H. Bakker, Birgitte Oppers-
Walgreen, Brenda J. M. Pisa, Henry B. P. M. Dijkman, Karel J. M. Assmann, 
and Jo H. M. Berden. 2000. “Expression of Agrin, Dystroglycan, and Utrophin in 
Normal Renal Tissue and in Experimental Glomerulopathies.” American Journal 
of Pathology 156(5):1749–65. 
Radford, David J., Caroline O. S. Savage, and Gerard B. Nash. 2000. “Treatment of 
Rolling Neutrophils with Antineutrophil Cytoplasmic Antibodies Causes 
Conversion to Firm Integrin-Mediated Adhesion.” Arthritis and Rheumatism 
43(6):1337–45. 
Radice, G. L., M. C. Ferreira-Cornwell, S. D. Robinson, H. Rayburn, L. A. Chodosh, 
M. Takeichi, and R. O. Hynes. 1997. “Precocious Mammary Gland Development 
 283 
in P-Cadherin-Deficient Mice.” The Journal of Cell Biology 139(4):1025–32. 
Raje, Shailja, Kumud Pandav, and Ritu Barthwal. 2020. “Binding of Anticancer Drug 
Adriamycin to Parallel G-quadruplex DNA [D-(TTAGGGT)] 4 Comprising Human 
Telomeric DNA Leads to Thermal Stabilization: A Multiple Spectroscopy Study.” 
Journal of Molecular Recognition 33(2). 
Ransick, Andrew, Nils O. Lindström, Jing Liu, Qin Zhu, Jin Jin Guo, Gregory F. 
Alvarado, Albert D. Kim, Hannah G. Black, Junhyong Kim, and Andrew P. 
McMahon. 2019. “Single-Cell Profiling Reveals Sex, Lineage, and Regional 
Diversity in the Mouse Kidney.” Developmental Cell 51(3):399-413.e7. 
Regele, H. M., E. Fillipovic, B. Langer, H. Poczewki, I. Kraxberger, R. E. Bittner, and 
D. Kerjaschki. 2000. “Glomerular Expression of Dystroglycans Is Reduced in 
Minimal Change Nephrosis but Not in Focal Segmental Glomerulosclerosis.” 
Journal of the American Society of Nephrology 11(3):403–12. 
RegeneRx - NCT00311766. 2012. “A Phase 2 Study on Effect of Thymosin Beta 4 
on Wound Healing in Patients With Epidermolysis Bullosa - Full Text View - 
ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/NCT00311766?term=thymosin+beta+4&
draw=2&rank=6). 
RegeneRx - NCT00598871. 2010. “A Phase 2 Study of the Safety and Efficacy of 
Thymosin Beta 4 for Treating Corneal Wounds - Study Results - 
ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/results/NCT00598871?term=thymosin+b
eta+4&draw=2&rank=3). 
RegeneRx - NCT00832091. 2010. “Study of Thymosin Beta 4 in Patients With 
Venous Stasis Ulcers - Study Results - ClinicalTrials.Gov.” ClinicalTrials.Gov. 
Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/results/NCT00832091?term=thymosin+b
eta+4&draw=2&rank=1). 
RegeneRx - NCT01311518. 2015. “A Study of the Safety and Efficacy of Injectable 
Thymosin Beta 4 for Treating Acute Myocardial Infarction - Full Text View - 
ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/NCT01311518?term=thymosin+beta+4&
draw=1&rank=4). 
RegeneRx - NCT01393132. 2015. “Comparative Study of Thymosin Beta 4 Eye 
 284 
Drops vs. Vehicle in the Treatment of Severe Dry Eye - Study Results - 
ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/results/NCT01393132?term=thymosin+b
eta+4&draw=2&rank=5). 
RegeneRx - NCT03578029. 2019. “Evaluation of the Safety and Efficacy Study of 
RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa - Full 
Text View - ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://clinicaltrials.gov/ct2/show/NCT03578029?term=NCT03578029&draw=2
&rank=1). 
RegeneRx - NCT03937882. 2020. “Assessment of the Safety and Efficacy of RGN-
259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 - Full Text View - 
ClinicalTrials.Gov.” ClinicalTrials.Gov. Retrieved January 20, 2021 
(https://www.clinicaltrials.gov/ct2/show/NCT03937882?term=thymosin+beta+4&
draw=2&rank=11). 
Reidy, Kimberly and Frederick J. Kaskel. 2007. “Pathophysiology of Focal 
Segmental Glomerulosclerosis.” Pediatric Nephrology 22(3):350–54. 
Reiser, J., W. Kriz, M. Kretzler, and P. Mundel. 2000. “The Glomerular Slit 
Diaphragm Is a Modified Adherens Junction.” Journal of the American Society of 
Nephrology : JASN 11(1):1–8. 
Reiser, Jochen and Mehmet M. Altintas. 2016. “Podocytes.” F1000Research 5. 
Reiser, Jochen, Jun Oh, Isao Shirato, Katsuhiko Asanuma, Andreas Hug, Thomas 
M. Mundel, Karen Honey, Kazumi Ishidoh, Eiki Kominami, Jordan A. Kreidberg, 
Yasuhiko Tomino, and Peter Mundel. 2004. “Podocyte Migration during 
Nephrotic Syndrome Requires a Coordinated Interplay between Cathepsin L 
and Alpha3 Integrin.” The Journal of Biological Chemistry 279(33):34827–32. 
Renga, Giorgia, Vasilis Oikonomou, Silvia Moretti, Claudia Stincardini, Marina M. 
Bellet, Marilena Pariano, Andrea Bartoli, Stefano Brancorsini, Paolo Mosci, 
Andrea Finocchi, Paolo Rossi, Claudio Costantini, Enrico Garaci, Allan L. 
Goldstein, and Luigina Romani. 2019. “Thymosin Β4 Promotes Autophagy and 
Repair via HIF-1α Stabilization in Chronic Granulomatous Disease.” Life 
Science Alliance 2(6):e201900432. 
Rhaleb, Nour Eddine, Saraswati Pokharel, Umesh Sharma, and Oscar A. Carretero. 
2011. “Renal Protective Effects of N-Acetyl-Ser-Asp-Lys-Pro in 
Deoxycorticosterone Acetate-Salt Hypertensive Mice.” Journal of Hypertension 
 285 
29(2):330–38. 
Robinson, R. C., K. Turbedsky, D. A. Kaiser, J. B. Marchand, H. N. Higgs, S. Choe, 
and T. D. Pollard. 2001. “Crystal Structure of Arp2/3 Complex.” Science 
294(5547):1679–84. 
Rodewald, R. and M. J. Karnovsky. 1974. “Porous Substructure of the Glomerular 
Slit Diaphragm in the Rat and Mouse.” The Journal of Cell Biology 60(2):423–
33. 
Romero, Stéphane, Christophe Le Clainche, Dominique Didry, Coumaran Egile, 
Dominique Pantaloni, and Marie France Carlier. 2004. “Formin Is a Processive 
Motor That Requires Profilin to Accelerate Actin Assembly and Associated ATP 
Hydrolysis.” Cell 119(3):419–29. 
Roselli, Séverine, Olivier Gribouval, Nicolas Boute, Mireille Sich, France Benessy, 
Tania Attié, Marie Claire Gubler, and Corinne Antignac. 2002. “Podocin 
Localizes in the Kidney to the Slit Diaphragm Area.” American Journal of 
Pathology 160(1):131–39. 
Rosenberg, Avi Z. and Jeffrey B. Kopp. 2017. “Focal Segmental 
Glomerulosclerosis.” Clinical Journal of the American Society of Nephrology 
12(3):502–17. 
Rouiller, Isabelle, Xiao Ping Xu, Kurt J. Amann, Coumaran Egile, Stephan Nickell, 
Daniela Nicastro, Rong Li, Thomas D. Pollard, Niels Volkmann, and Dorit 
Hanein. 2008. “The Structural Basis of Actin Filament Branching by the Arp2/3 
Complex.” Journal of Cell Biology 180(5):887–95. 
Rould, Mark A., Qun Wan, Peteranne B. Joel, Susan Lowey, and Kathleen M. 
Trybus. 2006. “Crystal Structures of Expressed Non-Polymerizable Monomeric 
Actin in the ADP and ATP States.” Journal of Biological Chemistry 
281(42):31909–19. 
Rubin, Jeffrey D., Tien V. Nguyen, Kari L. Allen, Katayoun Ayasoufi, and Michael A. 
Barry. 2019. “Comparison of Gene Delivery to the Kidney by Adenovirus, 
Adeno-Associated Virus, and Lentiviral Vectors after Intravenous and Direct 
Kidney Injections.” Human Gene Therapy 30(12):1559–71. 
Ruff, Dennis, David Crockford, Gino Girardi, and Yuxin Zhang. 2010. “A 
Randomized, Placebo-Controlled, Single and Multiple Dose Study of 
Intravenous Thymosin Β4 in Healthy Volunteers.” Annals of the New York 
Academy of Sciences 1194:223–29. 
 286 
Rutledge, Elizabeth A., Christine L. Halbert, and David W. Russell. 1998. “Infectious 
Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes 
Other Than AAV Type 2.” Journal of Virology 72(1):309–19. 
Ryu, Yun Kyoung, Jae Wook Lee, and Eun Yi Moon. 2015. “Thymosin Beta-4, Actin-
Sequestering Protein Regulates Vascular Endothelial Growth Factor Expression 
via Hypoxia-Inducible Nitric Oxide Production in Hela Cervical Cancer Cells.” 
Biomolecules and Therapeutics 23(1):19–25. 
Sacchetti, Marta and Alessandro Lambiase. 2014. “Diagnosis and Management of 
Neurotrophic Keratitis.” Clinical Ophthalmology 8:571–79. 
Safer, Daniel, Marshall Elzinga, and Vivianne T. Nachmias. 1991. “Thymosin B4 and 
Fx, an Actin- Sequestering Peptide, Are Indistinguishable.” The Journal of 
Biological Chemistry 266(7):4029–32. 
Safer, Daniel, Rajasree Golla, and Vivianne T. Nachmias. 1990. “Isolation of a 5-
Kilodalton Actin-Sequestering Peptide from Human Blood Platelets.” Cell 
Biology 87:2536–40. 
Samnegård, Bjoörn, Stefan H. Jacobson, Georg Jaremko, Bo Lennart Johansson, 
Karin Ekberg, Britta Isaksson, Linda Eriksson, John Wahren, and Mats Sjöquist. 
2005. “C-Peptide Prevents Glomerular Hypertrophy and Mesangial Matrix 
Expansion in Diabetic Rats.” Nephrology Dialysis Transplantation 20(3):532–38. 
Sanders, Mitchell C., Allan L. Goldstein, and Yu-Li Wang. 1992. “Thymosin B4 (Fx 
Peptide) Is a Potent Regulator of Actin Polymerization in Living Cells.” Cell 
Biology 89:4678–82. 
Savin, Virginia J., Ram Sharma, Mukut Sharma, Ellen T. McCarthy, Suzanne K. 
Swan, Eileen Ellis, Helen Lovell, Bradley Warady, Sripad Gunwar, Arnold M. 
Chonko, Mary Artero, and Flavio Vincenti. 1996. “Circulating Factor Associated 
with Increased Glomerular Permeability to Albumin in Recurrent Focal 
Segmental Glomerulosclerosis.” New England Journal of Medicine 334(14):878–
83. 
Scheen, André J. 2015. “Pharmacokinetics, Pharmacodynamics and Clinical Use of 
SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney 
Disease.” Clinical Pharmacokinetics 54(7):691–708. 
Schell, Christoph and Tobias B. Huber. 2017. “The Evolving Complexity of the 
Podocyte Cytoskeleton.” Journal of the American Society of Nephrology 
28:3166–74. 
 287 
Schießl, Ina Maria, Anna Hammer, Veronika Kattler, Bernhard Gess, Franziska 
Theilig, Ralph Witzgall, and Hayo Castrop. 2016. “Intravital Imaging Reveals 
Angiotensin II-Induced Transcytosis of Albumin by Podocytes.” Journal of the 
American Society of Nephrology 27(3):731–44. 
Schievenbusch, Stephanie, Ingo Strack, Melanie Scheffler, Roswitha Nischt, Oliver 
Coutelle, Marianna Hösel, Michael Hallek, Jochen Wu Fries, Hans Peter Dienes, 
Margarete Odenthal, and Hildegard Büning. 2010. “Combined Paracrine and 
Endocrine AAV9 Mediated Expression of Hepatocyte Growth Factor for the 
Treatment of Renal Fibrosis.” Molecular Therapy 18(7):1302–9. 
Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark 
Longair, Tobias Pietzsch, Stephan Preibisch, Curtis Rueden, Stephan Saalfeld, 
Benjamin Schmid, Jean-Yves Tinevez, Daniel James White, Volker Hartenstein, 
Kevin Eliceiri, Pavel Tomancak, and Albert Cardona. 2012. “Fiji: An Open-
Source Platform for Biological-Image Analysis.” Nature Methods 9(7):676–82. 
Schneider, Remington R. S., Diana G. Eng, J. Nathan Kutz, Mariya T. Sweetwyne, 
Jeffrey W. Pippin, and Stuart J. Shankland. 2017. “Compound Effects of Aging 
and Experimental FSGS on Glomerular Epithelial Cells.” Aging 9(2):524–46. 
Schouten, Marcel, Willem Joost Wiersinga, Marcel Levi, and Tom van der Poll. 2008. 
“Inflammation, Endothelium, and Coagulation in Sepsis.” Journal of Leukocyte 
Biology 83(3):536–45. 
Schuh, Melina. 2011. “An Actin-Dependent Mechanism for Long-Range Vesicle 
Transport.” Nature Cell Biology 13(12):1431–36. 
Schultz, Brian R. and Jeffrey S. Chamberlain. 2008. “Recombinant Adeno-
Associated Virus Transduction and Integration.” Molecular Therapy 16(7):1189–
99. 
Schwarz, Karin, Matias Simons, Jochen Reiser, Moin A. Saleem, Christian Faul, 
Wihelm Kriz, Andrey S. Shaw, Lawrence B. Holzman, and Peter Mundel. 2001. 
“Podocin, a Raft-Associated Component of the Glomerular Slit Diaphragm, 
Interacts with CD2AP and Nephrin.” Journal of Clinical Investigation 
108(11):1621–29. 
Seldin, Donald W. and Gerhard Giebisch. 2008. The Kidney: Physiology & 
Pathophysiology 1-2. Vol. 1. 4th ed. edited by R. J. Alpern and S. C. Hebert. 
New Haven, Connecticut, USA: Elsevier. 
Senís, Elena, Chronis Fatouros, Stefanie Große, Ellen Wiedtke, Dominik Niopek, 
 288 
Ann-Kristin Mueller, Kathleen Börner, and Dirk Grimm. 2014. “CRISPR/Cas9-
Mediated Genome Engineering: An Adeno-Associated Viral (AAV) Vector 
Toolbox.” Biotechnology Journal 9(11):1402–12. 
Sethi, Sanjeev. 2018. “The Changing Spectrum of Heroin-Associated Kidney 
Disease.” Clinical Journal of the American Society of Nephrology 13(7):975–76. 
Sethi, Sanjeev, Fernando C. Fervenza, Yuzhou Zhang, Ladan Zand, Nicole C. 
Meyer, Nicolò Borsa, Samih H. Nasr, and Richard J. H. Smith. 2013. “Atypical 
Postinfectious Glomerulonephritis Is Associated with Abnormalities in the 
Alternative Pathway of Complement.” Kidney International 83(2):293–99. 
Shankar, Anoop, Ronald Klein, and Barbara E. K. Klein. 2006. “The Association 
among Smoking, Heavy Drinking, and Chronic Kidney Disease.” American 
Journal of Epidemiology 164(3):263–71. 
Shibata, Shigeru, Miki Nagase, and Toshiro Fujita. 2006. “Fluvastatin Ameliorates 
Podocyte Injury in Proteinuric Rats via Modulation of Excessive Rho Signaling.” 
J Am Soc Nephrol 17:754–64. 
Shibuya, Kazuyuki, Keizo Kanasaki, Motohide Isono, Haruhisa Sato, Mitsugu Omata, 
Toshiro Sugimoto, Shin Ichi Araki, Keiji Isshiki, Atsunori Kashiwagi, Masakazu 
Haneda, and Daisuke Koya. 2005. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline 
Prevents Renal Insufficiency and Mesangial Matrix Expansion in Diabetic Db/Db 
Mice.” Diabetes 54(3):838–45. 
Shirato, I, T. Sakai, K. Kimura, Y. Tomino, and W. Kriz. 1996. “Cytoskeletal Changes 
in Podocytes Associated with Foot Process Effacement in Masugi Nephritis.” 
The American Journal of Pathology 148(4):1283–96. 
Shirato, Isao. 2002. “Podocyte Process Effacement in Vivo.” Microscopy Research 
and Technique 57(4):241–46. 
Shirato, Isao, Hiltraud Hosser, Kenjiro Kimura, Tatsuo Sakai, Yasuhiko Tomino, and 
Wilhelm Kriz. 1996. “The Development of Focal Segmental Glomerulosclerosis 
in Masugi Nephritis Is Based on Progressive Podocyte Damage.” Virchows 
Archiv 429(4–5):255–73. 
Shoskes, Daniel A. and Alan W. McMahon. 2012. Urology - Volume 2. 10th ed. 
edited by L. R. Kavouissi, A. W. Partin, A. C. Novick, and C. A. Peters. 
Philadelphia: Elsevier Saunders. 
Sidorenkov, Grigory and Gerjan Navis. 2014. “Safety of ACE Inhibitor Therapies in 
Patients with Chronic Kidney Disease.” Expert Opinion on Drug Safety 
 289 
13(10):1383–95. 
Silacci, P., L. Mazzolai, C. Gauci, N. Stergiopulos, H. L. Yin, and D. Hayoz. 2004. 
“Gelsolin Superfamily Proteins: Key Regulators of Cellular Functions.” Cellular 
and Molecular Life Sciences 61(19–20):2614–23. 
Sit, Soon-Tuck and Ed Manser. 2011. “Rho GTPases and Their Role in Organizing 
the Actin Cytoskeleton.” Journal of Cell Science 124:679–83. 
Siton, Orit and Anne Bernheim-Groswasser. 2014. “Reconstitution of Actin-Based 
Motility by Vasodilator-Stimulated Phosphoprotein (VASP) Depends on the 
Recruitment of F-Actin Seeds from the Solution Produced by Cofilin.” Journal of 
Biological Chemistry 289(45):31274–86. 
Smadel, Joseph E. 1937. “Experimental Nephritis in Rats Induced by Injection of 
Anti-Kidney Serum: III. Pathological Studies of the Acute and Chronic Disease.” 
Journal of Experimental Medicine 65(4):541–56. 
Smart, N., C. A. Risebro, A. A. D. Melville, K. Moses, R. J. Schwartz, K. R. Chien, 
and P. R. Riley. 2007. “Thymosin Beta-4 Is Essential for Coronary Vessel 
Development and Promotes Neovascularization via Adult Epicardium.” Annals of 
the New York Academy of Sciences 1112(1):171–88. 
Smart, Nicola, Sveva Bollini, Karina N. Dubé, Joaquim M. Vieira, Bin Zhou, Sean 
Davidson, Derek Yellon, Johannes Riegler, Anthony N. Price, Mark F. Lythgoe, 
William T. Pu, and Paul R. Riley. 2011. “De Novo Cardiomyocytes from within 
the Activated Adult Heart after Injury.” Nature 474(7353):640–44. 
Smart, Nicola, Alison A. Hill, James C. Cross, and Paul R. Riley. 2002. “A Differential 
Screen for Putative Targets of the BHLH Transcription Factor Hand1 in Cardiac 
Morphogenesis.” Mechanisms of Development 119(SUPPL. 1):S65–71. 
Smith, Benjamin A., Karen Daugherty-Clarke, Bruce L. Goode, and Jeff Gelles. 
2013. “Pathway of Actin Filament Branch Formation by Arp2/3 Complex 
Revealed by Single-Molecule Imaging.” Proceedings of the National Academy of 
Sciences of the United States of America 110(4):1285–90. 
Song, Kibbeum, Hye Ju Han, Sokho Kim, and Jungkee Kwon. 2020. “Thymosin Beta 
4 Attenuates PrP(106-126)-Induced Human Brain Endothelial Cells 
Dysfunction.” European Journal of Pharmacology 869:172891. 
Sonntag, F., K. Kother, K. Schmidt, M. Weghofer, C. Raupp, K. Nieto, A. Kuck, B. 
Gerlach, B. Bottcher, O. J. Muller, K. Lux, M. Horer, and J. A. Kleinschmidt. 
2011. “The Assembly-Activating Protein Promotes Capsid Assembly of Different 
 290 
Adeno-Associated Virus Serotypes.” Journal of Virology 85(23):12686–97. 
Sonntag, Florian, Svenja Bleker, Barbara Leuchs, Roger Fischer, and Jürgen A. 
Kleinschmidt. 2006. “Adeno-Associated Virus Type 2 Capsids with Externalized 
VP1/VP2 Trafficking Domains Are Generated Prior to Passage through the 
Cytoplasm and Are Maintained until Uncoating Occurs in the Nucleus.” Journal 
of Virology 80(22):11040–54. 
Sosne, Gabriel. 2018. “Thymosin Beta 4 and the Eye: The Journey from Bench to 
Bedside.” Expert Opinion on Biological Therapy 18(sup1):99–104. 
Sosne, Gabriel, Chi Chao Chan, Khoan Thai, Michael Kennedy, Elizabeth A. Szliter, 
Linda D. Hazlett, Hynda K. Kleinman, Gabriel Sosne, Chi Chao Chan, Khoan 
Thai, Michael Kennedy, Elizabeth A. Szliter, Linda D. Hazlett, Hynda K. 
Kleinman, Gabriel Sosne, Chi Chao Chan, Khoan Thai, Michael Kennedy, 
Elizabeth A. Szliter, Linda D. Hazlett, Hynda K. Kleinman, Gabriel Sosne, Chi 
Chao Chan, Khoan Thai, Michael Kennedy, Elizabeth A. Szliter, Linda D. 
Hazlett, Hynda K. Kleinman, Gabriel Sosne, Chi Chao Chan, Khoan Thai, 
Michael Kennedy, Elizabeth A. Szliter, Linda D. Hazlett, and Hynda K. 
Kleinman. 2001. “Thymosin Beta 4 Promotes Corneal Wound Healing and 
Modulates Inflammatory Mediators in Vivo.” Experimental Eye Research 
72(5):605–8. 
Sosne, Gabriel, Patricia L. Christopherson, Ronald P. Barrett, and Rafael Fridman. 
2005. “Thymosin-Β4 Modulates Corneal Matrix Metalloproteinase Levels and 
Polymorphonuclear Cell Infiltration after Alkali Injury.” Investigative 
Ophthalmology and Visual Science 46(7):2388–95. 
Sosne, Gabriel, Steven Dunn, David Crockford, Chaesik Kim, and Elizabeth Dixon. 
2013. “Thymosin Beta 4 Eye Drops Significantly Improve Signs and Symptoms 
of Severe Dry Eye in a Physician-Sponsored Phase 2 Clinical Trial | IOVS | 
ARVO Journals.” Investigative Ophthalmology & Visual Science 54:6033. 
Sosne, Gabriel and George W. Ousler. 2015. “Thymosin Beta 4 Ophthalmic Solution 
for Dry Eye: A Randomized, Placebo-Controlled, Phase II Clinical Trial 
Conducted Using the Controlled Adverse Environment (CAETM) Model.” Clinical 
Ophthalmology (Auckland, N.Z.) 9:877–84. 
Sosne, Gabriel, Ping Qiu, Patricia L. Christopherson, and Michelle Kurpakus 
Wheater. 2007. “Thymosin Beta 4 Suppression of Corneal NFκB: A Potential 
Anti-Inflammatory Pathway.” Experimental Eye Research 84(4):663–69. 
 291 
Sosne, Gabriel, Ping Qiu, and Michelle Kurpakus-Wheater. 2007. “Thymosin Beta 4: 
A Novel Corneal Wound Healing and Anti-Inflammatory Agent.” Clinical 
Ophthalmology 1(3):201–7. 
Sosne, Gabriel, Elizabeth A. Szliter, Ronald Barrett, Karen A. Kernacki, Hynda 
Kleinman, and Linda D. Hazlett. 2002. “Thymosin Beta 4 Promotes Corneal 
Wound Healing and Decreases Inflammation in Vivo Following Alkali Injury.” 
Experimental Eye Research 74(2):293–99. 
Sosne, Gabriel, Lihua Xu, Lisa Prach, Linda K. Mrock, Hynda K. Kleinman, John J. 
Letterio, Linda D. Hazlett, and Michelle Kurpakus-Wheater. 2004. “Thymosin 
Beta 4 Stimulates Laminin-5 Production Independent of TGF-Beta.” 
Experimental Cell Research 293(1):175–83. 
Srivastava, A., E. W. Lusby, and K. I. Berns. 1983. “Nucleotide Sequence and 
Organization of the Adeno-Associated Virus 2 Genome.” Journal of Virology 
45(2):555–64. 
Srivastava, D., A. Saxena, J. M. Dimaio, and I. Bock-Marquette. 2007. “Thymosin 
Beta4 Is Cardioprotective after Myocardial Infarction.” Annals of the New York 
Academy of Sciences 1112(1):161–70. 
Srivastava, Swayam Prakash, Julie E. Goodwin, Keizo Kanasaki, and Daisuke Koya. 
2020. “Metabolic Reprogramming by N -acetyl-seryl-aspartyl-lysyl-proline 
Protects against Diabetic Kidney Disease.” British Journal of Pharmacology 
177(16):3691–3711. 
Stark, Kevin, Seppo Vainio, Galya Vassileva, and Andrew P. McMahon. 1994. 
“Epithelial Transformation of Metanephric Mesenchyme in the Developing 
Kidney Regulated by Wnt-4.” Nature 372(6507):679–83. 
Steinert, Peter M., Jonathan C. R. Jones, and Robert D. Goldman. 1984. 
“Intermediate Filaments.” The Journal of Cell Biology 99(1):22–27. 
Steinmetz, Michel O., Kenneth N. Goldie, and Ueli Aebi. 1997. “A Correlative 
Analysis of Actin Filament Assembly, Structure, and Dynamics.” Journal of Cell 
Biology 138(3):559–74. 
Stengel, Bénédicte, Michelle E. Tarver–Carr, Neil R. Powe, Mark S. Eberhardt, and 
Frederick L. Brancati. 2003. “Lifestyle Factors, Obesity and the Risk of Chronic 
Kidney Disease.” Epidemiology 14(4):479–87. 
Streck, Christian J., Paxton V. Dickson, Catherine Y. C. Ng, Junfang Zhou, John T. 
Gray, Amit C. Nathwani, and Andrew M. Davidoff. 2005. “Adeno-Associated 
 292 
Virus Vector-Mediated Systemic Delivery of IFN-β Combined with Low-Dose 
Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma 
Models.” Clinical Cancer Research 11(16):6020–29. 
Stump, Craig S. 2011. “Physical Activity in the Prevention of Chronic Kidney 
Disease.” Cardiorenal Medicine 1(3):164–73. 
Stumvoll, Michael, Christian Meyer, Gabriele Perriello, Maryl Kreider, Stephen Welle, 
and John Gerich. 1998. “Human Kidney and Liver Gluconeogenesis: Evidence 
for Organ Substrate Selectivity.” American Journal of Physiology - 
Endocrinology and Metabolism 274(5):E817–26. 
Suarez, Cristian, Jérémy Roland, Rajaa Boujemaa-Paterski, Hyeran Kang, Brannon 
R. McCullough, Anne Cécile Reymann, Christophe Guérin, Jean Louis Martiel, 
Enrique M. De La Cruz, and Laurent Blanchoin. 2011. “Cofilin Tunes the 
Nucleotide State of Actin Filaments and Severs at Bare and Decorated Segment 
Boundaries.” Current Biology 21(10):862–68. 
Subbarayan, Meena S., Charles Hudson, Lauren D. Moss, Kevin R. Nash, and Paula 
C. Bickford. 2020. “T Cell Infiltration and Upregulation of MHCII in Microglia 
Leads to Accelerated Neuronal Loss in an α-Synuclein Rat Model of Parkinson’s 
Disease.” Journal of Neuroinflammation 17(1):1–16. 
Succar, Lena, Ross A. Boadle, David C. Harris, and Gopala K. Rangan. 2016. 
“Formation of Tight Junctions between Neighboring Podocytes Is an Early 
Ultrastructural Feature in Experimental Crescentic Glomerulonephritis.” 
International Journal of Nephrology and Renovascular Disease 9:297–312. 
Succar, Lena, Julia Lai-Kwon, David J. Nikolic-Paterson, and Gopala K. Rangan. 
2014. “Induction Monotherapy with Sirolimus Has Selected Beneficial Effects on 
Glomerular and Tubulointersititial Injury in Nephrotoxic Serum Nephritis.” 
International Journal of Nephrology and Renovascular Disease 7:303–13. 
Sugiyama, Seigo, Hideaki Jinnouchi, Akira Yoshida, Kunio Hieshima, Noboru 
Kurinami, Katsunori Jinnouchi, Motoko Tanaka, Tomoko Suzuki, Fumio 
Miyamoto, Keizo Kajiwara, and Tomio Jinnouchi. 2019. “Renoprotective Effects 
of Additional SGLT2 Inhibitor Therapy in Patients With Type 2 Diabetes Mellitus 
and Chronic Kidney Disease Stages 3b-4: A Real World Report From A 
Japanese Specialized Diabetes Care Center.” Journal of Clinical Medicine 
Research 11(4):267–74. 
Suh, J. H. and J. H. Miner. 2013. “The Glomerular Basement Membrane as a Barrier 
 293 
to Albumin.” Nature Reviews Nephrology 9:470–77. 
Suleiman, Hani Y., Robyn Roth, Sanjay Jain, John E. Heuser, Andrey S. Shaw, and 
Jeffrey H. Miner. 2017. “Injury-Induced Actin Cytoskeleton Reorganization in 
Podocytes Revealed by Super-Resolution Microscopy.” JCI Insight 2(16). 
Suliman, Hagir B., Martha Sue Carraway, Abdelwahid S. Ali, Chrystal M. Reynolds, 
Karen E. Welty-Wolf, and Claude A. Piantadosi. 2007. “The CO/HO System 
Reverses Inhibition of Mitochondrial Biogenesis and Prevents Murine 
Doxorubicin Cardiomyopathy.” Journal of Clinical Investigation 117(12):3730–
41. 
Sun, Yu Bo Yang, Xinli Qu, Xueming Zhang, Georgina Caruana, John F. Bertram, 
and Jinhua Li. 2013. “Glomerular Endothelial Cell Injury and Damage Precedes 
That of Podocytes in Adriamycin-Induced Nephropathy” edited by M. P. 
Rastaldi. PLoS ONE 8(1):e55027. 
Suraneni, Praveen, Boris Rubinstein, Jay R. Unruh, Michael Durnin, Dorit Hanein, 
and Rong Li. 2012. “The Arp2/3 Complex Is Required for Lamellipodia 
Extension and Directional Fibroblast Cell Migration.” Journal of Cell Biology 
197(2):239–51. 
Svitkina, Tatyana. 2018. “The Actin Cytoskeleton and Actin-Based Motility.” Cold 
Spring Harbor Perspectives in Biology 10(1):a018267. 
Szrejder, Maria, Patrycja Rachubik, Dorota Rogacka, Irena Audzeyenka, Michał 
Rychłowski, Stefan Angielski, and Agnieszka Piwkowska. 2020. “Extracellular 
ATP Modulates Podocyte Function through P2Y Purinergic Receptors and 
Pleiotropic Effects on AMPK and CAMP/PKA Signaling Pathways.” Archives of 
Biochemistry and Biophysics 695:108649. 
Tabatabaeifar, Mansoureh, Tanja Wlodkowski, Ivana Simic, Helga Denc, Geraldine 
Mollet, Stefanie Weber, John Julius Moyers, Barbara Brühl, Michael Joseph 
Randles, Rachel Lennon, Corinne Antignac, and Franz Schaefer. 2017. “An 
Inducible Mouse Model of Podocin-Mutation-Related Nephrotic Syndrome” 
edited by S. E. Dryer. PLOS ONE 12(10):e0186574. 
Takeda, Tetsuro. 2003. “Podocyte Cytoskeleton Is Connected to the Integral 
Membrane Protein Podocalyxin through Na+/H+-Exchanger Regulatory Factor 2 
and Ezrin.” Clinical and Experimental Nephrology 7(4):260–69. 
Takeda, Tetsuro, Tammie McQuistan, Robert A. Orlando, and Marilyn G. Farquhar. 
2001. “Loss of Glomerular Foot Processes Is Associated with Uncoupling of 
 294 
Podocalyxin from the Actin Cytoskeleton.” Journal of Clinical Investigation 
108(2):289–301. 
Takeya, Ryu, Kenichiro Taniguchi, Shuh Narumiya, and Hideki Sumimoto. 2008. 
“The Mammalian Formin FHOD1 Is Activated through Phosphorylation by 
ROCK and Mediates Thrombin-Induced Stress Fibre Formation in Endothelial 
Cells.” The EMBO Journal 27(4):618–28. 
Tang, Mei-Chuan, Li-Chuan Chan, Yi-Chen Yeh, Cheng-Yu Chen, Teh-Ying Chou, 
Wei-Shu Wang, and Yeu Su. 2011. “Thymosin Beta 4 Induces Colon Cancer 
Cell Migration and Clinical Metastasis via Enhancing ILK/IQGAP1/Rac1 Signal 
Transduction Pathway.” Cancer Letters 308(2):162–71. 
Tarantal, Alice F., C. Chang I. Lee, Michele L. Martinez, Aravind Asokan, and R. 
Jude Samulski. 2017. “Systemic and Persistent Muscle Gene Expression in 
Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector.” 
Human Gene Therapy 28(5):385–91. 
Teramoto, Keisuke, Yu Tsurekawa, Mary Ann Suico, Shota Kaseda, Kohei Omachi, 
Tsubasa Yokota, Misato Kamura, Mariam Piruzyan, Tatsuya Kondo, Tsuyoshi 
Shuto, Eiichi Araki, and Hirofumi Kai. 2020. “Mild Electrical Stimulation with Heat 
Shock Attenuates Renal Pathology in Adriamycin-Induced Nephrotic Syndrome 
Mouse Model.” Scientific Reports 10(1):1–12. 
Tham, El Li, Simon J. Freeley, Siobhan Bearder, Fernanda Florez Barros, Mark S. 
Cragg, Attila Mócsai, and Michael G. Robson. 2020. “VISTA Deficiency Protects 
from Immune Complex-Mediated Glomerulonephritis by Inhibiting Neutrophil 
Activation.” Journal of Autoimmunity 113:102501. 
Thomas, Clare E., Theresa A. Storm, Zan Huang, and Mark A. Kay. 2004. “Rapid 
Uncoating of Vector Genomes Is the Key to Efficient Liver Transduction with 
Pseudotyped Adeno-Associated Virus Vectors.” Journal Of Virology 78(6):3110–
22. 
Tian, Xuefei and Shuta Ishibe. 2016. “Targeting the Podocyte Cytoskeleton: From 
Pathogenesis to Therapy in Proteinuric Kidney Disease.” Nephrology Dialysis 
Transplantation 31(10):1577–83. 
Tipping, Peter G. and Stephen R. Holdsworth. 2006. “T Cells in Crescentic 
Glomerulonephritis.” Journal of the American Society of Nephrology 17(5):1253–
63. 
Toda, Naohiro, Kiyoshi Mori, Masato Kasahara, Akira Ishii, Kenichi Koga, Shoko 
 295 
Ohno, Keita P. Mori, Yukiko Kato, Keisuke Osaki, Takashige Kuwabara, 
Katsutoshi Kojima, Daisuke Taura, Masakatsu Sone, Taiji Matsusaka, Kazuwa 
Nakao, Masashi Mukoyama, Motoko Yanagita, and Hideki Yokoi. 2017. “Crucial 
Role of Mesangial Cell-Derived Connective Tissue Growth Factor in a Mouse 
Model of Anti-Glomerular Basement Membrane Glomerulonephritis.” Scientific 
Reports 7(1):1–16. 
Tolliday, Nicola, Lynn VerPlank, and Rong Li. 2002. “Rho1 Directs Formin-Mediated 
Actin Ring Assembly during Budding Yeast Cytokinesis.” Current Biology 
12(21):1864–70. 
Tompa, Peter. 2005. “The Interplay between Structure and Function in Intrinsically 
Unstructured Proteins.” FEBS Letters 579(15):3346–54. 
Torres, Vicente E., Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared 
J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, 
and Frank S. Czerwiec. 2012. “Tolvaptan in Patients with Autosomal Dominant 
Polycystic Kidney Disease.” New England Journal of Medicine 367(25):2407–
18. 
Tratschin, J. D., M. H. West, T. Sandbank, and B. J. Carter. 1984. “A Human 
Parvovirus, Adeno-Associated Virus, as a Eucaryotic Vector: Transient 
Expression and Encapsidation of the Procaryotic Gene for Chloramphenicol 
Acetyltransferase.” Molecular and Cellular Biology 4(10):2072–81. 
Tryggvason, Karl, Timo Pikkarainen, and Jaakko Patrakka. 2006. “Nck Links Nephrin 
to Actin in Kidney Podocytes.” Cell 125(2):221–24. 
Tu, Ling, Xizhen Xu, Huaibing Wan, Changqing Zhou, Juanjuan Deng, Gang Xu, 
Xiao Xiao, Yipu Chen, Matthew L. Edin, James W. Voltz, Darryl C. Zeldin, and 
Dao Wen Wang. 2008. “Delivery of Recombinant Adeno-Associated Virus-
Mediated Human Tissue Kallikrein for Therapy of Chronic Renal Failure in 
Rats.” Human Gene Therapy 19(4):318–30. 
Tung, Chun-Wu, Yung-Chien Hsu, Ya-Hsueh Shih, Pey-Jium Chang, and Chun-
Liang Lin. 2018. “Glomerular Mesangial Cell and Podocyte Injuries in Diabetic 
Nephropathy.” Nephrology 23:32–37. 
Turner, Jeffrey M., Carolyn Bauer, Matthew K. Abramowitz, Michal L. Melamed, and 
Thomas H. Hostetter. 2012. “Treatment of Chronic Kidney Disease.” Kidney 
International 81(4):351–62. 
Ullman-Culleré, Mollie H. and Charmaine J. Foltz. 1999. “Body Condition Scoring: A 
 296 
Rapid and Accurate Method for Assessing Health Status in Mice.” Laboratory 
Animal Science 49(3):319–23. 
Vallon, Volker, Kenneth A. Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott 
C. Thomson, Hermann Koepsell, and Timo Rieg. 2011. “SGLT2 Mediates 
Glucose Reabsorption in the Early Proximal Tubule.” J Am Soc Nephrol 22:104–
12. 
Vartiainen, Maria K., Tuija Mustonen, Pieta K. Mattila, Pauli J. Ojala, Irma Thesleff, 
Juha Partanen, and Pekka Lappalainen. 2002. “The Three Mouse Actin-
Depolymerizing Factor/Cofilins Evolved to Fulfill Cell-Type-Specific 
Requirements for Actin Dynamics.” Molecular Biology of the Cell 13(1):183–94. 
Vasilopoulou, Elisavet, Maria Kolatsi-Joannou, Maja T. Lindenmeyer, Kathryn E. 
White, Michael G. Robson, Clemens D. Cohen, Neil J. Sebire, Paul R. Riley, 
Paul J. Winyard, and David A. Long. 2016. “Loss of Endogenous Thymosin Β4 
Accelerates Glomerular Disease.” Kidney International 90(5):1056–70. 
Vasilopoulou, Elisavet, Paul R. Riley, and David A. Long. 2018. “Thymosin-Β4: A 
Key Modifier of Renal Disease.” Expert Opinion of Biological Therapy 
18(Sup1):185–92. 
Vavylonis, Dimitrios, David R. Kovar, Ben O’Shaughnessy, and Thomas D. Pollard. 
2006. “Model of Formin-Associated Actin Filament Elongation.” Molecular Cell 
21(4):455–66. 
Vincent, K. A., S. T. Piraino, and S. C. Wadsworth. 1997. “Analysis of Recombinant 
Adeno-Associated Virus Packaging and Requirements for Rep and Cap Gene 
Products.” Journal of Virology 71(3):1897–1905. 
Vladar, Eszter K., Roy D. Bayly, Ashvin M. Sangoram, Matthew P. Scott, and Jeffrey 
D. Axelrod. 2012. “Microtubules Enable the Planar Cell Polarity of Airway Cilia.” 
Current Biology 22(23):2203–12. 
Vogelmann, Stefanie U., W. James Nelson, Bryan D. Myers, and Kevin V. Lemley. 
2003. “Urinary Excretion of Viable Podocytes in Health and Renal Disease.” 
American Journal of Physiology - Renal Physiology 285(1 54-1):F40. 
Vogtländer, Nils P. J., Henk Jan Visch, Marinka A. H. Bakker, Jo H. M. Berden, and 
Johan van der Vlag. 2009. “Ligation of α-Dystroglycan on Podocytes Induces 
Intracellular Signaling: A New Mechanism for Podocyte Effacement?” edited by 
J. Z. Rappoport. PLoS ONE 4(6):e5979. 
Wagner, Mark C., George Rhodes, Exing Wang, Vikas Pruthi, Ehtesham Arif, Moin 
 297 
A. Saleem, Sarah E. Wean, Puneet Garg, Rakesh Verma, Lawrence B. 
Holzman, Vince Gattone, Bruce A. Molitoris, and Deepak Nihalani. 2008. 
“Ischemic Injury to Kidney Induces Glomerular Podocyte Effacement and 
Dissociation of Slit Diaphragm Proteins Neph1 and ZO-1.” Journal of Biological 
Chemistry 283(51):35579–89. 
Wagner, Nicole, Kay Dietrich Wagner, Yiming Xing, Holger Scholz, and Andreas 
Schedl. 2004. “The Major Podocyte Protein Nephrin Is Transcriptionally 
Activated by the Wilms’ Tumor Suppressor WT1.” Journal of the American 
Society of Nephrology 15(12):3044–51. 
Walker, P. Roy, Catherine Smith, Tony Youdale, Julie Leblanc, James F. Whitfield, 
and Marianna Sikorska. 1991. “Topoisomerase II-Reactive Chemotherapeutic 
Drugs Induce Apoptosis in Thymocytes.” Cancer Research 51(4):1078–85. 
Wang, Dan, Phillip W. L. Tai, and Guangping Gao. 2019. “Adeno-Associated Virus 
Vector as a Platform for Gene Therapy Delivery.” Nature Reviews Drug 
Discovery 18(5):358–78. 
Wang, Juan, Teruo Hidaka, Yu Sasaki, Eriko Tanaka, Miyuki Takagi, Terumi 
Shibata, Ayano Kubo, Juan Alejandro Oliva Trejo, Lining Wang, Katsuhiko 
Asanuma, and Yasuhiko Tomino. 2018. “Neurofilament Heavy Polypeptide 
Protects against Reduction in Synaptopodin Expression and Prevents Podocyte 
Detachment.” Scientific Reports 8(1):1–14. 
Wang, Mingao, Ruichan Liu, Xibei Jia, Suhong Mu, and Rujuan Xie. 2010. “N-Acetyl-
Seryl-Aspartyl-Lysyl-Proline Attenuates Renal Inflammation and 
Tubulointerstitial Fibrosis in Rats.” International Journal of Molecular Medicine 
26(6):795–801. 
Wang, Siyuan, Cheng Chen, Ke Su, Dongqing Zha, Wei Liang, JL Hillebrands, Harry 
van Goor, and Guohua Ding. 2016. “Angiotensin II Induces Reorganization of 
the Actin Cytoskeleton and Myosin Light-Chain Phosphorylation in Podocytes 
through Rho/ROCK-Signaling Pathway*.” Renal Failure 38(2):268–75. 
Wang, Yang, Yi Ping Wang, Yuet-Ching Tay, and David C. H. Harris. 2000. 
“Progressive Adriamycin Nephropathy in Mice: Sequence of Histologic and 
Immunohistochemical Events.” Kidney International 58(4):1797–1804. 
Wang, Yanshu and Jeremy Nathans. 2007. “Tissue/Planar Cell Polarity in 
Vertebrates: New Insights and New Questions.” Development 134(4):647–58. 
Wang, Yuan Min, Yiping Wang, David C. H. Harris, Stephen I. Alexander, and 
 298 
Vincent W. S. Lee. 2015. “Adriamycin Nephropathy in BALB/c Mice.” Pp. 
15.28.1-15.28.6 in Current Protocols in Immunology. Vol. 108. Hoboken, NJ, 
USA: John Wiley & Sons, Inc. 
Wartiovaara, Jorma, Lars Göran Öfverstedt, Jamshid Khoshnoodi, Jingjing Zhang, 
Eetu Mäkelä, Sara Sandin, Vesa Ruotsalainen, R. Holland Cheng, Hannu 
Jalanko, Ulf Skoglund, and Karl Tryggvason. 2004. “Nephrin Strands Contribute 
to a Porous Slit Diaphragm Scaffold as Revealed by Electron Tomography.” 
Journal of Clinical Investigation 114(10):1475–83. 
Weaver, Alissa M., Andrei V. Karginov, Andrew W. Kinley, Scott A. Weed, Yan Li, J. 
Thomas Parsons, and John A. Cooper. 2001. “Cortactin Promotes and 
Stabilizes Arp2/3-Induced Actin Filament Network Formation.” Current Biology 
11(5):370–74. 
Weber, A, V. T. Nachmias, C. R. Pennise, M. Pring, and D. Safer. 1992. “Interaction 
of Thymosin SS4 with Muscle and Platelet Actin: Implications for Actin 
Sequestration in Resting Platelets.” Biochemistry 31:6179–85. 
Weber, A., C. R. Pennise, V. T. Nachmias, D. Safer, and M. Pring. 1992. “Interaction 
of Thymosin Β4 with Muscle and Platelet Actin : Implications for Actin 
Sequestration in Resting Platelets.” Biochemistry 31(27):6179–85. 
Wegner, A., T. P. Walsh, K. Ruhnau, Y. Yamashiro-Matsumura, F. Matsumura, E. 
Yokota, and K. Maruyama. 1989. “Effects of CapZ, an Actin Capping Protein of 
Muscle, on the Polymerization of Actin.” Biochemistry 28(21):8506–14. 
Wegner, Binytha, Abass Al-Momany, Stephen C. Kulak, Kathy Kozlowski, Marya 
Obeidat, Nadia Jahroudi, John Paes, Mark Berryman, and Barbara J. 
Ballermann. 2010. “CLIC5A, a Component of the Ezrin-Podocalyxin Complex in 
Glomeruli, Is a Determinant of Podocyte Integrity.” American Journal of 
Physiology - Renal Physiology 298(6):F1492-503. 
Wei, Changli, Shafic El Hindi, Jing Li, Alessia Fornoni, Nelson Goes, Junichiro 
Sageshima, Dony Maiguel, S. Ananth Karumanchi, Hui Kim Yap, Moin Saleem, 
Qingyin Zhang, Boris Nikolic, Abanti Chaudhuri, Pirouz Daftarian, Eduardo 
Salido, Armando Torres, Moro Salifu, Minnie M. Sarwal, Franz Schaefer, 
Christian Morath, Vedat Schwenger, Martin Zeier, Vineet Gupta, David Roth, 
Maria Pia Rastaldi, George Burke, Phillip Ruiz, and Jochen Reiser. 2011. 
“Circulating Urokinase Receptor as a Cause of Focal Segmental 
Glomerulosclerosis.” Nature Medicine 17(8):952–60. 
 299 
Wei, Chuanyu, Sandeep Kumar, Il-Kwon Kim, and Sudhiranjan Gupta. 2012. 
“Thymosin Beta 4 Protects Cardiomyocytes from Oxidative Stress by Targeting 
Anti-Oxidative Enzymes and Anti-Apoptotic Genes” edited by R. Mohanraj. 
PLoS ONE 7(8):e42586. 
Weil, E. Jennifer, Kevin V. Lemley, Clinton C. Mason, Berne Yee, Lois I. Jones, 
Kristina Blouch, Tracy Lovato, Meghan Richardson, Bryan D. Myers, and Robert 
G. Nelson. 2012. “Podocyte Detachment and Reduced Glomerular Capillary 
Endothelial Fenestration Promote Kidney Disease in Type 2 Diabetic 
Nephropathy.” Kidney International 82(9):1010–17. 
Welsh, Gavin I. and Moin A. Saleem. 2012. “The Podocyte Cytoskeleton-Key to a 
Functioning Glomerulus in Health and Disease.” Nat. Rev. Nephrol 8:14–21. 
Welte, Michael A. 2004. “Bidirectional Transport along Microtubules.” Current 
Biology 14(13):R525–37. 
Westhaus, Adrian, Marti Cabanes-Creus, Arkadiusz Rybicki, Grober Baltazar, 
Renina Gale Navarro, Erhua Zhu, Matthieu Drouyer, Maddison Knight, Razvan 
F. Albu, Boaz H. Ng, Predrag Kalajdzic, Magdalena Kwiatek, Kenneth Hsu, 
Giorgia Santilli, Wendy Gold, Belinda Kramer, Anai Gonzalez-Cordero, Adrian J. 
Thrasher, Ian E. Alexander, and Leszek Lisowski. 2020. “High-Throughput in 
Vitro, Ex Vivo, and in Vivo Screen of Adeno-Associated Virus Vectors Based on 
Physical and Functional Transduction.” Human Gene Therapy 31(9–10):575–89. 
Wharram, Bryan L., Meera Goyal, Patrick J. Gillespie, Jocelyn E. Wiggins, David B. 
Kershaw, Lawrence B. Holzman, Robert C. Dysko, Thomas L. Saunders, Linda 
C. Samuelson, and Roger C. Wiggins. 2000. “Altered Podocyte Structure in 
GLEPP1 (Ptpro)-Deficient Mice Associated with Hypertension and Low 
Glomerular Filtration Rate.” Journal of Clinical Investigation 106(10):1281–90. 
Wioland, Hugo, Berengere Guichard, Yosuke Senju, Sarah Myram, Pekka 
Lappalainen, Antoine Jégou, and Guillaume Romet-Lemonne. 2017. 
“ADF/Cofilin Accelerates Actin Dynamics by Severing Filaments and Promoting 
Their Depolymerization at Both Ends.” Current Biology 27(13):1956-1967.e7. 
Wise, T., G. J. MacDonald, J. Klindt, and J. J. Ford. 1992. “Characterization of 
Thymic Weight and Thymic Peptide Thymosin-Beta 4: Effects of 
Hypophysectomy, Sex, and Neonatal Sexual Differentiation.” Thymus 
19(4):235–44. 
Wolfe, Robert A., Valarie B. Ashby, Edgar L. Milford, Akinlolu O. Ojo, Robert E. 
 300 
Ettenger, Lawrence Y. C. Agodoa, Philip J. Held, and Friedrich K. Port. 1999. 
“Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis 
Awaiting Transplantation, and Recipients of a First Cadaveric Transplant.” New 
England Journal of Medicine 341(23):1725–30. 
Wollina, Uwe, Tim Graefe, and Kerstin Karte. 2000. “Treatment of Relapsing or 
Recalcitrant Cutaneous T-Cell Lymphoma with Pegylated Liposomal 
Doxorubicin.” Journal of the American Academy of Dermatology 42(1 I):40–46. 
Wong, Jenny S., Elizabeth Iorns, Michelle N. Rheault, Toby M. Ward, Priyanka 
Rashmi, Ursula Weber, Marc E. Lippman, Christian Faul, Marek Mlodzik, and 
Peter Mundel. 2012. “Rescue of Tropomyosin Deficiency in Drosophila and 
Human Cancer Cells by Synaptopodin Reveals a Role of Tropomyosin α in 
RhoA Stabilization.” The EMBO Journal 31(4):1028–40. 
Woodrum, Diane T., Steven A. Rich, and Thomas D. Pollard. 1975. “Evidence for 
Biased Bidirectional Polymerization of Actin Filaments Using Heavy Meromyosin 
Prepared by an Improved Method.” Journal of Cell Biology 67(1):231–37. 
Worawichawong, Suchin, Louis Girard, Kiril Trpkov, James C. Gough, Daniel B. 
Gregson, and Hallgrimur Benediktsson. 2011. “Immunoglobulin A-Dominant 
Postinfectious Glomerulonephritis: Frequent Occurrence in Nondiabetic Patients 
with Staphylococcus Aureus Infection.” Human Pathology 42(2):279–84. 
World Health Organisation. 2018. “International Nonproprietary Names for 
Pharmaceutical Substances (INN) RECOMMENDED International 
Nonproprietary Names: List 80.” WHO Drug Information 32(3):425–508. 
Woychyshyn, Boyan, Joan Papillon, Julie Guillemette, Jose R. Navarro-Betancourt, 
and Andrey V Cybulsky. 2020. “Genetic Ablation of SLK Exacerbates 
Glomerular Injury in Adriamycin Nephrosis in Mice.” American Journal of 
Physiology-Renal Physiology 318(6):F1377–90. 
Wu, Haijing, Yi Lo, Albert Chan, Ka Sin Law, and Mo Yin Mok. 2016. “Rel B-modified 
Dendritic Cells Possess Tolerogenic Phenotype and Functions on Lupus Splenic 
Lymphocytes in Vitro.” Immunology 149(1):48–61. 
Wu, Jinzi and Liang Jun Yan. 2015. “Streptozotocin-Induced Type 1 Diabetes in 
Rodents as a Model for Studying Mitochondrial Mechanisms of Diabetic β Cell 
Glucotoxicity.” Diabetes, Metabolic Syndrome and Obesity: Targets and 
Therapy 8:181–88. 
Wu, Xili, Peng An, Bingyu Ye, Xingmin Shi, Huimin Dang, Rongguo Fu, and 
 301 
Chenglin Qiao. 2014. “Artemisinin Ameliorated Proteinuria in Rats with 
Adriamycin-Induced Nephropathy through Regulating Nephrin and Podocin 
Expressions.” Journal of Traditional Chinese Medicine 34(1):63–68. 
Wyss, Markus, Rima Kaddurah-Daouk, F. Hoffmann-, and La Roche. 2000. 
“Creatine and Creatinine Metabolism.” Physiological Reviews 80(3):1107–1213. 
Xiao, P. J. and R. J. Samulski. 2012. “Cytoplasmic Trafficking, Endosomal Escape, 
and Perinuclear Accumulation of Adeno-Associated Virus Type 2 Particles Are 
Facilitated by Microtubule Network.” Journal of Virology 86(19):10462–73. 
Xiao, W., N. Chirmule, S. C. Berta, B. McCullough, G. Gao, and J. M. Wilson. 1993. 
“Gene Therapy Vectors Based on Adeno-Associated Virus Type 1.” Journal of 
Virology 73(5):3994–4003. 
Xiao, Wu, Kenneth H. Warrington, Patrick Hearing, Jeffrey Hughes, and Nicholas 
Muzyczka. 2002. “Adenovirus-Facilitated Nuclear Translocation of Adeno-
Associated Virus Type 2.” Journal of Virology 76(22):11505–17. 
Xiao, X., J. Li, and R. J. Samulski. 1996. “Efficient Long-Term Gene Transfer into 
Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector.” 
Journal of Virology 70(11):8098–8108. 
Xie, Kewei, Chenqi Xu, Minfang Zhang, Minzhou Wang, Lulin Min, Cheng Qian, Qin 
Wang, Zhaohui Ni, Shan Mou, Huili Dai, Huihua Pang, and Leyi Gu. 2019. “Yes-
Associated Protein Regulates Podocyte Cell Cycle Re-Entry and 
Dedifferentiation in Adriamycin-Induced Nephropathy.” Cell Death and Disease 
10(12):1–15. 
Xie, Kewei, Mingli Zhu, Peng Xiang, Xiaohuan Chen, Ayijiaken Kasimumali, Renhua 
Lu, Qin Wang, Shan Mou, Zhaohui Ni, Leyi Gu, and Huihua Pang. 2017. 
“Protein Kinase A/CREB Signaling Prevents Adriamycin-Induced Podocyte 
Apoptosis via Upregulation of Mitochondrial Respiratory Chain Complexes.” 
Molecular and Cellular Biology 38(1):e00181-17. 
Xie, Qing, Weishu Bu, Smita Bhatia, Joan Hare, Thayumanasamy Somasundaram, 
Arezki Azzi, and Michael S. Chapman. 2002. “The Atomic Structure of Adeno-
Associated Virus (AAV-2), a Vector for Human Gene Therapy.” Proceedings of 
the National Academy of Sciences of the United States of America 
99(16):10405–10. 
Xiong, Ye, Asim Mahmood, Yuling Meng, Yanlu Zhang, Zheng Gang Zhang, Daniel 
C. Morris, and Michael Chopp. 2011. “Treatment of Traumatic Brain Injury with 
 302 
Thymosin Β4in Rats: Laboratory Investigation.” Journal of Neurosurgery 
114(1):102–15. 
Xu, Baogang J., Yu Shyr, Xiubin Liang, Li Jun Ma, Ellen M. Donnert, Jeremy D. 
Roberts, Xueqiong Zhang, Valentina Kon, Nancy J. Brown, Richard M. Caprioli, 
and Agnes B. Fogo. 2005. “Proteomic Patterns and Prediction of 
Glomerulosclerosis and Its Mechanisms.” Journal of the American Society of 
Nephrology 16(10):2967–75. 
Xu, Han, Na Guan, Ya Li Ren, Qi Jiao Wei, Ying Hong Tao, Guo Sheng Yang, Xiao 
Ya Liu, Ding Fang Bu, Ying Zhang, and Sai Nan Zhu. 2018. “IP3R-Grp75-
VDAC1-MCU Calcium Regulation Axis Antagonists Protect Podocytes from 
Apoptosis and Decrease Proteinuria in an Adriamycin Nephropathy Rat Model.” 
BMC Nephrology 19(1):140. 
Xu, Weiwei, Yan Ge, Zhihong Liu, and Rujun Gong. 2014. “Glycogen Synthase 
Kinase 3β Dictates Podocyte Motility and Focal Adhesion Turnover by 
Modulating Paxillin Activity: Implications for the Protective Effect of Low-Dose 
Lithium in Podocytopathy.” The American Journal of Pathology 184(10):2742–
56. 
Xue, B. and R. C. Robinson. 2016. “Actin-Induced Structure in the Beta-Thymosin 
Family of Intrinsically Disordered Proteins.” Pp. 55–71 in Vitamins and 
Hormones. Vol. 102. Academic Press Inc. 
Xue, Bo, Cedric Leyrat, Jonathan M. Grimes, and Robert C. Robinson. 2014. 
“Structural Basis of Thymosin-Β4/Profilin Exchange Leading to Actin Filament 
Polymerization.” Proceedings of the National Academy of Sciences of the United 
States of America 111(43):E4596-605. 
Yacoub, Rabi, Habib Habib, Ayham Lahdo, Radwan Al Ali, Leon Varjabedian, 
George Atalla, Nader Kassis Akl, Saleem Aldakheel, Saeed Alahdab, and Sami 
Albitar. 2010. “Association between Smoking and Chronic Kidney Disease: A 
Case Control Study.” BMC Public Health 10(1):731. 
Yamada, Hiroyuki, Naritoshi Shirata, Shinichi Makino, Takafumi Miyake, Juan 
Alejandro Oliva Trejo, Kanae Yamamoto-Nonaka, Mitsuhiro Kikyo, Maulana A. 
Empitu, Ika N. Kadariswantiningsih, Maiko Kimura, Koichiro Ichimura, Hideki 
Yokoi, Masashi Mukoyama, Akitsu Hotta, Katsuhiko Nishimori, Motoko 
Yanagita, and Katsuhiko Asanuma. 2020. “MAGI-2 Orchestrates the 
Localization of Backbone Proteins in the Slit Diaphragm of Podocytes.” Kidney 
 303 
International. 
Yamaji, Satoshi, Atsushi Suzuki, Heiwa Kanamori, Wataru Mishima, Ryusuke 
Yoshimi, Hirotaka Takasaki, Maki Takabayashi, Katsumichi Fujimaki, Shin 
Fujisawa, Shigeo Ohno, and Yoshiaki Ishigatsubo. 2004. “Affixin Interacts with 
α-Actinin and Mediates Integrin Signaling for Reorganization of F-Actin Induced 
by Initial Cell-Substrate Interaction.” Journal of Cell Biology 165(4):539–51. 
Yamashita, Atsuko, Kayo Maeda, and Yuichiro Maéda. 2003. “Crystal Structure of 
CapZ: Structural Basis for Actin Filament Barbed End Capping.” EMBO Journal 
22(7):1529–38. 
Yang, Chun, Wenhong Tian, Sisi Ma, Mengmeng Guo, Xiao Lin, Fengying Gao, 
Xiaoyan Dong, Mingming Gao, Yuhui Wang, George Liu, and Xunde Xian. 2020. 
“AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia 
and Rescue of Neonatal Death in ApoC2-Deficient Hamsters.” Molecular 
Therapy - Methods and Clinical Development 18:692–701. 
Yang, Fang, Xiao Ping Yang, Yun He Liu, Jiang Xu, Oscar Cingolani, Nour Eddine 
Rhaleb, and Oscar A. Carretero. 2004. “Ac-SDKP Reverses Inflammation and 
Fibrosis in Rats with Heart Failure after Myocardial Infarction.” Hypertension 
43(2 I):229–36. 
Yang, Heung Mo, Shin Wook Kang, Jihye Sung, Kyeongsoon Kim, and Hynda 
Kleinman. 2020. “Purinergic Signaling Involvement in Thymosin Β4-Mediated 
Corneal Epithelial Cell Migration.” Current Eye Research 45(11):1352–58. 
Yang, J. and Y. Liu. 2001. “Dissection of Key Events in Tubular Epithelial to 
Myofibroblast Transition and Its Implications in Renal Interstitial Fibrosis.” 
American Journal of Pathology 159(4):1465–75. 
Yang, Jae Won, Anne Katrin Dettmar, Andreas Kronbichler, Heon Yung Gee, Moin 
Saleem, Seong Heon Kim, and Jae Il Shin. 2018. “Recent Advances of Animal 
Model of Focal Segmental Glomerulosclerosis.” Clinical and Experimental 
Nephrology 22(4):752–63. 
Yang, Nuo, Yan Zhang, Jiang Tao Wang, Chen Chen, Yan Song, Jian Min Liang, Di 
Hui Ma, and Yan Feng Zhang. 2020. “Effects of Dexamethasone on Remodeling 
of the Hippocampal Synaptic Filamentous Actin Cytoskeleton in a Model of 
Pilocarpine-Induced Status Epilepticus.” International Journal of Medical 
Sciences 17(12):1683–91. 
Yaoita, Eishin, Hidetake Kurihara, Yutaka Yoshida, Tsutomu Inoue, Asako Matsuki, 
 304 
Tatsuo Sakai, and Tadashi Yamamoto. 2005. “Role of Fat1 in Cell-Cell Contact 
Formation of Podocytes in Puromycin Aminonucleoside Nephrosis and Neonatal 
Kidney.” Kidney International 68(2):542–51. 
Yi, Mixuan, Lei Zhang, Yu Liu, Man J. Livingston, Jian-Kang Chen, N. Stanley 
Nahman, Fuyou Liu, and Zheng Dong. 2017. “Autophagy Is Activated to Protect 
against Podocyte Injury in Adriamycin-Induced Nephropathy.” American Journal 
of Physiology-Renal Physiology 313(1):F74–84. 
Yin, Lei, Youying Mao, Hejie Song, Ye Wang, Wei Zhou, and Zhen Zhang. 2017. 
“Vincristine Alleviates Adriamycin-Induced Nephropathy through Stabilizing 
Actin Cytoskeleton.” Cell and Bioscience 7(1):10. 
Ylä-Herttuala, Seppo. 2012. “Endgame: Glybera Finally Recommended for Approval 
as the First Gene Therapy Drug in the European Union.” Molecular Therapy 
20(10):1831–32. 
Yoshimi, Michihiro, Takashige Maeyama, Mizuho Yamada, Naoki Hamada, Jyutaro 
Fukomoto, Tomonobu Kawaguchi, Kazuyoshi Kuwano, and Yoichi Nakanishi. 
2008. “Recombinant Human Erythropoietin Reduces Epithelial Cell Apoptosis 
and Attenuates Bleomycin-Induced Pneumonitis in Mice.” Respirology 
13(5):639–45. 
Yoshimura, Yasuhiro and Ryuichi Nishinakamura. 2019. “Podocyte Development, 
Disease, and Stem Cell Research.” Kidney International 96(5):1077–82. 
Yoshioka, T., T. Okada, Y. Maeda, U. Ikeda, M. Shimpo, T. Nomoto, K. Takeuchi, M. 
Nonaka-Sarukawa, T. Ito, M. Takahashi, T. Matsushita, H. Mizukami, Y. 
Hanazono, A. Kume, S. Ookawara, M. Kawano, S. Ishibashi, K. Shimada, and 
K. Ozawa. 2004. “Adeno-Associated Virus Vector-Mediated Interleukin-10 Gene 
Transfer Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice.” Gene 
Therapy 11(24):1772–79. 
Young, J. D., A. J. Lawrence, A. G. Maclean, B. P. Leung, I. B. Mcinnes, B. Canas, 
D. J. C. Pappin, and R. D. Stevenson. 1999. “Thymosin Β4 Sulfoxide Is an Anti-
Inflammatory Agent Generated by Monocytes in the Presence of 
Glucocorticoids.” Nature Medicine 5(12):1424–27. 
Yousef, George M. and Eleftherios P. Diamandis. 2001. “The New Human Tissue 
Kallikrein Gene Family: Structure, Function, and Association to Disease.” 
Endocrine Reviews 22(2):184–204. 
Yu, F. X., S. C. Lin, M. Morrison-Bogorad, M. A. Atkinson, and H. L. Lin. 1993. 
 305 
“Thymosin Beta 10 and Thymosin Beta 4 Are Both Actin Monomer Sequestering 
Proteins.” Journal of Biological Chemistry 268:502–9. 
Yu, Fu-Xin, Sheng-Cai Lin, Marcelle Morrison-Bogorad, Mark A. L. Atkinson, and 
Helen L. Yin. 1993. “Thymosin B10 and Thymosin B4 Are Both Actin Monomer 
Sequestering Proteins.” The Journal of Biological Chemistry 268(1):502–9. 
Yu, Fu-Xin -X, Helen L. Yin, Marcelle Morrison-Bogorad, and Sheng-Cai -C Lin. 
1994. “Effects of Thymosin Β4 and Thymosin Β10 on Actin Structures in Living 
Cells.” Cell Motility and the Cytoskeleton 27(1):13–25. 
Yu, Haiyang, Hani Suleiman, Alfred H. J. Kim, Jeffrey H. Miner, Adish Dani, Andrey 
S. Shaw, and Shreeram Akilesh. 2013. “Rac1 Activation in Podocytes Induces 
Rapid Foot Process Effacement and Proteinuria.” Molecular and Cellular Biology 
33(23):4755–64. 
Yu, Miao, Shimin Le, Artem K. Efremov, Xiangjun Zeng, Alexander Bershadsky, and 
Jie Yan. 2018. “Effects of Mechanical Stimuli on Profilin- and Formin-Mediated 
Actin Polymerization.” Nano Letters 18(8):5239–47. 
Yu, Seyoung, Won Il Choi, Yo Jun Choi, Hye Youn Kim, Friedhelm Hildebrandt, and 
Heon Yung Gee. 2020. “PLCE1 Regulates the Migration, Proliferation, and 
Differentiation of Podocytes.” Experimental and Molecular Medicine 52(4):594–
603. 
Yuan, Huaiping, Emiko Takeuchi, and David J. Salant. 2002. “Podocyte Slit-
Diaphragm Protein Nephrin Is Linked to the Actin Cytoskeleton.” American 
Journal of Physiology-Renal Physiology 282(4):F585–91. 
Yuan, Jing, Yan Shen, Xia Yang, Ying Xie, Xin Lin, Wen Zeng, Yingting Zhao, Maolu 
Tian, and Yan Zha. 2017. “Thymosin Β4 Alleviates Renal Fibrosis and Tubular 
Cell Apoptosis through TGF-β Pathway Inhibition in UUO Rat Models.” BMC 
Nephrology 18(1):314. 
Zhang, Jiong, Kim M. Hansen, Jeffrey W. Pippin, Alice M. Chang, Yoshinori 
Taniguchi, Ronald D. Krofft, Scott G. Pickering, Zhi-Hong Liu, Christine K. 
Abrass, and Stuart J. Shankland. 2012. “De Novo Expression of Podocyte 
Proteins in Parietal Epithelial Cells in Experimental Aging Nephropathy.” 
American Journal of Physiology-Renal Physiology 302(5):F571–80. 
Zhang, Yanshu, Aiko Yoshida, Nobuaki Sakai, Yoshitsugu Uekusa, Masahiro 
Kumeta, and Shige H. Yoshimura. 2017. “In Vivo Dynamics of the Cortical Actin 
Network Revealed by Fast-Scanning Atomic Force Microscopy.” Microscopy 
 306 
66(4):272–82. 
Zhang, Yuqing, Louis W. Feurino, Qihui Zhai, Hao Wang, William E. Fisher, Changyi 
Chen, Qizhi Yao, and Min Li. 2008. “Thymosin Beta 4 Is Overexpressed in 
Human Pancreatic Cancer Cells and Stimulates Proinflammatory Cytokine 
Secretion and JNK Activation.” Cancer Biology & Therapy 7(3):1–5. 
Zheng, Xiao Yan, Yi Fei Lv, Shuang Li, Qian Li, Qian Nan Zhang, Xue Ting Zhang, 
and Zhi Ming Hao. 2017. “Recombinant Adeno-Associated Virus Carrying 
Thymosin Β4 Suppresses Experimental Colitis in Mice.” World Journal of 
Gastroenterology 23(2):242–55. 
Zheng, Zongyu, Kai M. Schmidt-Ott, Streamson Chua, Kirk A. Foster, Rachelle Z. 
Frankel, Paul Pavlidis, Jonathan Barasch, Vivette D. D’Agati, and Ali G. 
Gharavi. 2005. “A Mendelian Locus on Chromosome 16 Determines 
Susceptibility to Doxorubicin Nephropathy in the Mouse.” Proceedings of the 
National Academy of Sciences of the United States of America 102(7):2502–7. 
Zhong, Fang, Haibing Chen, Yifan Xie, Evren U. Azeloglu, Chengguo Wei, Weijia 
Zhang, Zhengzhe Li, Peter Y. Chuang, Belinda Jim, Hong Li, Firas Elmastour, 
Jalish M. Riyad, Thomas Weber, Hongyu Chen, Yongjun Wang, Aihua Zhang, 
Weiping Jia, Kyung Lee, and John C. He. 2018. “Protein S Protects against 
Podocyte Injury in Diabetic Nephropathy.” Journal of the American Society of 
Nephrology 29(5):1397–1410. 
Zhong, Li, Baozheng Li, Cathryn S. Mah, Lakshmanan Govindasamy, Mavis 
Agbandje-McKenna, Mario Cooper, Roland W. Herzog, Irene Zolotukhin, 
Kenneth H. Warrington, Kirsten A. Weigel-Van Aken, Jacqueline A. Hobbs, 
Sergei Zolotukhin, Nicholas Muzyczka, and Arun Srivastava. 2008. “Next 
Generation of Adeno-Associated Virus 2 Vectors: Point Mutations in Tyrosines 
Lead to High-Efficiency Transduction at Lower Doses.” Proceedings of the 
National Academy of Sciences of the United States of America 105(22):7827–
32. 
Zhong, Li, Xiaohuai Zhou, Yanjun Li, Keyun Qing, Xiao Xiao, Richard Jude Samulski, 
and Arun Srivastava. 2008. “Single-Polarity Recombinant Adeno-Associated 
Virus 2 Vector-Mediated Transgene Expression In Vitro and In Vivo: Mechanism 
of Transduction.” Molecular Therapy 16(2):290–95. 
Zhou, Qingzhang, Wenhong Tian, Chunguo Liu, Zhonghui Lian, Xiaoyan Dong, and 
Xiaobing Wu. 2017. “Deletion of the B-B’ and C-C’ Regions of Inverted Terminal 
 307 
Repeats Reduces RAAV Productivity but Increases Transgene Expression.” 
Scientific Reports 7(1):1–13. 
Zhou, Wuding and Steven H. Sacks. 2001. “Why Is Erythropoietin Made in the 
Kidney? The Kidney Functions as a Critmeter.” American Journal of Kidney 
Diseases 38(2):415–25. 
Zhou, Xiaohuai, Xinghua Zeng, Zhenghong Fan, Chengwen Li, Thomas McCown, R. 
Jude Samulski, and Xiao Xiao. 2008. “Adeno-Associated Virus of a Single-
Polarity DNA Genome Is Capable of Transduction in Vivo.” Molecular Therapy 
16(3):494–99. 
Zhou, Yunfeng, Xiaomu Kong, Pan Zhao, Hang Yang, Lihong Chen, Jing Miao, 
Xiaoyan Zhang, Jichun Yang, Jie Ding, and Youfei Guan. 2011. “Peroxisome 
Proliferator-Activated Receptor-α Is Renoprotective in Doxorubicin-Induced 
Glomerular Injury.” Kidney International 79(12):1302–11. 
Zhu, Jian, Li-Ping Su, Yue Zhou, Lei Ye, Kok-Onn Lee, and Jian-Hua Ma. 2015. 
“Thymosin Β4 Attenuates Early Diabetic Nephropathy in a Mouse Model of Type 
2 Diabetes Mellitus.” American Journal of Therapeutics 22(2):141–46. 
Ziegler, Tilman, Markus Kraus, Wira Husada, Florian Gesenhues, Qui Jiang, Olaf 
Pinkenburg, Teresa Trenkwalder, Karl Ludwig Laugwitz, Ferdinand Le Noble, 
Christian Weber, Christian Kupatt, and Rabea Hinkel. 2018. “Steerable 
Induction of the Thymosin Β4/MRTF-A Pathway via AAV-Based Overexpression 
Induces Therapeutic Neovascularization.” Human Gene Therapy 29(12):1407–
15. 
Zincarelli, Carmela, Stephen Soltys, Giuseppe Rengo, and Joseph E. Rabinowitz. 
2008. “Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism 
in Mice after Systemic Injection.” Molecular Therapy 16(6):1073–80. 
Ziyadeh, Fuad N. 2004. “Mediators of Diabetic Renal Disease: The Case for TGF-β 
as the Major Mediator.” Journal of the American Society of Nephrology 15(1 
SUPPL.):S55–57. 
Zou, Jun, Eishin Yaoita, Yusuke Watanabe, Yutaka Yoshida, Masaaki Nameta, 
Huiping Li, Zhenyun Qu, and Tadashi Yamamoto. 2006. “Upregulation of Nestin, 
Vimentin, and Desmin in Rat Podocytes in Response to Injury.” Virchows Archiv 
448(4):485–92. 
Zou, Min-Shu, Jian Yu, Jian-Hua Zhou, Guo-Ming Nie, Dong-Sheng Ding, Li-Man 
Luo, Hong-Tao Xu, and Wei-Sun He. 2010. “1,25-Dihydroxyvitamin D3 
 308 
Ameliorates Podocytopenia in Rats with Adriamycin-Induced Nephropathy.” 
International Medicine 49:2677–86. 
Zou, Min Shu, Jian Yu, Guo Ming Nie, Wei Sun He, Li Man Luo, and Hong Tao Xu. 
2010. “1, 25-Dihydroxyvitamin D3 Decreases Adriamycin-Induced Podocyte 
Apoptosis and Loss.” International Journal of Medical Sciences 7(5):290–99. 
Zou, Yizhou, Peter Stastny, Caner Süsal, Bernd Döhler, and Gerhard Opelz. 2007. 
“Antibodies against MICA Antigens and Kidney-Transplant Rejection.” New 
England Journal of Medicine 357(13):1293–1300. 
Zuo, Yiqin, Bongkwon Chun, Sebastian A. Potthoff, Naj Kazi, Tyler J. Brolin, 
Diclehan Orhan, Hai-Chun Yang, Li-Jun Ma, Valentina Kon, Timo Myöhänen, 
Nour-Eddine Rhaleb, Oscar A. Carretero, and Agnes B. Fogo. 2013. “Thymosin 
Β4 and Its Degradation Product, Ac-SDKP, Are Novel Reparative Factors in 
Renal Fibrosis.” Kidney International 84(6):1166–75. 
 
